NATIONAL QUALITY FORUM

+ + + + +

MEASURE APPLICATION PARTNERSHIP JOINT MEDICAID ADULT AND CHILD TASK FORCE

+ + + + +

WEDNESDAY MAY 24, 2017

+ + + + +

The Task Force met at the National Quality Forum, 9th Floor Conference Room, 1030 15th Street, N.W., Washington, D.C., at 9:00 a.m., Harold Pincus and Richard Antonelli, Co-Chairs, presiding.

MEMBERS PRESENT:

RICHARD ANTONELLI, MD, Co-Chair HAROLD PINCUS, MD, Co-Chair TERRY ADIRIM, MD, MPH, FAAP, Office of the Assistant Secretary of Defense for Health Affairs KATHRYN BEATTIE, MD, St. Luke's Children's Hospital ANDREA BENIN, MD, Children's Hospital Association\* DIANE CALMUS, JD, National Rural Health Association ANN GREINER, MUP, Patient-Centered Primary Care Collaborative MARY KAY JONES, Centene Corporation SUE KENDIG, JD, MSN, WHNP-BC, FAANP, National Association of Nurse Practitioners in Women's Health DEBORAH KILSTEIN, RN, MBA, JD, Association for Community Affiliated Plans RACHEL LA CROIX, PhD, PMP, Florida Agency for Health Care Administration

MEMBERS PRESENT:

ROANNE OSBORNE-GASKIN, MD, MBA, FAAFP, MDwise, Inc. AMY POOLE-YAEGER, MD, Centene Corporation AMY RICHARDSON, MD, MBA, Aetna Medical CLARKE ROSS, DPA, American Association on Health and Disability CAROL SAKALA, PhD, MSPH, National Partnership for Women & Families MARISSA SCHLAIFER, RPh, MS, Independent Consultant, Academy of Managed Care Pharmacy GREGORY CRAIG, American Nurses Association SUBJECT MATTER EXPERTS (VOTING): KIM ELLIOTT, PhD, CPHQ, Health Services Advisory Group FEDERAL GOVERNMENT MEMBERS PRESENT (NON-VOTING): SUMA NAIR, MS, RD, Office of Quality Improvement LISA PATTON, PhD, Substance Abuse and Mental Health Services Administration MARSHA SMITH, MD, MPH, FAAP, Centers for Medicare & Medicaid Services NQF STAFF: SHANTANU AGRAWAL, MD, MPhil, President and Chief Executive Officer HELEN BURSTIN, MD, Chief Scientific Officer SHACONNA GORHAM, MS, PMP, Senior Project Manager MIRANDA KUWAHARA, Policy Analyst DEBJANI MUKHERJEE, MPH, Senior Director MAY NACION, MPH, Project Manager SUZANNE THEBERGE, Senior Project Manager\*

ALSO PRESENT:

MARY APPLEGATE, MD, FAAP, FACP, Ohio Department of Medicaid

LINDSAY COGAN, Bureau of Quality Measurement and Evaluation, New York State Department of Health

LEKISHA DANIEL-ROBINSON, MSPH, Maternal-

Infant Health Technical Director, Centers for Medicare and Medicaid Services

KAREN MATSUOKA, PhD, Division of Quality and Health Outcomes, Centers for Medicare and Medicaid Services

GIGI RANEY, LCSW, Centers for Medicare and

Medicaid Services

\* present by teleconference

## CONTENTS

| Welcoming Remarks  | 4         |
|--|-----------|
| Introductions of Task Force Members<br>and Disclosures of Interest for the<br>MAP Child Task Force Members           | 6         |
| Overview of Adult Task Force Session   | 24        |
| Key Considerations from CMS  | 28        |
| CMS/State Perspective Panel<br>Dr. Mary Applegate  | 1         |
| CMS/State Perspective Panel<br>Lekisha Daniel-Robinson   | 37        |
| Issues of Shared Importance: Adult and<br>Child Continuum of Care: Looking at<br>Maternal and Infant Health Measures |           |
| Across Core Sets   | )8        |
| Public Comment   | 7         |
| Issues of Shared Importance (Continued) 18   | 30        |
| Public Comment   | <b>!7</b> |
| Public Comment   | 51        |
| Supporting States' Ability to Report<br>Measures and Recommendations to  |           |
| Strengthen the Core Sets   | 55        |
| Public Comment   | )8        |
| Summarize Progress   | .2        |
| Adjourn  | .3        |

| 1  | PROCEEDINGS                                       |
|----|---|
| 2  | 9:03 a.m.   |
| 3  | MS. MUKHERJEE: Hi, welcome everybody.             |
| 4  | My name's Debjani Mukherjee. I'm the senior       |
| 5  | director for the Medicaid Adult and Child Core    |
| 6  | Set Project here, and this morning we are I'm     |
| 7  | glad and happy to have our CEO Shantanu Agarwal   |
| 8  | here to say some welcoming remarks, and then      |
| 9  | we'll get started with our day two for Medicaid   |
| 10 | Combined Adult and Child Program. Shantanu.       |
| 11 | DR. AGRAWAL: Thank you very much. I               |
| 12 | was sitting here talking to Helen, telling her I  |
| 13 | had to go get my BLS refresher today, because you |
| 14 | have to do that, and then I almost choked on my   |
| 15 | melon and luckily she's certified, yes. Could     |
| 16 | have saved my life.                               |
| 17 | Thanks everybody for attending. So                |
| 18 | this is actually my first time going through the  |
| 19 | Medicaid MAP process. I've been here about four   |
| 20 | months now, so learning as I go. I really want    |
| 21 | to thank Harold and Rich, our co-chairs today. I  |
| 22 | know that you guys are, this is sort of a three-  |

Neal R. Gross and Co., Inc. Washington DC

day process. So I'll be interested to see what
 all the results are. But thank you again for
 your leadership.

You know MAP is, as you all well know, 4 5 is an extremely important process for NQF. It's an important process for CMS. 6 Certainly 7 identifying core sets that states can adopt is a 8 vital mission for us. It's extremely important. 9 I know that my staff is really dedicated to this because it's a good way to help lead to quality 10 improvement in the Medicaid program. 11

12 One thing that we have tried new this 13 year, and you've already seen on the Medicare MAP 14 work is identification of measures that could 15 potentially be removed from these programs or 16 removed from the core sets. I think that is a 17 great place.

So as we think about where the gaps in measurement are, and certainly this committee is dedicated to addressing those gaps, at the same time being able to look across the portfolio and identify areas where, you know, a measure might

actually be removed I think is an important message to send for quality improvement in measurement overall, that we are really focused at NQF and through our committees on having the right measures.

It's not about having the right number 6 7 of measures or any other criteria, and it's also 8 I think a really worthwhile message to send to 9 providers -- thank you -- that you know, we understand that there's a certain amount of 10 11 burden related to measurement, and therefore 12 having the right measures that are actually going 13 to lead to improvement that haven't been topped 14 out, that are scientifically still rigorous and valid, I think that is an absolutely great 15 16 message to send to them.

Too often, I think they get an impression of the contrary. So I just want to again thank you for all the work. I think taking on this additional look at the portfolio is absolutely great, and with that I will turn it back.

1

2

3

4

1 MS. MUKHERJEE: Thank you. So as we 2 get started, what I will do is go over a quick update of some of the break times, as well as our 3 housekeeping. So as you know, all know the 4 5 restrooms are straight down the hall to the right, and then please keep your cell phones on 6 7 mute and if you need to take a call, you can step 8 outside right by the reception desk where you 9 signed in. If you would like to speak, please use 10 11 your tent cards and stand them up. That way we 12 know to call on you, and our break times today will be 11:00, 1:00 and 2:50, and we'll try to 13 14 keep to these because we have public comments right before, and we would like to allow for the 15 16 public to have an opportunity to put their 17 comments in. 18 Even though public comment happens 19 after voting, we would like to let you know that we do consider their comments and sort of discuss 20 21 them afterwards. You all have laptops and by now 22 you're probably logged in, but it's guest and

1 NQFguest, and with that I will turn it over to 2 Rich to say some welcoming remarks. CO-CHAIR ANTONELLI: I blew the 3 4 introduction. No pressure. So I'm Rich 5 Antonelli. I'm a general pediatrician and 6 medical director of Integrated Care, Boston 7 Children's Hospital. I have the absolute 8 privilege of co-chairing this task force, the 9 joint task force with Harold Pincus who's a friend and actually a long-standing mentor for me 10 11 and the NQF staff. So basically is Karen here? 12 CO-CHAIR PINCUS: I thought you were 13 my mentor. 14 CO-CHAIR ANTONELLI: Well, that's sign of a healthy relationship I think. 15 Okav. So 16 we're going to -- I wanted to introduce -- so if 17 she's running late, am I pivoting from my talking 18 points. 19 So Helen is pinch hitting for Okay. 20 Elisa to do the DOIs today, so we'll go through 21 that process first, so that will buy us some time before we launch with our CMS colleagues. 22

Neal R. Gross and Co., Inc. Washington DC

| 1  | DR. BURSTIN: Great. Good morning                 |
|----|--|
| 2  | everybody. Thank you again for coming back.      |
| 3  | Those of you who spent yesterday with us on the  |
| 4  | Adult Task Force, and welcome to our Child Task  |
| 5  | Force members. Today we did disclosures          |
| 6  | yesterday with the Adult Task Force members. I   |
| 7  | don't know that we necessarily need to go around |
| 8  | again. Maybe just as we walk around, if you      |
| 9  | could just indicate your name and your           |
| 10 | organization, just for the sake of the Child     |
| 11 | folks, so everybody knows who's who.             |
| 12 | I believe we only have the chairs as             |
| 13 | subject matter experts and Kim Elliott, so we'll |
| 14 | save you guys for the end because their          |
| 15 | disclosures are slightly different. So as we go  |
| 16 | around the room, if you're on the Child Task     |
| 17 | Force, we specifically want you as an            |
| 18 | organizational member to only disclose if you    |
| 19 | have more than a \$10,000 interest in any entity |
| 20 | that you think would be affected by the          |
| 21 | recommendations of this group.                   |
| 22 | We fully expect that as an                       |

organizational member, you're going to bring your 1 2 organization's viewpoint, so that in and of itself is not a conflict. It is simply a 3 4 disclosure of who you're representing at the 5 So let's just start with that, and we'll table. come back to the feds at the end too, if that's 6 7 okay. Just introduce 8 Go ahead, please. 9 yourself and your organization if we did disclosures with you yesterday, just so everybody 10 11 knows who everybody is. 12 MEMBER LA CROIX: I forgot about that, 13 sorry. I'm Rachel La Croix. I'm here on behalf of the National Association of Medicaid 14 Directors, and I also work for Florida Medicaid 15 16 in Tallahassee, Florida. 17 MEMBER KILSTEIN: Good morning. I'm 18 Deborah Kilstein. I am Vice President for 19 Quality Management and Operational Support at the Association of Community Affiliated Plans or 20 21 ACAP. We represent 60 non-profit safety net health plans in 29 states. 22

| I  | -   |
|----|---|
| 1  | MEMBER OSBORNE-GASKIN: Good morning.              |
| 2  | Roanne Osborne-Gaskin, representing American      |
| 3  | Academy of Family Physicians. I'm senior medical  |
| 4  | director at MDwise, a Medicaid Managed Care Plan  |
| 5  | in Indianapolis, Indiana.                         |
| 6  | MEMBER CALMUS: I'm Diane Calmus, and              |
| 7  | I'm representing the National Rural Health        |
| 8  | Association.                                      |
| 9  | MEMBER JONES: Good morning. I'm Mary              |
| 10 | Kay Jones. I'm vice president of Quality          |
| 11 | Improvement for Centene Corporation, which you    |
| 12 | may not know it as Centene, but we have 23        |
| 13 | different health plans that are they all have     |
| 14 | their own little name, but we're one of the I     |
| 15 | think the largest Medicaid managed care plans.    |
| 16 | MEMBER SCHLAIFER: Hi. I'm Marissa                 |
| 17 | Schlaifer. I'm an independent consultant, and     |
| 18 | I'm here representing the Academy of Managed Care |
| 19 | Pharmacy.   |
| 20 | MEMBER ROSS: Hi. I'm Clarke Ross.                 |
| 21 | I am employed by the American Association on      |
| 22 | Health and Disability, but I'm here representing  |
|    |   |
|    |   |

the Consortium for Citizens With Disabilities, 1 2 which is a Washington, D.C. coalition of 113 national disability organizations, and I'm also 3 the father of a 26 year-old son with co-occurring 4 5 disabilities. Hi. I'm Sue Kendig. 6 MEMBER KENDIG: 7 I am representing the American Association of 8 Nurse Practitioners, and I am in integration 9 specialist in women's health at SSM-St. Mary's in St. Louis, and serve as director of Policy for 10 the National Association of Nurse Practitioners 11 12 in Women's Health and do independent policy 13 consulting. 14 DR. PATTON: Well, that was pretty good timing. Good morning everyone. Lisa 15 I'm the division director for Evaluation 16 Patton. 17 Analysis and Quality in the Center for Behavioral 18 Health Statistics and Quality at SAMHSA within 19 HHS. 20 DR. SMITH: Good morning. I'm Marsha 21 Smith, I'm the medical officer in the Center for Clinical Standards and Quality at the Centers for 22

Medicare and Medicaid Services. Our division is
 responsible for the public reporting, clinical
 quality and performance measures.

4 MS. NAIR: Good morning. Suma Nair. 5 I'm here representing the Health Resources and Services Administration. I'm the director of 6 7 Quality Improvement at the Community Health 8 Center Program. Serve about 25 million patients 9 across the country, half of which are Medicaid beneficiaries. 10

11 MEMBER BEATTIE: Good morning. I'm 12 Kathryn Beattie. I'm the executive medical director and administrator for St. Luke's 13 14 Children's Hospital, which is in Boise, Idaho. It's the most remote children's hospital in the 15 16 country, and I'm here representing America's 17 Essential Hospitals.

MEMBER RICHARDSON: Good morning. I'm
Amy Richardson, also a general pediatrician, and
I am the Aetna Medicaid Senior National Medical
Director for Pediatrics.

22

DR. BURSTIN: Again, if you have any

disclosures for the Child Task Force folks as we 1 2 go around please. MEMBER BEATTIE: I have no 3 4 disclosures. 5 MEMBER RICHARDSON: I'm an Aetna shareholder as well as employee. 6 7 MR. CRAIG: Good morning. I'm Gregory 8 I'm representing the American Nurses Craig. 9 Association. I have no disclosures. 10 MEMBER SAKALA: Good morning. I'm 11 Carol Sakala representing the National 12 Partnership for Women and Families, and I have no 13 disclosures. 14 MEMBER GREINER: Good morning. I'm Ann Greiner, president and CEO of the Patient-15 16 Centered Primary Care Collaborative, and we work 17 to make primary care more central, more vibrant 18 and more patient-centered. I have no 19 disclosures. 20 MEMBER POOLE-YAEGER: Hi. I'm Amv 21 Poole-Yaeger. I am SVP of Medical Affairs for 22 Centene Corporation, along with -- I work there

for Mary Kay. I have the disclosure of being an 1 2 employer and a shareholder of Centene, and I am also a pediatrician and very excited to be here. 3 4 DR. APPLEGATE: Good morning. I'm 5 Mary Applegate. I am also a pediatrician and an 6 internist, and I serve as the medical director for Ohio's Medicaid Program. 7 I have no 8 disclosures. 9 DR. BURSTIN: Great, thank you, and I 10 believe on the phone we have Andrea Benin. Good 11 morning, Andrea. Are you with us? 12 MEMBER BENIN: Yep, hi. It's Andrea 13 Benin. I have no disclosures. I am representing 14 the Children's Hospital Association. I'm a pediatric infectious disease doctor, and I'm the 15 16 senior vice president for Quality and Patient 17 Safety at Connecticut Children's Medical Center. 18 Thanks. 19 DR. BURSTIN: Perfect, thanks. Now 20 we'll just move on to the couple of SME, subject 21 matter experts, as we like to refer to them. Ι believe we have Kim and we'll also have Rich do 22

his introduction and disclosures as well. 1 This 2 is slightly different. Subject matter experts sit as individuals. You don't sit representing 3 4 any organization. 5 So we'll ask you a bit more detail, rather than just disclosure of financial 6 interests. So any activities you believe in your 7 8 subject matter that might be related to the 9 Committee's deliberations, grants, consulting, et cetera. We know who you are. We've looked at 10 your CV, so we don't need a recitation of these 11 12 very impressive CVs, Dr. Antonelli. So just 13 briefly. Thank you, Kim. 14 DR. ELLIOTT: Just have to get my buttons right. Kim Elliott, and I work for 15 16 Health Services Advisory Group currently. I've 17 worked in the Medicaid program for about 15 years 18 overall, the clinical programs for all of the 19 different populations, and prior to that I worked 20 in health plans and quality and really every 21 area. I have no disclosures. CO-CHAIR ANTONELLI: Rich Antonelli, 22

medical director of Integrated Care, Boston
 Children's Hospital, and I also have no
 disclosures.

I'm Harold Pincus. 4 CO-CHAIR PINCUS: 5 I'm a professor and vice chair of Psychiatry at Columbia. I also am director of Quality and 6 Outcomes Research at New York Presbyterian 7 8 Hospital. In terms of my disclosures, I have 9 consulted for Mathematica Policy Research and also for the National Academy for State Health 10 11 Policy, and I'm on committees for the American 12 Psychiatric Association and the World Health 13 Organization. I have research that's been 14 supported by NIH and several private foundations. Thank you, Harold. 15 DR. BURSTIN: Ι 16 think that -- we'll just have Terry, as soon as 17 she settles in, introduce herself, and if you 18 have any disclosures. 19 MEMBER ADIRIM: Sure, yeah. Hi, I'm 20 Terry Adirim. I'm sorry I'm late. It took me

22

21

Neal R. Gross and Co., Inc. Washington DC

two hours to go 15 miles. I just thought I had

to say that. But I am representing the American

www.nealrgross.com

Academy of Pediatrics. I have no -- nothing to
 disclose.

My current position is Deputy Assistant Secretary for Health Services Policy and Oversight for the Military Health System, but that's not why I'm here so --

DR. BURSTIN: Okay, wonderful, and
Gigi, we skipped over you, if you'd like to
introduce yourself and use your mic.

10 MS. RANEY: Hi. My name is Gigi 11 Raney and I'm work in the Division of Quality and 12 Health Outcomes at the Center for Medicaid and CHIP Services. I am filling in this morning for 13 14 Karen Matsuoka, who is the director of Quality for Medicaid and CHIP, as well as our division 15 16 director and hopefully she'll get here soon.

DR. BURSTIN: Thank you everybody. So just one last comment. Thank you for those disclosures. Please at any point during the course of the deliberations, if you have any concern about a comment someone has made or something that you think signifies any potential

1 bias, please come forward to the chairs or myself 2 or any other senior staff at NQF. It's always better in our experience 3 4 to try to address those things in real time, 5 rather than hearing about them after the fact. So with that, I'll turn it back over to the 6 7 chairs, Rich or whoever. 8 MS. MUKHERJEE: We'll just go around 9 quickly and introduce staff, and Elisa, do you want to start? 10 11 MS. MUNTHALI: Good morning. Elisa 12 Munthali, Vice President for Quality Measurement. 13 Welcome. 14 Good morning, everyone. MS. KUWAHARA: 15 My name is Miranda Kuwahara. I'm the project 16 analyst for both Adult and Child. 17 MS. NACION: Hello. My name is May 18 Nacion. I'm the project manager for the Child 19 Task Force. 20 MS. GORHAM: Good morning. I'm 21 Shaconna Gorman. I'm the senior project manager for both Child and Adult Task Forces. 22

| I  | ∠   |
|----|---|
| 1  | MS. MUKHERJEE: And I'm still Debjani,             |
| 2  | so with that, I will turn it over to Rich to get  |
| 3  | us started with our objectives and sort of an     |
| 4  | overview of our meeting.                          |
| 5  | CO-CHAIR ANTONELLI: Some of this will             |
| 6  | be a little bit of a deja vu for our Adult        |
| 7  | members, but I'm going to err on the side of      |
| 8  | reviewing it all for the at least for the         |
| 9  | Child side today.                                 |
| 10 | So the meeting objective is                       |
| 11 | considering states' experiences implementing the  |
| 12 | core sets; develop recommendations for            |
| 13 | strengthening both child and adult core sets; and |
| 14 | formulating strategic guidance to CMS about       |
| 15 | strengthening the measure set over time to meet   |
| 16 | the program goals.                                |
| 17 | So it will be a combination of looking            |
| 18 | at measures and thinking strategically as well.   |
| 19 | In the morning, we'll have a presentation from    |
| 20 | CMS as well as the state panelist, kind of give   |
| 21 | us a view from the front lines, if you will. CMS  |
| 22 | will provide an overall update on the Medicaid    |
|    |   |

core set related activities, and then we'll hear
 from our state panelists today.

The rest of day we'll work through 3 issues of shared relevance between child and 4 So including maternal and perinatal 5 adult. health, asthma measures, and supporting states to 6 7 participate in reporting, and then you should 8 have received all the supporting documents for 9 today's work, as we go from slide to slide to reference if you need some help identifying where 10 11 we're at, so please ask the staff. 12 Next slide. All right. There we go.

13 So the charge, basically we've gone through this, 14 so I just want to bring us down to that final Basically, MAP members from the 15 one. 16 Coordinating Committee, Harold and I there, and 17 then the network groups that share this 18 particular interest, we're going to get the view 19 from the states, view from CMS in particular, 20 look at some of the gap areas. 21 Harold is going to give us a review of

some of the adult work that was discussed

yesterday, and think about measures for removal 1 2 from the set as well. This notion of parsimony is near and dear to my heart as we're promoting 3 4 new measures going forward. 5 The next slide. This is the structure of our delivered process. The Adult Task Force 6 7 met yesterday, shared interest today. Tomorrow is Child only. 8 9 The next slide. As I mentioned, 10 maternal and perinatal health measures, asthma measures across the age spectrum, and supporting 11 12 state's ability to participate in reporting of the measures in the core sets. Be mindful that 13 14 those are voluntary expectations, okay. Harold is going to take us through a 15 16 recap of yesterday, and as you're listening to 17 this, especially the Child Health folks, I want 18 to sort of put you on alert. Today is 19 specifically a crossover today, so be thinking 20 about opportunities to build on gap areas from 21 yesterday that have relevance across the age 22 spectrum. Harold.

| CO-CHAIR PINCUS: So yesterday, we had             |
|---|
| quite a productive meeting. We heard from Judy    |
| Zerzan, who's the Medicaid medical director for   |
| Colorado, who presented to us about some of the   |
| very innovative and interesting work in Colorado. |
| We also actually were fortunate to have Rachel La |
| Croix on our panel, who was able to also fill us  |
| in on some of the activities in Florida on a      |
| regular basis.                                    |
| I think it's really important that we             |
| hear from I guess, you know, the people in the    |
| states that are responsible for actually          |
| implementing and interacting and using the        |
| information that's being provided through the     |
| Medicaid core set.                                |
| And so there were a number of specific            |
| things that we did. First is with regard to       |
| specific measures related to the core set, there  |
| was one measure that we recommended for removal   |
| and two measures that we provided conditional     |
| support for.                                      |
| The measure recommended for removal               |
|   |
|   |

was Measure 0476, which is the Antenatal Steroids 1 2 Measure, and the reasons for that was that there's a very high reporting rate for this. 3 Of course, all the states it's a 4 5 required reporting for the Joint Commission on Accreditation. It's already being collected in a 6 7 number of ways. You know, it appears to have 8 been pretty much topped out, and so it was 9 recommended for removal to reduce the overall 10 reporting burden. 11 The two measures that received 12 conditional support that were sort of nominated 13 and received conditional support, one was a 14 concurrent use of opioids and benzodiazepines. It was conditional support because the measure is 15 16 not currently NQF-endorsed and there was a 17 feeling that obviously we are facing a major 18 crisis in terms of opioid abuse, and this 19 specifically also addressed an issue in 20 polypharmacy that was considered one of the high 21 priority areas.

22

And also particularly we're

particularly focused on reducing deaths and mortality from opioid use. And so that was being recommended and it's currently in the endorsement pipeline.

The second one that was conditionally 5 recommended was the use of the CAHPS for home and 6 7 community-based services experience, and the sense was that there's a clear gap in terms of 8 9 home and community-based services measures, and a desire to also increase the number of 10 11 beneficiary-reported experience measures, and to 12 sort of fill both of those roles. It's something 13 that's also in the pipeline for endorsement, and 14 so that was also recommended.

The other thing that we did that I 15 16 think was a major portion of the day's discussion 17 was go through a reexamination of the gaps and 18 priorities among the gaps. So we went through kind of eliciting both people's thoughts about 19 20 gaps, looking at past recommendations around 21 gaps, and then went through the exercise of 22 adding little dots to different categories.

> Neal R. Gross and Co., Inc. Washington DC

1

2

3

What came out at the end of this were 1 2 really sort of -- we also try to identify where there is an overlap in some of the gaps that were 3 previously identified. 4 So we identified nine areas in sort of 5 descending order of priority in terms of the 6 7 number of little dots that they got, was number one behavioral health and particularly 8 9 integration of behavioral health with primary care and psychosocial care and social services, 10 11 as well as thinking about this concept of integration across the continuum of care, both 12 13 outpatient and inpatient, and in long-term care 14 services, and also thinking about the potential for getting measures that address outcomes in 15 16 this area. 17 Number two was assessing and 18 addressing social determinants of health was the

19 second highest priority. The third was long-term 20 services and support of home and community-based 21 services.

22

We learned that there was some

interesting, innovative stuff going on in terms 1 2 of some work that's being done with the Innovation Accelerator Program that CMS has been 3 involved with, as well as some work that's been 4 5 supported by the University of Minnesota or that has been conducted by the University of 6 7 Minnesota, supported by the Administration for 8 Community Living as well as NIDLRR.

9 So that's another area for -- in terms 10 of a high priority. Particularly relevant for our joint day today was maternal and reproductive 11 12 health was identified sort of as a fourth 13 priority, and particularly focusing on well woman 14 care, postpartum complications and access to obstetrics care, especially in rural areas as 15 16 major areas.

17 The fifth area was efficiency 18 measures. There's a relative lack of those. the 19 sixth and seventh areas were pretty close in 20 terms of their level of support. The sixth was 21 new or chronic opioid use, and the seventh was 22 beneficiary reported outcomes as an area for

further development of priorities.

1

| 2  | The eighth was workforge issues in                |
|----|---|
| 2  | The eighth was workforce issues, in               |
| 3  | particular thinking about primary care provider   |
| 4  | burnout as a particular focus, and finally again  |
| 5  | polypharmacy made it to the list as well. So      |
| 6  | that pretty much summarizes where we were by the  |
| 7  | end of the day.                                   |
| 8  | I think that, you know, it was a very             |
| 9  | useful day both in terms of understanding some of |
| 10 | the issues that are and some of the               |
| 11 | innovations that states are undertaking, as well  |
| 12 | as sort of understanding some of the challenges   |
| 13 | that CMS faces as well.                           |
| 14 | CO-CHAIR PINCUS: So go to the next                |
| 15 | slide. So for, okay. So just sort of to remind    |
| 16 | people what's the purpose of actually developing  |
| 17 | these child and adult core sets, is that there's  |
| 18 | really three goals that's been set out for that.  |
| 19 | One is to increase the number of states reporting |
| 20 | core set measures, and to increase the number of  |
| 21 | measures that were reported by each state.        |
| 22 | So this is a kind of a crowd sourcing             |
|    |   |

sort of process that we're going through. 1 But 2 the most important thing is that we want to increase the number of states that are actually 3 4 using it for quality improvement, that ultimately 5 we don't want to just do measurement for measurement's sake, but we actually want to drive 6 7 improvement at the state level through --8 So part of our job is to select 9 measures that actually will help to achieve these 10 qoals. 11 Next slide please. From the CMS point of view and Gigi may want to sort of add to this, 12 13 the core set measures really are part of a 14 regular report that they put out in terms of the 15 Child Health Quality report and Adult Health 16 Quality report, and produce for both states and 17 for many other stakeholders various analyses 18 using that data, and also obviously to inform 19 policy and program decisions that they make. You 20 want to add to that Gigi at all? 21 MS. RANEY: I think we'll speak to that when I do Karen's slides. 22

| 1  | CO-CHAIR PINCUS: Okay.                            |
|----|---|
| 2  | MS. RANEY: Thanks.                                |
| 3  | CO-CHAIR PINCUS: Next slide, and I                |
| 4  | guess we're there.                                |
| 5  | MS. RANEY: Well, as you can tell,                 |
| 6  | I'm Karen. So I'm going to attempt to fill in     |
| 7  | for her shoes as best I can.                      |
| 8  | I think Harold and Rich both set us               |
| 9  | off well and we are really glad to welcome them   |
| 10 | back as well as the members of the panel who were |
| 11 | here yesterday, those who have been here in prior |
| 12 | years as well as our new members, because this is |
| 13 | really is our opportunity to hear from the field, |
| 14 | not only from the states and stakeholders who are |
| 15 | generally quite vocal in telling us what things   |
| 16 | work and what don't, but also to learn a little   |
| 17 | bit more about what's going on and where the      |
| 18 | needs are for that.                               |
| 19 | So we really do appreciate you guys               |
| 20 | taking so much time out of your day and your      |
| 21 | schedules to come here and participate with us.   |
| 22 | We do know that there is a tight schedule today   |
|    |   |

Neal R. Gross and Co., Inc. Washington DC

and that Harold and Rich are going to be cracking the whip on sticking to that so we're not here until six o'clock tonight. But we also do want to make sure there's an opportunity for robust discussion.

Next slide please. So in terms of 6 7 building a foundation for quality membership, 8 there are really three components that we have 9 been focusing on at CMS, and that is measurement and analysis and quality improvement. 10 Today 11 we're focused on that measurement section of 12 that.

The quality 13 Next slide please. 14 measurement reporting program. Next slide. As 15 you've already heard about, is a voluntary 16 reporting by states. So we just want to make 17 sure that everyone understands that when we're 18 talking about quality measures here today and 19 tomorrow, we're talking about state level 20 reporting. 21 We're not talking about provider level

reporting or individual accountability, but

Neal R. Gross and Co., Inc. Washington DC

22

1

2

3

4

really understanding what's going on at a state 1 2 level. So every year the states voluntarily provide CMS with data on the adult and child core 3 set measures, and these are measure sets, one for 4 5 children and one for adults that our stakeholders have told us are the key indicators for health 6 care access for the beneficiaries we serve. 7 Now while quality measurement itself 8 9 is not new to the Medicaid populations, what distinguishes our core sets is that the states 10 11 that participate in this program are measuring these key indicators of quality in a consistent 12

14 specifications, which really helps give us a 15 national picture of what's going on in Medicaid 16 and where issues and concerns might be.

way against a uniform set of measure

This consistency allows us to compare performance across the states in an apples to apples fashion, which we haven't been able to do before with this population.

21 So you'll see here that we currently 22 have 27 measures in the core set and 30 measures

| 1  | in the adult set, and you're going to hear this   |
|----|---|
| 2  | word quite a bit today. We heard it yesterday a   |
| 3  | lot. We always laugh when we say it, but          |
| 4  | parsimony is really the name of the game here.    |
| 5  | It takes a lot of money, a lot of                 |
| 6  | training and a lot of effort for states every     |
| 7  | time we make changes to our adult and child core  |
| 8  | sets, because they have to invest in that.        |
| 9  | So we really would like to encourage              |
| 10 | people to be thoughtful and considerate about the |
| 11 | measure changes that they're recommending, not    |
| 12 | only measures for addition but measures for       |
| 13 | removal, and we'd also like you to consider, you  |
| 14 | know, proposing measures for removal not only     |
| 15 | that might be low reporting but those that might  |
| 16 | be high reporting as well, that might not feel    |
| 17 | like they are necessarily needed anymore, that we |
| 18 | might be doing well on or know what's going on.   |
| 19 | So looking at both of those things                |
| 20 | because we're kind of looking at I think Karen    |
| 21 | said it yesterday, sort of a one-in, one-out kind |
| 22 | of thing generally. The MAP gives us a bunch of   |

1 great recommendations. I think we had 2 recommendations for six measures to be added last 3 year to the adult measure set, and we added 4 three.

Three was a really big number, and we 5 sweated a lot over whether we wanted to add three 6 7 measures or two measures. So you know, these are 8 recommendations and they are very valuable, and 9 then we take those recommendations and then we take those recommendations and we do a lot of 10 stakeholder input and feedback about the 11 12 recommendations that the MAP gives us before we make a decision. 13

But the big difference between the Medicaid MAP and the Medicare MAP is that they are recommendations and they are not requirements. So I just want to make that part of it a little bit clear.

19 Next slide, please. I think we
20 already went through this a little bit and Harold
21 just went over it. Our goal is to increase the
22 number of states reporting and to increase that,

and to improve the quality of data reported. In order to do that, CMS actually does have a contract with a technical analysis and analytics contract with Mathematica, that does help us to support the states in measure questions and reporting.

So they do work really closely with us
on that and hand in hand. So we just want to
make sure that whether we do provide support as
much as we can to states for the reporting of
these measures, okay.

12 So the next slide please. So the 13 input that we're requesting from the MAP this 14 year in that slide looks really tiny from here, 15 and we just want to talk about what you guys 16 think makes a measure useful. So it's not only is it evidence-based but also is there room for 17 18 improvements and that states can or will 19 implement something as well.

20 So when we're looking at measures, we 21 want you consider reviewing measures not only 22 with low reporting rates that should be

> Neal R. Gross and Co., Inc. Washington DC

1

2

3

4

5
considered for removal, but also the measures 1 2 that high reporting rates, and that we are really focused on trying to make some incremental 3 4 changes. Again, that word parsimony comes to 5 mind. Okay. Next slide please. One of the things 6 7 that we've really been working on over the last 8 few years is alignment. As you guys are all 9 aware, more measures sets are coming out every They're across the board. 10 day it feels like. 11 When we're thinking about alignment, we're 12 looking at alignment not only within CMS and CMS 13 programs, but also with states programs. 14 We have the AHIP collaborative measure sets that came out last year. 15 There are the 16 certified community behavioral health clinic

17 measure sets that came out a couple of years ago 18 and, you know, dozens and dozens of reporting 19 systems, whether it's through Medicare or other 20 things.

21 So we're looking at alignment and we 22 think that that's really important. But we also need to keep in mind the level of reporting in
 populations, and that what we're looking at is
 state level reporting.

Another thing that we are thinking about in terms of alignment, and this is a fun one to add into the mix is the age ranges for reporting, because oftentimes the CMS age ranges are a little bit different than the HEDIS age ranges, based on our coverage and how that works out.

11 So you know, it's just trying to keep 12 things consistent if at all possible, and we know 13 that that adds some confusion. But it's 14 definitely something that we're aware of and want 15 to bring forward to you for consideration when 16 you're looking at measures, is some of those 17 alignment things.

18 And then under statute that state 19 reporting on these measure sets is voluntary, so 20 we really do work with the states and appreciate 21 their work on that.

So with that, the next slide is about

Neal R. Gross and Co., Inc. Washington DC

| 1  | resources, and these are all links that you guys  |
|----|---|
| 2  | can click on for with lists of our adult and      |
| 3  | child core set measures and the different kinds   |
| 4  | of measures that are going on, and as you know,   |
| 5  | I'm not Karen. But you can email her if you've    |
| 6  | got any questions about this presentation. I      |
| 7  | hope that if you guys have any questions also,    |
| 8  | I'll be happy to answer them. Thank you.          |
| 9  | CO-CHAIR ANTONELLI: So why don't I                |
| 10 | open it up, any comments or questions for Karen's |
| 11 | surrogate today, and Gigi thank you. Thank you    |
| 12 | for the prep that led up to the meeting today and |
| 13 | for pinch hitting so well. So comments or         |
| 14 | questions. Harold.                                |
| 15 | CO-CHAIR PINCUS: So Gigi, just is                 |
| 16 | there something I've just been curious about.     |
| 17 | Since the origins of the child and adult programs |
| 18 | are somewhat different, is there anything in      |
| 19 | terms of how CMS approaches the child that        |
| 20 | differs with how it approaches the adult          |
| 21 | components of this? So the general sort of        |
| 22 | policy level approach.                            |

| 1  | MS. RANEY: I think what we found,                 |
|----|---|
| 2  | and I think everyone here is probably aware is    |
| 3  | that there are fewer measures for pediatrics. So  |
| 4  | one of the ways that CMS has focused on that is   |
| 5  | through our pediatric quality measures and        |
| 6  | reporting program, the PQMP program, which either |
| 7  | Kamila Mistry from AHRQ or Renee Fox will speak a |
| 8  | little bit about either today or tomorrow.        |
| 9  | But because there are fewer measures,             |
| 10 | we have focused more energy and effort on issuing |
| 11 | grants, in partnership with AHRQ, to try and help |
| 12 | develop some measures in that area, to try and    |
| 13 | help address some gap areas. With adults, it's    |
| 14 | been a little different because Medicare has been |
| 15 | in this field for a long time, as well as all of  |
| 16 | the other stakeholders that are here.             |
| 17 | The number of measures is a lot                   |
| 18 | broader. So I think we've done a little bit more  |
| 19 | measure development-focused work or supporting    |
| 20 | measure development in that area than we have     |
| 21 | done in adults. But otherwise, I think what       |
| 22 | we're trying to do is have a good understanding   |

1 of the quality of care and what's going on in 2 those spaces, and really have measure sets reflect those broadly. 3 4 CO-CHAIR ANTONELLI: May I presume 5 that if Andrea wants to weigh in, that she has a way of jumping into the conversation? 6 7 Yeah. All right. So any other 8 comments or questions before we move on? So I 9 think Mary Applegate, we're moving you into the -- from the dugout to the on deck circle straight 10 11 away. You ready? 12 DR. APPLEGATE: I am. First of all, 13 thank you so much for letting me come to speak to 14 I think I've met a few of you perhaps ten you. years ago when I was -- before kindergarten I 15 16 suppose. 17 Yes. So I recognize many of you. I'm 18 so delighted to kind of come full circle and 19 bring kind of additional layers of experience and 20 insight into the whole measurement scene. 21 So just to give you some of the 22 perspective, you know, I'm there when the babies

1 are born. I resuscitate them. I was the coroner 2 in our county for a bunch of times, so I was 3 there when they did. I did hospice, and as I 4 looked at the care over this period of time, it 5 actually struck me that we're not measuring the 6 right things that are actually helping us take 7 better care of people.

8 So of course then, in an effort to try 9 to help more people I get to medicate, and then I 10 realize, oh, we have to report different things 11 that perhaps are even farther away from what 12 matters at the patient level, that the clinician 13 then can actually use a barometer or speedometer 14 of are they close to what they need to be doing or not improve the health of the community they 15 16 serve.

17 So I've been in Medicaid full time for 18 five years and there's been a massive 19 transformation in just reporting for reporting's 20 sake, as I heard someone mention, to realizing 21 that the program was design to pay for services. 22 It was not necessarily designed to make people

better.

1

| 2  | But now, in the days of value-based               |
|----|---|
| 3  | purchasing, our job has shifted to managing the   |
| 4  | health of populations. So what do we need in a    |
| 5  | measure to actually manage the health of          |
| 6  | populations, and that's actually what I'm going   |
| 7  | to talk about.                                    |
| 8  | So I'm here to talk about grown-ups,              |
| 9  | pediatrics, but specifically the maternity sector |
| 10 | today. So how do I advance slides? Do I need      |
| 11 | to come sit next to you? Okay. Go ahead and go    |
| 12 | to the next slide. So just a snapshot of what     |
| 13 | Ohio looks like. We're the seventh largest        |
| 14 | Medicaid state. We cover over three million       |
| 15 | people and close to 90 percent are in managed     |
| 16 | care, with efforts underway to get everybody into |
| 17 | managed care.                                     |
| 18 | We talk a little bit about why, but               |
| 19 | essentially the idea is if you're going to have a |
| 20 | system of care, a basic tenet is get everybody    |
| 21 | into the system. Then once they're in the         |
| 22 | system, identify folks who have special needs and |

then reliably apply evidence-based practice in a way that's patient-centered, so not just patientcentered medical home, but that honors personal choice.

So to your comments about home and 5 community-based services. So that's actually 6 7 what we're trying to do. So here you have the additional populations that we're going to be 8 9 moving in, all the foster and adopted kids, breast and cervical cancer programs. We tried to 10 get the BCMH children in, and we're looking at 11 12 managed long-term supports and services as well. We expanded the Medicaid benefit to 13 14 over 700,000 people in Ohio since 2014, and I'll 15 show you the cost implications of that, and we 16 have about 80 to 100,000 folks in long term care 17 and community supports.

So just a snapshot, if you want to
advance this slide. Here are the age ranges. So
you can see we cover long-term care, so we have
this large elderly population.

22

1

2

3

4

Next, and this is what has happened to

So you'll actually see the family. enrollment. Since we have reproductive health folks here, the family planning waiver folks with a very limited 4 Medicaid benefit is that top blue stripe, and you can see that as the purple expansion population gets bigger, that population pretty much melts into it.

8 So more than 80 percent of the people 9 with that limited family planning waiver got the full benefit with the expansion of the Medicaid 10 So you can actually see where CFC and 11 program. 12 ABD is here. So those parts are not different 13 from any other states. Go ahead. This is what 14 has happened to expenditures. So I think what 15 may show at the most though is this next graph.

16 So we had a -- if you can advance to 17 the next one, or maybe did I take it out? What I 18 wanted to show is that we are capped by JMOC 19 actually, by our legislature, to a three percent 20 growth rate, and even though we expanded to that 21 700,000 extra population, we are still under that 22 three percent growth rate.

(202) 234-4433

1

2

3

5

6

7

| 1  | There's been massive reform in Ohio to            |
|----|---|
| 2  | try to contain costs, and that's actually one of  |
| 3  | the reasons that we're supporting managed care,   |
| 4  | so you can manage the budget better, and then you |
| 5  | can put all the requirements into a structure.    |
| 6  | So here's the maternity core set, and of the      |
| 7  | three core sets that we're talking about, this is |
| 8  | the one that I actually have least issues with,   |
| 9  | because it actually is most closely aligned with  |
| 10 | what clinicians need to do and what patients      |
| 11 | actually need.                                    |
| 12 | We are very much looking forward to               |
| 13 | getting the specs for the contraception measure.  |
| 14 | What's important about measures too is not just   |
| 15 | the measure itself but to my comments about what  |
| 16 | do you need to manage the population, it directly |
| 17 | correlates to inter-pregnancy interval            |
| 18 | measurement at a population level for a high risk |
| 19 | population level.                                 |
| 20 | So that's a great example of                      |
| 21 | alignment. The adult quality grant was very       |
| 22 | useful to us because it provided the resources to |
|    |   |

get all of the coding and all of the work done. So that's actually one of the enabling factors for volunteer reporting, is providing the resources to actually get the initial work and then just maintaining the reporting is actually not that difficult.

7 There were comments related to the 8 antenatal steroids earlier. We totally agree 9 with our Perinatal Quality Collaborative. We actually looked to see what happened with 10 11 antenatal steroids and it turns out that patients 12 were actually getting it. It just wasn't being 13 documented or captured between inpatient and 14 outpatient and other settings. So we absolutely 15 agree.

We would suggest, however, that in our population health management mission that all of the measure sets actually tie in population health measurement, even if it's more difficult. So for example in this set, be very helpful to have preterm birth rates. So what are we trying to move in maternity care? We can probably

> Neal R. Gross and Co., Inc. Washington DC

1

2

3

4

5

prevent half of all preterm births in the
 country, half.

So if we can move agencies and 3 4 entities towards knowing what preterm birth rates are, identifying women at risk for preterm birth 5 and then reliably getting them, you know, 6 7 progesterone antenatal steroids, delivering in 8 the right setting, you know, kind of a 9 standardized package of things that actually helps outcomes, that is really, really helpful. 10 11 Okay, go ahead. So what I'd like to 12 point out here is what performance has been over 13 the last 20 years or so. So this is postpartum 14 care, and you can see the line there from 1998, 15 and then you can see the line here. I'm trying 16 to read the -- the dotted red line is actually 17 average. Now it's about five percentage points 18 difference. 19 So in 20 years, I would argue we 20 should be able to do better than just a five 21 percent difference. So we need measures that are

actually actionable and easily understood. So

Neal R. Gross and Co., Inc. Washington DC

one of the reasons for this is women lost their coverage after the babies were born, and then our highest risk women actually never show up for a postpartum visit.

So the health system itself, in a fee-5 6 for-service universe, does not know who's not So as systems have 7 there. Does that make sense? 8 transformed, we've gone to 100 percent 9 attribution model? So in Ohio, every single person who's eligible for Medicaid will be 10 11 assigned to a primary care clinician and 12 practice, and somebody knows to be looking for 13 that.

14 So to my concept of get everybody in 15 the system and makes sure someone knows, it's 16 also a reason that managed care is helpful. So 17 that's actually one of the reasons for poor 18 performance. This also is a great measure 19 because it is marker for who -- which children 20 may die. 21

21 So in our state, the lack of 22 postpartum visit is correlated to infant

> Neal R. Gross and Co., Inc. Washington DC

1

2

3

mortality. So again tying to a population health measure is a really important piece. So the postpartum visit is an opportunity, and then we have to talk a little bit more about what really happens and can it be at home and in other settings as well. Okay, next.

7 What I would like to show is that 8 there is a difference between MACPRO and what we 9 do with HEDIS, which is Medicare managed care So there's some duplication. 10 only. So to the 11 extent to which we can eliminate duplication, 12 that's great. So if our state were 100 percent 13 managed care, then actually there would be no 14 usefulness in reporting something that has this tiny little fee-for-service. 15

16 The trends often go the same 17 direction, but I'll show you that for some other 18 measures they don't correlate at all. What we 19 have done here is we've separated it by managed 20 care plans, because if we have managed care 21 plans, they have to know how they're doing as 22 well. So we want measures that matter at the

1

plan level as well.

| 2  | The idea here would be if one plan is             |
|----|---|
| 3  | doing a whole lot better, the other plans can     |
| 4  | talk to them to figure out what did you end up    |
| 5  | doing, especially if it's about preterm birth or  |
| 6  | infant mortality. We are not competing on         |
| 7  | safety. So if they have figured out mechanisms    |
| 8  | or ways to work with communities, we actually     |
| 9  | want them to work together.                       |
| 10 | In the current environment, there's               |
| 11 | actually no good way for entities to work         |
| 12 | together. So I'll show you some examples of what  |
| 13 | we've done with this particular measure that gets |
| 14 | us there. Go ahead. So reporting challenges.      |
| 15 | The administrative burden, duplication of effort. |
| 16 | Some measures with hybrid methodology simply      |
| 17 | measure the amount of effort that the plans take  |
| 18 | in pulling records to get their numbers to look   |
| 19 | better.   |
| 20 | They're not actually getting more                 |
| 21 | people to their postpartum visit, for example,    |
| 22 | and I have a graph to show you the difference     |
|    |   |

between those. So if you really want a measure, 1 2 it needs to be the same across the board, so that you're measuring something that's close to the 3 4 person. 5 So you can presume that the error in documentation is, you know, the delta is about 6 7 the same. So just measuring administrative 8 effort is just not at all on target for what 9 people actually need, and it will never get you to outreach efforts, for example. It just gets 10 11 to, you know, pulling charts. 12 Although I would say that if our EHR 13 vendors standardize certain things, that would 14 really help. So the measures have to be meaningful at the practice or at the best 15 16 evidence level. So that's actually a litmus test 17 for us as well, and then managing the work load. 18 As I mentioned before, all the coding that goes 19 into it. 20 The other thing is I heard the note 21 that the measure needs to be useful for driving

improvement and some are and some aren't. You

Neal R. Gross and Co., Inc. Washington DC

don't really know what a good number is and what you're supposed to be.

Go ahead. So here's an example of 3 4 timeliness of prenatal care matching. MACPRO 5 matches HEDIS in this particular one. But if you go to postpartum visits, which is the next slide, 6 you'll see that it doesn't. So they don't 7 8 totally -- so what are we supposed to do with 9 that, right? So since our leverage point is with 10

11 managed care, the only thing we can really manage 12 is the managed care number, unless we want to go 13 to 30,000 different providers and try to figure 14 out how to standardize what they're doing in fee-15 for-service.

Next. This is the example of hybrid, which are the straight lines on the top, versus administrative only. So you'll notice administrative only sort of line up. I just did it for a year. But the other just measures the effort that the plans did to make certain marks, and what happens for us is by contract, if

> Neal R. Gross and Co., Inc. Washington DC

1

they're less than a 25th percentile nationally, we find them. So you'll notice they'll all be clustered around the 25th percentile.

We have other things we can do to 4 5 drive measures like auto -- what we've done for the maternity measures, is we have measures that 6 7 include the low birth weight CHIPRA measure, the 8 pre- and postpartum visits as well as we want to 9 do preterm birth weights, and that's how autoassignment happens. They don't get new families 10 11 unless they're doing a good job for that 12 population.

So the other method that you can use is we've clustered pay-for-performance measures around reproductive health, because essentially managed care plans manage money. They actually don't manage people. So for them to manage a population, you know, they didn't get the memo, we have a new job. They didn't get that.

20 So essentially they chose Medicare-21 like patients, the diabetic hypertensive in the 22 hospital or SNF. We missed 100 percent of all

> Neal R. Gross and Co., Inc. Washington DC

1

2

the \$3 million babies and of course the impact on 1 2 the life and life trajectory for those families is incredible. 3 4 So those were the things that we did 5 within the program that can actually move a measure, as examples of why measures could be 6 useful. But again, if we can stick to 7 8 administrative, we can get rid of kind of the 9 noise in the system. Go ahead. So issues for 10 11 consideration. We want voluntary reporting, but 12 I think all the caveats about if it's actually 13 useful to the state, you won't have a single bit 14 of trouble getting voluntary reporting. So if it's in line with what we have to do, absolutely 15 16 no problem, especially if there's some technical 17 assistance. 18 We have to transition from reporting 19 only to moving population health outcomes. So 20 that focus actually changes what our measure 21 does, and I mentioned the rest. 22 So go ahead. So this is a measure of

alignment. If you want to move the yellow box,
it has to matter at the patient and at the
community on the bottom. It has to matter at the
clinician and health system and the managed care
plan, and then it has to translate into the
population, which of course is what you want us
to report at the very top.

8 So unless you can follow the yellow 9 boxes, what we see is mutually harmful activities, you know. One thing doesn't help 10 11 another. So I like this graph just because 12 people can kind of get it intuitively. Go ahead. The other thing to take into consideration is 13 14 what levers do we have to actually move the 15 measure.

So this is in Ohio and in other 16 17 states. Many of them are SEM states. We have 18 two different ways we're doing that. One is 19 through episodes of care. So if we're moving the 20 measure a different way and the reporting doesn't 21 count the same, then we're just creating extra So what we've shown here is a perinatal 22 work.

episode of care in the red, and the four measures 1 2 that go with it, and you'll notice the postpartum visit rate is right there, along with the 3 terrible status of 50 percent showing up is a 4 standard that's met by 75 percent of the 5 clinicians in Ohio. 6 7 Half are getting discharged into the 8 I mean it's painful for me to look wilderness. 9 So that's a very powerful lever. at this. Next, and then what happens is at the 10 clinician level, so to my point about the 11 12 alignment, they get a map of where they are costwise. 13 But on that red grid there, they get a 14 checkmark or an X if they're actually passing that 50 percent quality, pseudo-quality bar. 15 So we've tried to make the data transparent to the 16 17 alignment. 18 Go ahead. So issues for 19 consideration. You already mentioned the 20 difference in ages. So what we need to do is 21 follow populations longitudinally. So do our

measures actually do that, and I'll give you the

Neal R. Gross and Co., Inc. Washington DC

well child example. If we can see that
 altogether, then we actually have a different
 view of the gap.

4 And then the measures need to hang 5 together as indicators of the health of the population. So do they do that. So that's 6 7 actually another question, and it's a good way to 8 actually look at gaps. And then I mentioned 9 here, even though I'm not part of the pediatric set, I have just have to talk about school 10 11 performance as a massive, massive gap.

12 So as a pediatrician, the way I know 13 my kids are doing well is they're thriving in 14 school, and then we already referenced social vulnerability measures and composite measures 15 16 that actually could be really helpful. So 17 there's been a bit written, and then population 18 health measures. Interpregnancy intervals 19 specifically and preterm birth dates are 20 important for the maternity core set. 21 Then just to mention what measures are 22 important in actually saving lives. So we have

two massive public health crises in the country, infant mortality, particularly disparities in infant mortality and the opioid and drug problem. So you mentioned the opioid part. I'm just wondering if we can add the infant mortality and preterm birth part.

7 Go ahead. So we all want smart 8 measures that are aligned, and we should give 9 some consideration to composite measures too so that there's a view. It's almost like writing a 10 11 term paper. You put everything on the table and 12 then you pull it together in a way so that 13 intuitively people can understand what you're 14 doing.

So I'll give you some examples. 15 So 16 what we've done in Ohio is instead of laundry 17 list of all the good stuff, we have this 18 depiction, which I described to you before, of who the people are in Medicaid. We have healthy 19 20 adults and kids along the first stripe. We have 21 women of reproductive age. You notice they get their own stripe, those with chronic conditions 22

> Neal R. Gross and Co., Inc. Washington DC

1

2

3

4

5

1 and behavioral health issues.

| 2  | Then on the right side, you can see               |
|----|---|
| 3  | the key measures we're actually going to move.    |
| 4  | We're going to move preventive screens. We're     |
| 5  | going to reduce preterm birth and infant          |
| 6  | mortality. We're going to integrate behavioral    |
| 7  | health to your earlier comments, and then if you  |
| 8  | have a chronic condition, we're going to manage   |
| 9  | it well.  |
| 10 | At the very top of that, by design, we            |
| 11 | are actually not going to tolerate a gap based on |
| 12 | race or place. So unless we design it for that,   |
| 13 | we want to do each measure by that. We have       |
| 14 | difficulties getting race data because minorities |
| 15 | are the ones who actually don't volunteer race,   |
| 16 | and we're not allowed to require it now that      |
| 17 | you're not going to the counties anymore. So we   |
| 18 | lost our racial gap.                              |
| 19 | So what we've done is we've mapped the            |
| 20 | state by disparate communities, and we're doing   |
| 21 | the measure by those communities compared to the  |
| 22 | rest of the state, as a way to get around it.     |

I'm going to show you some examples. So how to make measures meaningful.

Go ahead. What we have is we're holding the plans accountable. So what you have in the three stripes are actually the three population streams, and if you're a plan, pick your color and then see how you're doing across the entire thing, so that you have a view of your population.

So what this has told us is our 10 11 managed care plans don't pay attention to women 12 of reproductive age, sadly. So this is a way to 13 actually drive improvement. So on the bottom 14 here we have prenatal care, postpartum care and I 15 can't quite read the last one. But you can pick 16 one of the plans, and this is all public, so you 17 can actually pick UHC or Centene, Buckeye. You 18 can pick your plan and see. Go ahead. 19 And what I want to show here is that

20 longitudinal view. So in the blue, we have well
21 checks and the black on top are the older
22 preschool kids and then the bottom line is

Neal R. Gross and Co., Inc. Washington DC

1

So at one view, I have an idea of 1 adolescents. 2 what's happening to well care for children. But unless they're clustered together, I don't have a 3 4 view to be able to tell the primary care docs 5 hey, you guys need to show up at school where the You can't just rely on preschool 6 teenagers are. 7 office visits, just as an example. Go ahead.

8 Then by plan, we actually show them 9 which measures are improving how much, and then also what their patient satisfaction is along the 10 So we've seen, for example, that plans 11 bottom. 12 pay patients \$20 for their A1C or something like 13 that could be drawn, and you know, to me as a 14 primary care doc that just makes me crazy. I'm like you're just making your numbers better. 15

16 If you paid the cab ride or found 17 them, I would have taken care of their 18 depression, made sure they didn't run out of 19 medicine, made sure they're not alone, you know, 20 et cetera, et cetera. So this kind of feedback 21 to the plans is really, really important if 22 they're accountable, and you can imagine the next

thing is going to be feedback to the health
 systems and the clinicians as well, and that's
 what's coming.

4 Next. In primary care, we organized 5 it the same way, and you notice we have a number of women's health measures. So in primary care, 6 we're saying you're responsible for low birth 7 8 weight babies. You're responsible for timely 9 prenatal care. Guess what happened? You can't make us responsible. We don't know who they are. 10

11 I'm like you're taking care of the 12 preemie. Do you not know when the mother is 13 pregnant? Do you think you can help her get 14 progesterone, and every time we ask these kinds 15 of questions it's yes, yes, yes. So we are 16 totally investing in reorganizing the primary 17 care infrastructure, specifically with measures, 18 certain measures in mind that we're hoping 19 totally line up with all of our quality and 20 federal partners. 21 We totally revamped this when AHAB

22 came out with theirs. We had it kind of

Neal R. Gross and Co., Inc. Washington DC

www.nealrgross.com

solidified between Medicaid and the top five 1 2 payers in Ohio, and then we kind of revamped trying to -- this is claims-based. We realized 3 4 we need to go to eCQMs, although that year 5 requirement, 11 out of 12 months eligibility. 6 It's a huge problem. We have to tell people how 7 they're doing as they go. So it needs to -- what 8 we've done is we've done a rolling year of 9 eligibility. So even eCQMs won't actually solve this for us. Go ahead. 10

So then what I really want to show is improvements are local. So you have to tell communities how they're doing. This is preterm birth rates by the three largest cities, so that if one city is doing better than another, again they can help each other, just like the plans can.

And then to make it real, we have the targets for improvements that would be real. How many preterm babies do you have to save to actually make that be a real difference and not random. So we have to bring the math and science

> Neal R. Gross and Co., Inc. Washington DC

www.nealrgross.com

1 to it as well.

| 2  | Next. Community members don't do                  |
|----|---|
| 3  | graphs really. You have to make this information  |
| 4  | intuitively obvious, and so we have color-coded   |
| 5  | it so that you can compare the big three C's, you |
| 6  | know, Cleveland, Columbus, and Cincinnati, how    |
| 7  | are they relative to each other. So I would       |
| 8  | suggest that the first city, which is the         |
| 9  | Columbus area, needs to go help Cincinnati, which |
| 10 | is on the right as it relates to this measure.    |
| 11 | Then what you see on the bottom is                |
| 12 | Franklin County, a trend over time, which is also |
| 13 | important. You have to tell communities are you   |
| 14 | getting better or not. It turns out that in       |
| 15 | Franklin County, we have a massively organized    |
| 16 | effort with all the health systems. In 1-800      |
| 17 | give me a prenatal visit today, taking            |
| 18 | progesterone to scale and safe sleep. So this     |
| 19 | would suggest that that's actually working.       |
| 20 | Next. So then you have to tell the                |
| 21 | plans how they're doing by population. Again,     |
| 22 | this is not their main business or they didn't    |

| 1  | think it was but it is. And then next, what I     |
|----|---|
| 2  | want to show you is that even though we have an   |
| 3  | infant mortality crisis in Ohio, prenatal care    |
| 4  | and postpartum visits still are awful.            |
| 5  | So we have everybody saying we want to            |
| 6  | help but we can't do the very basics. So this is  |
| 7  | actually news to them. So that's actually what    |
| 8  | we need to do. I think I'm actually wrapping up   |
| 9  | here. Is that it?                                 |
| 10 | Then what we did for those top five               |
| 11 | measures is we did for those top five measures is |
| 12 | we actually have this scorecard, and we have in   |
| 13 | gray highlights demographically similar           |
| 14 | communities, so that you can see relative         |
| 15 | ranking. We actually give this to the             |
| 16 | communities on a quarterly basis, in conjunction  |
| 17 | with our public health partners.                  |
| 18 | So that's actually what we use your               |
| 19 | measures for. This may really far away from what  |
| 20 | you're thinking that we're talking about, but to  |
| 21 | make it useful, that's actually what we've had to |
| 22 | do. So to the extent to which we can do this for  |

| 1  | an entire population stream that's standardized, |
|----|--|
| 2  | so that you know where the gaps are and where    |
| 3  | you're losing people, that's really, really      |
| 4  | useful to us.                                    |
| 5  | So that's it. That's actually the                |
| 6  | Medicaid community measure view. Thank you.      |
| 7  | CO-CHAIR ANTONELLI: Thank you very               |
| 8  | much. We're going to take some time to get some  |
| 9  | comments and questions now from the Task Force.  |
| 10 | Thank you Mary for stepping in, and we have our  |
| 11 | CMS presenter on deck. So I see your last is     |
| 12 | it Sue Kendig? Yeah. Your cup was in the way.    |
| 13 | So we'll go Sue and then Clark, and then over    |
| 14 | here. Okay.                                      |
| 15 | MEMBER KENDIG: That was great, thank             |
| 16 | you. I have a couple of questions for you. I     |
| 17 | have a lot of questions actually. So you talked  |
| 18 | about first of all, you talked about             |
| 19 | postpartum visits and how they correlate with    |
| 20 | infant mortality, and then on Slide 163 I missed |
| 21 | your comment. You said something about they      |
| 22 | missed all of the \$3 million babies.            |
|    |  |

| 1  | So my first the first part of that                |
|----|---|
| 2  | question, I guess is do you have a little more    |
| 3  | background on how missing that postpartum visit,  |
| 4  | how is that sort of the red flag around infant    |
| 5  | mortality?  |
| 6  | So that's a great question. So a                  |
| 7  | separate effort is actually doing predictive      |
| 8  | modeling. So we took five years of infant         |
| 9  | mortality in Medicaid and then got all of the     |
| 10 | information we could about social determinants in |
| 11 | claims, to try to figure out what might be a      |
| 12 | marker.   |
| 13 | DR. APPLEGATE: So the analysis not                |
| 14 | totally done, but there's a two to two and a half |
| 15 | times higher rate for infants dying for mothers   |
| 16 | who don't show up at a postpartum visit. So it's  |
| 17 | a marker for other things. Do you have            |
| 18 | transportation? Does someone even care about you  |
| 19 | to show up? Is it useful to you?                  |
| 20 | There's all that other stuff that goes            |
| 21 | into it that I actually think is part of it,      |
| 22 | which is part of my request to really look at     |
|    |   |

social vulnerability types of measures, which may correlate more, but I don't have a claim for it. So it's a proxy for other things.

4 MEMBER KENDIG: Yeah. That was what 5 I was wondering, because doing similar work in Missouri, we're actually familiar with some of 6 the things that are going on in Ohio like Cradle 7 8 Cincinnati and I think Columbus has an effort, 9 Jay Iams's effort at Ohio State, and I'm wondering when you're talking about all of these 10 11 markers and the social determinants and so forth, 12 because you commented on even though everybody 13 wants to work on this, we still have these 14 declines -- you know, we still have high rates of no visits and so forth. 15

16 How are all of those community-based 17 efforts that one would think are addressing 18 social determinants that would then impact this? 19 Do you have a sense on how we can better capture 20 that, because that was a discussion yesterday. 21 DR. APPLEGATE: Yes. So one thing I didn't reference is that Ohio has invested over 22

> Neal R. Gross and Co., Inc. Washington DC

1

2

\$26 million through managed care into the high priority communities, specifically to end the infant mortality disparities gap. What we did is we asked the communities what do you think you need. This was on the heels of City Match or the Ohio Equity Institute.

7 That process was not necessarily 8 neighborhood friendly in that they had all this 9 science of picking upstream and downstream 10 measuring, what do you want to do and they landed 11 on something like progesterone and then realized 12 they didn't have what they needed to actually 13 move it.

14 So we developed a scorecard of 15 community-based efforts that started with how 16 many African-American women actually showed up to 17 community events, Every Day Democracy, racism 18 discussions.

We don't here in these circles
necessarily realize how hostile the health system
is and how dis and untrusted we may be in a lot
of the communities of color. We absolutely do

Neal R. Gross and Co., Inc. Washington DC

1

2

3

4

5

1

not appreciate that.

| 2  | So we're simply measuring African-                |
|----|---|
| 3  | American women show up to events, and then how    |
| 4  | many get into evidence-based programs like        |
| 5  | Centering, using community health workers or home |
| 6  | visiting, those three efforts, because the Safe   |
| 7  | Sweep and general education is kind of canvassed  |
| 8  | over all of them.                                 |
| 9  | So the jury's still out on that. I                |
| 10 | think our legislature wants results yesterday.    |
| 11 | It's taken decades to get there. I asked them     |
| 12 | please to give us three to five years to at least |
| 13 | figure out better indicators, and I do think the  |
| 14 | big gap there is around the social vulnerability  |
| 15 | pieces, and I also again acknowledge for women of |
| 16 | reproductive age, we will get absolutely nowhere  |
| 17 | without the Department of Education.              |
| 18 | We must get African-American women                |
| 19 | educated out of high school, delaying their first |
| 20 | pregnancy as a direct link to poverty. So we've   |
| 21 | learned this from third world countries and       |
| 22 | Bangladesh is probably one of the best examples,  |

in which family size was seven to begin. They undertook an effort like this. Family size went down to two, and guess what happened? These were the women we gave microloans to. They have their own businesses and actually brought themselves out of poverty.

7 So we must learn from the rest of the 8 world, but without education, you know, again 9 this alignment. We actually will never able to 10 meaningfully impact the health of our -- the 11 women in our program as much as we could.

12 Yes, so the postpartum visit. We also 13 have this adult-quality grant, where we try to 14 improve postpartum visits, and it was all about 15 connecting to the women. The women are very 16 isolated, interestingly enough. They're alone, 17 frightened, distrustful of everyone, often 18 traumatized, and so just accessing the system or 19 having it mean anything to them, you know, those 20 are the issues that we actually ran into. 21 So it's a marker for those other things, but then you can have a plan for it. 22 If

Washington DC

1

2

3

4

5

6

www.nealrgross.com
| 1  | you have a way to identify who are the pool of   |
|----|--|
| 2  | people to focus those efforts on, we can.        |
| 3  | Totally separate for opioid-challenged mothers,  |
| 4  | by the way. Yes.                                 |
| 5  | CO-CHAIR ANTONELLI: So I want to make            |
| 6  | sure that I focus this. I mean I'm glad that I   |
| 7  | flew to Washington today just to hear you speak, |
| 8  | even though the Cavaliers beat the Celtics.      |
| 9  | DR. APPLEGATE: Yeah, sorry about                 |
| 10 | that.  |
| 11 | CO-CHAIR ANTONELLI: This is awesome,             |
| 12 | but that said, I want to keep people, you know,  |
| 13 | be mindful these as much as we'd like to         |
| 14 | applaud this, think about this in the terms of   |
| 15 | the themes that we need to do to promote         |
| 16 | measurement, what some of the challenges are of  |
| 17 | the state. So we and we can talk a little bit    |
| 18 | about Ohio-specific challenges and opportunities |
| 19 | that engage.                                     |
| 20 | So I want to go to Clarke and then I             |
| 21 | think it was Terry, Ann and then over to Diane,  |
| 22 | and then I think we probably only have until     |
|    |  |

| 1  | about 10:00. Oh, and then Harold. We have only    |
|----|---|
| 2  | until about 10:20, because our CMS colleague is   |
| 3  | here next. Will you be here throughout the day    |
| 4  | today?  |
| 5  | FEMALE PARTICIPANT: Yes, yes.                     |
| 6  | CO-CHAIR ANTONELLI: Okay, Clark.                  |
| 7  | MEMBER ROSS: Thank you. I had two                 |
| 8  | questions on the Buckeye Dashboard, Slide 171.    |
| 9  | You have four population groups on the right-hand |
| 10 | column. Are there other targeted population       |
| 11 | groups, and specifically I'm thinking about       |
| 12 | children with intellectual developmental          |
| 13 | disabilities.                                     |
| 14 | DR. APPLEGATE: So we did not take out             |
| 15 | children with special health care needs           |
| 16 | separately, because this is the place we're       |
| 17 | starting, and then I think that's actually a next |
| 18 | layer, as is the home and community-based         |
| 19 | services population. So we have a whole bunch of  |
| 20 | work around that, but it doesn't show up at a     |
| 21 | dashboard that's at this high level.              |
| 22 | MEMBER ROSS: Okay, and then the                   |
|    |   |

second question is how you deal with co-occurring 1 2 folks. So 40 percent of individuals in the state developmental disability systems across the 3 country also have a co-occurring mental illness, 4 5 and most everybody tends to separate behavioral health out and children's special needs or 6 7 persons with disabilities. So how do you think 8 about and cross-walk this co-occurring dynamic? 9 DR. APPLEGATE: So we put them in the behavioral health bucket, if that was their 10 11 primary -- on a claim if that was in the primary 12 spot on the claim. So at least half of the 13 disabled population actually is in that behavioral health condition. 14 So we have a map of what percent of 15 16 our population has which co-occurring conditions, which -- I didn't include it here. But that was 17 18 specifically to give the plans a view of who we 19 are trying to take care of and what their needs 20 are, and we have more granular stakeholder and 21 other sorts of meetings. 22 In our CPC and primary care

initiative, all of the practices are required to 1 2 have a patient advisory council, and that has directly resulted in, you know, structural 3 4 improvements, better access, different 5 communication, more focus on choice and selfdirected care. It's actually been pretty 6 7 amazing. 8 MEMBER ADIRIM: That was a really 9 great, very informative presentation. Thank you very much. I have very simple two questions. 10 11 One, and you might have said it and I might have 12 missed it, but how many of the adult and the 13 child course, how many of those measures does 14 Ohio report out on? So I have the list. 15 DR. APPLEGATE: 16 We report on about three-quarters of them. 17 MEMBER ADIRIM: Okay, and then you did 18 have a slide on some of your reporting 19 challenges. How do you -- how does your state 20 determine which measures that you want -- is it 21 feasibility? Is it your state-specific 22 priorities? Like what are some of your thoughts

and decisions that go around that? 1 2 DR. APPLEGATE: Right. So we pick the ones that most closely align with actually 3 getting people better. So it's actually not any 4 more complicated than that. 5 We will be working really hard with 6 7 the contraception measure once we get the specs 8 for the reasons that I discussed. It rolls up 9 into a population level and is directly relevant to what the clinician has to do at the point of 10 11 service. 12 So that test was actually the best 13 filter, and I used the postpartum example as an 14 example for why we report. We lined up the TA, the adult quality measure grant with our TY 15 16 project. The measures at the clinician practice, 17 primary care specialist, episode level, plan 18 level. I mean it was an example of what you can do with a measure that actually --19 20 Now we moved to the community, 21 hopefully help move that postpartum visit to

actually help address the issues related to

Neal R. Gross and Co., Inc. Washington DC

22

infant mortality and disparities. So that's the
 reason I used the postpartum measure. So it was
 no more complicated than that.

MEMBER GREINER: Great presentation 4 5 and impressive what you're doing in Ohio. You mentioned that you were reorganizing primary 6 7 care, and I had a little bit of an answer to my question, which was how are you doing that 8 9 through CPC+ and maybe other ways as well. Do you feel like the measures reflect what you're 10 11 trying to achieve with reorganized primary care? 12 DR. APPLEGATE: What's new in primary 13 care is bringing the sort of focus to the 14 populations they serve. So even patients that

are medical homes still largely were fee for 15 16 service. That's all about can the plans and 17 other payers, so not just public payers, but 18 private plans, can we get together and tell 19 practices these are the people who were in a behavioral health institution five counties away. 20 21 These are the people who showed up with admissions and ER visits, so that they can work 22

1 the list.

| 2  | You do conduct yourself differently if           |
|----|--|
| 3  | you're trying to take care of a population. So   |
| 4  | the measures that are actually in there are a    |
| 5  | start, but I think the real deal is can we feed  |
| 6  | back information in a timely way. So again, you  |
| 7  | know, maybe that rolling eligibility piece based |
| 8  | on an attribution model, that then allows for    |
| 9  | financial gain if you do a better job.           |
| 10 | So that's the other part with fee for            |
| 11 | service, is the measures absolutely must be      |
| 12 | amendable to value-based purchasing. So that's   |
| 13 | the other thing that perhaps I didn't say quite  |
| 14 | so plainly.                                      |
| 15 | MEMBER JONES: Did you do any                     |
| 16 | breakout? I mean you focused kind of on the      |
| 17 | urban areas. Did you look at y our rural areas?  |
| 18 | I know access, especially in the obstetrics      |
| 19 | space, is really a huge concern in rural areas   |
| 20 | and one that's getting worse.                    |
| 21 | One of the concerns that we hear a lot           |
| 22 | from providers is that their statistics look     |
|    |  |

horrible compared to these urban providers, for 1 2 reasons that are kind of outside of the controls. I had -- one Colorado physician to me 3 said I'm not going to stop providing birth 4 5 services, but I keep getting dinged by the insurance companies in her case, and was being 6 7 pestered by the state Medicaid agency because she 8 has a higher C-section rate during the winter. 9 Well, she says I have patients that live two 10 hours away and there's a snowstorm and there's 11 going to be no ability to even helicopter them 12 out. 13 So there's always that concern about 14 kind of the measurement in that rural space and we kind of balance those competing criterion. 15 16 But I guess I'm just curious if that's something 17 you guys have looked at, if you've kind of looked 18 at those rural numbers, looked at kind of the 19 places where they're stopping providing obstetric 20 services, what the impact on prenatal care, all 21 of it, yes. DR. APPLEGATE: So we have looked at 22

| 1  | that, and you'll be surprised to note that some   |
|----|---|
| 2  | of our rural counties actually do better. I       |
| 3  | think there are less malpractice concerns because |
| 4  | their relationship with their patients is         |
| 5  | actually better. I think the biggest issue we     |
| 6  | have is not delivering a really high risk baby at |
| 7  | a Level 1 hospital. I think that's actually part  |
| 8  | of it.  |
| 9  | What we found with expansion is that              |
| 10 | our advanced practice nurses really stepped up to |
| 11 | fill the gap, and as we've had a broader array of |
| 12 | workforce, we've actually done less inappropriate |
| 13 | intervention it appears. So for example, our      |
| 14 | advanced practice nurses do the best in all of    |
| 15 | our perinatal episodes, interestingly enough.     |
| 16 | So to me this is fantastic, you know.             |
| 17 | From the lowliest, you know, come the greatest    |
| 18 | and interestingly enough even within Medicaid,    |
| 19 | we're out-performing some of the commercial       |
| 20 | payers in some areas. So we acknowledge that      |
| 21 | transportation and communication we have areas    |
| 22 | that don't even have cell service, in Appalachia, |

Neal R. Gross and Co., Inc. Washington DC

I

for example.

1

| 2  | So while we acknowledge that, I think             |
|----|---|
| 3  | if we get to the social determinants measure ever |
| 4  | and put those two things together, that will give |
| 5  | us a better view.                                 |
| 6  | CO-CHAIR PINCUS: Terrific                         |
| 7  | presentation, Mary. So a lot of what you          |
| 8  | describe in terms of your efforts, I think some   |
| 9  | of the undercurrent around it is really built     |
| 10 | around the notion of what I term ruthless follow- |
| 11 | up, not letting people fall through the cracks.   |
| 12 | To do that, you need to have sort of              |
| 13 | the an appropriate sort of structural             |
| 14 | infrastructure, at both the practice level and    |
| 15 | also at the plan level. How are you trying to     |
| 16 | make sure that that's there and that's booked?    |
| 17 | What are some are using some and it follows up    |
| 18 | on some of the stuff that Ann was talking about.  |
| 19 | How are you making sure that that                 |
| 20 | infrastructure is actually there? To what extent  |
| 21 | are you using some of these recognition programs  |
| 22 | and other kinds of programs, both in terms of     |

sort of information system infrastructure but 1 2 also, you know, the practice care management infrastructure to track these populations? 3 DR. APPLEGATE: Yes. That's actually 4 5 a great question. What I didn't include is perhaps one of the points of biggest contention, 6 7 and that is whose job is what, right? There has 8 to be an assignment of roles and responsibilities 9 including hearing the patient voice, right. So in our primary care model, we actually have 10 practice requirements, like 24-7 access to 11 12 someone who can diagnose and treat and actually 13 have the EHR. 14 That doesn't mean we're recreating 15 emergency rooms, because a lot of times you 16 simply need to talk to someone and try to understand what's going on. 17 There are 18 requirements around team-based care, risk 19 tiering, population management, the patient 20 experience, and then there are efficiency 21 measures about ED use, inpatient stays, generic 22 prescribing, for example.

(202) 234-4433

On the plan side, this is the 1 2 controversy, what are they to do? They must be responsive, even if the person has not agreed to 3 be in official care management that has all these 4 5 requirements around how fast you do the assessment and if you have a delegate you find 6 7 them if they haven't done things. 8 That is not what practices need. They 9 need things like you know what? The VH provider won't call me back. 10 I have transportation 11 issues. They can't understand me accent-wise or 12 language-wise. Those are the things that the 13 plans can actually help with. But I would 14 suggest that as much as care management is a huge part of our managed care plan program, there 15 16 could be other entities closer to the ground who 17 do it better. 18 So right now in primary care, they're 19 responsible -- the primary care clinicians are 20 getting this per member per month fee from one 21 dollar for a well child to \$22, I think, for the

> Neal R. Gross and Co., Inc. Washington DC

third tier risk, and that's actually how they're

22

1 spending their money is on -- we thought it might 2 enhance primary care fees, so that we wouldn't burn out the clinicians guite so much, because 3 4 they wouldn't have to see 30 people in a day. 5 But it turns out they simply have 6 different types of staff in their office. So the 7 plan requirements really are quite different. 8 They must communicate. 9 Initially, it's a fight over 10 attribution. They don't belong to me, you know. 11 How did you decide this? We are actually 12 structuring specifically quality improvement 13 efforts to get into the nitty-gritty with the 14 plans for how they're communicating this 15 information. 16 Practices still want faxes, and you 17 know what, the plans can't do 200,000 faxes in 18 one day. I mean it's just untenable. So we do 19 have a delineation of roles and responsibilities 20 that go with it. 21 CO-CHAIR PINCUS: One sort of related 22 question is how big are the incentives at the

practice level? We had some discussion yesterday 1 2 that surprisingly, some of the financial incentives, even very easy ways of expanding 3 revenues such as reporting depression 4 5 assessments, are simply not being used at a practice level. So I was curious about whether, 6 7 how large the financial incentives are that you're putting in place. 8

9 DR. APPLEGATE: Yeah. So it's -- so if it's the whole population, it's \$1 per member 10 11 per month for someone who's totally healthy and 12 needs a well check. Fee for service works fine 13 if you don't need much, right. So there's not 14 much incentive there, although there may need to 15 be some outreach or you may need to have your 16 practitioner physically show up at the school.

Up to \$22, and what may happen is if you have someone who has 12 different social risk factors, that's actually not going to be enough. So what has to happen is the health care dollar cannot fix the entire social system, right. That's not actually what we're trying to do here,

but we do need to prioritize which things need to
 be addressed, that actually directly bear on the
 health outcome.

4 CO-CHAIR PINCUS: Thank you very much. 5 We're going to pivot now. So Lekisha Daniel-6 Robinson from CMS is there. So for those of you 7 tracking from a distance, we're going backwards a 8 little bit.

9 MS. DANIEL-ROBINSON: So good 10 morning everyone. Always a little bit of a 11 challenge to follow Dr. Applegate, because she 12 gives such an in-depth view of care within her 13 state. But she is also a part of the driving 14 force around the CMCS maternal and infant health So if we can advance to the next 15 initiative. 16 slide.

This initiative was based on an expert panel, which Dr. Applegate co-chaired along with a couple of other people in the room. So Deborah Kilstein, Carol Sakala were a part of that expert panel, that really worked over the course of a year to identify a number of opportunities that

CMS and states could engage, to improve maternal
 and infant health outcomes.

With that feedback, what we launched 3 the initiative in 2014, really as a way to 4 explore program and policy opportunities to 5 improve outcomes along with our state partners. 6 7 So the effort supports state to improve 8 measurement, obviously engage providers and 9 beneficiaries, identify quality improvement 10 opportunities and more recently to implement 11 value-based payment strategies.

12 Next slide. The activity -- well, I 13 should talk about the strategies very briefly. 14 We identify four key strategies that would be needed to advance the effort. So one, engaging 15 16 state providers and beneficiaries, which you 17 know, has not typically -- when we talk about 18 providers and beneficiaries, has not typically 19 been the realm in which CMS works, but clearly as 20 Dr. Applegate referenced, that is where you're 21 going to see the movement.

22

So we have to figure out ways to get

down to those levels in partnership with our 1 2 Leveraging our federal partnerships. states. So we've worked with the CDC, Centers for Disease 3 Control and Prevention, Office of Population 4 5 Affairs, HRSA and others as a part of this effort, strengthening technical assistance to the 6 7 states and measuring quality and improving performance. 8

9 Some of the key activities of the 10 initiative to date have been an improving postpartum care learning series. 11 I know Dr. 12 Applegate talked a bit about the importance of the postpartum visit, and during the deliberation 13 14 of the expert panel, there was a lot of discussion about using that visit as the 15 16 opportunity to address contraception care. So to 17 think about not just what happened in that 18 pregnancy, but preparing the women for health 19 throughout her life, but also thinking about 20 those things that may need to be addressed to 21 impact a subsequent pregnancy.

22

We have had a contraceptive access

That grant provided funding, a small 1 grant. 2 amount of funding albeit, to 13 states, to collect and report on two contraceptive care 3 4 measures. One is now currently in the child and 5 adult core set. So it's the postpartum contraceptive care measure, and the other is a 6 7 contraceptive care measure for all women of reproductive age. 8

9 So the grant has contributed to the understanding behind, and even the specifications 10 11 in that measure. We've had a mobile messaging piloting project, thinking about the beneficiary 12 13 level. Again, what are the ways we can begin to 14 impart the education that's needed to the 15 beneficiary, and connect them to their care. 16 Then finally as a mentioned, the value-based 17 payment strategy. I'll touch on that briefly a 18 little bit later.

Next slide, please. So at the heart
of all of our activities is the core set. As you
may know, the core set is made up of measures -the maternity core set is made up of measures

from both the child and adult core set. However, I don't like to look at it like that because it really doesn't matter, right?

It's really, you know, it's clearly a 4 5 dyad relationship and the initial core set for children, you know, the membership of the 6 7 committee that was looking at identifying that 8 core set was really thinking about what are some 9 of the prenatal aspects that would impact the 10 outcome of that pregnancy, and then the discussion was picked up once we went -- moved to 11 12 identifying an adult core set, and that's where 13 we picked up the postpartum care measure.

14 Now at this point, I think people want to make sure that measures related to improving 15 16 perinatal care are incorporated in the core set. 17 And so, you know, I think you'll find some in 18 either core set. So there's antenatal steroid 19 and the adult core set. However, that's really 20 about improving the function of the potentially 21 pre-term baby.

22

1

2

3

So I'd like to look at the core set

for maternity care as a whole, whichever side it fits on, you know, it fits on based on your deliberations. But it's really about impacting those outcomes. Next slide, please. So the measure is related to maternity or perinatal care in the

7 child core set. So two are really well reported
8 on by our states. It's the well child visits
9 within the first 15 months of life, as well as
10 time limits of prenatal care.

Some of the others are a little bit less frequently reported but still have a high number of states reporting, and then I would say the behavioral health risk assessment is probably the lowest for a number of reasons in terms of feasibility at the state level.

Next slide. The postpartum care rate,
as you can see, is one of the more frequently
reported measures by states, and then less so are
the antenatal steroids and the elective delivery
measure.

22

1

2

3

4

5

6

Next slide. So I just wanted to share

briefly some of the more recent -- the most 1 2 recent reporting of some of the key measures. Timeliness of prenatal care is at about 82 3 4 percent. This is based on federal fiscal year 5 2015 reporting, you know, which is the most recent data that we have available to us. 6 Next slide. The frequency of prenatal 7 8 reporting is at 64 percent. 9 Next slide. Low birth weight infants. You know, I think we continue to see -- I think 10 11 there some consistency in this rate at 8.9 12 percent, and obviously if you were to look at a 13 map, there are some areas that -- where the 14 disparities are a lot greater, on probably all of 15 the measures related to prenatal care, but 16 certainly this one. 17 And then finally the postpartum care 18 rate at 58 percent. So one of the things we did 19 as a part of the maternal and infant health 20 initiative was to really focus on the postpartum 21 care rate. At 58 percent, there's certainly some 22 opportunity there. Clearly, Dr. Applegate talked

about what could happen during that visit if we could get them there. So we took a little bit of a look there.

Next slide. We worked with ten states 4 5 on the Postpartum Care Acting Learning Series, which really was to think about ways that could 6 drive improvement in that visit rate within those 7 8 They partnered with their managed ten states. 9 care organizations, Healthy Start sites in their 10 states. They partnered with other local groups 11 to do some pilot tests of change.

12 Now we used the postpartum care 13 measure, and at the outset it's probably useful 14 to say that there are some challenges with it. Α few of them are listed here. There's probably --15 16 well actually no. The last one sort of captures 17 it. But global billing has an impact on 18 assessing whether or not it happens. It also creates sort of a slightly perverse incentive in 19 20 terms of ensuring that it occurs. 21 Therefore, there's also problems with

tracking. So there's the global bill piece,

Neal R. Gross and Co., Inc. Washington DC

22

1

2

3

www.nealrgross.com

which is unintended effects for occurrence and 1 2 there's the tracking of it, and then there's also the fact that the measure only tracks whether or 3 not a visit occurred, and it really doesn't look 4 5 into some of the content pieces. Nevertheless, we find that it's still 6 7 a very useful measure for the reason that we've already discussed. 8 9 Next slide. So that out of the way, 10 we have used it and you know, I would say that 11 with those ten states our findings sort of 12 reflected a bit of your findings, in that 13 connecting women through community health workers 14 or other care coordinator type extenders was very useful in the states that pilot, did some pilot 15 16 activities to improve the visit rates. 17 And then the other, which was, you 18 know, very low tech, very small but was found to 19 be very significant was just reminding women 20 about the postpartum visit. Like you know, very 21 basic. But these are some things that the states found could be useful. 22

| [  |   |
|----|---|
| 1  | Next slide. So I talked a bit about               |
| 2  | the content, you know, was missing from the       |
| 3  | visit. So the other aspect that the states        |
| 4  | focused on was how to get how to ensure that      |
| 5  | women were getting what they needed from the      |
| 6  | postpartum visit. In our ten states that we       |
| 7  | worked with, I can tell you that the standard was |
| 8  | very different by state.                          |
| 9  | So some states followed like ACOG                 |
| 10 | standards. There were, you know, I would say      |
| 11 | there are like of the ten states now, only ten,   |
| 12 | there were six different six or seven             |
| 13 | different sets of standards that they were        |
| 14 | following. I mean so a standard is good, right,   |
| 15 | but there isn't that consistency. So the content  |
| 16 | piece, you know, I think is something that still  |
| 17 | needs to be worked on the field.                  |
| 18 | Nevertheless, one of the things that              |
| 19 | we found, which was very helpful, was tying       |
| 20 | reimbursement to things like checklists was       |
| 21 | useful. So one of the states incorporated         |
| 22 | they sort of unbundled their perinatal fee and    |

incorporated a separate payment structure to allow for the postpartum visit and tied certain elements to that visit, including completion of the Edinburgh Postpartum Scale to screen for maternal depression.

6 And then the other was looking at 7 reproductive life planning. So ensuring that 8 contraception counseling was occurring. Those 9 were some of the key aspects that the states 10 found to be helpful in the efforts.

Next slide. So you know, building on the work that -- the pilot work that was done with those ten states, and sort of moving forward and thinking about some of the other activities that are going on in this sphere.

16 So we've had activities such as the 17 major investment CMS made with strong start, 18 looking at approaches to delivering care such as 19 home visiting, birthing centers and others, in 20 addition to some of the QI work that we've been 21 doing, thinking about how we can use that, what 22 other reforms are necessary.

1

2

3

4

5

And so reimbursement is probably that 1 2 big missing piece, where Medicaid financing has not necessarily always kept pace with the latest, 3 and perhaps in the case of maternity maybe not 4 5 even the latest. But the things that we've known from the past 20 to 30 years about what actually 6 has an impact on care. 7 8 So we're working with the Innovation 9 Accelerator Program at CMS to -- of the support states, and thinking about some of those local 10 practices. So whether it's CHW, whether it's 11 12 home visiting or some other things. 13 Thinking about your question related 14 to rural care, what are some of the care delivery models that can help and assist a state with 15 16 improving their outcomes in all of these measures 17 with the reimbursement tied to it. 18 So this is clearly an area that we 19 will continue to use our core set measures to 20 assess the outcomes of. So I think I'll pause 21 there. So more information on the maternal-22 infant health initiative. I just gave you a very

brief highlight. It's available on our website. 1 2 CO-CHAIR ANTONELLI: Thank you very I'm open for comments or questions from 3 much. 4 the Task Force. I can't see the -- yeah.  $\mathbf{Bv}$ 5 tomorrow I'll know your face. Amy, and then 6 Harold. 7 MEMBER POOLE-YAEGER: Yeah, thank you. 8 I just wanted to comment that I completely agree 9 with your comment about the global billing being 10 a huge barrier in this. We have, you know, 11 managed care plans in 23 states. I can tell you 12 the number one correlating factor between 13 postpartum rates is whether there's a lot of 14 global billing in the state or not. So somebody, you know, it does a lot 15 of times reflect the effort that it takes to try 16 17 to find out whether they had one or not, and I 18 always worry about do we really know how many 19 people are going in to get those prenatal visits 20 because of that sort of thing. So you know, 21 anything we can do to try to help, you know, move 22 people toward this does make sense. This is

something we should be tracking. We need to know when they're going in order to be able to help make sure they're getting there when they need to so --

5 MS. DANIEL-ROBINSON: Yeah, and I 6 think we found another state that they -- if I'm 7 not mistaken, they still did the global bill, but 8 they found another mechanism to ensure that there 9 was tracking. So that at least a date was 10 submitted for the occurrence of that postpartum 11 visit.

12 CO-CHAIR PINCUS: I was wondering 13 whether you could expand upon your last goal up 14 there, in terms of informing value-based payment 15 opportunities and how you're thinking about that, 16 and what are the various alternatives you're 17 looking at.

18 MS. DANIEL-ROBINSON: So we're right 19 now in the process of identifying states that 20 we're going to support, and it's really focused 21 on the care delivery models of interest to them. 22 So if they are interested in thinking about how

> Neal R. Gross and Co., Inc. Washington DC

1

2

3

4

to ensure that home visiting services are 1 2 appropriately financed within their state, then that will be that particular state's focus. 3 4 And so we're really leaving it open to 5 the areas and the avenues that the states would like to pursue, but ensuring that they are tying 6 7 the outcomes to, you know, the quality measures. 8 One of the key elements that was necessary for 9 those submitting expressions of interest was that they needed to come with a care delivery 10 opportunity that had some data behind it. 11 12 So you know, it had to show within 13 their local community that this particular model 14 had an impact on outcomes in some way. You know, we're not making it an extremely rigorous 15 16 exercise because, you know, there is -- we don't 17 want to create too much of a burden. But at the 18 same time I think we know enough already about in 19 general, you know, the kinds of models that have 20 an impact on outcomes. So that's how we're 21 thinking. Did that address your question? Okay. 22 CO-CHAIR ANTONELLI: Mary, and then

Sue.

1

| 2  | DR. APPLEGATE: This will be quick,                |
|----|---|
| 3  | thank you. I did want to mention that             |
| 4  | independent of billing, like you shouldn't use    |
| 5  | billing as a way to track your population. So     |
| 6  | the way that we're solving for this, you know,    |
| 7  | these are claims measures. So we're making this   |
| 8  | assumption that that's how you track people. So   |
| 9  | to my earlier comment about what do you need to   |
| 10 | manage a population, essentially every patient    |
| 11 | that you have come to your practice, after you've |
| 12 | done their H&P, their history and physical, you   |
| 13 | have an idea. Like when a diabetic is there, I    |
| 14 | know I need to get these five things one over the |
| 15 | course of the next year because it's part of      |
| 16 | evidence-based care.                              |
| 17 | So if you're an OB, you need to know              |
| 18 | everybody I deliver actually has to be seen. So   |
| 19 | there has to be a flag in your EHR or your paper  |
| 20 | record, if you still have paper, to ensure that   |
| 21 | the person gets seen. So it's separate from       |
| 22 | billing, and I think that's how we did it. We     |

have a 50 percent gain share. If the OB's cost
 for OB care come in less than the state average,
 they get to keep half.

So if you're a small town doc, do you 4 5 know how much money that is for you? That is so much money compared to what is spent in the city, 6 7 realizing you have to pass a 50 percent C-section 8 mark and about 50 percent postpartum visit rates. 9 This is very, very doable. That link to the 10 finances is really important, but you have to 11 change your system at the point of service, so 12 that you know who needs what they show up.

13 MEMBER KENDIG: Just a quick question. 14 In both of the presentations, we talked about measures and sort of impact on infant mortality. 15 16 I'm wondering if there has been any attention to the measures and their link to maternal 17 18 mortality, particularly in light of data around 19 suicides, substance use disorder and so forth? 20 DR. APPLEGATE: So may I comment? 21 That's actually a great comment. Within Medicaid, there's actually tension between 22

measures within the hospital, which we think should be owned and done by the hospital versus those in between systems and at a population level.

5 There's still a lot of maternal 6 hemorrhage out there and for most hospitals for 7 licensure requirements, they actually have to 8 have processes and measurements in place, just 9 like they have to monitor catheter-related 10 infections and ventilator-associated ammonias and 11 that kind of thing.

12 So there are a couple of things. One 13 is kind of postpartum visit count. Anywhere 14 along the first like three months, officially the measure is the end of the month in which the 60th 15 16 day occurred. In the old days, computers only 17 went to accuracy of a month. So can any visit 18 The issue that we have with postpartum happen? 19 visits also is that the, you know, you know what 20 you're going to be doing 51 days from now because 21 it has to be within 56 days.

22

1

2

3

4

So that reminder is actually really

important. These are people who often live day to day. Life is chaotic and uncertain. So the connectivity to maternal harm might be sensitive also to the social vulnerability scores as well. But many of them are within-hospital kinds of measures.

7 MS. DANIEL-ROBINSON: So just to add 8 to that, you know certainly Dr. Applegate 9 addressed it, we are internally looking at maternal mortality separately or thinking about 10 But at the same time we think that the 11 that. 12 care delivered as assessed by the measures in a 13 core set are part of those factors that drive 14 maternal mortality. So we see the core set as still this overarching mechanism to look at the 15 16 various outcomes of maternal care. 17 MEMBER POOLE-YAEGER: I just wanted to 18 add that, you know, I completely agree with Dr.

19 Applegate, that I don't think global billing -20 you know, I don't think that claims is the way to
21 measure.

22

1

2

3

4

5

6

I'm just -- I'm just highlighting the

fact that if you're going to compare states and you're going to look at rates and you're going to say oh, the state is really terrible in a particular rate and this state is really high, it very much varies because there's different billing patterns in every state.

So you know, we need more electronic 7 8 health record connectivity so that we can get a 9 standard playing field for -- it sounds like a 10 lot of what this, you know, Committee wants to do 11 is try to come up with things that we can do to 12 You're not comparing apples to compare states. 13 apples when you, you know, with some of these 14 measures so --

MS. DANIEL-ROBINSON: So I could 15 16 actually pile on, right, if you wanted to. So 17 just a little bit. So even in the data that we 18 have on postpartum care, it's looking at trends 19 is a challenge, because even within states there 20 has been a lot of changes from year to year. So 21 some states report on certain segments of the 22 population, which makes it a challenge to even

1

compare it back to a prior year.

| 2  | Changes in methodologies, just slight             |
|----|---|
| 3  | quirks in the data. So there's certainly that.    |
| 4  | But then at the same time though, we hear I think |
| 5  | anecdotally but with some evidence that the       |
| 6  | visits are not happening, you know. So you know   |
| 7  | again, we put the challenges out there to show    |
| 8  | that we recognize that there are they exist.      |
| 9  | But at the same time, you know, there's still the |
| 10 | opportunity to use them to help drive change.     |
| 11 | CO-CHAIR ANTONELLI: If this is too                |
| 12 | long of a question, we can take it off line. But  |
| 13 | I'm intrigued by something. I really love your    |
| 14 | opening statement about that this is one          |
| 15 | continuum, right. That appeals to me as a         |
| 16 | pediatrician because, you know, my work doesn't   |
| 17 | stop when they leave me. Hopefully I've           |
| 18 | optimized the hand off to the adult side.         |
| 19 | So this really integrative or broad               |
| 20 | expectation from CMS, and then finding a partner  |
| 21 | like Dr. Applegate in Ohio, who's saying give me  |
| 22 | things that actually make an outcome. So I'm      |

sort of celebrating the positive synergy. 1 It's 2 possible that there aren't 51 Dr. Applegates. So for those states that are thinking 3 4 about value-based but in a very narrow way, that 5 potentially could even be somewhat destructive to this broad, because you guys are laying the 6 7 groundwork for what the literature calls a life course approach, and I'm celebrating that. 8 9 But as it -- so now I'm phrasing this as somebody who embraces value-based outcomes and 10 life course. How can we collectively influence 11 12 the dynamic to grow more Medicaid state level 13 leaders, who then in negotiations with their 14 respective MCOs and/or ACOs actually say this is 15 great stuff? 16 MS. DANIEL-ROBINSON: That's a 17 really good question, and I think -- I don't know 18 if Karen has any thoughts on this, but one of the 19 ways I think I would perhaps start is thinking 20 about our projects in general, is that we're 21 really using the states that we're going to 22 support as part of that test case, and you know,
at the end it's not our hope that this just kind
 of goes away and dies, you know, at or maybe I
 shouldn't say die.

But that just sort of lives and 4 5 resides within those few states. I think along the way, we would like to share some of the 6 7 outcomes of that effort, and really perhaps even reconvene appropriate groups to move to think 8 9 about that integration a little bit more. So you 10 know, it's supporting the states. I think that's 11 perhaps the Step 1. But thinking about how then 12 we do something more expansive, not just within 13 our states but -- state Medicaid programs but to 14 think about some of the other partnerships that can help support our state Medicaid agencies. 15

16 CO-CHAIR ANTONELLI: Thank you. So 17 actually I'm going to stop it here, because I'm 18 getting a little bit of a virtual hook. We will 19 reconvene at the top of the hour. That's 11:00 20 a.m. Eastern for people listening in. I want to 21 thank our colleagues from CMS. I thank Dr. 22 Applegate from the great state of Ohio, and thank

|    | 1<br>1  |
|----|---|
| 1  | you to both of the Task Forces. See you at        |
| 2  | 11:00.  |
| 3  | (Whereupon, the above-entitled matter             |
| 4  | went off the record at 10:46 a.m. and resumed at  |
| 5  | 11:03 a.m.)                                       |
| 6  | CO-CHAIR PINCUS: Okay. So now comes               |
| 7  | the, I think sort of the in some ways the core    |
| 8  | of our look at the core set, to really look at    |
| 9  | the overlap between areas of importance between   |
| 10 | the Adult and Child Task Forces. So we're going   |
| 11 | to be looking at specific measures that are       |
| 12 | cutting across maternal and perinatal health      |
| 13 | measures, and then a little bit later we're going |
| 14 | to be looking at asthma measures, as these are    |
| 15 | sort of crossover kinds of issues. So Shaconna.   |
| 16 | MS. GORHAM: Okay, next slide. All                 |
| 17 | right. So as we talked about those shared         |
| 18 | issues, we want to look at the actual measures    |
| 19 | that are shared are aligned between both the      |
| 20 | adult and the child core set and they some        |
| 21 | were mentioned already.                           |
| 22 | So we have the chlamydia screening                |
|    |   |

measure, which is NQF 0033 on both core sets. But we also have the contraceptive care postpartum woman, NQF 2902 with different age groups but -- age groups reported, but again on both core sets.

Then we have the single measure with 6 7 the rate split across the measure set, and that 8 is the timeliness of prenatal care is on the 9 child set, and the postpartum care on the adult Not listed on your slide but also shared 10 set. 11 between the two core sets is Measure 0576, which 12 is the follow-up after hospitalization for mental 13 illness, and then we also have the BMI screening 14 on the adult core set. It is not endorsed, but on the child core set the weight assessment is 15 16 Measure 0024.

Next slide. Okay. So our topic for
today at this moment, we're looking at the
maternal and perinatal care. So I would like to
again thank our presenters this morning, because
that is the perfect segue into our discussion.
There are 11 measures in the area of perinatal

Neal R. Gross and Co., Inc. Washington DC

1

2

3

4

and maternity care across the child and adult core set.

So really highlighting the fact that 3 the mother's health and health care is extremely 4 5 influential on that of her child or her children. The perinatal measures have a large presence in 6 7 the child core set, and a few are contained in 8 the adult core set, again reflecting the long-9 standing importance of Medicaid in providing health coverage to low income women and babies. 10 11 During this discussion, the Task Force 12 will review relevant perinatal and maternity measures in both sets, to kind of see that full 13 14 picture of quality, acknowledging that there are those 11 measures across the set which may seem 15 16 like a large number, but some still view a gap in 17 the core set in this area. 18 So we'll go to the next slide. So if 19 you look at your diagram, we kind of just broke 20 those measures up. You'll see that the child 21 core set measures are relevant again, the health 22 of the infant, the health of the infant and a

> Neal R. Gross and Co., Inc. Washington DC

1

pregnant woman, and there are six measures currently in the child core set and three of those are shared. In the adult core set, we have two maternity-related measures, and three which are shared.

Next slide. So in preparation for 6 7 this year's review, staff compiled a list of endorsed measures and PQMP measures that may not 8 9 be endorsed, that address the 2016 gap areas for 10 your consideration. In doing so, we gathered 32 11 total measures to be considered in the area, 22 12 endorsed and 10 PQMP measures that have not yet 13 been endorsed.

14 So this is a good time, I'm going to stop for one minute, and just talk about the 15 16 measure universe. So in the little bit of pre-17 work that we sent you all, you had the big Excel 18 sheet, which lists all of the gap areas and all 19 of the measures in those gap areas. So on that 20 maternity and perinatal tab were all of the 21 measures that I'm referring to.

22

1

2

3

4

5

So if you'd take a minute and pull out

your discussion guide, it was sent in an email. So you can find it in the email attachment, and it is also on your Committee SharePoint page. So while you're doing that, I just want to kind of walk through, and this is for really the benefit of the Child Task Force. We did this yesterday with the Adult Task Force.

8 The Adult Task Force have one 9 discussion guide, and the Child Task Force has another. So for some of our returning members, 10 you will notice that the discussion guide is 11 12 different. We have walked into modern times now, 13 so we're using the discussion guide much like is 14 used with the other MAP work groups, as well as the Coordinating Committee. 15

So I just want to walk you through it, because it is arranged a little differently. If you go down, we are now in Day 2. So if you go down to Day 2 on your agenda -- it was also emailed. (Off microphone comments.)

22

1

2

3

4

5

6

7

MS. GORHAM: Also if you look on the

Neal R. Gross and Co., Inc. Washington DC

web page.

1

| 2  | MS. NACION: So a quick reference                 |
|----|--|
| 3  | would be to look at the NQF Project web page     |
| 4  | under MAP Medicaid. It's also listed there under |
| 5  | the Materials. Oh, it's called the               |
| 6  | (Off microphone comments.)                       |
| 7  | MS. NACION: MAP Medicaid Discussion              |
| 8  | Guide.   |
| 9  | MS. GORHAM: Yes. Okay, you all have              |
| 10 | it? Okay. So if you'd move down to Day 2, I      |
| 11 | just want to point you to the bottom of Day 2.   |
| 12 | You have measures recommended by task force      |
| 13 | numbers, and you have the gap area of maternal   |
| 14 | and reproductive health. So if you would click   |
| 15 | on that, and this is for the Child Task Force.   |
| 16 | The Adult Task Force is a little different.      |
| 17 | So let's look at the Child Task Force.           |
| 18 | You will see the three measures listed under the |
| 19 | gap area of maternal and reproductive health is  |
| 20 | what we called it. So let's use the first        |
| 21 | measure as an example. If you click on the       |
| 22 | Measure Specifications, it's not on yours if     |

you click on Measure Specifications, you will see everything about that particular measure, all of the specs.

Scroll down a little bit more, and you 4 5 will see the information we provided as a result of the preliminary analysis, okay. Adult folks, 6 7 why you do not see measures recommended is 8 because there were no measures recommended by 9 Task Force members on the Adult side. So yours is a little different. You don't have those 10 11 measures, no.

12 And just because we're here, Child 13 Task Force, if you look in the gray box to your 14 right in the upper right corner, if you click on 15 Measures, those are also all of the gap areas in 16 which task force members or your peers 17 recommended, measures to be discussed and voted 18 on today.

19 Then if you click on the tab that says 20 "Gap Areas," you have all of the gaps in which we 21 were able to identify measures for. So those 22 would be the measures that you saw on the Excel

> Neal R. Gross and Co., Inc. Washington DC

1

2

If you click on Measure Repository 1 spreadsheet. 2 that takes you out, and you can log in and actually pull up the Excel spreadsheet if for 3 some reason you would like to do that. 4 5 All right. So I just wanted to start 6 the presentation so we can do that, so you'll 7 know as we're discussing some of these measures 8 where some of the information, you can find some 9 of the information. Okay, so let's go back to Slide 187. 10 11 And so I spoke about the list of the 12 32 measures, the total of 32. The list also includes the two measures recommended in 2016 not 13 14 vet added. So that is the PC05 breast milk 15 feeding measure, which was also recommended by a 16 Child Task Force member. 17 I will share updates on endorsement 18 activities regarding the frequency of ongoing 19 prenatal care as well as the timeliness of 20 prenatal and postpartum care in just a minute. 21 So we can go to the next slide. So we talked a lot about this a little earlier. 22

Lekisha presented some of CMS findings on these 1 2 two measures. These two measures have lost endorsement. Endorsement was removed in 2016. 3 4 If we go to the next slide, I won't 5 stay on this slide at all, because Lekisha did an excellent job of presenting. I will say that, 6 7 just to kind of repeat the reporting for 2015. 8 So in FY 2015, 29 states reported the frequency 9 of ongoing prenatal care, which is an increase from 2012, which 25 states reported. 2013, 27 10 states reported and then in 2014 28 states 11 12 reported the measure. Lekisha also discussed some of the 13 14 reasons why this measure was not reported. But what I would like to do, if we go to the next 15 16 slide, and then one more slide, and look at some 17 of the reasons why this measure lost endorsement. 18 So again, this measure is found on the child core 19 It was recently reviewed for maintenance set. 20 endorsement. 21 The committee agreed that the measure

22

Neal R. Gross and Co., Inc. Washington DC

did not meet the evidence criteria, because this

measure is considered a proxy for access and 1 2 there is no empirical evidence for the visit schedule or number of visits associated with 3 4 improvement in outcomes. Therefore, they did not 5 recommend the measure for continued endorsement. After the NQF public comment period, 6 7 the developer withdrew this measure for 8 consideration of endorsement, so endorsement was 9 removed. I'll just mention that 10 DR. BURSTIN: 11 Carol Sakala, the co-chair, is sitting at our So if there's any specific questions, 12 table. 13 it's great to have her here. Thanks. 14 Yes, okay. So if we go MS. GORHAM: to the next slide, timeliness of prenatal care. 15 16 Again, we saw this slide a little earlier, so I 17 won't go into details about this slide. I will 18 just remind you in 2015, 38 states reported this measure, which is an increase from previous 19 20 31 states reported in 2012, 33 states in years. 21 2013 and 36 states in 2014. 22 Next slide. Okay. We can go to the

next slide. So this -- okay. This is the
 postpartum care rate and this is on the adult
 core set. Again, we saw this and so in 2015, 35
 states reported on this measure, which is an
 increase from previous years.

So if you go down one more slide, and 6 7 then the next slide, okay. So again, this is in 8 the adult core set. The previous was in the 9 child core set. The Prenatal and Reproductive Health Committee did not reach consensus on 10 11 validity on this measure. They noted the limited 12 number of codes and the fact that the measure is 13 not addressed, addressing the content of the 14 visits.

Of course our CSAC made the final 15 16 recommendation and voted not to recommend this 17 measure, due to lack of empirical evidence and 18 validity issues. Endorsement was removed. So I 19 think I'll stop there and if there are any 20 questions about those measures, again Carol is 21 here. 22 MEMBER SAKALA: I just want to add one

more comment about the postpartum care measure, and that is that it -- if you just have a visit before 21 days, it doesn't count and there's a lot of concern about that as disincenting, for example, appropriate support for breast feeding, wound care and other issues that would arise very early on.

8 All right. MS. GORHAM: If no more 9 comments, we can move on. Okay. So we want to talk about, as we kind of get in our process for 10 11 today, the measure selection criteria. We 12 reviewed for the adults yesterday, but I 13 definitely want to review for the Child Task 14 Force.

The measure selection criteria 15 16 developed to -- was developed to assist MAP with 17 identifying the characteristics that are 18 associated with an ideal measure set, either for 19 public reporting like the core sets or a payment 20 program, and are consistent across all of MAP. 21 They are not absolute rules; rather, they are meant to just provide some general guidance on 22

1

making the measure selection decisions.

2 The central focus should be on the selection of high quality measures that address 3 the NOS. Competing priorities often need to be 4 weighted against one another, and these measure 5 selection criteria can be used as a reference 6 7 when you are evaluating the strengths and weaknesses of a program set. 8 9 In addition to the measure selection criteria, some additional factors that influence 10 the choice of measures include we favor endorsed 11 12 measures when possible, because of the confidence 13 in the scientific properties; the ability to use 14 administrative data; whether the measure captures a reasonably broad segment of the Medicaid 15 16 population and also could catalyze quality 17 improvement action in an area with low performance or recognized disparity. 18 19 Whether the measure is designed for 20 use at a health plan or population level, or/and 21 whether the measure is aligned with other So some of the criteria listed on your 22 programs.

slide include, and I won't read them all, just 1 2 NQF endorsement. Program measure set is responsive to specific program goals and 3 requirements; program measure set enables 4 measurement of person- and family-centered care 5 and services; program measure set includes a 6 consideration for health care disparities and 7 cultural competency, just to list a few of them. 8 9 Next slide. So potential reasons for removal from the core set. When considering 10 measures for potential removal, please consider 11 12 some of the following. Some include multiple 13 years where the measure has multiple years of 14 very low reporting, whether the measure does not provide actionable information for state Medicaid 15 16 programs; if there's a superior measure on the 17 same topic that has become available. 18 You have a voting decision handout at your desk right in front of you. I named some of 19 20 those potential reasons for removal, not all. 21 Please read them all. But we wanted to look at and I will turn it over to Harold and Rich for 22

discussion, if there are measures that we would
 like remove. Let me just talk a little bit about
 the process.

So we have both task forces here. 4 We 5 encourage conversations together because these are again measures and issues that are shared. 6 When we vote though, we will vote separately. 7 So 8 you may have noticed that our set up or our 9 seating is very strategic. We have the Child Task Force on the right and we have the Adult 10 11 Task Force on the left.

12 The first three members on the left 13 are joint members, so they are both the adult and 14 child task forces. So they will vote on Harold will begin facilitating the 15 measures. 16 voting process for the adults, since the Adult 17 folks landed first at NQF yesterday, and then 18 Rich will pick up with the voting process for the 19 child, since you all will be staying with us 20 another day. So we kind of did that 21 strategically and purposefully. So with that, I will turn it over to Harold. 22

| I  | 1<br>1  |
|----|---|
| 1  | CO-CHAIR PINCUS: So obviously the                 |
| 2  | question at hand is are there measures that       |
| 3  | now are we asking only the adult side now, or are |
| 4  | we asking   |
| 5  | (Off microphone comment.)                         |
| 6  | CO-CHAIR PINCUS: So from the adult                |
| 7  | side, are there any measures, at least in the     |
| 8  | maternal and child component, that you would      |
| 9  | consider removing? Obviously these two we just    |
| 10 | kind of just discussed are potential options for  |
| 11 | that. Anybody want to make a motion on that?      |
| 12 | Remember the endorsement has been removed from    |
| 13 | both of these measures, and one of them has been  |
| 14 | withdrawn. So Rachel, yeah.                       |
| 15 | MEMBER LA CROIX: I do understand and              |
| 16 | appreciate the concerns with these measures and   |
| 17 | why they are no longer being endorsed. At the     |
| 18 | same time from a state reporting perspective,     |
| 19 | these are measures that plans and states I think  |
| 20 | are pretty used to, since they have been part of  |
| 21 | HEDIS for a long time and are relatively easy to  |
| 22 | report on.  |
|    |   |

| 1  | While I would very much like to see               |
|----|---|
| 2  | measures that look more at the content of the     |
| 3  | sets and making sure that certain things happen   |
| 4  | that could directly lead to better outcomes,      |
| 5  | until such measures are available I would be okay |
| 6  | with retaining these measures.                    |
| 7  | CO-CHAIR PINCUS: Other thoughts?                  |
| 8  | Deborah.  |
| 9  | MEMBER KILSTEIN: Again, my only                   |
| 10 | concern with the postpartum visit rate is the     |
| 11 | limitation on the days, and I think that we're    |
| 12 | only seeing a slice of the answer to that         |
| 13 | question about postpartum rates and we're not     |
| 14 | we're not seeing or encouraging. We may be        |
| 15 | disincentivizing earlier visits in some cases.    |
| 16 | So I do have concerns about that measure and what |
| 17 | it actually, you know, the information that it's  |
| 18 | providing.  |
| 19 | On the other hand, I see that, you                |
| 20 | know, there's nothing else being put forward as a |
| 21 | replacement right now, which makes it makes it    |
| 22 | difficult to make that decision.                  |
|    |   |

|    | 12  |
|----|---|
| 1  | CO-CHAIR PINCUS: I mean which is not              |
| 2  | to say that we're after we have this              |
| 3  | discussion about removal, we have discussions     |
| 4  | about suggestions for adding measures. So think   |
| 5  | of it also in terms of are there measures that    |
| 6  | you might add that might be replacements. You     |
| 7  | know, Carol, you might want to just talk a little |
| 8  | bit about the thinking of the through the         |
| 9  | endorsement process or removing endorsement and   |
| 10 | just  |
| 11 | MEMBER SAKALA: What the Perinatal and             |
| 12 | Reproductive Health Committee went through?       |
| 13 | CO-CHAIR PINCUS: Yeah.                            |
| 14 | MEMBER SAKALA: Yeah. So I think it                |
| 15 | has been summarized pretty well, that first of    |
| 16 | all going through the evidence part, which comes  |
| 17 | early on in the flow of NQF consensus development |
| 18 | processes, both of those are sitting at expert    |
| 19 | opinion and in that last few years, NQF has       |
| 20 | really raised the bar to say we'd like to be      |
| 21 | seeing a strong, systematic review there.         |
| 22 | So that was the first kind of big red             |
|    |   |
|    |   |

flag in our deliberations, and also I think 1 2 there's a question about whether keeping something sitting there allows complacency as 3 4 opposed to creating a tension that we'd better 5 get this filled. So that's, you know, I think one thought. 6 7 I know NCQA is working on another 8 content measure, and there's also some potential 9 around the depression, a couple of depression measures which are being specified for prenatal 10 11 and postpartum women. It's depression screening 12 and follow-up with the like Edinburgh measures, 13 the screening tools that are used. 14 So there are some potential things that are kind of coming up pretty close in the 15 16 pipeline, and I think that's a possible 17 consideration. Also the postpartum contraceptive 18 care was a new postpartum content measure added 19 last time. 20 CO-CHAIR PINCUS: Other comments? Ι 21 wonder if Mary, you might just want to comment on it as well? 22

| ĺ  |  |
|----|--|
| 1  | DR. APPLEGATE: So I want to make sure            |
| 2  | I'm not hoarding the conversation. There's a lot |
| 3  | to say here. So I have to agree that the systems |
| 4  | are calibrated to the current measure, so        |
| 5  | typically what we need in transition. So we      |
| 6  | would be in favor of eliminating just that very  |
| 7  | narrow window in which you need to be seen, and  |
| 8  | then including that entire period.               |
| 9  | The AMA/PCPI measure actually is quite           |
| 10 | good, that has those four components.            |
| 11 | Gestational diabetes, retesting the depression   |
| 12 | screening, contraception attention and the one   |
| 13 | that we can't get by claims is breast feeding    |
| 14 | support. But I think as we get to the electronic |
| 15 | health record derived measures, I think all of   |
| 16 | those are possible.                              |
| 17 | When we ran our measure for any visit,           |
| 18 | not just during that period of time, the system  |
| 19 | is calibrated to the six week follow-up. So 80   |
| 20 | percent of the visits actually did happen there. |
| 21 | So we can't use that as, you know. We have to    |
| 22 | recognize again, pushing down to the level of    |
|    |  |

patient what we need. So I think getting rid of 1 2 that restriction there is just as important as the timeliness of prenatal care not being 3 But I 4 measured from the time you're enrolled. mean gestational agent for prenatal visit. 5 So I think we have to bridge the what 6 7 do you need life course wise, population health-8 wise as it relates to the delivery of health 9 services actually in the measure, and I actually think we can do it, you know. We can link vital 10 11 stats and claims together to actually be able to 12 get the measures that are meaningful on the 13 ground, and that's what clinicians and patients 14 both need. That then lines up with not an expert 15 16 opinion, but with best practice. So let me come back 17 CO-CHAIR PINCUS: 18 to the Adult Task Force. Are there -- is there 19 anybody who wants to make a motion about removal? 20 (Off microphone comment.) 21 MEMBER CALMUS: Are both of those measures a part of the adult? 22

| 1  | MS. GORHAM: The postpartum rate is                |
|----|---|
| 2  | the only measure that is a part of the Adult Task |
| 3  | Force.  |
| 4  | MEMBER CALMUS: That was that was                  |
| 5  | what I was being confused by.                     |
| 6  | MS. GORHAM: The other two are the                 |
| 7  | prenatal care rate and the frequency of ongoing   |
| 8  | prenatal care are on the Child Task Force.        |
| 9  | CO-CHAIR PINCUS: But can the Adult                |
| 10 | Task Force members make a recommendation for      |
| 11 | removal of the ones that are on the Child Task    |
| 12 | Force? Okay. So you can only make a               |
| 13 | recommendation for the post for the prenatal.     |
| 14 | Rachel.   |
| 15 | MEMBER LA CROIX: Instead of proposing             |
| 16 | to remove, could we I don't know if we can do     |
| 17 | that through this venue, but propose that for the |
| 18 | adult core set the postpartum care measure would  |
| 19 | tweak that day requirement? No, okay.             |
| 20 | (Off microphone comment.)                         |
| 21 | MEMBER LA CROIX: Oh okay. Great                   |
| 22 | minds think alike.                                |
|    |   |
|    |   |

| 1  | DR. MATSUOKA: I think this is a theme            |
|----|--|
| 2  | that we heard through both days so far. So I     |
| 3  | think it's something that we might just think    |
| 4  | about. It would of course, we would have to      |
| 5  | know that it's deviating from specs of an        |
| 6  | endorsed measure or in this case a non-endorsed  |
| 7  | measure.   |
| 8  | But you know, I think to address some            |
| 9  | of these, we want meaningful measures. So if     |
| 10 | it's a matter of a simple tweak, we can think    |
| 11 | about, you know, asking our contractors to think |
| 12 | about that.                                      |
| 13 | CO-CHAIR PINCUS: Deborah, and then               |
| 14 | Marissa.   |
| 15 | MEMBER KILSTEIN: Is it possible to               |
| 16 | right now, I mean it's a measure and it was      |
| 17 | supported. Is it possible to have a vote to      |
| 18 | change the support from full support from the    |
| 19 | Committee to conditional support, which would    |
| 20 | signal to CMS that it needs it's not NQF-        |
| 21 | endorsed and it needs to be looked at and        |
| 22 | potentially reconsidered? I don't know if that's |
|    |  |

Neal R. Gross and Co., Inc. Washington DC

1 an option. 2 CO-CHAIR PINCUS: Yeah. I assume that's an option. 3 So I don't know what that 4 MS. GORHAM: 5 needs to be a formal recommendation of CMS, because they know that it is not an endorsed 6 7 But we certainly can include the note measure. 8 in the report. 9 CO-CHAIR PINCUS: Marissa. I don't know if 10 MEMBER SCHLAIFER: 11 this is an appropriate question, and I realize 12 that we're voting separately. But it seems like 13 discussing together makes sense. So I was just 14 wondering Carol, and tell me if this is an appropriate question, if you take off your --15 16 since you've spent more time focusing on this 17 measure with the Committee discussion, if you 18 take off the endorsement hat and you put on this 19 committee hat, do you have it --20 You know, I realize that wasn't what 21 the Committee discussed, but do you see a place

22

for this until something else? If you don't want

1 to answer that that's fine.

| 2  | MEMBER SAKALA: Thank you for asking.             |
|----|--|
| 3  | These measures have bugged me for a really long  |
| 4  | time. I feel that you I mean you know that in    |
| 5  | the pregnancy, you know that the woman has a     |
| 6  | place to go. But other than that, I don't know   |
| 7  | what they tell us and there's so much that we    |
| 8  | need to get out of prenatal care and postpartum  |
| 9  | care.  |
| 10 | I feel these are so low bar at a time            |
| 11 | when we're trying to ratchet up and also we're   |
| 12 | hearing from the service provider community, you |
| 13 | know, please give us important measures. Give us |
| 14 | a few that matter. So my personal feeling is I   |
| 15 | think these need to go. But thank you for        |
| 16 | asking.  |
| 17 | CO-CHAIR PINCUS: You want to say                 |
| 18 | anything else, Marissa?                          |
| 19 | MEMBER SCHLAIFER: No. Well, I feel               |
| 20 | like this is far enough outside my expertise.    |
| 21 | I'm not sure that I feel comfortable making the  |
| 22 | motion to remove it, but based on that, I think  |

| 1  | it sounds like we need a motion to remove it. So  |
|----|---|
| 2  | if someone else won't make the motion, I will.    |
| 3  | But I don't know that I'm the best person.        |
| 4  | CO-CHAIR PINCUS: Sue.                             |
| 5  | MEMBER KENDIG: I'll make the motion               |
| 6  | to remove it.                                     |
| 7  | CO-CHAIR PINCUS: Is there a second?               |
| 8  | MEMBER SCHLAIFER: I'll second.                    |
| 9  | CO-CHAIR PINCUS: Okay. So we can                  |
| 10 | have a formal vote on that. Kim?                  |
| 11 | DR. ELLIOTT: I was just going to say,             |
| 12 | I think it's a really positive movement because   |
| 13 | right now it really is looking at counts and it   |
| 14 | really isn't focusing on content, and I think     |
| 15 | that's the direction that we're all trying to     |
| 16 | head, is to really effective and actionable sorts |
| 17 | of visits and measurement.                        |
| 18 | CO-CHAIR PINCUS: So we have a motion              |
| 19 | on the table now and it's been seconded. Is       |
| 20 | there any discussion, either for or against? And  |
| 21 | to be clear, is the recommendation are we only    |
| 22 | allowed to give, make a recommendation for        |
|    |   |

| I  |   |
|----|---|
| 1  | removal, or can it be a recommendation for        |
| 2  | removal but with some specific sort of additional |
| 3  | comments attached to it? Yeah.                    |
| 4  | (Off microphone comment.)                         |
| 5  | CO-CHAIR PINCUS: So sort of a                     |
| 6  | conditional removal? Okay. Further discussion?    |
| 7  | So let me just try to summarize what I think      |
| 8  | people are not saying. So it sounds like people   |
| 9  | are somewhat reluctant to fully remove any        |
| 10 | examination of this issue from the core set.      |
| 11 | On the other hand, they don't like                |
| 12 | this measure, and so that there is a desire to    |
| 13 | number one, think of a kind of transitional phase |
| 14 | of removing this measure as currently             |
| 15 | constituted, or making adjustments to this        |
| 16 | measure as currently constituted, but making a    |
| 17 | very strong recommendation to CMS that they move  |
| 18 | very quickly in replacing this measure with       |
| 19 | something better. Does that capture? Does         |
| 20 | anybody okay.                                     |
| 21 | So do we need to vote on that? Okay.              |
| 22 | So I guess we have to vote on what I just said.   |
|    |   |
|    |   |

1

| -  | bue:  |
|----|---|
| 2  | MEMBER KENDIG: So in going down that              |
| 3  | path where we're saying quickly replace it with   |
| 4  | something that is meaningful and actionable, is   |
| 5  | that conditional support? I'm just trying to      |
| 6  | clarify what button we're pushing to get where.   |
| 7  | CO-CHAIR PINCUS: Yes, okay. So I'll               |
| 8  | leave that to Miranda.                            |
| 9  | MS. GORHAM: So you're voting for                  |
| 10 | removal with the conditions that Harold stated,   |
| 11 | and so the way the voting slide is set up         |
| 12 | already, because we did this pre-meeting, it will |
| 13 | be yes or no. But the yes is saying that I'm      |
| 14 | voting for removal, and we'll list the conditions |
| 15 | in the report, and no is, no you're not voting    |
| 16 | for removal. And so right now only the Adult      |
| 17 | Task Force members are voting.                    |
| 18 | CO-CHAIR PINCUS: So what button do we             |
| 19 | push?   |
| 20 | MS. KUWAHARA: All right. We're going              |
| 21 | to take it to a vote. This is our test slide.     |
| 22 | The adult has practice, though. I think we're     |
|    |   |

good to go with our clickers. So for Measure No. 1 2 1517, prenatal and postpartum care, timeliness of 3 prenatal care. I'm sorry. Here we go. 4 (Off microphone comments.) We're good. 5 MS. KUWAHARA: So for 6 Measure No. 1517, prenatal and postpartum care, postpartum care rate, please cast your votes at 7 8 this time and you'll want to point your clickers 9 in this direction. We're waiting on one more 10 response. Great. 11 (Voting.) 12 MS. KUWAHARA: So 100 percent of our 13 eight voting members voted to -- what did we call 14 this? CO-CHAIR PINCUS: Yeah, voted to sort 15 16 of conditional removal. 17 MS. KUWAHARA: There we go. 18 DR. BURSTIN: I think basically, 19 there's just yes/no. I mean the most important 20 role of MAP, as we've heard repeatedly from our 21 colleagues at CMS, is they just want to have the comments. Harold did a great job summarizing it. 22

Essentially, there is an urging to move away from
 this measure as specified, and I think they've
 heard great conversations, I think.

4 CO-CHAIR PINCUS: Yeah. So 5 transitional steps of like at least temporarily 6 to fix this measure temporarily in terms of the 7 dates, and but a very strong recommendation to 8 move towards a more substantive measure. So now 9 the Child?

10 CO-CHAIR ANTONELLI: So we're going to 11 go through a similar process now for the one 12 that's in the Child core set. That's 1391, 13 ongoing prenatal. Open it up for questions or 14 comments, but Carol, I'd be happy to give you --15 in your chairperson hat, do you want to give us 16 any background on this one that you may not have 17 already said on the prior?

18 MEMBER SAKALA: I think it's just 19 basically the same kind of issues, that we don't 20 know what happened, what the woman's experience 21 of care was, what the outcomes were, what the 22 resource use was. It just doesn't tell us the

things that I think we really want to be learning.

3 CO-CHAIR ANTONELLI: And if I can just 4 probe once more, the approach to mitigation or 5 the conditionality that we just went through on 6 the adult side, from your perspective, applies to 7 this measure as well?

8 MEMBER SAKALA: Well, I think like 9 personally, I really want to move forward, create attention with a gap, to get these filled with 10 However, I will share that I 11 better measures. 12 had lunch yesterday with a vice president of Maternal/Child Services for a very large health 13 14 plan and said what's your thought about this, 15 because she knows the issues.

16 She said I'd like to see a three-year 17 transition, because we are investing millions and 18 millions of dollars and have a lot of programs 19 set up around these measures. So when do we stem 20 the hemorrhage here of focus? It's -- I don't 21 have a good answer, but I just want to share that 22 conversation.

(202) 234-4433

1

| I  |  |
|----|--|
| 1  | CO-CHAIR PINCUS: All right, Terry.               |
| 2  | MEMBER ADIRIM: Hi, yeah. I just have             |
| 3  | a quick question. Maybe it's not that quick,     |
| 4  | about this measure. What was the evidence that   |
| 5  | got it NQF-endorsed? Like what, you know, how is |
| 6  | this measure meant? You know, is it tied to any  |
| 7  | kind of outcomes that have been demonstrated in  |
| 8  | the literature? Like what, how did it get        |
| 9  | endorsed?  |
| 10 | MEMBER SAKALA: I'm sorry that I can't            |
| 11 | remember. Two rounds back, I was staffing it at  |
| 12 | that time. I wasn't a member of the Committee    |
| 13 | and I don't remember the specifications. But I   |
| 14 | think we've had a lot of emotionality around     |
| 15 | prenatal care is a good thing and by getting     |
| 16 | prenatal visits you save so many dollars or      |
| 17 | whatever.  |
| 18 | But the fact of the matter is, the               |
| 19 | women who get prenatal care have better life     |
| 20 | circumstances, more enabling, are more likely to |
| 21 | have wanted pregnancies, can get to the visits,  |
| 22 | have work, jobs that are flexible or whatever.   |
|    |  |
|    |  |

So I think we really don't have that evidence in 1 2 the way that we would like to have it. MS. GORHAM: We also have Suzanne on 3 4 the phone, who staffed the Committee, and so she 5 would like to add to your comment Carol. Hi everyone. This is 6 MS. THEBERGE: 7 Suzanne Theberge. I was the senior project manager on the team. Actually, I think Carol 8 9 really covered it. I mean we know there is some 10 linkage between prenatal care and improved 11 outcomes, but we don't know what it is and we 12 don't know what exactly is the quality of care. 13 So the committee just really felt that 14 frequency does not equal quality, and I think 15 Carol stated it well. 16 MEMBER BENIN: Sorry. This is Andrea. 17 Can I ask a question? 18 CO-CHAIR ANTONELLI: Yes Andrea, go 19 ahead. 20 MEMBER BENIN: Do we have an alternate 21 measure of access? 22 MS. THEBERGE: I don't know if this is

No. Now this measure, I mean 1 a question to me. 2 I think the Committee really discussed this as a measure of a proxy to access to care, and it 3 does, I think, assess to some extent the 4 5 challenges that women face in accessing care. But you know, in terms of getting, finding a 6 provider, getting to that provider, 7 8 transportation, et cetera. 9 But we don't -- we don't really have 10 anything, anything better and I think, Carol, you 11 may also remember that this was a real struggle 12 for the Perinatal and Reproductive Health 13 Committee, you know, again is something better 14 than nothing. I'll just point out, 15 DR. BURSTIN: 16 just to add to Suzanne's point, that the evidence 17 requirements changed significantly between 2012 18 and 2016. So our bar is higher. You have to 19 have quality, quantity and consistency of 20 evidence for the measure focus, and that wasn't 21 the case in the first round. 22 CO-CHAIR PINCUS: Deborah.

| 1  | MEMBER KILSTEIN: I just want to                   |
|----|---|
| 2  | clarify. Are we voting or are we discussing both  |
| 3  | the frequency and the timeliness measure?         |
| 4  | MEMBER POOLE-YAEGER: Thanks. I just               |
| 5  | wanted to, you know, we've been following these   |
| 6  | measures for many, many years, and I would agree  |
| 7  | with the statement about a lot of time and effort |
| 8  | has been put into trying to raise them. On the    |
| 9  | other hand, you know, do I think that some of     |
| 10 | these are really giving us a good idea of the     |
| 11 | health of our population? You know, probably      |
| 12 | not. I can give you an example on the timeliness  |
| 13 | of prenatal care, since the measure looks for,    |
| 14 | you know, first trimester if you're continuously  |
| 15 | enrolled.   |
| 16 | But 75 percent of our moms come in                |
| 17 | just when they're pregnant and then disenroll.    |
| 18 | It's that 42-day window which in the majority of  |
| 19 | people are coming in in the second trimester,     |
| 20 | which I don't know that anybody's going to think  |
| 21 | that that's the first time you should get a       |
| ~~ |   |

22 prenatal visit, you know.

(202) 234-4433
|    | · · · · · · · · · · · · · · · · · · ·             |
|----|---|
| 1  | So I'm interested in, you know, I like            |
| 2  | there's a measure called WOEP, which is Weeks     |
| 3  | of Enrollment in Pregnancy that NQF has, and I    |
| 4  | think they may have actually retired it or        |
| 5  | something. But it tells you it can tell you       |
| 6  | at what gestational age did the mom get. That     |
| 7  | seems like a much more at least for our first     |
| 8  | access to care measure, that makes a lot of       |
| 9  | sense. I don't know if there's and I'm not        |
| 10 | recommending measures, but I do I do also         |
| 11 | worry   |
| 12 | The other point was I heard somebody              |
| 13 | at one point at some say oh, maybe we should      |
| 14 | stop covering prenatal care because there's no    |
| 15 | evidence to suggest that it makes a difference.   |
| 16 | So we've just got to be really careful if we're   |
| 17 | going to come out and say oh, we don't want to    |
| 18 | you know, we don't think there's evidence to      |
| 19 | suggest that prenatal care is linked to outcomes, |
| 20 | and then somebody's going to take that down the   |
| 21 | wrong path. So                                    |
| 22 | CO-CHAIR PINCUS: Mary.                            |
|    |   |

1 DR. APPLEGATE: So just a reality 2 check. I think it's a strong statement to say no to a measure. We have to stop doing stuff that 3 actually doesn't work. So hats off to colleagues 4 around postpartum, realizing that the system will 5 have to transition hopefully to the better 6 7 measure. 8 These two measures are actually quite 9 different. Frequency has absolutely nothing to You could show up in triage 20 10 do with outcome. times, and that just tells you perhaps that 11 12 you're not treating the person's anxiety. It has 13 nothing to do with the outcome of that delivery, 14 that timeliness may be a measure of a bunch of other things including access, but what you --15 16 what I need, you know, on the ground is 17 gestational age at first prenatal visit. 18 So the timing of the managed care plan 19 process for how long, 42 days to get them in, has 20 absolutely no bearing on it. So in the value-21 based purchasing piece, let's measure actually 22 what we really need that actually may matters,

and that is we have to time and date the 1 2 pregnancies. They need to be seen between six and eight weeks. 3 4 So in the days when we had expert 5 opinion, there was no -- the assumption was that 6 most people were healthy and you were just 7 looking for preeclampsia. So times have changed. 8 We have a burden of chronic disease in pregnant 9 women. So I think if the answer is no, that's 10 11 a really strong statement and these two are 12 actually separate, frequency has absolutely 13 nothing to do with it. Timeliness actually is 14 important. CO-CHAIR ANTONELLI: Would anybody 15 16 like to make a motion? Yes. Microphone, please. I'd like to move 17 MEMBER RICHARDSON: 18 that we remove this from the core set, 13 --19 (Off microphone comment.) 20 MEMBER RICHARDSON: We're talking 21 about 1391, correct? 1391. 22 CO-CHAIR ANTONELLI: Any seconds?

| 1  | Kim.  |
|----|---|
| 2  | DR. ELLIOTT: I second that motion.                |
| 3  | CO-CHAIR ANTONELLI: Okay.                         |
| 4  | Discussion? So there was a pretty robust          |
| 5  | discussion about conditions. We don't have to     |
| 6  | have that, but I feel for the sake of some degree |
| 7  | of continuity, we at least need to have it raised |
| 8  | in the context of 1391.                           |
| 9  | Carol, I don't want to put you on the             |
| 10 | spot, but you bring a lot of experience to this.  |
| 11 | So would you like to raise a comment with respect |
| 12 | to conditions in the report that will go to CMS?  |
| 13 | MEMBER SAKALA: So for 1391, it's                  |
| 14 | sounding like maybe we can just recommend removal |
| 15 | straight up.                                      |
| 16 | CO-CHAIR ANTONELLI: So I'm not going              |
| 17 | to ask for a change in motion, because that's     |
| 18 | consistent with the motion on the table. Are      |
| 19 | there any comments?                               |
| 20 | (No audible response.)                            |
| 21 | CO-CHAIR ANTONELLI: Okay. So there                |
| 22 | are no comments. Andrea, I assume you're not on   |
|    |   |

1 mute. 2 MEMBER BENIN: Correct. CO-CHAIR ANTONELLI: Okay. 3 So do you want to see if we had coffee for breakfast this 4 5 morning and then proceed to the vote? MS. GORHAM: And before we start to 6 7 vote, just so that for transparency for the 8 transcript, Andrea will be voting. She will be 9 chatting her vote, and we will actually use the clicker here for her. 10 11 MEMBER BENIN: Thank you. 12 MS. KUWAHARA: All right. For the 13 Child Task Force only, we're going to do a test 14 run with your new clickers today. If you had 15 coffee with your breakfast this morning, please 16 press 1. If not press 2 and you'll want to direct your votes in this direction. 17 18 (Voting.) 19 MS. KUWAHARA: All right. I think 20 everything seems to be working properly, so we'll move on to Measure No. 1391. Measure No. 1391, 21 22 frequency of ongoing prenatal care. If you

choose to vote to remove this measure, please 1 2 If not, press 2. press 1. 3 (Voting.) MS. KUWAHARA: I think we're still 4 5 waiting on one more vote. We're going to try this one more time. Okay. Please cast your 6 7 votes one more time. 8 (Voting.) 9 MS. KUWAHARA: If anyone is seeing a horizontal line on their clickers, that's 10 11 potentially problematic. So please let us know if that's what you're seeing. 12 13 CO-CHAIR ANTONELLI: We're getting 14 Andrea's vote. 15 MS. KUWAHARA: Okay. Well, we do have 16 quorum, so we're going to view the results. 100 percent of the 12 members voted to remove -- I'm 17 18 sorry, 1391, 1391 from the core set. 19 CO-CHAIR ANTONELLI: So does that mean 20 that we didn't get everybody who's an eligible 21 voter to vote? Is it possible somebody abstained? 22

MS. GORHAM: We have 13 members on the 1 2 Child core set, excluding the federal reps. For some reason we're only getting 12 votes in. 3 We 4 need nine for quorum, so we do have quorum. So 5 we can move on, but for some reason we're not getting a vote. 6 7 CO-CHAIR ANTONELLI: Yeah, because I 8 quess I'm -- I would like to be convinced that 9 that's not because there's a technical problem, because the vote is what it is. It doesn't 10 11 matter with respect to the quorum. But if we 12 start getting close, I don't want to go into a 13 vote where we're not sure if there's a glitch. 14 So can we maybe redo the coffee question? 15 MS. KUWAHARA: Sure. CO-CHAIR ANTONELLI: So the goal is 16 17 all 12 voting members of the Child Task Force, 18 please vote whether you had coffee or not this 19 morning. 20 (Voting.) 21 MS. KUWAHARA: Here we go. We're 22 great.

|    | ш. — — — — — — — — — — — — — — — — — — —        |
|----|---|
| 1  | CO-CHAIR ANTONELLI: We're good?                 |
| 2  | MS. KUWAHARA: Yes.                              |
| 3  | MS. GORHAM: So actually though, Ann             |
| 4  | is not here in the room and she didn't vote. So |
| 5  | maybe it is her clicker that is not working,    |
| 6  | because we have 12, yeah. If you can do hers.   |
| 7  | MS. KUWAHARA: We're not capturing               |
| 8  | that vote.                                      |
| 9  | MS. GORHAM: Okay. So then it's that             |
| 10 | clicker.  |
| 11 | MS. KUWAHARA: Okay. Okay, all right.            |
| 12 | Mystery solved.                                 |
| 13 | CO-CHAIR ANTONELLI: So did we just              |
| 14 | test Ann's clicker? So we're good to go. We     |
| 15 | don't need to repeat the coffee question again, |
| 16 | okay. Whew. All right. Let's let us go on       |
| 17 | next. So the Task Force has recommended removal |
| 18 | of 1391 from the core set.                      |
| 19 | Right, okay. So the we want to                  |
| 20 | open it up to find out if there are other       |
| 21 | measures that the Task Force would like to      |
| 22 | consider for removal, in addition to what we    |
|    |   |

discussed already. I'm sorry, 1517. 1 So in 2 addition to -- okay, all right. So let's do 1517, then we'll open it 3 So 1517, prenatal postpartum care. Open for 4 up. comments and Carol, I'll be happy to call on you. 5 I have a clarifying 6 MEMBER BENIN: In the current child 7 question. It's Andrea. core set, is it those prenatal and postpartum 8 9 care that are in there, or is it just part of the I cannot tell. 10 measure? 11 MS. GORHAM: It is just the prenatal 12 care portion of the measure. So the measure is 13 one measure, but the rate is split. So for the 14 child core set, the prenatal is on that core set. So we -- you will still need to vote on 1517 as 15 16 it relates to the child core set. 17 MEMBER BENIN: I see. 18 CO-CHAIR ANTONELLI: Okay, Carol. 19 MEMBER SAKALA: Mary, I just wanted to 20 ask you to clarify what you said about needing 21 the gestational age. Are you saying that you 22 need a better measure than this for your

purposes? So even though you like documenting
the woman has a place to go, you -- this is not a
good measure for you?

DR. APPLEGATE: Yes. Let me clarify. 4 5 Right now, the specifications of the measure relate to time from enrollment to time seen for a 6 7 prenatal visit. Well, your time from enrollment 8 in a plan is not a patient-centered view. It's 9 an enrollment process system kind of measure that 10 actually doesn't get to what you really need, 11 which is the women need to show up between six 12 and eight weeks.

13 So I need -- the patient version of 14 this is gestational age at first visit, which then tells you access and real timeliness that 15 16 the entire system can focus on as being most 17 associated with being able to identify and 18 implement treatment for high-risk pregnancies. 19 Hi, this is Andrea. MEMBER BENIN: 20 Could we get clarification on that, because that 21 is not what I'm reading in the measure spec. The 22 measure spec reads the percentage that gets a

prenatal care visit in the first trimester, or within 42 days. I mean obviously you have to be enrolled in the first trimester.

DR. APPLEGATE: I think that's totally 4 5 true, but the majority of people are getting into that denominator with the -- when you're 6 7 enrolled, you know, not in the first trimester. So it's only the continuously enrolled. 8 So 9 again, a lot of our Medicaid members are just becoming enrolled because they're pregnant. 10

11 So they're getting -- they're getting 12 enrolled and of course they're going in for their 13 prenatal visit. That's why they got their 14 insurance so they could go to the doctor. So 15 it's really just measuring the people that have 16 access to their -- you know, that already know to 17 get into their care.

We have lower rates in the people that are continuously enrolled than those that come in. So I think it is totally not measuring what we want to measure.

MEMBER BENIN: Except it's measuring

Neal R. Gross and Co., Inc. Washington DC

22

1

2

the effectiveness of once you're enrolled, being 1 2 able to get in. I mean it's measuring the effectiveness of your program. It may not be 3 4 measuring the population health issue. But it is 5 measuring --6 DR. APPLEGATE: Correct, correct, 7 correct. 8 Right. MEMBER BENIN: So it's 9 measuring how well the program works, which is 10 important. 11 DR. APPLEGATE: Yes. So this is Mary, 12 just to be clear about that, that's one of many 13 variables. So does the measure actually work if 14 our focus is really trying to get to a better outcome and you're only measuring one of ten 15 16 pieces and it's not the most important piece? 17 MEMBER POOLE-YAEGER: I would also 18 add, you know, I think we may -- they may, and I 19 don't know the spec that well. They'd be able to 20 split it, you know, so because you can look at 21 the people that are continuously enrolled versus the people that come in and still look at both of 22

them, you know, to sort of see, you know, what 1 2 weeks did get your first care and then also were you getting your care within the first 42 days 3 4 after you've enrolled in the program. 5 You know, that might be a -- again, 6 just to -- if we want to put in a conditional 7 removal with the thought that we don't like this 8 measure but we know something important is there, 9 that we want to try to get that too. So hold on --10 CO-CHAIR ANTONELLI: 11 MEMBER BENIN: I can imagine --12 CO-CHAIR ANTONELLI: Andrea, just --13 MEMBER BENIN: Yeah. I mean I can 14 imagine some -- I'm sorry. Hold on please 15 CO-CHAIR ANTONELLI: 16 for a second. So hold on to the thought about a 17 potential condition. I want to continue to 18 solicit comments. Okay Andrea, go ahead. 19 MEMBER BENIN: No, go ahead. I'11 20 come back. 21 CO-CHAIR ANTONELLI: No, no. You're 22 -- I'm holding a spot in the queue for you. Go

| 2  | MEMBER BENIN: I guess I would just                |
|----|---|
| 3  | say then that while we may have a gap around this |
| 4  | other metric about what gestational age do people |
| 5  | actually get in, it does sound to me as though    |
| 6  | this metric has some value in measuring something |
| 7  | different. So I would just that's what I'm        |
| 8  | hearing, if I'm understanding correctly.          |
| 9  | CO-CHAIR ANTONELLI: Okay. Other                   |
| 10 | comments? Amy.                                    |
| 11 | MEMBER RICHARDSON: So exactly there               |
| 12 | is something embedded in here that may be of      |
| 13 | value, but you're in fact measuring, trying to    |
| 14 | measure two things with one measure.              |
| 15 | CO-CHAIR ANTONELLI: A little closer               |
| 16 | to your mic, please.                              |
| 17 | MEMBER RICHARDSON: I'm sorry. You're              |
| 18 | trying to measure two things with one measure,    |
| 19 | and wouldn't it be cleaner if we recommended a    |
| 20 | replacement that measures what we're after,       |
| 21 | because I think Dr. Poole-Yaeger is correct, that |
| 22 | from a Medicaid perspective, mostly what we're    |

| 1  | measuring is not what Dr. Applegate wants.        |
|----|---|
| 2  | CO-CHAIR ANTONELLI: Other comments?               |
| 3  | You guys count, too.                              |
| 4  | (No audible response.)                            |
| 5  | CO-CHAIR ANTONELLI: All right. Would              |
| 6  | somebody like to make a motion? We're talking     |
| 7  | about 1517.                                       |
| 8  | MEMBER POOLE-YAEGER: Can I move for               |
| 9  | that conditional, removal with the conditional    |
| 10 | here?   |
| 11 | CO-CHAIR ANTONELLI: Sure. Please                  |
| 12 | articulate it.                                    |
| 13 | MEMBER POOLE-YAEGER: Again, I don't               |
| 14 | I don't want to say that we I'm worried           |
| 15 | we're removing the frequency of prenatal care.    |
| 16 | If we remove the timeliness of prenatal care and  |
| 17 | the postpartum care, somebody's going to think    |
| 18 | that prenatal care doesn't matter anymore.        |
| 19 | So I would move that we say that we               |
| 20 | think there needs to be maybe a replacement to    |
| 21 | this, make it conditional in asking for more work |
| 22 | on a transition to something that's more, you     |

| 1  | know.  |
|----|--|
| 2  | (Off microphone comments.)                       |
| 3  | MEMBER POOLE-YAEGER: Conditional move            |
| 4  | to what did they do with that?                   |
| 5  | CO-CHAIR ANTONELLI: So the adults                |
| 6  | MEMBER POOLE-YAEGER: Conditional                 |
| 7  | removal.   |
| 8  | CO-CHAIR ANTONELLI: Yeah. The adults             |
| 9  | voted to remove with conditions that CMS should  |
| 10 | consider for timely, i.e. rapid replacement.     |
| 11 | MEMBER POOLE-YAEGER: Right, right.               |
| 12 | I would say we should probably align with what   |
| 13 | the adults said on this.                         |
| 14 | CO-CHAIR ANTONELLI: Yes, okay.                   |
| 15 | Second that motion anyone? If you could speak it |
| 16 | please, so we can                                |
| 17 | MEMBER ADIRIM: I second.                         |
| 18 | CO-CHAIR ANTONELLI: Yes, okay. So                |
| 19 | comments?  |
| 20 | MEMBER BENIN: This is Andrea. I                  |
| 21 | would just comment that in the current situation |
| 22 | with so much uncertainty, it makes me really     |
|    |  |

Neal R. Gross and Co., Inc. Washington DC

| 1  |   |
|----|---|
| 1  | anxious to remove metrics around access, and so I |
| 2  | just want us to be a little bit cautious about    |
| 3  | how the conditional activity gets discussed.      |
| 4  | CO-CHAIR ANTONELLI: Yes. I can't see              |
| 5  | your name.  |
| 6  | MEMBER BEATTIE: Kathryn.                          |
| 7  | CO-CHAIR ANTONELLI: Kathryn.                      |
| 8  | MEMBER BEATTIE: I'd just agree with               |
| 9  | that, that I'm really uncomfortable with us       |
| 10 | removing all of these measures around prenatal    |
| 11 | access, and would be more comfortable with        |
| 12 | recommending retaining it with a conditional of   |
| 13 | an expectation of revision or recommendation for  |
| 14 | revision.   |
| 15 | CO-CHAIR ANTONELLI: So potentially                |
| 16 | you would like to raise another motion? Yes?      |
| 17 | MEMBER BEATTIE: You only asked for a              |
| 18 | motion to remove it, so I did not                 |
| 19 | CO-CHAIR ANTONELLI: Well no. I                    |
| 20 | didn't ask. I asked for a motion and what came    |
| 21 | to the floor is what came out. So right now, the  |
| 22 | point of discussion is what's on the floor. But   |

I'm very happy to entertain that. 1 2 But I think we're going to have to vote with the one that's on the floor, and we can 3 come to that one. But I -- but the comment is 4 5 still -- the period for making comments on the motion on the floor still exists. 6 MEMBER POOLE-YAEGER: And to clarify, 7 8 is this just postpartum one or is it postpartum 9 and prenatal, since we have -- this is timely, just timeliness of prenatal. This is not 10 timeliness of postpartum. Only the prenatal 11 12 piece of the --13 CO-CHAIR ANTONELLI: The prenatal 14 piece, yes, 1571. 15 MEMBER POOLE-YAEGER: Okay. 16 CO-CHAIR ANTONELLI: 1517. 17 MEMBER POOLE-YAEGER: Yes. 18 MEMBER ADIRIM: And maybe somebody 19 maybe from CMS can clarify, that if this were the 20 motion that, you know, for removal under the 21 condition that there's something suitable to replace it, what that means to satisfy what she's 22

saying down there? 1 2 CO-CHAIR ANTONELLI: Will you weigh in, Karen? 3 4 DR. MATSUOKA: Yeah. So to I think 5 Helen's point and I'm sure Rich made it this 6 morning, it's really the conversation that's 7 happening now that is instructive to us beyond 8 just the vote. So I wouldn't worry so much about 9 is it conditional removal, conditional keeping. I think we hear the thrust of the policy 10 11 recommendation. 12 MS. GORHAM: We'll be sure, staff, to 13 include this in the report, so that it will be public as well as CMS will have it. It will be a 14 15 livable document, if you will. 16 CO-CHAIR ANTONELLI: Any other 17 comments? Otherwise, I'm going to open for the 18 vote of the motion on the floor. 19 (No audible response.) 20 CO-CHAIR ANTONELLI: Okay. So we have 21 -- is your card an artifact? Yes, okay, okay. 22 All right. So let's get ready for the vote and

1 the motion on the floor, and it is essentially to 2 vote for removal of the 1517, the portion that is in the child set, but essentially with the robust 3 language about the transition and the timeliness 4 5 of that. So essentially it mirrors exactly what 6 came out of the Adult Task Force. Okay, tee us 7 8 up, please. 9 MS. KUWAHARA: Polling is open. You 10 may now cast your votes. 11 (Voting.) 12 MEMBER BENIN: What are the choices? 13 I can't see them. 14 MS. KUWAHARA: Andrea, we're asking 15 should this measure be removed -- well, 16 conditionally removed for rapid replacement. 17 This is Measure No. 1517, prenatal and postpartum 18 care, timeliness of prenatal care. One is yes, 19 you would like to remove this measure and two is 20 no. 21 MEMBER BENIN: Thank you. 22 (Voting.)

| 1  | MS. KUWAHARA: Seventy-five percent of             |
|----|---|
| 2  | our 12 voting members voted to conditionally      |
| 3  | remove this measure from the core set.            |
| 4  | CO-CHAIR ANTONELLI: All set? Okay.                |
| 5  | So with respect to I guess I'm going to           |
| 6  | address my opening of invitation for other        |
| 7  | potential measures that the task force would like |
| 8  | to bring forward for consideration of removal?    |
| 9  | Carol.  |
| 10 | MEMBER SAKALA: So I'd like to raise               |
| 11 | the issue of the behavioral health risk           |
| 12 | assessment for pregnant women, which is not NQF-  |
| 13 | endorsed. It's a PCPI it's in the PCPI core       |
| 14 | set, but never really went through that testing   |
| 15 | process, and was picked up some years ago.        |
| 16 | It's for the Child set, it's the                  |
| 17 | least reported measure only for states. I feel    |
| 18 | that Rebecca Gee was here two years ago with      |
| 19 | wearing the hat of the Louisiana State Medicaid   |
| 20 | medical director, saying basically that this just |
| 21 | didn't have feasibility of collection. I've       |
| 22 | since heard that from Elliott Main, and then this |
|    |   |

morning on Mary's slides, I saw data source
challenging.

3 So if we're looking to kind of weed 4 out measures that aren't really going places, 5 where we need them to go, maybe this is one of 6 them and it could be with -- it's a very 7 important concept, but we need a good measure to 8 be able to collect it.

9 CO-CHAIR ANTONELLI: Thank you. Any other -- in fact, maybe why don't we do it this 10 11 If people want to make suggestions for way? 12 measures, and then we can discuss them, and in the interim I don't know if it's possible to have 13 14 the staff pull up any measure so that if we're 15 being asked to evaluate, we can actually see them 16 in writing.

So can you do that? So hold on to that. Let me open it up, and actually just so that I'm clear, am I -- is Harold going to ask the same line of questioning to the Adult side, or should I just --

22

CO-CHAIR PINCUS: We already did that

1 yesterday.

| 2  | CO-CHAIR ANTONELLI: Oh, you did this             |
|----|--|
| 3  | yesterday. Okay. So this is just on the Child    |
| 4  | side. So would anybody else like to suggest      |
| 5  | measures for consideration for removal from the  |
| 6  | Child core set? Andrea?                          |
| 7  | MEMBER BENIN: No, I'm all set.                   |
| 8  | CO-CHAIR ANTONELLI: You're good,                 |
| 9  | okay. So can we get a can we get the measure     |
| 10 | up on the screens please?                        |
| 11 | For the sake of time management, Carol           |
| 12 | as we're getting the staff is pulling this up,   |
| 13 | would you like to add any more commentary? You   |
| 14 | don't need to. I can open it up more broadly.    |
| 15 | But I figure if you want to add something else.  |
| 16 | MEMBER SAKALA: I'm sorry. I wish I               |
| 17 | could even enumerate the components of it, but I |
| 18 | can't.   |
| 19 | CO-CHAIR ANTONELLI: Okay, good.                  |
| 20 | MEMBER SAKALA: But maybe, you know,              |
| 21 | maybe Mary can discuss what are the issues that  |
| 22 | they've experienced in Ohio.                     |

|    | το:   |
|----|---|
| 1  | CO-CHAIR ANTONELLI: Yeah. Are you                 |
| 2  | okay with that?                                   |
| 3  | DR. APPLEGATE: So I'm not a total                 |
| 4  | expert on this particular measure, but there's a  |
| 5  | lot of manual work that's related to it. So it's  |
| 6  | not a claims-based measure. So that's a whole,    |
| 7  | you know, it's in magnitudes probably three- and  |
| 8  | four-fold. It's not just double.                  |
| 9  | CO-CHAIR ANTONELLI: Thank you.                    |
| 10 | CO-CHAIR PINCUS: Rachel may also have             |
| 11 | some comments.                                    |
| 12 | MEMBER LA CROIX: Yeah. I was just                 |
| 13 | going to say due to how complex this measure has  |
| 14 | looked and since it has looked like there would   |
| 15 | be a high burden for data collection on it,       |
| 16 | Florida Medicaid hasn't even pursued adding it to |
| 17 | our health plan reporting.                        |
| 18 | CO-CHAIR ANTONELLI: Thank you, thank              |
| 19 | you.  |
| 20 | MS. GORHAM: And this is not an NQF-               |
| 21 | endorsed measure, so we don't have as much        |
| 22 | information as you would as we would have for     |
|    |   |
|    |   |

Neal R. Gross and Co., Inc. Washington DC

We can -- I can share with you 1 other measures. 2 some reporting information if that would all help for this --3

I could share the DR. BURSTIN: 4 5 I found it online if people want to components. PCPI's list is probably --6 hear it.

CO-CHAIR ANTONELLI: So Helen, why 7 8 don't you give us the components and, Shaconna, 9 if you can give us some idea of the uptake, and that will feed the conversation. Okay, Helen. 10 11 I don't know if Shaconna DR. BURSTIN: 12 has anything to add on this, but it is --13 includes depression screening, alcohol use 14 screening, tobacco use screening, drug use, illicit and prescription screening, intimate 15 16 partner violence screening and to satisfactorily 17 meet the numerator, all screening components must 18 be performed, and the denominator is all 19 patients, regardless of age who give birth during 20 a 12-month period, seen at least for prenatal 21 care. 22

Those are the specs as they stood in

| 1  | 2012. I don't know if they've been updated at    |
|----|--|
| 2  | all. Shawn, do you know?                         |
| 3  | PARTICIPANT: Nope.                               |
| 4  | DR. BURSTIN: Is anyone using them?               |
| 5  | (Off microphone comment.)                        |
| 6  | DR. BURSTIN: Okay. I was asking                  |
| 7  | Shawn from ACOG if anybody they knew was using   |
| 8  | it. Okay.  |
| 9  | CO-CHAIR ANTONELLI: And staff's going            |
| 10 | to let us know a little bit about implementation |
| 11 | while we're go ahead.                            |
| 12 | MEMBER POOLE-YAEGER: We have a health            |
| 13 | plan in Louisiana, so I and I know Rebecca Gee   |
| 14 | is as passionate as anybody. So if anybody can   |
| 15 | get this, you know, measure reported in the      |
| 16 | OB/GYN community she probably could have. So     |
| 17 | that's just I mean my comment on that. If she    |
| 18 | couldn't get it done there in Louisiana, it's    |
| 19 | going to be really hard for states to do that so |
| 20 |  |
| 21 | MEMBER SAKALA: And she had a grant to            |
| 22 | make it work and couldn't do it with the grant.  |
|    |  |
|    |  |

| 1  | CO-CHAIR ANTONELLI: Okay, Kim.                    |
|----|---|
| 2  | DR. ELLIOTT: I think some of the                  |
| 3  | challenges come into system design as well. If    |
| 4  | you have carve-outs for behavioral health,        |
| 5  | sometimes that creates some payment issues with   |
| 6  | states and with health plans, and also some       |
| 7  | states don't pay for the screenings and           |
| 8  | assessments.                                      |
| 9  | If it's not a paid for service, it's              |
| 10 | much harder to, one, get providers to provide the |
| 11 | service, but also to have administrative data or  |
| 12 | any claims data that would support it. So just    |
| 13 | it's a very challenging measure from an           |
| 14 | implementation standpoint, not that all of the    |
| 15 | things that are included in it aren't critically  |
| 16 | important. But it's just a challenging measure    |
| 17 | as written.                                       |
| 18 | CO-CHAIR ANTONELLI: Okay. Amy.                    |
| 19 | MEMBER RICHARDSON: So as you read the             |
| 20 | specs, it seems to me that it's almost everything |
| 21 | but the kitchen sink in behavioral health, and    |
| 22 | you could prioritize some of those. My only fear  |
|    |   |

with sort of saying no as a group to this is the
message that behavioral health issues,
particularly substance use disorder in pregnant
women is not important and it clearly is
important, and it's important to our babies in
particular.

7 But this is a not only technically 8 hard, but it's kind of another one of those we're 9 measuring everything but the kitchen sink in one measure, and cleaner is better. 10 So the message 11 being if we remove it, we remove it but we are 12 not downplaying the importance of behavioral 13 health screening and intervention during 14 pregnancy. Thank you. 15 CO-CHAIR ANTONELLI: Marv? 16 DR. APPLEGATE: Just one comment. Ι 17 totally agree. The best measures are the ones

18 that are tightly coupled with an action plan that 19 actually moves the measure.

20 So this has so many things in it that 21 it gets very complicated, depending on the 22 community that you might live in, and it's also

| 1  | not clear that you can actually take it on in the |
|----|---|
| 2  | health system, because all the social             |
| 3  | determinants of health actually weigh into this   |
| 4  | as well. So I totally echo the sentiment.         |
| 5  | The other thing, to the earlier                   |
| 6  | comments about what are the public health crises, |
| 7  | actually is around drug use, opioid and           |
| 8  | polypharmacy use, which is tightly coupled,       |
| 9  | actually close to 100 percent of our folks who    |
| 10 | have that issue also smoke.                       |
| 11 | So one of the things that we need to              |
| 12 | with measures is also bring focus to the fire,    |
| 13 | you know. Where is the fire? This does            |
| 14 | absolutely everything. So not only is there a     |
| 15 | data collection issue, if I'm the doc and I have  |
| 16 | or the nurse or whoever, and I have all of        |
| 17 | these things, what do I actually do?              |
| 18 | Generally what they do is they pick               |
| 19 | one or they refer it out and there's no feedback  |
| 20 | loop so nothing happens. So it's not actionable   |
| 21 | or feasible.                                      |
| 22 | CO-CHAIR ANTONELLI: Deborah.                      |
|    |   |
|    |   |

| 1  | MEMBER KILSTEIN: I've got a question             |
|----|--|
| 2  | about the measure, and maybe I'm reading         |
| 3  | something that's old. Is that from is the        |
| 4  | data source expected to be electronic medical    |
| 5  | records for this? Okay. So that's, you know.     |
| 6  | So I would think that's part of what's making    |
| 7  | this very difficult in terms of collection. Not  |
| 8  | that the measure isn't important, but trying to  |
| 9  | get the EMR data would be very difficult.        |
| 10 | CO-CHAIR ANTONELLI: Okay. So a                   |
| 11 | motion? Yes, oh yeah. Actually, so the staff     |
| 12 | has called this up. I don't know if I've ever    |
| 13 | seen it, but Shaconna, just for the sake of due  |
| 14 | diligence, why don't you share what you have     |
| 15 | here. You've got utilization information?        |
| 16 | MS. GORHAM: Right. So on the screen,             |
| 17 | we have just the specs, but the actual reporting |
| 18 | for the information. So this measure was first   |
| 19 | reported in 2013. At that time, two states       |
| 20 | reported the measure and in 2014 and 2015 four   |
| 21 | states reported that measure. 2015, 45 states    |
| 22 | did not report the measure.                      |
|    |  |

| 1  | Reasons include some of what we heard             |
|----|---|
| 2  | earlier. Data elements from electronic health     |
| 3  | records are necessary for calculation, but are    |
| 4  | unavailable; not reporting due to the need for    |
| 5  | EHR access; chart review; resting this year, plan |
| 6  | to report next year; MCOs are not required to     |
| 7  | submit this HEDIS measure; budget constraints are |
| 8  | just a few of some of the reasons shared.         |
| 9  | I would like to just remind everyone              |
| 10 | that in your supplementary material that we sent  |
| 11 | out, you do have all of this information in what  |
| 12 | was called the chart packs. That was sent as      |
| 13 | well as CMS created a document called Background  |
| 14 | Information for MAC Task Forces, and that         |
| 15 | gathered all of the reasons why the states did    |
| 16 | not report a certain measure. So I read a few,    |
| 17 | but that those two documents are really           |
| 18 | comprehensive.                                    |
| 19 | CO-CHAIR ANTONELLI: Thank you, and                |
| 20 | thanks to the NQF staff for being able to do this |
| 21 | so quickly. So Carol, do you have a comment or    |
| 22 | are you going to respond to my request for a      |

1 motion? Yes, go ahead please. 2 MEMBER SAKALA: So I would like to recommend that we remove this measure, 3 4 accompanied by a message that these are crucial 5 issues for this population and we would recommend, as early as possible, prioritizing and 6 ensuring feasible collection and linking to 7 8 action that addresses identified problems. 9 CO-CHAIR ANTONELLI: Motion's been 10 made. Second? 11 MEMBER LA CROIX: I will second. 12 CO-CHAIR ANTONELLI: Okay. Comments about the motion on the floor? 13 14 (No audible response.) 15 CO-CHAIR ANTONELLI: Ready to vote. 16 MS. KUWAHARA: All right. For Andrea 17 on the phone, we are looking at behavioral health 18 risk assessment for pregnant women. We are 19 asking if this measure should be removed. If you 20 would like to remove this measure, select 1, yes or 2, no. You may now cast your votes. 21 22 (Voting.)

| I  | 17   |
|----|--|
| 1  | MS. KUWAHARA: Ninety-two percent of              |
| 2  | our 12 voting members selected to remove this    |
| 3  | measure.   |
| 4  | CO-CHAIR ANTONELLI: All right. Thank             |
| 5  | you very much to the Child Task Force and since  |
| 6  | we've already asked for additional measures, we  |
| 7  | can move beyond this point now to talk about     |
| 8  | potential additions, so Shaconna.                |
| 9  | MS. GORHAM: So give us one minute to             |
| 10 | confer over here. We're trying to debate. We     |
| 11 | have lunch scheduled for 12:30, I believe. So    |
| 12 | I'm not quite sure if lunch is back there. It's  |
| 13 | here, okay. So why don't we take a few before    |
| 14 | we start a brand new discussion, why don't we    |
| 15 | take a few minutes, grab lunch?                  |
| 16 | So we're a little bit behind, so let's           |
| 17 | take about 15 minutes, grab lunch and then we'll |
| 18 | actually have a working lunch. Does that sound   |
| 19 | okay?  |
| 20 | MS. GORHAM: All right. So let's do               |
| 21 | public comment actually before lunch. We can     |
| 22 | grab public comments and then pick up lunch.     |
|    |  |
|    |  |

| 1  | Operator, if you can open the line please?        |
|----|---|
| 2  | OPERATOR: Okay. At this time, if you              |
| 3  | would like to make a comment, please press star   |
| 4  | and then the number one.                          |
| 5  | (No audible response.)                            |
| 6  | OPERATOR: And there are no public                 |
| 7  | comments at this time.                            |
| 8  | MS. GORHAM: In the room, do we have               |
| 9  | any comments?                                     |
| 10 | MR. CURRIGAN: Just to save time for               |
| 11 | later discussion, I wanted to get you ahead of    |
| 12 | talking about exclusive breast feeding and most   |
| 13 | of moderately effective contraception.            |
| 14 | The 27-member panel of the Perinatal              |
| 15 | and Reproductive Health Panel that decided,       |
| 16 | endorsed, made recommendations for endorsement    |
| 17 | and then went to CSAC, had a 91 percent approval  |
| 18 | for overall suitability for exclusive breast      |
| 19 | feeding, breast milk feeding during the hospital  |
| 20 | stay, and an 80 percent overall suitability and   |
| 21 | recommendation for endorsement for both the most  |
| 22 | to moderately contraceptive care measure, and the |

LARC measure.

1

| 2  | So I just want to have you save some             |
|----|--|
| 3  | time and remember that the 27-member panel has   |
| 4  | already recommended for endorsement and it has   |
| 5  | been accepted for endorsement. They are endorsed |
| 6  | measures suitable for public reporting and       |
| 7  | accountability at the health plan level. Thanks. |
| 8  | MS. GORHAM: Operator, can you open               |
| 9  | the line just a little bit longer for public     |
| 10 | comments for those on the phone please?          |
| 11 | OPERATOR: Yes. Again, as a reminder              |
| 12 | you may press star 1 to ask a question.          |
| 13 | (No audible response.)                           |
| 14 | MS. GORHAM: Okay.                                |
| 15 | OPERATOR: And there are still no                 |
| 16 | public comments at this time.                    |
| 17 | MS. GORHAM: All right, thank you. So             |
| 18 | we'll take a 15-minute break and grab some lunch |
| 19 | and come back.                                   |
| 20 | (Whereupon, the above-entitled matter            |
| 21 | went off the record at 12:23 p.m.)               |
| 22 | MS. GORHAM: All right. Let's go                  |
|    |  |

ahead and get started. We don't want to get too 1 2 far behind. If everyone can make their way back to their seats. So we discussed measures for 3 4 potential removal. 5 Now we want to look at measures for potential addition to the core set. 6 So when considering potential additions to the core set, 7 we definitely want to let the measure selection 8 9 criteria guide us in our decisions and I reviewed those earlier. 10 11 Also feedback from state 12 implementation is very important. So Dr. 13 Applegate's presentation was very important, as 14 well as some of the information in your chart packs and so forth. And then we also want to let 15 16 the gap areas guide us and those gap areas were 17 identified by you and your peers last year. 18 Yesterday, the adult task force went over gaps 19 again, and tomorrow the child task force will 20 discuss gaps. 21 This year, as we continually try to 22 improve the process, we have incorporated the
preliminary analysis in the discussion guide. So we went over the discussion guide. We'll discuss a little bit about the preliminary analysis. As you know, MAP as a whole utilized the preliminary analysis and we just started for the task force this year.

So if we can go to the next slide. So
as we try to continually align this meeting with
other MAP meetings, we have adopted this
preliminary algorithm. So I'll review the seven
criteria used in the algorithm, and again we have
the answers to these questions in your decision,
in your discussion guide, I'm sorry.

14 So things to consider when completing 15 the preliminary analysis. Does the measure 16 address a critical quality objective not 17 currently addressed in the program set? Some 18 measures are outcome measures. So we know that 19 outcome measures are the decided preference for 20 the community. Does the measure address a 21 quality challenge?

22

1

2

3

4

5

6

Does the measure support efficient use

of resources and alignment? Does the measure --1 2 can the measure be feasibly reported? Is the measure NOF-endorsed? If a measure is in a 3 current set, are there implementation issues that 4 5 have been identified with the measure? We also wanted to consider the 6 7 following Medicaid-specific subcriteria when 8 completing the algorithm for these meetings. So 9 we looked at the Medicaid adult and child population, the high impact areas and the health 10 conditions associated, data collection and 11 12 measure implementation feasibility, the issues related to resources needed for implementation, 13 and the threat of variation. 14 So the potential need for variable 15 16 measure prior to implementation at the state 17 level. We discussed voting earlier, and we 18 discussed kind of the quorum. We want to make 19 sure that 66 percent of task forces, the task 20 force members are available. So for the adult, 21 that means seven voting members, and for the 22 child, nine voting members.

We will ask you, or your chairs will 1 2 ask you again if you're supporting the measure, if you're conditionally supporting the measure. 3 Again, we usually do not use the do not support 4 5 too much here in MAP in the Medicaid meetings, but we do want -- if you elect to conditionally 6 7 support a measure for addition, that you state 8 what that condition is. 9 So again, you have your colorful handout in front of you just as a reminder. 10 So as we move through the slides, you have that in 11 12 front of you. Some of the conditions that you 13 can specify for conditional support, excuse me, 14 are things such as pending endorsement, whether 15 or not the measure is NQF-endorsed. You can say 16 that, you know, you want that measure to go 17 through the process before CMS adds the measure 18 to the core set. You can also specify if there is 19 20 something that needs to be changed or addressed by the measure steward. I know there's just a 21

few reasons for conditional support.

Neal R. Gross and Co., Inc. Washington DC

Next slide. So last year we heard 1 2 from you all that wanted to know some of the measures that were recommended from the previous 3 4 years, but not yet adopted from by CMS. This 5 contraceptive care measure 2903 was recommended by the adult task force but not yet accepted by 6 7 CMS. 8 So now I will turn it over to Harold. 9 We did not have any task force members on the adult side to recommend any maternal or perinatal 10 11 care measures. That does not mean that you can't 12 elect to do so now, but I will just say that as we continue discussion, that the task force 13 members for the child core set that did 14 recommend, you will be asked to be the lead 15 16 discussant as you know, and you'll kick off the 17 discussion when we get there. But until then, 18 I'll turn it over to Harold. 19 CO-CHAIR PINCUS: So we have another 20 opportunity, if members of the adult task force 21 wish to recommend measures at this point. 22 Anybody wish to do that? Marissa.

| MEMBER SCHLAIFER: I'm not                        |
|--|
| recommending a measure, but I just had a         |
| question, maybe a process question. Is it worth  |
| looking at what the? I guess are any of child    |
| the things recommended by the child task force   |
| members things that we should also consider? Is  |
| that   |
| MS. GORHAM: So we can definitely do              |
| that. I know, as you know Marissa, because you   |
| have been on the task force for a while, that    |
| some of the conversation in the previous years,  |
| that some of the measures should be on both task |
| forces because we have moms becoming moms a lot  |
| younger. And so maybe we should kind of share    |
| all of the measures, so we can flip it for that  |
| case.  |
| Yes. That is totally fine. So us                 |
| advance to Slide 208, and we can look at the     |
| recommendations made by the child task force in  |
| 2015 and 2016, and these measures were not       |
| adopted by CMS.                                  |
| So we have the two PC05, the exclusive           |
|  |
|  |

breast milk feeding, and it's the same measure.
 One is the original measure, the paper measure
 and then one is the e-measure. We also have
 0477, and I believe that measure is not -- right.
 It's no longer endorsed. So 0477, the under 1500
 gram infant not delivered at appropriate levels
 of care.

8 Just while we're right here, I'll just 9 make a note of why that is no longer endorsed. The developer indicated that resubmission was too 10 much work for a measure that the steward itself 11 12 is no longer using. So uncertainty that others 13 were truly using it as a quality measure, and 14 that the best role seemed to be a populationlevel measure, rather than a hospital-level 15 16 measure, which was the steward's main interest. 17 Then we have 2903, the contraceptive 18 care, most and moderately effective method was also recommended but not added by CMS, and we can 19 20 go to the next slide. We can --21 DR. MATSUOKA: So it's a couple of 22 different things. I think an overarching thing

that we aim for is parsimony. So that's an overarching just principle. So for adding some things in, what can come out. We ask that particular question to all the groups that we then take your recommendations to and get further input from.

7 So we bring it to our various 8 different work groups that we have with our state 9 partners to get their input, our grantees and internally within CMCS as well. And so when we 10 11 run those kinds of considerations, global 12 considerations through, we get that input in and 13 then out pops what ends up becoming the things 14 that we either decide to take out or put in. So that's sort of a global comment. 15

In particular though, for the PC05 issue, I think here, not unlike the behavioral health risk measure, I think unanimously everyone recognized that breast feeding in general was an incredibly important part of good maternal/infant health that we start to monitor.

22

1

2

3

4

5

6

We weren't quite sure the extent to

which we wanted to give, you know, if you want to 1 2 think about a spot on our core set list is like valuable real estate. Like do we want the breast 3 4 feeding measure that we picked to be something 5 exclusively in the hospital setting? We would ideally have liked to see something that either 6 7 bridges those settings of care or maybe even has 8 something that's more ambulatory focused, as 9 opposed to hospital focused.

10 2903, contraceptive care. I think 11 that the reasoning there was that, as Lekisha 12 mentioned earlier this morning, we have a whole 13 maternal health initiative grant, looking to help 14 support states in being able to report this It's a brand new measure that was 15 measure. 16 developed at the Office of Population Affairs.

17 So I think part of our reasoning here 18 was that we wanted to gain a little bit more 19 experience working with the states on that 20 measure before we made a decision one way or the 21 other to put it on set. Infants not delivered at 22 appropriate level of care. It's not ringing any

| 1  | bells for me. I don't know if Lekisha, you        |
|----|---|
| 2  | recall the thinking around that.                  |
| 3  | MS. DANIEL-ROBINSON: I don't, but                 |
| 4  | again if that is a hospital-specific measure,     |
| 5  | there could be that could be part of the          |
| 6  | rationale. So measures that are specified, like   |
| 7  | the early elective delivery measure, it's not     |
| 8  | among the measures that are most reported. So     |
| 9  | anyway, that's all I recall on that one.          |
| 10 | DR. MATSUOKA: 2903, and I jumped                  |
| 11 | ahead a little bit to the next slide, is going to |
| 12 | be considered by the child group again, and it's  |
| 13 | a measure that is for ages 15 to 44. Should that  |
| 14 | also be discussed in terms of the adult group,    |
| 15 | and kind of discussed together and voted on by    |
| 16 | both groups, because otherwise you'd be           |
| 17 | collecting it for just a subset of populations.   |
| 18 | MEMBER KILSTEIN: That was the reason              |
| 19 | for my question.                                  |
| 20 | MS. GORHAM: So the purpose again, for             |
| 21 | you all being here together, is so that we can    |
| 22 | have that joint discussion. Just the purposes of  |
|    |   |

voting will be separate. But remember that 1 2 conversation is still considered a joint conversation. 3 4 CO-CHAIR PINCUS: So maybe, I mean as 5 a process point, since this is an overlap area, both sides of the room should engage in a 6 7 discussion but vote separately. 8 Yeah. MEMBER ADIRIM: I just wanted 9 to say the reason why I asked about 2903 and about what the decision-making that went around 10 11 it is that I don't know if it was last year or 12 the year before, but we had a pretty robust discussion around LARCs and how critical that 13 14 whole piece was. So I didn't want that to get 15 lost, how important that is to us on the child 16 core set so 17 CO-CHAIR PINCUS: Rachel. 18 MEMBER LA CROIX: I know that the 19 other contraceptive care measures were picked up 20 last year in the adult and child core set. Is 21 the difference between those and this one that 22 the other ones are specifically about postpartum

|    | l · · · · · · · · · · · · · · · · · · ·           |
|----|---|
| 1  | women, and so that's almost a subset of this      |
| 2  | measure? Is that correct?                         |
| 3  | MS. DANIEL-ROBINSON: So the                       |
| 4  | denominator's actually different, because this    |
| 5  | one is only                                       |
| 6  | MEMBER LA CROIX: This one's an all,               |
| 7  | okay.   |
| 8  | MS. DANIEL-ROBINSON: Right. This                  |
| 9  | one is all excluding the postpartum women, so it  |
| 10 | got separated out.                                |
| 11 | MEMBER LA CROIX: Okay.                            |
| 12 | MS. DANIEL-ROBINSON: All right.                   |
| 13 | CO-CHAIR PINCUS: Sue.                             |
| 14 | MEMBER KENDIG: Yeah. I was trying to              |
| 15 | remember, because I remember that discussion from |
| 16 | a few years ago and as I recall, the child side   |
| 17 | said yes and the adult said no, and I think I'm   |
| 18 | remembering that CMS has implemented tracking on  |
| 19 | both.   |
| 20 | But you know, I'm wondering if we                 |
| 21 | don't need to revisit this contraceptive care     |
| 22 | measure for all women because we have focused on  |
|    |   |

the maternal child piece and that's -- obviously that's important.

| 3  | But equally important is the pre-                 |
|----|---|
| 4  | pregnancy and the inter-pregnancy component that  |
| 5  | contraception supports. So it's almost a          |
| 6  | surrogate for do women even have access to care,  |
| 7  | to maintain optimal health pre-pregnancy and      |
| 8  | inter-pregnancy. So I would invite us to          |
| 9  | consider that from the adult perspective as well. |
| 10 | CO-CHAIR PINCUS: So do you want to                |
| 11 | make that a motion?                               |
| 12 | MEMBER KENDIG: Sure, yes. I think we              |
| 13 | need to revisit the contraceptive care and        |
| 14 | reinforce that recommendation as a measure of     |
| 15 | because it does promote well women care. I don't  |
| 16 | know if that's worded correctly for a motion.     |
| 17 | MS. GORHAM: Okay. So we can do that.              |
| 18 | Do we want to so just for the purposes of this    |
| 19 | is the second day of meetings for me, so just     |
| 20 | really to be really clear. So can we does it      |
| 21 | make sense, one, let's pull up these specs for    |
| 22 | the 2903. If we want to engage in that            |

Neal R. Gross and Co., Inc. Washington DC

1

conversation. But I want to kind of keep the 1 2 process clean if we can. So Carol actually recommended that measure, so she can be our lead 3 4 discussant, and then we can continue the 5 conversation and vote that way, if that is okay. CO-CHAIR PINCUS: Actually so I 6 7 pushed, knowing that Carol had already made that 8 recommendation, I pushed you to make it an 9 official motion, so that we can now have a joint discussion and then vote separately, okay. 10 11 MEMBER SAKALA: I'm fine to make that motion if that's what we need to carry the 12 13 process forward. 14 CO-CHAIR PINCUS: Is there a second 15 from the adult side? 16 MEMBER KENDIG: I'll second. 17 CO-CHAIR PINCUS: So and it's already 18 been proposed from the child side. So Carol, do 19 you want to sort of lead discussion about it? 20 MEMBER SAKALA: Sure. So during our 21 last webinar, we were invited to consider whether measures that we had recommended in the past but 22

were not brought into the core sets should be reconsidered.

3 So I'm taking you all up on that and 4 raising two of them today for reconsideration, 5 because when I think of just the concept of core 6 fundamental population health issues, I think 7 these measures really speak to that, and 8 certainly for the Medicaid population.

A large, have a really important role
in health equity as well in my view. Just as a
reminder, two years ago in 2015 both groups voted
to support this conditionally upon NQF
endorsement, which happened late last year. So
the different years are kind of tripping over
each other.

And I feel that the arguments include that, as Lekisha just said, this measure is complementary to the crucial piece that we put in place last year for postpartum women. I feel it is relevant to both of the core sets and could be age-stratified in the way we've done with other measures.

1

I feel that it fits well with the 1 2 adult priority gap of inter-conception care, and also the really quick results that Karen reviewed 3 on our webinar about the Medicaid medical 4 5 director priorities of reproductive health and then yesterday the adult group identified 6 7 reproductive health as a gap. 8 So I think it's fitting in really well 9 with all of these, and I would say that there's also growing evidence of a tie between access to 10 11 reproductive health services and some of the 12 maternal outcomes that we are experiencing a real 13 crisis about in this country. So I think that's 14 a broader contextual factor. Just to say that this is a new 15 16 measure. It just got endorsed formally a few 17 months ago, but to let you know that there is an 18 impressive record already, favorable record of 19 implementation. Lekisha mentioned CMCS' maternal and infant health initiative that funded 13 20 21 states to look at best practices around this 22 measure and how it's working out.

ASTHO has a contraceptive access 1 2 learning community supported by CMCS, Office of Population Affairs and CDC, with 27 states using 3 Title X is using an adapted version for 4 this. 5 its family planning annual report data. Planned Parenthood Federation of America has a continuous 6 7 quality improvement department which sponsored a 8 learning collaborative with 20 affiliates, with 9 the focus on how do we honor women's choice and 10 autonomy around these issues, and offer 11 contraceptive care. 12 I want to just hit it right on that though we didn't recommend this -- did recommend 13 14 this measure, there were concerns about the possibility of coercion. It's really important 15 16 in this discussion to recognize that there's no 17 intention that this goes to 100 percent, and some 18 people are a little uncomfortable with a 19 benchmark. 20 I don't think we have one in Healthy 21 People, but the developer says it would be 22 desirable to go above 85 percent. We're nowhere

Neal R. Gross and Co., Inc.

Washington DC

| 1  | near that. I think right now we can, you know,    |
|----|---|
| 2  | head in that direction with confidence. It's      |
| 3  | also important to recognize that in the present   |
| 4  | environment, too much contraception is not the    |
| 5  | problem. It's about access to contraception.      |
| 6  | So that's really the overwhelming                 |
| 7  | issue that we're facing, and I feel that the low  |
| 8  | income women served by Medicaid are paying a      |
| 9  | steep price, and this is intended to address care |
| 10 | by primary care providers, reproductive health    |
| 11 | providers, and others who would be offering this  |
| 12 | kind of care. I think if we make a difference,    |
| 13 | we could help them make a difference.             |
| 14 | And Lekisha, you may have some things             |
| 15 | to say about the work that your initiative and    |
| 16 | program has been doing in this.                   |
| 17 | MS. DANIEL-ROBINSON: Sure. So I                   |
| 18 | would just like to echo the fact that access is   |
| 19 | still a real issue. So we have 13 states that     |
| 20 | are funded to report on the measures, you know,   |
| 21 | and to provide that best practice information.    |
| 22 | But in addition, there were a couple of other     |

Neal R. Gross and Co., Inc. Washington DC states that have also contributed in terms of
 reporting on the measures.

3 There is a gap, you know. There is 4 certainly opportunity for improvement in access. 5 The other thing, in terms of the coercion piece, we do include, with the posting of the 6 7 specifications for the initiative, an 8 interpretation guide. So in that guide, it talks 9 about how you should look at these measures. 10 So you know, as you mentioned, there 11 is not a benchmark goal that you're looking for. 12 But you can use these measures to determine what 13 level of access. So particularly if you want to 14 look at a state or go below that level and look at whether health plans, there are challenges 15 16 within certain health plans, or within certain 17 geographic areas, those sorts of things, are ways 18 that we recommend use of the measures, 19 particularly when you're looking at like the LARC 20 pieces specifically. 21 So we do put that guidance out with 22 it, and you know, as you mentioned, the 13 states that we're supporting are also part of the ASTHO learning community and are really using the measure to drive the change, to look at what areas they need to focus on, whether it's, you know, some of the provider education pieces or the outreach.

7 I just heard about Delaware just the 8 They're doing -- they're about to other day. 9 launch a campaign in the next couple of days or so that will last for the rest of the year, that 10 will, you know, where we will actually 11 12 potentially see some changes in the measure, 13 where they've worked with partners to get rides 14 for people to get to the visits and things like 15 that.

So it's a way to measure the access, it's a way to look at it and that's one of the ways it's being used currently.

19 MEMBER SAKALA: So I guess I just have 20 a little bit of a question about the most to 21 moderately effective methods as opposed to other 22 methods. So I understand and thank you for

> Neal R. Gross and Co., Inc. Washington DC

1

2

3

4

5

explaining that this has to do with access to contraception, and it doesn't look like it may be much of a burden for the states to report because they're administrative claims.

I'm just -- I'm not sure -- the list 5 of contraceptive methods that are listed here 6 look pretty comprehensive to me versus another, 7 and maybe I'm not framing the question the right 8 9 But I'm just struggling a little with the way. most to moderately effective. If you just want 10 11 to, you know, that piece of it, I'm not sure what 12 that means exactly.

13 The other interesting thing that I 14 just noticed was there -- one of the exclusions 15 to those who are indicated for non-contraceptive 16 reasons, and I'm just trying to figure out how, 17 you know, how that necessarily would be excluded. 18 I mean suppose just -- and maybe I'm 19 just looking at it from the provider's side. 20 Somebody may decide that they don't want to have 21 a family or something like that. You know, would that be considered a non-contraceptive reason. 22

> Neal R. Gross and Co., Inc. Washington DC

1

2

3

| I may be getting too much in the weeds           |
|--|
| of, you know, exactly how it's going to play out |
| on the state level, but those were just little   |
| pieces that I was I just had questions about.    |
| MEMBER OSBORNE-GASKIN: So if you had             |
| your tubes tied, you wouldn't be expected to be  |
| provided, for example. That's, I think, what     |
| number one is all about, and I wasn't quite sure |
| if I heard, but it's the people who are at risk  |
| for an unintended pregnancy, so that's another   |
| piece of it. So just to take one example, a      |
| condom would be a relatively ineffective method  |
| or unreliable method.                            |
| So it's sorting out the list is                  |
| actually, you know, I don't know how many are    |
| there, but it's there are about, I have seen     |
| 13 or a lot of them. So eight are the is         |
| pulling out the ones that are really going to    |
| help women with fertility control.               |
| MEMBER GREINER: I really don't have              |
| a lot more to add, because that was beautifully  |
| by both, discussed the pros and the cons. I      |
|  |
|  |

think one of the things, because I don't know if 1 2 Karen had mentioned that this may be, that there was thoughts about it being implementable. 3 But it's administrative data. 4 5 So I would guess that if this were added to the core set, that we would have a good 6 7 number of states that would be reporting on it, 8 because I just can't imagine that this isn't a 9 priority for a good number of Medicaid programs 10 so --11 CO-CHAIR PINCUS: Marsha and then 12 Mary, and then I don't know. Andrea, do you want 13 to say something? MEMBER BENIN: 14 Sure. This is Andrea. I think, as some of you may remember, I am the 15 16 one who is strongly concerned about how this metric is written and risk for coercion. 17 I could 18 not possibly agree more with the comments that 19 were made about the need for access to 20 contraception for all women, and certainly for 21 women in this group who -- but women who want it. So what is -- has never been answered 22

for me is how does this denominator exclude people who don't want contraception, don't want to be on artificial hormones, you know, have health risks for being on artificial hormones, etcetera, etcetera. I think the coercion issues are potentially real.

7 What I would like to see happen here 8 is the development of a metric that, you know, 9 that we list as a gap, that there's a real need 10 for a development of a metric that gets at truly 11 women who are at risk for unintended pregnancy, 12 which I don't know how you do that with claims 13 data in the way that this is written right now.

14 Maybe I don't understand that claims data well enough, but you know, I'm not believing 15 16 that that is truly what the measure, you know, 17 what this metric measures. And so there, I just 18 think that we have to be a little bit balanced 19 about the, you know, this dire need that we have 20 to ensure people have access to contraception in 21 the current, you know, in the current environment 22 with the potential for, you know, really sending

> Neal R. Gross and Co., Inc. Washington DC

1

2

3

4

5

out a problematic messaging and problematic programming.

CO-CHAIR PINCUS: Thank you. I think Lekisha and Marsha just want to comment, in terms of sort of explaining stuff. So --

I had a question. 6 DR. SMITH: When 7 you were presenting, you mentioned that this 8 measure was new, but it was modified? I think 9 the endorsement is new, but it was modified for use in Title X programs? Could you explain how 10 11 that modification is? Because I used to work for 12 the state, and this was part of our performance 13 review.

We did have to offer contraceptives to women, and it was the form that they accepted and the rating was amongst, you know, the most effective. So I just wanted to know how is it modified for use in Title X?

MEMBER SAKALA: Thank you. I just
collected some information about how it's being
used right now, but I think Lekisha can answer
that.

1

|    | 20  |
|----|---|
| 1  | MS. DANIEL-ROBINSON: So the steward               |
| 2  | actually developed it for Title X. So it was      |
| 3  | initially tested in Title X and has been          |
| 4  | broadened to be collected and reported by a       |
| 5  | larger body of a larger body, so using claims     |
| 6  | data. So in terms of the modification, it was     |
| 7  | actually perhaps modified for claims data as      |
| 8  | opposed to, you know, modified for Title X. So    |
| 9  | does that answer your question, Dr. Smith?        |
| 10 | CO-CHAIR PINCUS: Mic.                             |
| 11 | DR. SMITH: We did not bill until                  |
| 12 | that's probably the modification for claims. But  |
| 13 | I just wondered to the question about coercion,   |
| 14 | you know, it has to be some counseling there that |
| 15 | is included and I don't know if that's one of the |
| 16 | codes that, you know, the woman was counseled and |
| 17 | she accepted the, or did not accept.              |
| 18 | So the measure is just demonstrating              |
| 19 | what forms, the rates of what forms of            |
| 20 | contraception were accepted. So that's all. I     |
| 21 | just wanted to know for sure. But I know that     |
| 22 | our experience was that we generally did not bill |
|    |   |

|    | 1  |
|----|--|
| 1  | Medicaid, but we did encourage our grantees      |
| 2  | through the health departments to bill, if they  |
| 3  | have that capability.                            |
| 4  | CO-CHAIR PINCUS: Lekisha, was there              |
| 5  | some other comment you wanted to make?           |
| 6  | MS. DANIEL-ROBINSON: Yes, right.                 |
| 7  | So two things. One, currently in development as  |
| 8  | a patient-reported outcomes measure, which would |
| 9  | be a complement to this.                         |
| 10 | So it would really assess the women's            |
| 11 | experience with contraceptive counseling and     |
| 12 | access to these services. So that's in           |
| 13 | development, and I'm sure at which time it is    |
| 14 | complete with the testing is complete and all of |
| 15 | that, it will be submitted for endorsement.      |
| 16 | That's part of the process.                      |
| 17 | The other thing I wanted to say is               |
| 18 | that I referenced the interpretation guide       |
| 19 | earlier, and that really talks about how to look |
| 20 | at this measure. So you really don't want to     |
| 21 | just take the measure and, you know, you get the |
| 22 | rate and that's the rate and you make some kind  |
|    |  |

1

of determination on that.

| 2  | It's the rate of the women who                    |
|----|---|
| 3  | received the services within the year. However,   |
| 4  | what you can do in terms of interpretation would  |
| 5  | be to take local level data or national level     |
| 6  | data, depending on how you're how you want to     |
| 7  | analyze the data.                                 |
| 8  | But you take another instrument that              |
| 9  | provides the unintended risk, you know, the       |
| 10 | unintended pregnancy risk, and that is what you   |
| 11 | use to determine whether or not there is unmet    |
| 12 | need in terms of access.                          |
| 13 | So that interpretation guide that's on            |
| 14 | the maternal and infant health page actually goes |
| 15 | into how you can look at that. But the raw rate   |
| 16 | in and of itself does not give you all of the     |
| 17 | information.                                      |
| 18 | CO-CHAIR PINCUS: Kathryn and then                 |
| 19 | Mary.   |
| 20 | MEMBER BEATTIE: The answer to my                  |
| 21 | question may be somewhere in this discussion but  |
| 22 | maybe someone can clarify it for me, which is how |
|    |   |

do we know from claims data that a woman 15 to 44 is truly at risk for unintended pregnancy, and it's similar to what Andrea on the phone is saying, which is how are we getting to that population? I'm not understanding how we exclude those who are -- it would not be an unintended pregnancy.

8 And so are they just -- we're assuming 9 oh, they're in the 15 percent if our goal is 85 10 percent, or are we looking at a gap in some data? 11 That just seems like an advanced level of 12 evaluation that most people aren't going to make 13 in looking at state to state, right? And we're 14 supposed to be respecting cultural components in these, and I do see practicing now in Idaho and 15 16 Utah that this may have some real concerns for 17 populations in our states. I just don't 18 understand how we're getting to that definition 19 in the denominator.

20 MS. DANIEL-ROBINSON: I think, again 21 in terms of interpretation, using your example at 22 the local level, the unintended risk there might

> Neal R. Gross and Co., Inc. Washington DC

1

2

3

4

5

6

be different.

1

| 2  | So one of the ways that we talk about             |
|----|---|
| 3  | in the interpretation guide is to look at the     |
| 4  | National Survey of Family Growth, that gives      |
| 5  | percentages. I mean you have to use something,    |
| 6  | right, to determine what's the percentage at risk |
| 7  | and that survey is one of the ways to do it.      |
| 8  | But I understand that there are also              |
| 9  | local, local instruments that provide that same   |
| 10 | kind of information. So it's again, I don't       |
| 11 | think that this measure is ever intended to be    |
| 12 | 100 percent of anything, or it's intended to be   |
| 13 | zero. But it's a it's a way to look at the        |
| 14 | range of services that are provided, and so       |
| 15 | MEMBER BEATTIE: I'm just not I'm                  |
| 16 | sorry. I'm not understanding how we're getting    |
| 17 | at accurate data to even meet the measure. So     |
| 18 | how is there a code where I define                |
| 19 | MS. DANIEL-ROBINSON: Unintended                   |
| 20 | pregnancy is not there isn't a code for           |
| 21 | unintended pregnancy in claims. I will say        |
| 22 | another thing about the measure.                  |

| 1  | It's being specified for electronic              |
|----|--|
| 2  | versions, and so in the future you actually will |
| 3  | get the unintended piece more accurately because |
| 4  | a question could be inserted into the electronic |
| 5  | record that will ascertain the women's           |
| 6  | reproductive health plans.                       |
| 7  | But at this point with the claims                |
| 8  | data, no, you won't have the precise assessment  |
| 9  | about what her risk or intentions are.           |
| 10 | MEMBER BEATTIE: So it might be                   |
| 11 | premature to try and build this I absolutely     |
| 12 | agree with the intention of improving access to  |
| 13 | contraceptive care that's effective. But I'm     |
| 14 | just concerned as to whether we're able to today |
| 15 | build a metric that actually measures what we're |
| 16 | looking to measure.                              |
| 17 | CO-CHAIR PINCUS: Okay. Let's hear                |
| 18 | from a few other people. Mary and Roanne, do you |
| 19 | have a question? Okay, and Kim, and then we also |
| 20 | the senior project manager for the standing      |
| 21 | committee that reviewed the endorsement actually |
| 22 | may have some comments. Available now or         |
|    |  |

| 1  | MS. GORHAM: Suzanne.                              |
|----|---|
| 2  | MS. THEBERGE: Yes, hi. The committee              |
| 3  | did discuss pretty extensively these questions    |
| 4  | around percentages and us getting at whether      |
| 5  | pregnancy is intended or unintended, and I think  |
| 6  | I don't know how much of the report from that     |
| 7  | project folks reviewed. Some of that discussion   |
| 8  | happened around some of the other two measures in |
| 9  | the sets.   |
| 10 | But you know, just wanted to re-echo              |
| 11 | that it was very clear that these are about       |
| 12 | access. It's never intended to be 100 percent.    |
| 13 | They're more looking to ensure that women who are |
| 14 | interested in accessing contraceptive methods can |
| 15 | do so and that it's not some kind of systemic     |
| 16 | blockage.   |
| 17 | There was actually some discussion; I             |
| 18 | was just checking the notes, and there was some   |
| 19 | discussion about the fact that yes, there are     |
| 20 | particular religious denominations that don't     |
| 21 | want to use contraception, but or that may be     |
| 22 | counseled against, but they are many of them      |
|    |   |

| 1  | actually are using contraception.                 |
|----|---|
| 2  | So I just want to flag that the                   |
| 3  | committee did discuss these topics pretty         |
| 4  | intensively.                                      |
| 5  | CO-CHAIR PINCUS: Mary.                            |
| 6  | DR. APPLEGATE: Okay. So just the                  |
| 7  | practical piece of things. We have women at high  |
| 8  | risk for pre-term birth. Spacing pregnancies is   |
| 9  | a very effective strategy. The uterus has to      |
| 10 | recover. So the ultimate measure we're trying to  |
| 11 | get to is inter-pregnancy interval for high risk  |
| 12 | women.  |
| 13 | Unless there's a measure for effective            |
| 14 | contraception, there would be maybe no way to do  |
| 15 | it. So for example Ohio did not participate       |
| 16 | because under DRGs, no one's going to do an \$800 |
| 17 | kit for the same cost of the entire delivery. So  |
| 18 | virtually our chances were zero, even if they     |
| 19 | were high risk high risk deliveries. So I         |
| 20 | just want to mention that.                        |
| 21 | And then in terms of intentionality,              |
| 22 | there have been tons of surveys. The PRAMS        |

I

survey is probably one of the more common ones. 1 2 But the surveys actually indicate in some communities the unintentional pregnancies are 50 3 to 70 percent, and the use of the contraception 4 5 might be less than ten percent. So that just tells us we have an 6 7 access problem. So the measure is intended to 8 drive whatever you need to do in your state or 9 your system to ensure that we provide the services that people, again the patient-centered 10 piece, that people think will work for them. 11 12 So we know for teenagers, they can't 13 think about a pill every single time. There may 14 be people in their household who have opinions about whether or not that's a good thing. 15 16 There's a respect for privacy and for dignity 17 that actually results in youth and people with 18 special chronic conditions, some of the disabled 19 population, that actually prefer LARCs for 20 example. 21 And there was virtually zero chance in Ohio postpartum. 22 If you wanted one, you actually

(202) 234-4433

Neal R. Gross and Co., Inc. Washington DC

www.nealrgross.com

So the measure is actually in 1 could not get one. 2 some ways a process measure, trying to get to inter-pregnancy intervals for high risk women. 3 4 So I think it's very important though to make 5 sure you understand that there is a gap, and essentially we're emotionally neutral. 6 7 But I can tell you if we eventually 8 get to the point of doing our measures by 9 disparate populations, we'll be able to make sure 10 that everyone knows that we're keeping track of 11 So this is about availability of very it. 12 effective, you know, medication and intervention 13 that actually can really help long-term outcomes. 14 CO-CHAIR PINCUS: So I have --15 MEMBER BENIN: Can I ask -- could I 16 ask a question about that comment? Would that be 17 okay? 18 CO-CHAIR PINCUS: Okay. But I just 19 want to say that I have Roanne, Amy, Kim, and Sue 20 in line. Okay, Andrea? 21 MEMBER BENIN: You want me to ask? You want to me to ask? 22 Okay. Okay.

| 1  | 2   |
|----|---|
| 1  | CO-CHAIR PINCUS: Yeah.                            |
| 2  | MEMBER BENIN: So I just would it                  |
| 3  | would be helpful for me to understand how having  |
| 4  | the feds indicate that this metric is on the list |
| 5  | makes a difference for the state's, you know,     |
| 6  | desire to do what needs to be done around         |
| 7  | contraception. I think clarification of that.     |
| 8  | I will also just comment that we do               |
| 9  | have the postpartum contraception metric on the   |
| 10 | list, which I understood that that was because of |
| 11 | that interval issue. So a little clarification,   |
| 12 | because I think that comment was really           |
| 13 | important. I just want to make sure I understand  |
| 14 | it.   |
| 15 | DR. APPLEGATE: Yeah. So from my                   |
| 16 | perspective, this is Mary again from my           |
| 17 | perspective, the immediate postpartum one is      |
| 18 | super-important because you've already proven     |
| 19 | that the mother is super-high risk because she's  |
| 20 | got this baby in the NICU, right, although        |
| 21 | admittedly at that time, if you're worried your   |
| 22 | baby's going to survive or not, that might not be |
|    |   |

I

1

a time that you're okay with waiting.

2 The message that we've had in Ohio, even for LARCs, is that we'll take them out 3 4 whenever you want. It just -- the clinicians 5 just don't care if they take them out. So that's the other piece of it is the messaging around no, 6 7 you can't have it taken out, I mean there are a 8 whole bunch of women. I think it was less than 9 ten percent, but there was still a number of women who actually had them taken out in the 10 11 three to nine month period or so. 12 The other measure gets to the front 13 end, which is my comments about the disabled and 14 young, very young mothers. So preventing or 15 delaying the age of their first pregnancy is 16 directly tied not just to outcomes, but also to 17 poverty. So if that's something that they want, 18 it's very, very difficult to actually try to be 19 able to have that. 20 So in essence it really is a measure 21 of access for this very specific part of reproductive health services. 22
| 1  | CO-CHAIR PINCUS: So Roanne.                       |
|----|---|
| 2  | MS. GORHAM: Before Roanne, can you                |
| 3  | give me one minute? I just want to, we have a     |
| 4  | new face at the table. So if you will allow me    |
| 5  | to just introduce Dr. Lindsay Cogan from New York |
| 6  | state. So please feel free to weigh into the      |
| 7  | conversation as we have it.                       |
| 8  | MEMBER OSBORNE-GASKIN: So I just                  |
| 9  | wanted to echo Mary's point that unintended       |
| 10 | pregnancies may be so I was thinking              |
| 11 | specifically of the teens. So the teenagers who   |
| 12 | definitely that is a group that you definitely    |
| 13 | don't want an unintended pregnancy, and that the  |
| 14 | age group actually may have to go a little bit    |
| 15 | younger than 15 to address that.                  |
| 16 | And so I could understand them having             |
| 17 | problems with access to care across all, you      |
| 18 | know, ethnic groups or, you know, all women. So   |
| 19 | even if the measure was a little more focused, as |
| 20 | you said you know, to disabled population or teen |
| 21 | pregnancy or something like that, I think that    |
| 22 | would be definitely focusing the measure a little |

1

2

bit better than just --

CO-CHAIR PINCUS: Kim.

DR. ELLIOTT: A lot of what I was 3 4 going to say has already been said, but I don't 5 think it's an access measure. I do think it's a process measure like Mary said. I also think 6 7 that if we're going to get to the point of doing 8 measurement on this across states that a lot of 9 states are very competitive and want to have the highest rates in most of the measures. 10 11 My concern would be comparing like a 12 Utah to a California or a New York, and how that 13 may appear in a report that goes to Congress or something like that, like Utah would be failing 14 when it's really a cultural or personal opinion 15

16 on use of birth control or birth control methods.
17 So I think we just need to be very cautious on
18 that.

CO-CHAIR PINCUS: Amy.

20 MEMBER POOLE-YAEGER: Yeah. I think 21 mainly what everybody's been saying. My, you 22 know, my first reaction when I hear this is like

19

| 1  | oh my gosh, somebody's going to tell me that I've |
|----|---|
| 2  | got to get, you know, the rate up to whatever.    |
| 3  | And so but I'm new to the Committee.              |
| 4  | So I don't, you know, when we approve it and it   |
| 5  | goes to CMS, I mean some of the words are oh,     |
| 6  | will it be even included in payment strategy and  |
| 7  | blah blah blah.                                   |
| 8  | So I think that maybe some of the                 |
| 9  | angst is around, you know, do we have any         |
| 10 | direction about, you know, with our approval,     |
| 11 | saying that it definitely would not be something  |
| 12 | that you I mean you said it's in a document,      |
| 13 | but I mean how does that make how do we make      |
| 14 | sure that it doesn't get used inappropriately     |
| 15 | when does that make sense, you know? That         |
| 16 | would make maybe me feel better too.              |
| 17 | MS. DANIEL-ROBINSON: And I would                  |
| 18 | probably say that that's a concern for many       |
| 19 | measures. You know, once it's out in that         |
| 20 | sphere, there is a loss of control from the       |
| 21 | owner.  |
| 22 | So it's really on to on the user.                 |
|    |   |
|    |   |

Again, our recommendation would not be to use 1 2 certain measures in that way. It should not be like a pay for performance type approach to get 3 Like that's -- that would never 4 to X, get level. 5 be our recommendation for this type of measure. But again, I don't know how one would 6 control that. 7 I mean so whether or not it 8 appears on the core set, it is in existence. It 9 is NQF-endorsed and could very well be used 10 incorrectly. 11 Sue and then Helen. CO-CHAIR PINCUS: 12 MEMBER KENDIG: You know, the coercion 13 argument comes up each time, and I think it's 14 important to remember also that having no evidence of offering a method is also -- could 15 also be construed as a coercive behavior. 16 So I think we also -- I think we need to balance that 17 18 argument with the flip side. 19 With regards to the comment about 20 having the postpartum measure, you know, this may 21 be one way to get to appropriate content, as 22 evidence of appropriate content in that

postpartum or maternal or well woman visit as well, because certainly for women's health care providers, all of these reproductive life planning is something that's included. In my view, this is capturing -- this is one method of capturing appropriateness of what is included in that care.

8 CO-CHAIR PINCUS: So Helen, and then 9 hopefully we're ready to vote on both the child 10 and the adult sides after this.

11 DR. BURSTIN: Great. Just one quick 12 Again, since you are MAP, consideration comment. 13 of payment and the way the measures are applied 14 are completely within your purview. So there's nothing that says we couldn't capture some of 15 16 this discussion, just to make you feel comfortable that this is about the measure and 17 18 its potential appropriateness for inclusion in 19 this program.

20 But we could certainly include and 21 will certainly include some of the dialogue 22 around how the measure could be used or would be

1

used around payment.

| 2  | DR. MATSUOKA: And just to underscore              |
|----|---|
| 3  | I think what Helen just mentioned, but also       |
| 4  | Lekisha with regard to use, just a reminder that  |
| 5  | these core set measures and this MAP task         |
| 6  | force is somewhat unique and different from other |
| 7  | MAP groups that you might be on, where you're     |
| 8  | talking about measures that are going to be done  |
| 9  | through rulemaking, that are going to be required |
| 10 | and perhaps payment attached to it.               |
| 11 | That's not this. These are state                  |
| 12 | level measures that are used for quality          |
| 13 | improvement purposes only, not payment.           |
| 14 | CO-CHAIR PINCUS: And is a voluntary               |
| 15 | program. Okay. I think we're ready to vote. So    |
| 16 | do you want to do the Adults first and then the   |
| 17 | child? Okay. So Miranda, you want to set that     |
| 18 | up?   |
| 19 | MS. KUWAHARA: No problem. Let's see.              |
| 20 | So Andrea, we are asking the question should      |
| 21 | Measure No. 2903, Contraceptive Care, Most and    |
| 22 | Moderately Effective Methods, be added to the     |

www.nealrgross.com

adult core set. Your options are 1 support, 2 1 2 conditional support, or 3 do not support. CO-CHAIR PINCUS: 3 Okay, and so --4 Okay. So just on the adult side, just 5 to say, has anybody put forward any conditions 6 for support? Because if we do vote for 7 conditional support, we have to say what the 8 conditions are. So nobody has put forward any 9 conditions. Okay. So we're really voting for 10 support or do not support. Okay. 11 All right. Adult Task MS. KUWAHARA: 12 Force, feel free to submit your responses. 13 We're waiting on -- there we go. 63 14 percent of the eight members voted to support this measure for the adult core set. 15 16 CO-CHAIR PINCUS: Okay. 63 percent, 17 so the measure --18 MS. KUWAHARA: Yes. 19 CO-CHAIR PINCUS: So the measure gets 20 support, okay. Rich, do you want to take it for 21 the child? 22 CO-CHAIR ANTONELLI: Yeah. I guess I

want to ask the question about adding conditions, because the conversation up to now has included both the adult and the child. So we're focusing on the child task force. Does anybody want to put forth a condition for this measure? Yes. Lean into the microphone please.

7 MEMBER RICHARDSON: I apologize. I'm 8 not entirely certain how to word this, but I do 9 think some nuance could be created around the denominator, how you define it. Is it just all 10 women of this age or could we be more accurate 11 12 about the -- who are we measuring this for? MEMBER POOLE-YAEGER: Can I have --13 14 just I'm sorry I'm new, so I'm just asking details here. So is this just going to be 15 16 conditions to the measure itself, or as you 17 mentioned, you know, how the measure is used? 18 Can we put a condition on how the measure is 19 We could, yeah. used?

20 So I would propose that we, you know, 21 that maybe we would have a motion to approve this 22 with the condition that we very clearly state the

1

2

3

4

5

6

use cases where we think, you know, where they 1 2 think this should be for quality improvement and not in a payment methodology or with no 3 4 particular benchmark or goal in mind. CO-CHAIR ANTONELLI: Okay. 5 Does that meet what you were promoting, Amy? 6 7 MEMBER POOLE-YAEGER: Yes. 8 CO-CHAIR ANTONELLI: Yes, okay. So 9 should I take that as a motion for a condition attached to this vote? 10 11 MEMBER POOLE-YAEGER: Yes, I will make 12 that motion. 13 CO-CHAIR ANTONELLI: Okay, and so 14 Shaconna and team, do we vote on the condition 15 before we vote on the measure, or do we --CO-CHAIR PINCUS: You will vote 1, 2, 16 17 3. 18 CO-CHAIR ANTONELLI: So we're going to 19 do all three? 20 CO-CHAIR PINCUS: Yes. 21 MS. GORHAM: And tell me what the 22 condition is again one more time, just so I have

it clear for the record. Just so I have it 1 2 clear. Rich, you can summarize for me if you 3 want. 4 CO-CHAIR ANTONELLI: Yeah. So 5 basically the -- your proposal is to accept the 6 measure, but with specification of how the measure will be implemented, right? So it 7 8 doesn't change the measure. It talks about the 9 implementation or the use. I think you used the term "use cases." 10 11 MEMBER POOLE-YAEGER: Use cases, 12 right. 13 CO-CHAIR ANTONELLI: So basically it 14 involves how it gets implemented and potentially 15 the data is interpreted, right? 16 MEMBER POOLE-YAEGER: Correct. 17 CO-CHAIR ANTONELLI: It doesn't change 18 the measure. 19 MEMBER POOLE-YAEGER: Right, no. You 20 know, I think we're probably stuck with the 21 denominator as it is, so but if we don't use it 22 for payment, we can kind of --

| 1  | CO-CHAIR ANTONELLI: Yeah.                        |
|----|--|
| 2  | MEMBER POOLE-YAEGER: Does that make              |
| 3  | sense?   |
| 4  | CO-CHAIR ANTONELLI: Okay. Staff, is              |
| 5  | that okay?                                       |
| 6  | MS. GORHAM: Yes, we got it.                      |
| 7  | CO-CHAIR ANTONELLI: Okay. So child               |
| 8  | task force, we're going to be voting this, and   |
| 9  | there are three options. So Miranda, do you want |
| 10 | to take us through this please?                  |
| 11 | MS. KUWAHARA: That's right. This is              |
| 12 | Measure No. 2903, Contraceptive Care Most and    |
| 13 | Moderately Effective Methods. We have three      |
| 14 | voting options. Number one, support for          |
| 15 | inclusion. Number 2, conditional support or      |
| 16 | number three, do not support. You may now cast   |
| 17 | your votes.                                      |
| 18 | Correct.   |
| 19 | CO-CHAIR PINCUS: With the condition.             |
| 20 | Support means no condition, yes. Carol.          |
| 21 | MEMBER SAKALA: So what if the                    |
| 22 | favorable votes are divided among the first two  |
|    |  |

categories? How does that -- does it roll up to
 something? Rolls up to conditional? Yeah down,
 okay. Thank you.

MS. KUWAHARA: And we are still waiting on one more vote. We have Andrea's. Okay, perfect. 15 percent of the 13 voting members voted to support the measure; 62 percent voted to conditionally support this measure; and percent voted to not support this measure.

10 DR. BURSTIN: Conditionally support. 11 MS. GORHAM: So we actually have two 12 more measures to discuss. BMI might take up more 13 time, but we actually have two more 14 recommendations for the child task force, and that is 0480 and 2830. Of course one again is 15 16 the paper measure, the other e-measure, and that recommendation for the PC05 exclusive breast milk 17 18 feeding was made by Carol.

19 MEMBER SAKALA: Just a point of 20 clarification. Our spreadsheet actually had a 21 third number suggesting that really those are 22 both one in the same and should be considered

1 together; is that correct?

| 2  | MS. GORHAM: That is, and Suzanne is              |
|----|--|
| 3  | still on the phone, so Suzanne correct me if I   |
| 4  | state this inappropriately. But the measure, the |
| 5  | way we number here at NQF, you have the parent   |
| 6  | measure and those two metrics fall below,        |
| 7  | underneath that parent measure, and you're       |
| 8  | talking about 0341. It is just the number        |
| 9  | system, but Suzanne, weigh in please.            |
| 10 | MS. THEBERGE: Yes. It has to do with             |
| 11 | the e-measure paired measure matching system.    |
| 12 | MEMBER SAKALA: Can't we consider them            |
| 13 | together because we learned during our standing  |
| 14 | committee work that they were essentially the    |
| 15 | same measure, just different opportunities for   |
| 16 | collection?                                      |
| 17 | MS. GORHAM: So then when after you               |
| 18 | all discuss, we can vote on that one measure     |
| 19 | number.  |
| 20 | MEMBER SAKALA: Okay.                             |
| 21 | CO-CHAIR ANTONELLI: So open up.                  |
| 22 | MEMBER SAKALA: So I proposed this one            |
|    |  |

again, and it has been supported through three
National Quality Forum consensus development
process rounds, and last year, as Sean from ACOG
said, it got 91 percent support by our Committee.
I understand from NQF staff that that's kind of
an outlier level of support, so it's very, very
strong.

8 And then the e-measure, as we just 9 discussed, is identical, but to facilitate more 10 collection options. Last year the child task 11 force recommended that this be added to the child 12 core set, and CMS did not add this one, but we 13 have the opportunity now to reconsider. I feel 14 that this is really foundational.

15 I mean I would have expected this to 16 go in the first year of the child core set 17 personally because it's preventive, because it's 18 relevant to a very large proportion of the 19 maternal and infant population, because it has 20 the potential to advance health equity and has 21 been used to really take populations in certain 22 facilities where they have fairly low historic

rates of breast feeding and support, provide the 1 2 support and show significant improvement. Also, constantly in my mind is what 3 we're learning about the developmental origins of 4 5 health and disease, the human microbiome. This is like really important for lifelong health and 6 has benefits for both the child and the woman, 7 and I have -- I think I have it here. 8 9 It's old and it's being updated, but 10 the AHRQ AHIP evidence report from 2009, systematic review for children, reduces risk of 11 12 otitis media, non-specific gastroenteritis, 13 severe lower respiratory tract infection, atopic 14 dermatitis, asthma, obesity, Type 1 and Type 2 diabetes, childhood leukemia and SIDS, and for 15 16 women, reduced risk of Type 2 diabetes, breast 17 and ovarian cancer, and I think they are looking 18 now at some of the studies that have come out 19 since then around cardiovascular health and other 20 things. 21 This to me is such a big win measure, 22 and helps us to not avoid problems that we might

otherwise deal with in this program. It is supported by ACOG, and the national average was 53 percent, and people have said it could be 4 closer to 70 percent, 70 to 80 percent, in that Again, we don't have a benchmark but we range. do know that there's a wide variation and a lot of opportunity for improvement.

8 As far as federal and other national 9 programs, it's used in the -- I wasn't quite clear on this, but read hospital inpatient 10 quality reporting, the EHR incentive program. 11 12 It's a measure in the CMS and AHIP core quality measures collaborative OB/GYN core set. 13 It's in the Joint Commission Perinatal Care core set and 14 collected by all hospitals with 300 or more 15 16 births, and publicly reported in quality check 17 and in CalHospitalCompare, which impacts about 18 one birth in eight in the country.

19 So again, this was a topic where 20 concerns with coercion were raised, but I would 21 share with you that almost everybody around our very large standing committee table has 22

> Neal R. Gross and Co., Inc. Washington DC

1

2

3

5

6

7

experienced at the point of care, and this was 1 2 not a big concern, and nine in ten supported it. So I think there's a certain kind of 3 reassurance that we can take away from that, and 4 again the fact of not ever expecting 100 percent 5 is -- often allays concern. 6 7 We would have preferred a downstream 8 I personally like exclusive measure later on. 9 breast feeding at six months. That's standard. I'd like to really go for that. But we have 10 11 difficulties with collection, and I can assure 12 you that the provider community will be 13 complaining because they would say there are so 14 many things they don't have control over. So that is a good reason to choose 15 16 this tried and true, established measure that is 17 a precursor to downstream success. So I propose 18 that we shouldn't let the perfect get in the way 19 of the good here, and address these powerful benefits to -- that could accrue to the Medicaid 20 21 population. Thank you. 22 CO-CHAIR ANTONELLI: All right. Let's

open -- Carol, thank you, open this for comments. 1 2 I want to remind people that we're considering the e-measure 2830, along with the paper measure 3 4 for the sake of time efficiency. So open for comments, questions. 5 MEMBER POOLE-YAEGER: So I will just 6 7 echo your passion for the benefits of breast 8 feeding and how this is core to improving health, 9 particularly breast feeding rates in Medicaid are lower than in commercial populations. 10 So we know that there's a gap there. I think the -- this is 11 12 sort of a hospital measure, right. 13 So the hospitals are going to have it. 14 They're going to get it. I think it's important 15 to say that it's important and again I'm sorry, 16 I'm new, so I keep asking all these questions. 17 But is putting it on the Medicaid core set, it's 18 going to put the burden on the Medicaid agencies 19 to report it, even though the hospitals are 20 reporting it? I don't know. 21 I'm just trying to think about the 22 burden for the states to try to get it, you know,

and is the value worth it if Joint Commission is 1 2 already sort of pushing them? I would love to say that we would have 3 4 more effort around how do we capture breast 5 feeding outside of the hospital as well. Can we do something around it? So I don't think I have 6 7 an answer, but that was just some comments. 8 The question is how MEMBER KILSTEIN: 9 would the state collect it from the hospitals for 10 just the Medicaid population? I mean if it's a population -- if it's a hospital-based measure 11 12 and it's for all population, how are they going to collect it for just Medicaid? Just a 13 14 question. I mean maybe somebody could answer that in terms of the collection. 15 DR. APPLEGATE: So this is Mary. 16 Perhaps I can address that, you know. 17 It's 2017. 18 Pretty much every state should be linking 19 Medicaid claims with vital stats. 20 CO-CHAIR ANTONELLI: Right. 21 DR. APPLEGATE: So we've got to get out of the dark ages. This is directly from 22

vital stats, and so if we're doing our linkage 1 2 which is better than 90 percent, we actually will have the data. So that opens up all of those 3 4 fields. We might also suggest that one reason it 5 doesn't get coded now is we didn't have a code in But I believe in ten, in ICD-10 we 6 ICD-9. I don't know if it's exclusive or 7 actually do. I'd have to look it up. 8 not. 9 But what gets coded is also what gets

10 paid, right. So I think even though this is a 11 hospital measure, you heard me comment about how 12 in Medicaid I'm not as interested in in-hospital 13 processes. However, the decision to breast feed 14 is made before you deliver. So now we're back 15 into the outpatient arena. It is supported or 16 discouraged by hospital practices and policies.

17 So at our hospital, we're in a rural 18 hospital. We have 80 percent breast feeding 19 rates, which is actually pretty amazing. But I 20 can tell you every single nurse is almost a 21 lactation consultant in and of themselves, and 22 the amount of time they spend to support the

1

women is amazing.

| 2  | So the hospitals absolutely are                   |
|----|---|
| 3  | present at a very critical time to provide that   |
| 4  | support, particularly if those services are also  |
| 5  | available after they leave the home, and then can |
| 6  | continue to be supported in the pediatric or      |
| 7  | general practice.                                 |
| 8  | CO-CHAIR ANTONELLI: Thank you. So                 |
| 9  | Karen, should I move you ahead of Lisa, because   |
| 10 | you want to respond directly to this.             |
| 11 | DR. MATSUOKA: Just a little bit of                |
| 12 | CO-CHAIR ANTONELLI: Okay. So Karen                |
| 13 | and then I want to go to Lisa, and then we'll     |
| 14 | come over to Lindsay.                             |
| 15 | DR. MATSUOKA: So my only comment is               |
| 16 | that yes, we're in 2017, but Mary, Ohio, you guys |
| 17 | are way ahead of the curve on so many things, and |
| 18 | this is one area where you definitely are, I      |
| 19 | think. So I just want to put that out there, and  |
| 20 | you know, Rachel, I don't know if you want to say |
| 21 | what Florida would be able to report on this      |
| 22 | measure. I'm not sure.                            |

| But the other thing I just wanted to              |
|---|
| add is that to this issue of, you know, where     |
| data is being collected and maybe reported        |
| elsewhere, I think Marsha and I just had a        |
| conversation at one of our breaks to see, you     |
| know, what we might be able to do at the federal  |
| level to source that data, so it doesn't so       |
| that we can do some of the data feedback to the   |
| states and not have to have the data be coming    |
| from the state.                                   |
| But I think, you know, that's just a              |
| conversation we started literally today. So       |
| hopefully this time next year we'll have more to  |
| report back. But my sense is that many states     |
| are not yet at where Mary is in Ohio.             |
| CO-CHAIR ANTONELLI: Okay, Lisa.                   |
| DR. PATTON: Thank you. Yeah, so                   |
| this is kind of more of an in the weeds           |
| measurement question, and in the interest of time |
| we don't have to get into it if we don't have     |
| time.   |
| But I was curious about with the                  |
|   |
|   |

exclusions, if there was consideration of looking 1 2 at the mom's health and so adverse outcomes during the delivery that might impede breast 3 4 feeding. So I just didn't know whether there had 5 been consideration of those kinds of exclusions as well, and probably a low rate event but --6 7 MEMBER SAKALA: So I can say that 8 exclusions that are listed on the -- I'm looking 9 at them in both places. Newborns who are admitted to the NICU, newborns transferred to an 10 acute care facility, and newborns who die during 11 12 the hospitalization, and there's always -- with 13 measure development, there's always a tension 14 between all of the little things you can add on and the burden of doing that. 15 16 I think one of the trade-offs is we're going to decide nowhere are we going to go near 17 18 100 percent to make it a feasible measure to 19 collect. 20 CO-CHAIR ANTONELLI: Lindsay. 21 MS. COGAN: Thank you, and I'm sorry 22 I was a little bit late today.

|    | 24  |
|----|---|
| 1  | CO-CHAIR ANTONELLI: Yeah. I was just              |
| 2  | going to say can you just take a moment to        |
| 3  | introduce yourself, and then you can go right to  |
| 4  | your comment.                                     |
| 5  | MS. COGAN: Sure, yes. So my name is               |
| 6  | Lindsay Cogan. I am the division director for     |
| 7  | the Division of Quality Measurement of the New    |
| 8  | York State Department of Health, and I'm a        |
| 9  | quality measurement subject matter expert and in  |
| 10 | charge of most of our reporting on the adult and  |
| 11 | child core set that New York does to CMS.         |
| 12 | So I was excited to hear both Deborah             |
| 13 | and Amy's question come up, because it's often    |
| 14 | one that percolates back at the state. You know,  |
| 15 | why are we being asked to look at a facility-     |
| 16 | based measure yet again in another way, and Mary, |
| 17 | I appreciate your comments. We do link vital      |
| 18 | stats with our Medicaid claims data. Now our      |
| 19 | vital stats data is old, doesn't come to us for   |
| 20 | two years. It's not timely, you know.             |
| 21 | You've got 19-1/2 million people in               |
| 22 | New York. It takes a while to process the         |
|    |   |

I

information. So it's not actionable at that
 point for us. So what we do is we do report it
 using vital stats.

Breast feeding exclusively in the 4 5 hospital is so poorly reported when we validate that against the medical record that it's not an 6 7 area that we've been pushing as we have other 8 areas within the birth certificate that we really 9 want to capture, like previous pre-term and other high risk markers of future or subsequent pre-10 11 term or low birth weight.

12 So I do -- I do kind of echo that 13 sentiment, that if we're already collecting this 14 at the facility level, where is our actionable So is it really that we want to tease out 15 piece. 16 Medicaid only and then go back to a facility and 17 tell them where they need to work, or is that 18 confusing when a facility is already working on a 19 measure for us to intervene as a state agency, 20 and give them yet another number that doesn't 21 jibe with what they're already reporting to the Joint Commission. 22

| 1  | CO-CHAIR ANTONELLI: Thank you. Amy,               |
|----|---|
| 2  | and then Mary, is your card up again? Okay, Amy.  |
| 3  | MEMBER RICHARDSON: Yes, thank you.                |
| 4  | So as a pediatrician, I might get drummed out of  |
| 5  | the tribe for raising questions, but here's what  |
| 6  | came to my mind and please don't understand or    |
| 7  | misunderstand. Completely agree with the health   |
| 8  | benefits of breast feeding. I'm not sure this is  |
| 9  | the measure and let me see if I can articulate    |
| 10 | why.  |
| 11 | Indeed, there is evidence that long-              |
| 12 | term breast feeding affects development and       |
| 13 | health. I'm not sure there's any evidence that    |
| 14 | two to four days, which is all this is measuring, |
| 15 | somewhere between two and four days of breast     |
| 16 | feeding changes health outcomes.                  |
| 17 | I think that the measure we really                |
| 18 | have to figure out how to get to is two things:   |
| 19 | the actually actionable piece, which is what's    |
| 20 | going on with the OB/GYNs and nurse midwives      |
| 21 | during the prenatal phase, because that's what    |
| 22 | really influences what you do after the baby's    |
|    |   |

born, and then the long-term piece.

1

| 2  | I say that because it went round and             |
|----|--|
| 3  | round in my immediately past job with hospitals, |
| 4  | who wanted us to support all kinds of incentives |
| 5  | and so forth for them meeting this, and had many |
| 6  | a person tell me from the hospital perspective   |
| 7  | off the record that they had already figured out |
| 8  | how to game the data. So we can do it, but our   |
| 9  | be sure we're getting what we think we want.     |
| 10 | CO-CHAIR ANTONELLI: Uh-huh. Terry.               |
| 11 | MEMBER ADIRIM: Well, I am speaking on            |
| 12 | behalf of the American Academy of Pediatrics and |
| 13 | I agree with you, and I'm a pediatrician. It is  |
| 14 | a very important measure concept.                |
| 15 | I think we need to be working towards            |
| 16 | promoting long-term breast feeding, but to       |
| 17 | Karen's point earlier about real estate on the   |
| 18 | core set, I think if it's not a measure that's   |
| 19 | going to get us to that longer-term breast       |
| 20 | feeding, that it may not be worth that precious  |
| 21 | real estate because if you look at the data,     |
| 22 | women who breast feed in the hospital, not that  |

1

many continue breast feeding.

2 So I would advocate for -- I hate 3 saying it, but not putting this particular 4 measure on the core set, and look for better 5 measures.

And again, we grappled with this in 6 7 the military health system, because we really 8 wanted to put this on our pediatric dashboard. 9 But for the reasons that you cite and for all kinds of others, we really wanted to look at 10 11 measures that are longer-term and the problem 12 with that is that the data's not reliable by 13 documentation. So that's my opinion. 14 CO-CHAIR ANTONELLI: Rachel.

15 I would just like to MEMBER LA CROIX: 16 echo a couple of the other comments mentioned and 17 Florida to our vital statistics data, and the 18 certificate data is sometimes delayed by about 19 two years also and has a lag. So there are 20 delays in our being able to report on some 21 maternal and child health status indicator 22 measures.

www.nealrgross.com

| I  | 2   |
|----|---|
| 1  | Also, our adult core set group                    |
| 2  | yesterday discussed a lot of difficulties with    |
| 3  | the antenatal steroids measure, which I think was |
| 4  | a similar hospital-based measure already being    |
| 5  | reported by the hospitals, but difficult to look  |
| 6  | at at a specifically Medicaid, and from our       |
| 7  | Florida Medicaid perspective, most of our         |
| 8  | population is on managed care. So we're also      |
| 9  | looking for measures that are valuable at a       |
| 10 | health plan level, not just at a state Medicaid   |
| 11 | level as well, and it's difficult to get to that  |
| 12 | with some of these hospital-based measures.       |
| 13 | MEMBER BENIN: I have a comment. This              |
| 14 | is Andrea.  |
| 15 | CO-CHAIR ANTONELLI: Andrea, go ahead.             |
| 16 | MEMBER BENIN: I would just like to                |
| 17 | strongly agree with Amy and Terry. While, you     |
| 18 | know, breast feeding is one of the most important |
| 19 | things we can do for children, this metric does   |
| 20 | not get us I think where we need to be as far as  |
| 21 | really understanding that.                        |
| 22 | In addition, there are lots of reasons            |
|    |   |
|    |   |

why exclusive breast feeding, you know, may not 1 2 be feasible but yet successful breast feeding might ultimately be feasible. 3 I would rather have us acknowledge a 4 5 gap in getting to a really good breast feeding So I would agree with them. 6 metric. Thank you. CO-CHAIR ANTONELLI: Okay. 7 So I am 8 going to raise the vote here. I'll start by 9 asking if, because we have to first decide if we're going to include conditional support in 10 11 So I'm not asking you to say you want to this. 12 support, but do we want to put a condition on 13 there so we're voting against three choices 14 versus two. MS. GORHAM: And before we do that, 15 16 let me just be very clear. Because CMS has 17 already told us that the addition of an e-measure 18 is a different form of reporting, we don't need 19 to vote on both of the measures, so we will only 20 vote on one. So would anybody 21 CO-CHAIR ANTONELLI: 22 like to propose a condition?

|    | 2   |
|----|---|
| 1  | (No audible response.)                            |
| 2  | CO-CHAIR ANTONELLI: Okay. So that                 |
| 3  | means Miranda, we're voting on two choices here,  |
| 4  | please.   |
| 5  | (Pause.)  |
| 6  | MS. KUWAHARA: So just to reiterate                |
| 7  | one last time, this is for Measure No. 0480,      |
| 8  | PC05, Exclusive Breast Milk Feeding. This also    |
| 9  | encompasses e-measure No. 2830 and it's all under |
| 10 | the parent measure number 3041. This is all one   |
| 11 | vote. We are going to vote for two options. One   |
| 12 | is support and three is do not support. Child     |
| 13 | task force members, you can cast your votes.      |
| 14 | 85 percent of the 13 respondents                  |
| 15 | voted not to support this measure.                |
| 16 | CO-CHAIR ANTONELLI: We'll open up for             |
| 17 | public comment. Operator, why don't we open up    |
| 18 | to the lines first and then we'll give people a   |
| 19 | chance in the room here to come up to the         |
| 20 | microphone.                                       |
| 21 | OPERATOR: At this time, if you would              |
| 22 | like to make a public comment. Please press star  |
|    |   |
|    |   |

then the number one. 1 2 (No audible response.) And there are no public 3 **OPERATOR:** comments from the phone line. 4 CO-CHAIR ANTONELLI: Thank you. 5 Public comments from the folks in the room here? 6 7 (No audible response.) CO-CHAIR ANTONELLI: 8 Okay. 9 MS. GORHAM: All right. I think we're 10 going to power through and not take a break, but definitely if you need to step out and take a 11 12 break, please do so. But I want to be respectful I know that we have some adult members 13 of time. 14 who would like to make their plane and trains on 15 time. So we're just going to keep on with our 16 asthma conversation, and I want to go rather 17 quickly but definitely stop me if I am moving a 18 little too fast or there are questions. 19 This before you is the summary slide 20 for the asthma measures. We did a search and 21 were found 12 total measures in the asthma universe, five endorsed, seven not endorsed. 22

Washington DC

Five of those seven not endorsed measures are PQMP measures.

Next slide. So I'll give you an 3 4 update on just some of the maintenance and loss 5 of endorsement in the asthma arena, if you move to the next slide. 1799, which is currently on 6 7 the child core set, lost endorsement in 2016. It 8 was recommended by the adult task force members 9 for a few years but never added. Here is again a slide 10 Next slide. 11 that you can also find in your chart packs, to 12 just kind of tell about the median percent of children ages 5 to 20 remain on asthma control 13 14 medication for at least 75 percent of their 15 treatment period. Sixteen states did not report 16 this measure, and some of those reasons include, 17 again, budget constraints. MCOs are not required 18 to submit this HEDIS measure. State-collected 19 information on this HEDIS measure for use of 20 inappropriate medication for people with asthma, 21 the states report on in all age bands in the combined rate. 22

1

2

| 1  | Those are just a few of the reasons              |
|----|--|
| 2  | not reported. Again, you can find a              |
| 3  | comprehensive list in the material that was sent |
| 4  | to you before the meeting.                       |
| 5  | Next slide, next slide. So to get to             |
| 6  | the reasons that endorsement was removed from    |
| 7  | this measure, the Pulmonary and Critical Care    |
| 8  | Standing Committee noted concerns over the       |
| 9  | evidence, especially with a study noting         |
| 10 | inaccuracy in the data analysis, as well as with |
| 11 | the long list of allowable medications.          |
| 12 | They pointed out that the measure does           |
| 13 | not address whether patients are getting the     |
| 14 | correct medications for their particular type of |
| 15 | asthma. The Committee and the CSAC then reviewed |
| 16 | the measure and could not reach consensus. We    |
| 17 | went to the CSAC 60 percent rate in order to     |
| 18 | approve the measure for endorsement was not      |
| 19 | achieved, and so the endorsement was removed.    |
| 20 | So again, in 2014, 2015 and 2016, this           |
| 21 | measure was recommended by the adult task force. |
| 22 | Because endorsement was removed, you can move to |

the next slide, was removed from this measure,
 CMS asked the staff to do an analysis on
 alternative ambulatory setting asthma measures,
 and we did that, and we also sent that to you
 pre-meeting in your material.

In doing that analysis to address the 6 7 gap, if in fact the task force votes to remove 8 and CMS removes that measure, we found two 9 measures, 0047 and also 1800. So 0047, the Pharmacological Therapy for Persistent Asthma, 10 and then 1800, Asthma Medication Ratio. 11 The 12 similarities of both 0047 and 1800, they both 13 address prescribing patterns and not medication 14 adherence, while 1799 addressed patient adherence to prescribing asthma medication. 15

Both 0047 and 1800 have comparable target populations and promote the use of longterm asthma control or medications. There is widespread use in both public reporting and quality improvement programs, and if we move to the next slide.

22

So just to add a little bit more

information about the two measures, 0047, measure 1 2 stratification captures information related to prescription type. 1800 focuses on a ratio, 3 making it easier to identify patients who may 4 5 have inappropriate prescription treatment plans, and then also 1800 is identical to 1799 in target 6 7 population, data source, and level of analysis, making the reporting burden minimal for states 8 9 that have experienced reporting on 1799. 10 So that was pretty quick, but that 11 gives you a little summary of the analysis that

12 we completed on those two measures in relation to 13 1799. I will turn it over to Harold. I will say 14 if we want to kind of take the same strategy we took with the maternal and perinatal health, we 15 16 do have a recommendation for 1800. So we can 17 have that lead discussant talk about 1800, then 18 have a joint discussion and then vote separately. 19 CO-CHAIR PINCUS: Yes. I would 20 suggest that we do maintain the sort of --21 maintain alignment, that's the word people have 22 been using, that we actually have a joint
discussion about potential replacements for the asthma measure.

Okay. So if we do that, 3 MS. GORHAM: we're going to pull up the specifications for 4 1800, and then I'm going to turn it over to 5 Terry, because she is the lead discussant. 6 7 MEMBER ADIRIM: If I may add, you 8 stole my thunder. I wrote everything down here. 9 Obviously, asthma is a very important condition for the Medicaid population. 10 It's highly 11 prevalent in both children and in adults. This 12 measure covers children and adults 5 to 64, which makes it a nice measure for both measure sets. 13 14 There's a lot of really good evidence for this particular measure, which is why it was 15 16 endorsed versus 1799 being unendorsed. It's also

a high cost condition. People with asthma have
frequent office visits and patient visits, and
controller medications reduce both emergency
department and inpatient admissions. So I would
imagine this would be very important to state
Medicaid agencies.

(202) 234-4433

1

2

|    | ∠   |
|----|---|
| 1  | So I'm not sure how much more I can               |
| 2  | add, but except that I'm very much for this       |
| 3  | particular measure. The only downside I saw with  |
| 4  | this particular measure is that as a              |
| 5  | communication tool, you have to explain it, what  |
| 6  | the numerator means and what the ratio means. So  |
| 7  | just by looking at the measure results, you don't |
| 8  | necessarily have an idea unless you know the      |
| 9  | measure. But it does have a lot of evidence to    |
| 10 | back it up as a for the outcomes that we're       |
| 11 | looking for.                                      |
| 12 | CO-CHAIR PINCUS: I was just                       |
| 13 | wondering, could you say something about that     |
| 14 | measure as compared to 1800 versus 0047?          |
| 15 | MEMBER ADIRIM: I don't know 0047. I               |
| 16 | recommended this one, so sorry. I mean I guess    |
| 17 | Shaconna maybe.                                   |
| 18 | CO-CHAIR PINCUS: Yeah. Helen, could               |
| 19 | you maybe discuss the distinctions, because I     |
| 20 | think this would be                               |
| 21 | DR. BURSTIN: Sure, as the resident                |
| 22 | internist. So yes, so 0047 went by drug           |
|    |   |
|    |   |

So it for example looked at the 1 class. 2 percentage of patients age 5 and older who are prescribed long term control medications, and 3 first it was inhaled corticosteroids. Second was 4 other alternative, long-term control medications 5 and then total patients prescribed long-term. 6 7 One of the issues that the Committee 8 had when they reviewed this was a long list of 9 meds, some of which are recommended, some of 10 which really are not anymore. So I think these 11 later two measures and the numbers are actually 12 helpful here. 0047 was a very early measure 13 submitted to NQF -- literally the 47th measure --14 and 1799 and 1800 represent newer measures NCQA 15 has recently adopted. 16 The advantage of these obviously is 17 that they do specifically give you a sense of are 18 patients getting the controller medications they 19 need, but also in comparison to the emergency 20 inhalers that they tend to use, which don't 21 actually control asthma.

22

So both of these did very well, just

Neal R. Gross and Co., Inc. Washington DC

www.nealrgross.com

different approaches. And 1800 I think is 1 2 probably the simpler of the two, since 1799 has two different rates. 3 4 CO-CHAIR PINCUS: So Marissa I see and 5 Lindsay. MEMBER SCHLAIFER: So I don't know if 6 7 there's too much more that needs to be said, 8 although I'll add a couple of things. So I can 9 also count this as making a motion, if that will help move things along. 10 11 CO-CHAIR PINCUS: Okav. 12 MEMBER SCHLAIFER: Yeah, and so I think when we talk about the two different 13 14 measures, I can also say I am not familiar with -- I mean I read up on it last night, but the 0047 15 measure, it's not one that I've seen used 16 17 anywhere. This measure is used commonly across 18 all types of programs. I think when -- just to 19 follow up on that comment, if this one is a little more -- takes a little more thought 20 because it's the ratio of controller medications 21 to rescue medications. 22

(202) 234-4433

Neal R. Gross and Co., Inc. Washington DC

www.nealrgross.com

|    | 20   |
|----|--|
| 1  | That's what we think about though when           |
| 2  | we think about treating asthma. The other        |
| 3  | measure, 0047, is just what percent of asthmatic |
| 4  | patients get a controller. But I think really    |
| 5  | when we look at quality, we're looking at        |
| 6  | looking at people who may have problems with     |
| 7  | their asthma, and not just any patient with      |
| 8  | asthma.  |
| 9  | So I would say for all reasons, this             |
| 10 | is the better of the two. And I'd like to make a |
| 11 | motion too.                                      |
| 12 | CO-CHAIR PINCUS: While you're at it,             |
| 13 | make a motion.                                   |
| 14 | MEMBER SCHLAIFER: I make a motion to             |
| 15 | include this to the adult core measure set.      |
| 16 | CO-CHAIR PINCUS: Okay. So now we                 |
| 17 | have a parallel set of motions, so that's good.  |
| 18 | Lindsay.   |
| 19 | MS. COGAN: I just kind of want to                |
| 20 | echo New York State support for this particular  |
| 21 | measure, and when we look at the medication      |
| 22 | needed from the asthma across commercial and     |
|    |  |

Medicaid, we see little to no variation. 1 When we 2 look at the asthma ratio measure across commercial and Medicaid, we see 20 percentage 3 4 point differences. We're at 80 percent in the 5 commercial and 60 percent among our Medicaid managed care with children. 6 7 So we have identified this is a key 8 area of the rescue to controller. So as a state, 9 we would definitely support the inclusion of this. 10 11 CO-CHAIR PINCUS: Other comments? Anybody speaking against this measure? 12 13 (No audible response.) 14 CO-CHAIR PINCUS: Anybody speaking to 15 recommend conditions for supporting this measure? 16 (No audible response.) 17 CO-CHAIR PINCUS: So I guess we're 18 ready to vote. I guess first the Adult and then 19 the Child? 20 MS. KUWAHARA: Yes. Bear with me for 21 just a moment. I have to do some on the fly 22 PowerPoint creation here.

|    | 2:  |
|----|---|
| 1  | (Pause.)  |
| 2  | MS. KUWAHARA: Okay. We'll begin with              |
| 3  | the Adult Task Force. This is for including       |
| 4  | Measure No. 1800, Asthma Medication Ratio. Your   |
| 5  | options are 1 support, 2 conditional support and  |
| 6  | 3 do not support. But because we didn't identify  |
| 7  | any conditions, your only options are 1 support   |
| 8  | and 3 do not support.                             |
| 9  | (Voting.)   |
| 10 | MS. KUWAHARA: One hundred percent of              |
| 11 | the eight voting members voted to support this    |
| 12 | measure.  |
| 13 | CO-CHAIR ANTONELLI: And I'm presuming             |
| 14 | that the Child folks are going to weigh in on the |
| 15 | conditions, so unless somebody feels that they    |
| 16 | didn't hear that, I'd like to proceed with the    |
| 17 | Child folks to vote. Do we want to on the         |
| 18 | Child side vote before we do the 1799 vote?       |
| 19 | MS. GORHAM: So the Child Task Force               |
| 20 | actually has two decisions to make. One, you all  |
| 21 | will be voting for removal of 1799 and you will   |
| 22 | also be voting for the addition of 1800.          |

| I  |   |
|----|---|
| 1  | CO-CHAIR ANTONELLI: So is it okay to              |
| 2  | proceed with this vote and then we'll do 1799?    |
| 3  | Okay, all right. So Child folks, we're going to   |
| 4  | be voting options number 1, support, or 3, do not |
| 5  | support. Miranda, there's no conditions on this   |
| 6  | one.  |
| 7  | MS. KUWAHARA: That's right.                       |
| 8  | CO-CHAIR PINCUS: Once again, this is              |
| 9  | 1800, Measure 1800 we're talking about.           |
| 10 | (Voting.)   |
| 11 | MS. KUWAHARA: And 100 percent of the              |
| 12 | 13 voting members voted to support this measure.  |
| 13 | MS. GORHAM: Before we move on, we                 |
| 14 | would like to take public comment because this    |
| 15 | concludes the voting for the asthma section, but  |
| 16 | we do want to entertain public comment.           |
| 17 | OPERATOR: And at this time if you                 |
| 18 | would like to make a public comment, please press |
| 19 | star then the number 1.                           |
| 20 | (No audible response.)                            |
| 21 | OPERATOR: And there are no public                 |
| 22 | comments at this time.                            |
|    |   |

|    | ∠   |
|----|---|
| 1  | MS. GORHAM: Okay, I'm sorry. I'm                  |
| 2  | jumping ahead of myself actually because we       |
| 3  | didn't vote on the removal for 1799 for the Child |
| 4  | Task Force. So let's do that.                     |
| 5  | CO-CHAIR ANTONELLI: Okay. So Child                |
| 6  | Task Force 1799. Can you put that on the screen   |
| 7  | for consideration? So be mindful that we just     |
| 8  | voted for support of 1800. So the vote before us  |
| 9  | would be to recommend removal of 1799. Comments   |
| 10 | or questions before we proceed to a vote?         |
| 11 | (No audible response.)                            |
| 12 | CO-CHAIR ANTONELLI: Okay. Hearing                 |
| 13 | and seeing none, Miranda.                         |
| 14 | MS. KUWAHARA: So we're voting to                  |
| 15 | remove Measure No. 1799, Medication Management    |
| 16 | for People with Asthma. This is for the Child     |
| 17 | Task Force. Your first option is yes, you would   |
| 18 | like this measure to be removed that's number     |
| 19 | one or number two, you would not like to see      |
| 20 | this measure removed.                             |
| 21 | (Voting.)   |
| 22 | MS. KUWAHARA: One hundred percent of              |
|    |   |
|    |   |

the 13 voting members voted to remove 1799 from
 the child core set.

Give us one minute. 3 MS. GORHAM: We 4 are teeing up for the discussion for the Adult 5 Task Force. We need to prioritize and rank our Before we do that, we just want to 6 measures. 7 make sure that we have all of the conversation 8 for the asthma measures. So give us one minute. 9 (Pause.) 10 MS. GORHAM: It is going to take us 11 about three minutes, so if you want to step out 12 real fast and take a break, then we can do that. 13 What we are going to do -- so I can just explain 14 to you, so each year when we make recommendations to CMS, we also like to rank those 15 16 recommendations. And so what we are doing now, 17 we're going to do the old-fashioned way of 18 ranking. We're going to use our dots like we did 19 yesterday. 20 And so the measures, you're going to 21 rank by importance, and so we will give you -- we

are going to pass out dots momentarily and you

22

(202) 234-4433

| 1  | have we have two three measures for               |
|----|---|
| 2  | conditional support and one for support. You can  |
| 3  | put your dot wherever you want. You will have     |
| 4  | three dots because we have four measures.         |
| 5  | Again, you can put them wherever you              |
| 6  | want and then however they fall out is what we    |
| 7  | will rank and send to CMS. So give us one minute  |
| 8  | while we do that.                                 |
| 9  | CO-CHAIR PINCUS: And just to point                |
| 10 | out that the conditions differ among the three    |
| 11 | conditionally supported ones. For the             |
| 12 | contraceptive care one, the conditional issue was |
| 13 | to be used for quality improvement not payment,   |
| 14 | for the CAHPS home and community-based services,  |
| 15 | it was the concern about looking into making      |
| 16 | it more readily actionable.                       |
| 17 | Actually, it was not conditional for              |
| 18 | the adults. It was conditional for the child,     |
| 19 | yes. So just to point that out. The               |
| 20 | contraceptive care was not conditional for the    |
| 21 | adults. Right, yeah. So one the home              |
| 22 | community-based was conditional to look into      |

making the results more actionable, and for the
 concurrent use of opioids and benzodiazepines,
 that was a weighty endorsement.

MS. MUKHERJEE: And you can put all of your three dots on one measure if you really feel strongly about sort of promoting or sort of ranking and sort of moving a measure up in the ranks.

9 CO-CHAIR PINCUS: And the Child group 10 won't do this until tomorrow afternoon obviously. 11 (Whereupon, the above-entitled matter 12 went off the record at 2:26 p.m. and resumed at 13 2:33 p.m.)

14 CO-CHAIR PINCUS: Okay. So just to announce the results of the prioritization, it 15 16 looks like the -- yeah, that 1800 -- the asthma 17 medication ratio -- got eight votes. The CAHPS 18 home and community-based services got seven, as 19 well as the concurrent use of opioids and 20 benzodiazepines also got seven, and the 21 contraceptive care one got five.

22

(Off microphone comments.)

| 1CO-CHAIR PINCUS: No. Colors are<br>meaningless, yeah. It's yellow, so you can't see<br>it.3it.4MS. GORHAM: So we had a question.5The colors mean nothing. It's really the number<br>of dots.7CO-CHAIR PINCUS: Yeah. So it was a<br>very close race.9MS. GORHAM: Okay. The contraceptive<br>care 2903 received five votes, okay. And<br>so just so that you will note, the Child Task<br>Force will do the same process after you all<br>discuss the rest of your measures tomorrow.14So with that, that concludes our<br>discussion on maternal and perinatal health, as<br>well as asthma, and we are going to move right<br>along. Actually, it puts us back on schedule, so<br>we are moving at a good pace. I'm going to turn<br>it over to Rich.20CO-CHAIR ANTONELLI: All right. So we21want to change the focus a bit, thinking about<br>supporting states' ability to report measures,   |    | 2  |
|--|----|--|
| 3       it.         4       MS. GORHAM: So we had a question.         5       The colors mean nothing. It's really the number         6       of dots.         7       CO-CHAIR PINCUS: Yeah. So it was a         8       very close race.         9       MS. GORHAM: Okay. The contraceptive         10       care 2903 received five votes, okay. And         11       so just so that you will note, the Child Task         12       Force will do the same process after you all         13       discuss the rest of your measures tomorrow.         14       So with that, that concludes our         15       discussion on maternal and perinatal health, as         16       well as asthma, and we are going to move right         17       along. Actually, it puts us back on schedule, so         18       we are moving at a good pace. I'm going to turn         19       it over to Rich.         20       CO-CHAIR ANTONELLI: All right. So we         21       want to change the focus a bit, thinking about | 1  | CO-CHAIR PINCUS: No. Colors are                  |
| 4MS. GORHAM: So we had a question.5The colors mean nothing. It's really the number6of dots.7CO-CHAIR PINCUS: Yeah. So it was a8very close race.9MS. GORHAM: Okay. The contraceptive10care 2903 received five votes, okay. And11so just so that you will note, the Child Task12Force will do the same process after you all13discuss the rest of your measures tomorrow.14So with that, that concludes our15discussion on maternal and perinatal health, as16well as asthma, and we are going to move right17along. Actually, it puts us back on schedule, so18we are moving at a good pace. I'm going to turn19it over to Rich.20CO-CHAIR ANTONELLI: All right. So we21want to change the focus a bit, thinking about  | 2  | meaningless, yeah. It's yellow, so you can't see |
| <ul> <li>The colors mean nothing. It's really the number</li> <li>of dots.</li> <li>CO-CHAIR PINCUS: Yeah. So it was a</li> <li>very close race.</li> <li>MS. GORHAM: Okay. The contraceptive</li> <li>care 2903 received five votes, okay. And</li> <li>so just so that you will note, the Child Task</li> <li>Force will do the same process after you all</li> <li>discuss the rest of your measures tomorrow.</li> <li>So with that, that concludes our</li> <li>discussion on maternal and perinatal health, as</li> <li>well as asthma, and we are going to move right</li> <li>along. Actually, it puts us back on schedule, so</li> <li>we are moving at a good pace. I'm going to turn</li> <li>it over to Rich.</li> <li>CO-CHAIR ANTONELLI: All right. So we</li> </ul>   | 3  | it.  |
| <ul> <li>of dots.</li> <li>CO-CHAIR PINCUS: Yeah. So it was a</li> <li>very close race.</li> <li>MS. GORHAM: Okay. The contraceptive</li> <li>care 2903 received five votes, okay. And</li> <li>so just so that you will note, the Child Task</li> <li>Force will do the same process after you all</li> <li>discuss the rest of your measures tomorrow.</li> <li>So with that, that concludes our</li> <li>discussion on maternal and perinatal health, as</li> <li>well as asthma, and we are going to move right</li> <li>along. Actually, it puts us back on schedule, so</li> <li>we are moving at a good pace. I'm going to turn</li> <li>it over to Rich.</li> <li>CO-CHAIR ANTONELLI: All right. So we</li> </ul>  | 4  | MS. GORHAM: So we had a question.                |
| 7CO-CHAIR PINCUS: Yeah. So it was a<br>very close race.9MS. GORHAM: Okay. The contraceptive10care 2903 received five votes, okay. And11so just so that you will note, the Child Task12Force will do the same process after you all13discuss the rest of your measures tomorrow.14So with that, that concludes our15discussion on maternal and perinatal health, as16well as asthma, and we are going to move right17along. Actually, it puts us back on schedule, so18we are moving at a good pace. I'm going to turn19it over to Rich.20CO-CHAIR ANTONELLI: All right. So we21want to change the focus a bit, thinking about  | 5  | The colors mean nothing. It's really the number  |
| <ul> <li>k very close race.</li> <li>MS. GORHAM: Okay. The contraceptive</li> <li>care 2903 received five votes, okay. And</li> <li>so just so that you will note, the Child Task</li> <li>Force will do the same process after you all</li> <li>discuss the rest of your measures tomorrow.</li> <li>So with that, that concludes our</li> <li>discussion on maternal and perinatal health, as</li> <li>well as asthma, and we are going to move right</li> <li>along. Actually, it puts us back on schedule, so</li> <li>we are moving at a good pace. I'm going to turn</li> <li>it over to Rich.</li> <li>CO-CHAIR ANTONELLI: All right. So we</li> </ul>  | 6  | of dots.   |
| <ul> <li>MS. GORHAM: Okay. The contraceptive</li> <li>care 2903 received five votes, okay. And</li> <li>so just so that you will note, the Child Task</li> <li>Force will do the same process after you all</li> <li>discuss the rest of your measures tomorrow.</li> <li>So with that, that concludes our</li> <li>discussion on maternal and perinatal health, as</li> <li>well as asthma, and we are going to move right</li> <li>along. Actually, it puts us back on schedule, so</li> <li>we are moving at a good pace. I'm going to turn</li> <li>it over to Rich.</li> <li>CO-CHAIR ANTONELLI: All right. So we</li> </ul>  | 7  | CO-CHAIR PINCUS: Yeah. So it was a               |
| <ul> <li>10 care 2903 received five votes, okay. And</li> <li>11 so just so that you will note, the Child Task</li> <li>12 Force will do the same process after you all</li> <li>13 discuss the rest of your measures tomorrow.</li> <li>14 So with that, that concludes our</li> <li>15 discussion on maternal and perinatal health, as</li> <li>16 well as asthma, and we are going to move right</li> <li>17 along. Actually, it puts us back on schedule, so</li> <li>18 we are moving at a good pace. I'm going to turn</li> <li>19 it over to Rich.</li> <li>20 CO-CHAIR ANTONELLI: All right. So we</li> <li>21 want to change the focus a bit, thinking about</li> </ul>   | 8  | very close race.                                 |
| 11 so just so that you will note, the Child Task<br>Force will do the same process after you all<br>discuss the rest of your measures tomorrow.<br>14 So with that, that concludes our<br>15 discussion on maternal and perinatal health, as<br>16 well as asthma, and we are going to move right<br>17 along. Actually, it puts us back on schedule, so<br>18 we are moving at a good pace. I'm going to turn<br>19 it over to Rich.<br>20 CO-CHAIR ANTONELLI: All right. So we<br>21 want to change the focus a bit, thinking about  | 9  | MS. GORHAM: Okay. The contraceptive              |
| Force will do the same process after you all<br>discuss the rest of your measures tomorrow.<br>So with that, that concludes our<br>discussion on maternal and perinatal health, as<br>well as asthma, and we are going to move right<br>along. Actually, it puts us back on schedule, so<br>we are moving at a good pace. I'm going to turn<br>it over to Rich.<br>CO-CHAIR ANTONELLI: All right. So we<br>want to change the focus a bit, thinking about  | 10 | care 2903 received five votes, okay. And         |
| 13 discuss the rest of your measures tomorrow.<br>14 So with that, that concludes our<br>15 discussion on maternal and perinatal health, as<br>16 well as asthma, and we are going to move right<br>17 along. Actually, it puts us back on schedule, so<br>18 we are moving at a good pace. I'm going to turn<br>19 it over to Rich.<br>20 CO-CHAIR ANTONELLI: All right. So we<br>21 want to change the focus a bit, thinking about   | 11 | so just so that you will note, the Child Task    |
| 14So with that, that concludes our15discussion on maternal and perinatal health, as16well as asthma, and we are going to move right17along. Actually, it puts us back on schedule, so18we are moving at a good pace. I'm going to turn19it over to Rich.20CO-CHAIR ANTONELLI: All right. So we21want to change the focus a bit, thinking about   | 12 | Force will do the same process after you all     |
| discussion on maternal and perinatal health, as<br>well as asthma, and we are going to move right<br>along. Actually, it puts us back on schedule, so<br>we are moving at a good pace. I'm going to turn<br>it over to Rich. CO-CHAIR ANTONELLI: All right. So we want to change the focus a bit, thinking about   | 13 | discuss the rest of your measures tomorrow.      |
| 16 well as asthma, and we are going to move right<br>17 along. Actually, it puts us back on schedule, so<br>18 we are moving at a good pace. I'm going to turn<br>19 it over to Rich.<br>20 CO-CHAIR ANTONELLI: All right. So we<br>21 want to change the focus a bit, thinking about  | 14 | So with that, that concludes our                 |
| 17 along. Actually, it puts us back on schedule, so<br>18 we are moving at a good pace. I'm going to turn<br>19 it over to Rich.<br>20 CO-CHAIR ANTONELLI: All right. So we<br>21 want to change the focus a bit, thinking about   | 15 | discussion on maternal and perinatal health, as  |
| 18 we are moving at a good pace. I'm going to turn<br>19 it over to Rich.<br>20 CO-CHAIR ANTONELLI: All right. So we<br>21 want to change the focus a bit, thinking about  | 16 | well as asthma, and we are going to move right   |
| <pre>19 it over to Rich. 20 CO-CHAIR ANTONELLI: All right. So we 21 want to change the focus a bit, thinking about</pre>   | 17 | along. Actually, it puts us back on schedule, so |
| 20 CO-CHAIR ANTONELLI: All right. So we<br>21 want to change the focus a bit, thinking about   | 18 | we are moving at a good pace. I'm going to turn  |
| 21 want to change the focus a bit, thinking about  | 19 | it over to Rich.                                 |
|  | 20 | CO-CHAIR ANTONELLI: All right. So we             |
| 22 supporting states' ability to report measures,  | 21 | want to change the focus a bit, thinking about   |
|  | 22 | supporting states' ability to report measures,   |
|  |    |  |

ways of strengthening the core sets. Sort of reflecting on our presentation from our CMS colleagues, not just in the morning but even the commentary that you guys fed into the measure discussion, thank you, and Mary from -- and now actually Lindsay as well as from the front, from -- whoops.

8 So thanking everybody from this --9 from CMS and the commentary that flowed into the 10 measure discussions, the sense of reality from 11 the front lines from Mary and from Lindsay as 12 well.

13 So this portion of the conversations 14 this afternoon really is in this space, that's 15 thinking pretty strategically, but there's going 16 to be a tactical component around the ability to 17 report some of these measures. So I think 18 Debjani, you're going to take us forward a little 19 bit here.

20 MS. MUKHERJEE: Sure. So there are a 21 couple of issues that sort of the task force 22 members and our chairs brought up to be discussed

> Neal R. Gross and Co., Inc. Washington DC

1

2

3

4

5

6

today during sort of this strategic reporting and 1 2 sort of increase in reporting discussion section, and some are more methodological such as 3 stratification segmentation, and sort of looking 4 at it for QI across age groups. 5 I know this topic is very near and 6 7 dear to Harold, and so I'm going to ask him to 8 talk a little bit about it. The other thing that 9 we're going to also look at is alignment. Before we get started, I just wanted to give you sort of 10 a brief overview of sort of the amount of 11 12 alignment we have right now. So for the adult core set, there's 13 14 some alignment with the AHIP core sets and about -- most of it around OB/GYN measures. 15 So the 16 elected delivery, antenatal steroids, some of the 17 screening measures, cervical cancer screening, 18 breast cancer screening, as well as sort of acute 19 and chronic care condition, high blood pressure 20 control diabetes testing and diabetes poor 21 control, so those are the ones. 22 And then as far as alignment with

> Neal R. Gross and Co., Inc. Washington DC

www.nealrgross.com

1 federal programs, for the adult side most of the 2 alignment is with PQRS and MIPS, and that's with 3 nine measures. And then on the child side, 4 there's also alignment mostly with MIPS. So I 5 just wanted to provide sort of a brief overview 6 of sort of the amount of alignment.

So considering that core sets are in 7 8 upwards of 20's and 30's, having nine to ten 9 measures aligned, it's still sort of on the lower level, sort of -- the amount of alignment, the 10 11 potential for further alignment still lies there. 12 So I wanted to start with that, and after that 13 we're going to sort of go back to the 14 methodological.

But before we started this, I wanted 15 16 to give sort of an overview and understanding of 17 what is the level of alignment right now. We 18 know there is some between the two core sets and 19 then we have screen shared now sort of the 20 alignment of the child and also the adult. So I 21 just went over sort of an aggregate of the 22 results there. And -- we can go back to the

1 methodological slides now.

| 2  | So as far as the methodology goes,                |
|----|---|
| 3  | stratification is something that can happen in    |
| 4  | many ways, and I just list out some of the        |
| 5  | potential ways of stratifying condition groups by |
| 6  | risk, by age, by any other factor of interest, as |
| 7  | just sort of things to discuss and for you to     |
| 8  | provide your input on what works and not works,   |
| 9  | especially for the Medicaid population at the     |
| 10 | state level, especially when we're looking across |
| 11 | adult and child and potentially trying to align   |
| 12 | collection of data.                               |
| 13 | Then we have some questions that I'll             |
| 14 | turn over to Rich for, but what we're trying to   |
| 15 | get here especially for staff to synthesize       |
| 16 | and write for the report is what are the          |
| 17 | elements of stratification. What works? We        |
| 18 | always hear about age. Is risk group something    |
| 19 | that we want to sort of talk about. Maybe what's  |
| 20 | the role of social determinants of health.        |
| 21 | You know, we've heard a lot about that            |
| 22 | today, and then also when we get to sort of the   |

issues of alignment and data collection, you 1 2 know, we've heard a lot of the challenges today. EHR and sort of interoperability have come up and 3 sort of connecting different databases. 4 Anything 5 else that we can sort of add to that list, as well as what -- how are states getting around 6 7 that would be great. With that, I'll turn it over to Rich 8 9 to start the conversation with stratification. So thinking about 10 CO-CHAIR ANTONELLI: 11 this idea about stratification within a 12 population -- in this case the population is defined as recipients of Medicaid -- how do we 13 14 optimize it or maximize stratification based on measurement, and how do we incorporate 15 16 stratification in the measure mechanics. 17 I think this -- I was actually pretty 18 interested to hear the narrative about an hour 19 and a half or so ago, where you were sort of drawing in terms of defining how some of the 20 21 current data flows that you're looking at actually get at a stratification, enabling you 22

1

and your team to identify disparities.

2 So I think that's the place that we're -- that we'd like to bring the conversation right 3 now in terms of stratification, risk or other 4 types of factors that would be meaningful. 5 So I think why don't we -- well, for the sake of time, 6 7 can you just go to the next slide so you can see what sort of some follow-on questions are going 8 9 to be, some of the -- some challenges. 10 So as we define some opportunities, 11 what are going to be some of the challenges going 12 forward, other types of alignments, issues that 13 states need in the near future. Life course, the 14 conversation this morning from CMS talking about for a lot of maternal and infant health. They 15 16 see that really as a continuum, which just brings 17 joy to my heart. 18 And then how can CMS facilitate 19 alignment at the state level, getting at that notion of can Karen build other connections the 20 21 way we have such robust performance in New York

22

Neal R. Gross and Co., Inc. Washington DC

and Ohio and move that forward.

(202) 234-4433

So that pretty much frames a lot of 1 2 the strategic questions that we would like to bring up right now. So opening this to the Adult 3 and the Child Task Force, if somebody would like 4 to start the conversation. Harold. 5 CO-CHAIR PINCUS: So it goes back to 6 7 something we talked about a little bit yesterday 8 in the Adult Task Force was sort of -- at least 9 my view is that there are sort of three buckets 10 of activities in a sense that quality measurement 11 gets applied to, and we tend to focus on the 12 quality improvement bucket and also on the 13 accountability bucket.

14 But there's also the sort of understanding and sort of knowledge gained kind 15 16 of bucket, which is basically built around sort 17 of understanding variation, so that one can set 18 priorities and identify where there's problems. 19 And so I think that we kind of underplay that a 20 little bit, often in terms of -- and one way of 21 understanding variation is to look at different 22 segments of the population, whether it's urban-

rural or whether it's by age or whether it's by
certain characteristics of the population,
minority and ethnic status and other
demographics, and also by different
comorbidities, and also looking at it in terms of
the different silos of care in which people get
their primary attention.

So one thing that we've been thinking 8 9 a lot about lately has been around issues of coordination and integration between behavioral 10 health -- between or within behavioral health and 11 general medical care, that interface there, and 12 13 thinking of ways by which one could address that 14 in a more effective way, looking at both -- you know, from the point of view of understanding 15 16 what's going on but also thinking about quality 17 improvement and -- particularly around 18 coordination, but also in terms of accountability 19 types of issues.

20 So to think about people with severe 21 forms of mental illness as a kind of disparities 22 population that could be in some ways easily

segmented out because it's on the basis of
 diagnosis, and in many cases you have claims data
 that allowed you to fairly easily pull out a
 segment of the population based upon diagnosis,
 you know, without a lot of additional data gathering.

7 The reason for looking at it from the 8 point of view of severe and persistent mental 9 illness is because that -- those individuals, that group suffers from a great deal of 10 11 comorbidities, as well as a number of other 12 health and social mediator-related issues that 13 result in a 10 to 20 year age gap in terms of 14 mortality, that they, you know, are more likely to die 10 to 20 years earlier than the general 15 16 population.

They also represent a kind of -- sort of a sentinel issue in terms of issues around coordination between behavioral health and general health care. It's also linked to issues around accountability, because if one thinks of -- you know, in terms of thinking about who is

accountable for the health care of individuals 1 2 with severe and persistent mental illness, it's not clear, you know, who is responsible. 3 If I'm a psychiatrist and I have a 4 5 patient with schizophrenia and diabetes, am I just responsible for the care of that 6 7 schizophrenia and the outcomes, or do I have some 8 responsibility for the outcomes for diabetes? 9 And on the other hand, what about their primary care provider? To what extent did they share 10 11 accountability for both of those? 12 If you have an expectation of shared 13 accountability, it essentially requires that the 14 primary care provider and myself talk to each 15 other in order to coordinate care. 16 And then if one can then pull out that 17 population and look at, for example, the relative 18 degree of diabetic control or of control of 19 hypertension and so on, or the degree to which 20 they access preventive health care services as 21 compared to the general population, that gives you kind of a hook to kind of look at number one, 22

setting a priority but also looking at how one can improve in that, especially when there's a disparity.

So I guess what I'm encouraging -- and 4 5 it's begun to do that because in fact there's an earlier point in time where this came up. 6 Ι There was a question 7 guess Helen stepped out. 8 about whether the -- if you're looking at a 9 segment of a denominator, does that have to be a separate measure or not? And the ultimate 10 11 decision was that it is a separate measure.

12 And so there's actually now a number 13 of different measures that are actually pulling 14 out severe mental illness as a separate category, and looking at that from the point of view of the 15 16 disparities population, and actually -- you know, we actually have sort of an editorial under 17 18 review to -- with respect to that review about 19 sort of actually adding this to the National 20 Disparities Report as an example of that. 21 So I just wanted to sort of introduce There's a couple of measures that 22 that notion.

> Neal R. Gross and Co., Inc. Washington DC

1

2

have been added to the adult core set that do look at this, and there's a number of measures that have been approved by the -- or have been endorsed by the Standing Committee for Behavioral Health in this area.

So I just wanted to sort of raise that 6 issue and to think about, you know, to what 7 8 extent -- and I know we had a little bit of 9 discussion about this the other day Karen, in terms of like how much additional burden does it 10 11 add to do that, because it's not without any 12 burden, and to think about when's the best time and under the best circumstances to do that. 13 14 DR. MATSUOKA: I would actually turn 15 it over to our state representatives here, 16 because it certainly has come from the context of 17 -- I forget which specific measures you were 18 talking about last time -- or yesterday, gosh, 19 yesterday. But certainly one of the --20 CO-CHAIR PINCUS: Because there were 21 several of the measures that were not -- that we had recommended that were not --22

1

2

3

4

5

| 1  | DR. MATSUOKA: That's right. Yes, and              |
|----|---|
| 2  | among the reasons for why we didn't move forward  |
| 3  | with them is because we heard from the state      |
| 4  | perspective that in fact stratification is        |
| 5  | essentially like having another new measure.      |
| 6  | It's not as simple it's not as simple as it       |
| 7  | may seem from the point of view of, you know,     |
| 8  | typical data. You have a data set and you just    |
| 9  | slice it in a different way.                      |
| 10 | So I would actually, you know, be                 |
| 11 | curious to hear from our state folks in the room  |
| 12 | who would be best able to answer that particular  |
| 13 | kind of question.                                 |
| 14 | MS. COGAN: Sure, I can speak to that.             |
| 15 | Harold, I know we had presented some data at a    |
| 16 | behavioral health summit a couple of weeks ago,   |
| 17 | where we showed some of our data stratified. So   |
| 18 | we do stratify all of our quality measures by     |
| 19 | things like serious mental illness. I'm going to  |
| 20 | talk about this a little bit tomorrow. We're      |
| 21 | going to start doing this more in the child space |
| 22 | with children with special health care needs, or  |
|    |   |

1

seriously emotionally disturbed children.

2 Stratification is one of the most powerful tools that we have. It's a way of using 3 the data that you already have in the best 4 5 possible way, into trying to determine where the needs are or where you may need to dig a little 6 7 deeper, or those alternative reasons why you may 8 see a lower rate in a certain population may 9 relate to something totally unrelated. But it 10 gives you that great starting point. 11 I was very strongly against having 12 separate measures that are pulling out sort of 13 the stratified population and standing them on 14 their own, because it kind of loses context. You take it out of the framework of wow, this 15 16 population is doing so poor. You put it on its 17 own, it loses that power back to the health care 18 setting that really says hey, there's something 19 not right here. 20 So I was pretty vocal when CMS asked 21 for some of the adult Medicaid states to comment

22

Neal R. Gross and Co., Inc. Washington DC

on whether you should do poor control, for

(202) 234-4433

www.nealrgross.com

instance, for just seriously mentally ill. 1 We 2 were very against that. We felt it was duplicative. We felt that looking through our 3 4 stratifications, that actually that population, 5 that wasn't where the issue was, that there were other issues, and that we know that that 6 7 population is younger. Maybe they haven't gotten 8 there yet. 9 But we felt like having an additional measure would have been -- it's just too much 10 11 Doing the stratification would have been burden. 12 much more powerful we felt. 13 DR. APPLEGATE: So perhaps it's no 14 surprise that states are already slicing and dicing existing measures by populations and by 15 16 criteria to try to develop insight into what's 17 actually going on. So I think one of the 18 challenges is we actually may not be doing it the 19 same way you are, and your way might be better 20 than our way. 21 So perhaps there's some cooperation 22 that could be helpful. Once we figure out what's

meaningful, then that's actually when it should 1 2 become an official measure, particularly in the context of transformation of the health care 3 delivery system. So for example, if we had 4 children, 50 percent of whom died because they 5 had a behavioral health condition, people would 6 7 be shrieking, absolutely shrieking. That is exactly what we have with the SPMI population 8 9 related to cardiovascular disease and diabetes. So as we're shifting and carving in 10 11 behavioral health services, as we're bringing our 12 behavioral health partners to value-based 13 purchasing and paying for six months of ADHD 14 care, and I'd like to do my first episode psychosis -- I'm not a psychiatrist -- first 15 16 episode psychosis episode of care. 17 Now, we're using data and transparency 18 in this feedback loop that actually can drive 19 performance, but in order to figure out what's 20 meaningful, we actually have to do some testing 21 on the ground. So to come out first and say this is the measure, you may be aiming for something 22

1 that's not right.

| 2  | So a little one degree error here is              |
|----|---|
| 3  | a 35 degree error, you know, down the road. So I  |
| 4  | think we have to be super careful. We also have   |
| 5  | to listen to our stakeholders. So you can slice   |
| 6  | and dice your information, but when I get to the  |
| 7  | community, then my numbers are so small I can't   |
| 8  | do anything. In the end, what we're trying to     |
| 9  | transform is care in that community.              |
| 10 | So I think there are a few anxieties,             |
| 11 | I suppose, about specifying exactly how           |
| 12 | stratification happens when and in which context, |
| 13 | depending on what the objective is. I do think    |
| 14 | the one stratification that would be helpful are  |
| 15 | in areas where the measures are gargantuan and    |
| 16 | the disparities are huge, and this is             |
| 17 | specifically around racial disparities.           |
| 18 | So we absolutely should measure the               |
| 19 | most common first public health kinds of measures |
| 20 | infant mortality, pre-term birth by this          |
| 21 | racial divide. Otherwise, we can't come up with a |
| 22 | plan to specifically close that gap. So since     |

that's so big, no matter what community I go to 1 2 in Ohio, there's a two and a half to threefold difference. And until I put it in front of people 3 -- you know, even the communities that have, you 4 know, the worst issues, they actually don't quite 5 understand it until we line them up according to 6 7 everyone else. So I do think that if there's a place 8 9 to start, we absolutely have to learn how to talk about disparities around racial and ethnic and 10 those minority populations before we ever get 11 12 into diagnosis-based ones, realizing that the 13 diagnosis doesn't tell you severity.

## CO-CHAIR ANTONELLI: Yes.

15 DR. PATTON: Yeah, so just a couple 16 of points I was going to mention. As part of the 17 group that led the development of the SMI and the 18 physical health comorbidity measures, you know, 19 the immediate driver for those was the sense of 20 health disparities around the SMI population, and 21 really trying to move the needle on diabetes and 22 cardiovascular screening and kind of get at some

of those mortality issues that Harold raised. 1 2 Sort the larger driver -- where I think we have great news to report at this point 3 -- is that, you know, in looking at 4 accountability, we're also very aware of the 5 disconnect between primary care and specialty 6 7 care, between community mental health centers and hospitals and so forth, and where that kind of 8 9 falls off. But we were -- we had lots of 10 conversations about the accountability issue. 11 And so CMS and SAMHSA are partnering 12 now -- along with others -- in the 223 program, 13 so the certified community behavioral health 14 So we now have a package of quality clinics. measures that are being used by these clinics 15 that are involved in this program, and we're now 16 in the demonstration phase of that. 17 18 I think, you know, our hope is that 19 that will alleviate some of that disconnect and 20 some of the accountability around, you know, when 21 people are in the communities and some of the ways to better track over time with those 22

outcomes.

1

| 2  | CO-CHAIR ANTONELLI: Can I just ask                |
|----|---|
| 3  | you to expound? When you use the word             |
| 4  | accountability, are you using it in the capital   |
| 5  | A, ACO sense, or small A, which means the         |
| 6  | patient-family caregiver unit just wants to know  |
| 7  | who the go-to entity is?                          |
| 8  | DR. PATTON: So our thinking, you                  |
| 9  | know, early on with the development of the        |
| 10 | measures was the small A, and over time with the  |
| 11 | context of health care and so forth it should     |
| 12 | yeah.   |
| 13 | CO-CHAIR ANTONELLI: Yeah, that's                  |
| 14 | great. Okay. I had Clarke and then Rachel.        |
| 15 | MEMBER ROSS: So I wanted to reinforce             |
| 16 | Harold's observations but broaden them, and there |
| 17 | are three other entities here at the National     |
| 18 | Quality Forum that demonstrate the broader        |
| 19 | approach. So June 6th and 7th, the Medicaid       |
| 20 | Innovation Committee meets, and who are the four  |
| 21 | targeted populations?                             |
| 22 | People with serious mental illness,               |
|    |   |

people with substance use disorder, people who 1 2 need long-term services and supports, particularly long-term -- home and community-3 based services, and individuals with, quote, 4 complex medical needs. So that's one forum. 5 The second forum is the work group on 6 persons dually eligible for Medicare and 7 8 Medicaid. So we've had a committee here since 9 2011 on dually eligible people. We have a set 10 aside program in the ACA targeted to dually 11 eligible people. 12 We have demos, we have an office in 13 CMS, because a proxy for these challenges is the 14 severity and complexity of illness and poverty reflected in the dually eligible population, and 15 16 we know who they are, or at least we can count --17 we can identify them. 18 And then third is National Quality 19 Forum has a disparities committee, and an issue that's been discussed in the last several months 20 21 -- I wish Helen was here -- Rich probably knows 22 Dr. Lisa Iezzoni from Harvard, who's a leading

disability researcher in the country, and she
 makes the same arguments Harold just made, except
 she uses severe disability, not severe mental
 illness, although severe mental illness is part
 of severe disability with paralysis, spina
 bifida, MS, Parkinson's.

7 So the National Quality Forum is 8 obviously grappling with how to define and put 9 parameters around this complex issue. It is 10 broader than severe mental illness, but severe 11 mental illness is obviously a most unmet and 12 severe population.

13 The last point is who's responsible. 14 Like it or not, whatever the performance, every 15 state in this country has a state mental health 16 authority, and every state in this country has an 17 intellectual and developmental disability 18 authority, and that's created a lot of problems. 19 But it also is a historic recognition that those 20 two populations -- so that reinforces Harold's 21 point -- are unique and have -- require unique 22 responses, or they're so prejudiced and biased

against that we created these two silo state 1 2 systems for them. But so just random thoughts about the 3 4 complexity in response to Harold's points. 5 CO-CHAIR ANTONELLI: Thank you. Ι think Rachel, Diane, Deb and Karen, are you in 6 7 the queue? So I think you might have been. So 8 Rachel, Karen, Deb, then Diane. 9 MEMBER LA CROIX: For Florida 10 Medicaid, we primarily are often looking at our performance measure data at plan level, and then 11 12 using our plan level data to then come up with 13 our statewide weighted rate, depending on plan 14 size for performance measures. We are not running all of these measures in-house based on 15 16 claims and encounter data. So the extent to which we could 17 18 stratify the data, we could do that using claims 19 and encounter data. But based on our plan-20 reported data, we haven't really been at a point 21 where we could do that with the information

they're reporting. It's typically the aggregate

Neal R. Gross and Co., Inc. Washington DC
rates and it's been audited by an NCQA certified auditor.

| 3  | One new thing we are requiring plans              |
|----|---|
| 4  | to do this year is to support that patient-level  |
| 5  | data file that NCQA started having. So we will    |
| 6  | be receiving that patient level data and could    |
| 7  | then do some stratified analyses on our end. I    |
| 8  | can't go ahead and commit resources to that. I'd  |
| 9  | have to run that through my management first.     |
| 10 | But that is something we'd be able to             |
| 11 | do. One thing that we did take a look at, kind    |
| 12 | of coming at it from the other direction and      |
| 13 | it's interesting you brought up the SMI           |
| 14 | population as an area of stratification. We do    |
| 15 | have an SMI specialty managed care plan in our    |
| 16 | Florida Medicaid program, and we found that they  |
| 17 | actually have been performing less while on a     |
| 18 | number of the mental and behavioral health        |
| 19 | measures than our standard managed care plans.    |
| 20 | So one thing that we have just started            |
| 21 | exploring internally is looking at the            |
| 22 | populations within those plans that they used for |

Neal R. Gross and Co., Inc. Washington DC

1

2

those measures, and then seeing whether the 1 2 average risk scores for their populations are markedly different, whether that's correlated at 3 all to the plan's rates for some of these 4 5 measures, looking at their rural versus urban populations, looking at racial and ethnic make-6 ups for those populations, specific to some of 7 those mental health measures, age breakouts. 8

9 We also -- since we do have an SMI 10 specialty plan, we have an SMI algorithm so we 11 can identify everyone who meets that algorithm, 12 whether they're in the specialty plan or not. So 13 also looking at within all of the plans what 14 percentage of their population for those mental health measures -- meaning the eligible member 15 16 criteria -- what percentage meet that SMI 17 algorithm.

So we have been trying to drill down and look at some of those things. But it hasn't been looking at the varied, just a specific group with a diagnosis and then how they have done on different measures.

|    | 2   |
|----|---|
| 1  | CO-CHAIR ANTONELLI: Karen.                        |
| 2  | DR. MATSUOKA: So this is just a                   |
| 3  | follow-up question, just to probe a little bit    |
| 4  | more deeply into making turning the               |
| 5  | recommendation into some concrete action. So      |
| 6  | first I want to hear from the state folks in the  |
| 7  | room, but then I also want to put it out to the   |
| 8  | rest of the group too. So Lindsay if I hear you   |
| 9  | right and maybe Mary you too rather than          |
| 10 | calling out so in the adult core set we've got    |
| 11 | not only the diabetes poor control measure, we've |
| 12 | got the diabetes poor control measure             |
| 13 | specifically for those individuals who also are   |
| 14 | SMI.  |
| 15 | So if I hear you correctly, for you               |
| 16 | guys it would have been preferable to just say we |
| 17 | should just have the diabetes Alc poor control    |
| 18 | measure, and then maybe suggest to the states     |
| 19 | that you think about stratifying by different     |
| 20 | condition groups like SMI.                        |
| 21 | So one is I just want to make sure I'm            |
| 22 | hearing that correctly. And if that's             |
|    |   |
|    |   |

Neal R. Gross and Co., Inc. Washington DC

|    | 4   |
|----|---|
| 1  | preferable, I'm curious to know what that would   |
| 2  | mean for you Rachel in Florida. Does it mean      |
| 3  | that we would because you do, sounds like,        |
| 4  | rely on NCQA having a spec at the plan level.     |
| 5  | But you actually would want us to somewhere       |
| 6  | indicate that another way to operationalize that  |
| 7  | would be for you to pull NCQA 2607.               |
| 8  | MEMBER LA CROIX: Yes.                             |
| 9  | DR. MATSUOKA: So if that's the                    |
| 10 | direction that we would go in, then I wonder if   |
| 11 | we can throw out to the group, you know, what are |
| 12 | your all thoughts about that as an approach?      |
| 13 | CO-CHAIR PINCUS: Let me just add sort             |
| 14 | of an intermediate approach, which is to think of |
| 15 | it as a set of two nested measures, you know,     |
| 16 | sort of the full population and then nestle it in |
| 17 | the specific population, segmented population.    |
| 18 | CO-CHAIR ANTONELLI: Yes. Well I have              |
| 19 | to pause for a second, because we've got other    |
| 20 | comments and/or questions, and then we will be    |
| 21 | I can't wait to hear the conversation on that,    |
| 22 | but I don't want to derail the people that have   |

gotten in the line. So if you can hold that
 thought, and then our state folks and everybody
 else get your responses ready.

But Deborah, then we're going to do Diane, and then I actually want to get in the queue, and then we'll open it up to Karen's provocative thought-provoking questions. Okay. MEMBER KILSTEIN: Well, my comment

9 relates to both what Rachel and Karen was asking, which is stratification. A lot of it depends on 10 11 what is the reporting level. So for example, a health plan that doesn't get race and ethnicity 12 13 data from their state, or has a behavioral health 14 carve-out can't report on some of these measures. That has to be done at the state level. 15 If at 16 all, it would have to be done at the state level.

17 So there are decisions that states 18 make that can, you know, decide whether or not it 19 can even be done at a plan level and rolled up, 20 or whether it can only be done at the state 21 level.

MEMBER CALMUS: So I think from a

Neal R. Gross and Co., Inc. Washington DC

policy perspective, this is actually really 1 2 desirable and something that we're seeing, you know, talked about in Washington a lot, the 3 desire to kind of use this data to eliminate 4 5 silos and hopefully to kind of figure out what non-health care, you know, social services can 6 improve health outcomes and kind of really have a 7 8 better way to judge and get to that data. 9 I think it's important that it's 10 really dependent on the measure, you know. For 11 some measures, looking at the rurality versus urban might be very important. For others, it 12 might not be. We're seeing a lot of disturbing 13 14 data coming out looking at reduced life expectancy in rural areas that I think, you know, 15 16 gets back to some of these issues. 17 It would be really helpful to have 18 some of this data separated out to be more 19 actionable, and we were talking yesterday a lot 20 about being actionable data. And so I think 21 that's a way that this could be used additionally 22 to really look at -- we talked about access to

maternity and OB services in rural. So you know, 1 2 looking at it as a way also to identify kind of failures of access within the system. 3 Having this data can be really helpful 4 5 in making sure -- in sending information to either the states or to Washington to say here's 6 where more resources are needed. So I think 7 8 that's another benefit for this sort of 9 stratification. 10 CO-CHAIR ANTONELLI: So I'm stepping out of my role as the chair and wearing my 11 12 medical director hat of integrated care for 13 Boston Children's, and I want to -- this 14 perspective is coming from the delivery system 15 side, with the hope that I've got a payer that 16 basically is saying how can we do this together, 17 right. So from the delivery system side. 18 If you think about the vignette that 19 Harold articulated, a patient with schizophrenia 20 and with diabetes, we know there's fragmentation 21 there. And if that fragmentation occurs just when there's multiple medical conditions, and then you 22

superimpose a behavioral health condition or two and things explode.

So what we do on the delivery system 3 4 side is actually look at those -- look at the 5 data, look at the utilization and presume that those patients -- the term that I use is they're 6 7 medically homeless. Everything is essentially 8 reactive. There's no single point of entry to 9 the system except the emergency department, etcetera, but we're actually measuring in those 10 11 spaces. 12 So I want to bring this conversation 13 -- for me, the idea here -- and Harold teed this 14 up, QI versus accountability, capital A versus small A. So how do you attack fragmentation? 15 16 You measure it. You can get data flows from 17 claims. We actually go to the families and 18 caregivers themselves, so we actually -- some of 19 our earliest data when we look at fragmentation 20 for these patients that have complex and multiple 21 chronic conditions actually comes from the families themselves. 22

> Neal R. Gross and Co., Inc. Washington DC

1

|    | · · · · · · · · · · · · · · · · · · ·             |
|----|---|
| 1  | So to the degree that there's a                   |
| 2  | capital A opportunity, meaning that we can        |
| 3  | meaningfully pull in, for example, housing, food  |
| 4  | security, appropriate behavioral health capacity, |
| 5  | that is great. The slicing and dicing on the      |
| 6  | quality side I also want to encourage that. I do  |
| 7  | react a little bit to having a different set of   |
| 8  | measures for the population, and I really like    |
| 9  | the notion of let's just look at the measures     |
| 10 | that we have, and then maybe decide that we need  |
| 11 | to add some on top of that.                       |
| 12 | So that's what it feels like from the             |
| 13 | delivery system side, and I do want to make the   |
| 14 | final comment as these are not mutually           |
| 15 | exclusive, right? So depending on the             |
| 16 | receptivity of your Medicaid leadership, your     |
| 17 | state, your region, you may start with a capital  |
| 18 | A accountability and say figure it out.           |
| 19 | Or you may start in the QI space, for             |
| 20 | people who are sitting and scrambling like where  |
| 21 | are we going to get appropriate housing           |
| 22 | resources, etcetera. So I really like that        |

approach to thinking about stratification. Okay, Harold had a comment. And then Karen, I'm going to ask you to tee up the question that you did, and then we're going to poll the group's thoughts on that.

1

2

3

4

5

CO-CHAIR PINCUS: So I think there's 6 7 been a very productive conversation. I look 8 forward to hearing some of the responses. Just a 9 couple of responses back, I agree with Clarke 10 that, you know, part of the issue in terms --11 especially the SMI and more broadly the disabled 12 population -- is that they do face 13 discrimination, both stigma as well as, you know 14 -- especially for people with physical disabilities -- there's practical discrimination 15 16 in terms of accessing, you know, general medical 17 services.

18 Also for, you know, for behavioral 19 health populations, people don't want them in 20 their waiting rooms. They also have, you know, 21 poor health hygiene. The medications they take 22 can interfere with or in some ways exacerbate the

conditions they have. So it really requires some kind of coordination.

The issue of carve-outs is kind of an 3 interesting issue because, you know, ultimately 4 to get adequate care for these populations, the 5 carve-outs have to talk to the med-surg plans, 6 7 and that's -- you know, either they have to be an integrated plan or there has to be some way by 8 9 which they communicate about their populations so 10 there can be an overall population management. 11 That's some ways -- you know, 12 depending on how things are set up with the 13 state, that's partly something to build into 14 contracts, you know, with both the carve-outs and the med-surg plans or, you know, within the so-15 16 called integrated plans, because integrated plans 17 are not so integrated often, you know, as you see 18 those. 19 But I think one of the really 20 important things is the actionability. I think 21 that having this sort of segmentation really enhances the actionability to be able to use that

22

1

2

www.nealrgross.com

to pinpoint where the problems are. You know, both at a population level but also begin to understand what actually are some potential ways to fix things.

I mean is it -- and just -- to even 5 just put it down at a clinical level, I mean is 6 7 the problem with my sort of patient with 8 diabetes, is it the fact that I'm not at all 9 encouraging that individual to adjust their diet or to inquire, from my point of view, about how 10 11 they've been sort of utilizing their -- you know, 12 utilizing their insulin levels, adjusting their 13 insulin levels, or for that matter maybe it's up 14 to me to adjust the anti-psychotic medication, so that it's less likely to cause metabolic 15 16 disturbances, and to be in touch with their 17 primary care provider with regard to what I'm 18 doing, so that there is a kind of joint strategy. 19 But like I said, it also goes up in 20 terms of how my practice at an organizational or 21 clinical level, what kind of information am I getting back. What kind of relationships exist 22

> Neal R. Gross and Co., Inc. Washington DC

1

2

3

between the CMHCs and the FQHCs in order to share 1 2 information to grease referral pathways and things like that. What kind of obligations are 3 put in place at the managed care plan level in 4 terms of that sharing of information, that 5 sharing of efforts around quality improvement? 6 So you know, it sort of forces a lot 7 8 of actions to respond by maintaining this kind of 9 sort of longitudinal follow-up on the data around 10 this segmentation. 11 CO-CHAIR ANTONELLI: Thank you. Okay, 12 You ask the question again and then Karen. 13 people, I'd love to have you riff on your 14 thoughts with that. So in a nutshell -- and 15 DR. MATSUOKA: 16 if we were to just use the Alc control measure as 17 an example, we have an A1c control measure for 18 anyone who has diabetes. But then to kind of be 19 a gauge for this behavioral health integration, we also added in Measure 2607 for the 2017 core 20 21 set which specifically looked at A1c control for those individuals with diabetes who also happen 22

to have a serious mental illness.

| 2  | So the question becomes, you know, is             |
|----|---|
| 3  | it better to just have the global Alc measure,    |
| 4  | and then suggest encourage states to stratify     |
| 5  | it by different kinds of, you know, condition     |
| 6  | groups or population groups? Or do we call out a  |
| 7  | separate measure, which seems to be the NQF way   |
| 8  | as well, which also happens to be the method that |
| 9  | states who really depend on their health plans to |
| 10 | submit aggregated data to the state would most    |
| 11 | likely be reporting these kinds of measures, or   |
| 12 | is there some kind of hybrid approach?            |
| 13 | MS. COGAN: I mean, I would agree with             |
| 14 | the hybrid approach. So I think where we stand    |
| 15 | is not having a separate measure to stratify the  |
| 16 | existing measure. The way that we do our          |
| 17 | stratification and Rachel we do the same thing    |
| 18 | that you're thinking of doing we've been          |
| 19 | collecting patient level data from our health     |
| 20 | plans for years.                                  |
| 21 | Taking that Medicaid ID and linking it            |
| 22 | back to our enrollment and eligibility, and then  |

we know things like race, age, region. We can look at their entire claims history, run a very simple algorithm to pull out SMI diagnoses, right, and we'd be happy to share that and spread that and have everybody do that, if they have those internal resources.

7 But it is resource intensive. So I 8 think a hybrid approach would probably be the 9 I just worry that going down this path of best. having separate measures, when does it end, 10 11 So you put one out there for SMI. right? So IDD 12 is next. Medically fragile children are right behind them, and then foster kids are here too. 13 14 So it just -- you're already at 27. So let's use what we have to the fullest ability 15 16 before we start tacking on additional measures 17 would be our suggestion. 18 CO-CHAIR ANTONELLI: So what's the

19 piece, Lindsay, of the hybrid component that's
20 attractive?

21 MS. COGAN: Because if a state like
22 Florida cannot pull together internally to

Neal R. Gross and Co., Inc. Washington DC

1

2

3

4

5

stratify what comes in from the health plans, you're essentially doing the same thing. So if you have the leverage to gather that from the health plans and pull in a separate measure for individuals with SMI, you're essentially doing the same thing.

7 At our state, we aren't going to add 8 another measure -- another hybrid Measure 411 on 9 top of the plans. We're just not going to do it. 10 So we're not going to report that measure. We're 11 going to stratify the one we have.

12 CO-CHAIR ANTONELLI: Yeah. But I 13 guess I'm just trying to figure out the hybrid 14 component from the state Medicaid perspective. 15 The status is you're going to use the measures 16 that you have and stratify?

17MS. COGAN: Yes. I think the hybrid18approach I'm talking about is across other19states. It's not within my state.

20 CO-CHAIR ANTONELLI: Okay. Oh okay, 21 okay. You've brought that up.

(Simultaneous speaking.)

Neal R. Gross and Co., Inc. Washington DC

22

1

2

3

4

5

| MS. COGAN: But so if I wanted to do               |
|---|
| it my way and Florida wanted to do it their way,  |
| we're still getting to the same I think we're     |
| still getting to the same path, which is you want |
| to look at this measure by individuals, serious   |
| mental illness.                                   |
| CO-CHAIR ANTONELLI: Thank you.                    |
| MS. COGAN: Fair enough, yeah. Sorry.              |
| It's doing hybrid.                                |
| CO-CHAIR ANTONELLI: Okay, Mary.                   |
| DR. APPLEGATE: So not to make things              |
| more complicated, but your diagnosis by itself is |
| not necessarily the only variable that gets you   |
| to a terrible outcome, for example. So one of     |
| the things that we're doing in our stratification |
| process is we actually look at the we do the      |
| linkage that you talked about, and then in the    |
| claims history we actually have an algorithm for  |
| what counts for uncoordinated care, and it's      |
| those people with the diagnosis that actually we  |
| need to target.                                   |
| So the measure itself, stratified by              |
|   |

|    | د<br>ا  |
|----|---|
| 1  | SPMI, is not enough. It's the people who          |
| 2  | actually have no indication of coordination in    |
| 3  | care. So if all of their claims only come from    |
| 4  | the CMHC, we're in trouble. If they only come     |
| 5  | from the physical health side of the world, we're |
| 6  | in trouble. If they have inpatient stays either   |
| 7  | utilization, kind of five pharmacies and six      |
| 8  | different prescribers, we're actually in trouble. |
| 9  | So our slicing and dicing also gets to            |
| 10 | the context. So that's actually what we need to   |
| 11 | develop a plan for how do you systematically get  |
| 12 | people better is focus on the folks who are most  |
| 13 | likely to do poorly, and in our system it ends up |
| 14 | being those who actually don't seem to be         |
| 15 | connected in any kind of logical way.             |
| 16 | CO-CHAIR ANTONELLI: Looking for                   |
| 17 | fragmentation. Yes.                               |
| 18 | DR. PATTON: Yeah. I was just going                |
| 19 | to say, you know, the long view for the measures  |
| 20 | for the SMI physical health comorbidity           |
| 21 | measures was certainly not that they would be     |
| 22 | needed, you know, forever. I mean the real hope   |
|    |   |

in developing those measures was that health care 1 2 would catch up, that that population -- the health disparities would be reduced and that 3 would -- we wouldn't need it to be separated. 4 5 I'll give you just a quick example. There's an NQF measure, depression with a suicide 6 7 screen. So it's a similar kind of issue in that, 8 you know, most of us working in mental health 9 would anticipate if you have a client with depression, you'd screen for suicide. 10 That 11 doesn't always happen. 12 So it's about driving the standard of 13 care, because over time what we would hope is 14 that any person presenting with a diagnosis of 15 depression would also have an accompanying 16 suicide screen. And so that it would just become 17 standard practice, and there would no longer be a 18 need to measure that because no one would ever 19 think about working with someone with depression 20 without assessing for suicidality. 21 CO-CHAIR PINCUS: Just one comment 22 actually to Mary. Lisa Kern from Weill Cornell

actually has a grant from the Commonwealth to 1 2 actually develop different ways of looking at fragmentation in terms of care, and she's 3 actually sort of testing out different 4 5 alternative models. Actually Larry Costello and I are both sort of on the grant as well. 6 7 (Pause.) 8 CO-CHAIR ANTONELLI: Okay. I think 9 we're good. Okay. I think we're about to get to the slide that talks about a public comment. 10 11 Operator, could you see if anybody would like to 12 weigh in for public comment please? 13 **OPERATOR:** If you would like to make 14 a public comment, please press star 1 on your telephone keypad. 15 16 (No audible response.) 17 OPERATOR: And we currently have no 18 public comments at this time. 19 CO-CHAIR ANTONELLI: Okay. 20 CO-CHAIR PINCUS: Wait. Can we have 21 that open for a few more seconds? 22 Of course. OPERATOR: Again, if you

would like to make a public comment, press star 1 2 1. 3 (Pause.) 4 (No audible response.) 5 CO-CHAIR ANTONELLI: Public comments 6 in the room? (No audible response.) 7 8 No public comments on the OPERATOR: 9 phone. Okay, Miranda. 10 CO-CHAIR ANTONELLI: 11 MS. KUWAHARA: All right, everyone. 12 Here we have our next steps. Tonight, our Adult Task Force will be leaving us and we'll continue 13 tomorrow with our Child Task Force. We have on 14 15 the screen a timeline of what's coming up. Some 16 highlights for you all. 17 We have public comment on our draft 18 report July 7th through August 6th, and then we 19 have our MAP Coordinating Committee. It's to be 20 determined. It will be some time in August, and 21 then final reports will be submitted to CMS 22 August 31. We will expect CMS to issue its

annual update to the Medicaid adult and child core sets late 2017.

Here we have listed the NOF project 3 staff if you ever need to reach out to us. **A11** 4 5 of you may contact us directly on the Committee SharePoint site. Our contact information is 6 7 listed there, and then our project contact 8 information is listed on this slide. We have 9 separate email addresses for both adult and child, and you can always visit our project page 10 11 for any meeting materials. All right.

12 CO-CHAIR PINCUS: So I just -- so I 13 just want to really thank actually the NQF staff 14 for their really sort of remarkable ability to 15 keep things organized and to provide us with the 16 information we need, and to sort of keep on moving us ahead. I also want to thank the CMS 17 18 staff, in terms of it's really been I think an 19 excellent partnership in terms of moving this 20 agenda ahead, and certainly, you know, with 21 representatives from the states that are so well 22 informed and active. It's really good to have

> Neal R. Gross and Co., Inc. Washington DC

1

1 that as part of this as well.

| 2  | I want to thank the members of the               |
|----|--|
| 3  | Adult Task Force. I mean, we did a lot of work   |
| 4  | and got a lot done, and you know, we really had  |
| 5  | very good discussions, and I think that helped   |
| 6  | inform the process going forward. So thank you   |
| 7  | all.   |
| 8  | DR. MATSUOKA: And I just want to join            |
| 9  | in and also thank the great NQF staff, all of    |
| 10 | you, the Adult Task Force members before you     |
| 11 | leave, you know. Thank you very much. But a      |
| 12 | special shout out to Harold. Thank you so much   |
| 13 | for chairing the Adult Committee very gracefully |
| 14 | and keeping us on time. So thank you Rich.       |
| 15 | MS. MUKHERJEE: Staff definitely would            |
| 16 | like to thank our Chairs.                        |
| 17 | (Applause.)                                      |
| 18 | MS. MUKHERJEE: Because without our               |
| 19 | Chairs, we would pretty much be a ship without a |
| 20 | captain. So thank you.                           |
| 21 | CO-CHAIR ANTONELLI: All right.                   |
| 22 | (Simultaneous speaking.)                         |
|    |  |

| 1  | CO-CHAIR ANTONELLI: And to remind the             |
|----|---|
| 2  | Child Task Force here that we're only halfway     |
| 3  | done actually in a journey that will last         |
| 4  | decades, but that's why we do the work we do.     |
| 5  | The Adult Task Force, it's really gratifying to   |
| 6  | actually sit in a room and look for the           |
| 7  | similarities rather than always looking for the   |
| 8  | differences. So thanks to the Adult Task Force.   |
| 9  | So I'm actually going to go in reverse            |
| 10 | order, just because it's different and it feels   |
| 11 | fresh. To CMS, thank you for the opportunity of   |
| 12 | this partnership. I'm mindful of tremendous       |
| 13 | pressures on Medicaid in general, and yet we're   |
| 14 | sitting in this room pruning out measures that    |
| 15 | don't really fit the bill.                        |
| 16 | Hearing from the front lines of                   |
| 17 | Medicaid leadership, we need better measures. I   |
| 18 | didn't get a sense in today's entire conversation |
| 19 | that we should take our foot off the gas pedal.   |
| 20 | I'm grateful for that, and I'm proud of the       |
| 21 | leadership that we saw today and the vision of    |
| 22 | CMS and our state leaders.                        |
|    |   |

Neal R. Gross and Co., Inc. Washington DC

www.nealrgross.com

|    |   | 31 |
|----|---|----|
| 1  | Then finally NQF, you guys are                    |    |
| 2  | absolutely phenomenal. So thanks for making this  |    |
| 3  | really hard job actually easy enough for a simple |    |
| 4  | PCP to do.  |    |
| 5  | MS. GORHAM: I want to echo all the                |    |
| 6  | thanks, but I made the joke earlier that          |    |
| 7  | yesterday, we ended at 4:03, and perhaps we would |    |
| 8  | end at 3:59. But actually you all were so         |    |
| 9  | fantastic today that we're actually ending at     |    |
| 10 | 3:25. So if you don't mind, then, definitely you  |    |
| 11 | are free for the day and again, thank you. We'll  |    |
| 12 | see the Child Task Force tomorrow.                |    |
| 13 | CO-CHAIR PINCUS: Thank you.                       |    |
| 14 | (Whereupon, the above-entitled matter             |    |
| 15 | went off the record at 3:25 p.m.)                 |    |
| 16 |   |    |
| 17 |   |    |
| 18 |   |    |
| 19 |   |    |
| 20 |   |    |
| 21 |   |    |
| 22 |   |    |
|    |   |    |

Α a.m 1:9 5:2 109:20 110:4,5 A1c 62:12 291:17 301:16,17,21 302:3 **ABD** 45:12 ability 4:16 23:12 80:11 122:13 265:22 266:16 303:15 310:14 able 6:21 24:7 33:19 48:20 62:4 72:9 100:2 116:21 130:11 154:17 156:2,19 166:8 175:20 188:14 210:14 214:9 216:19 237:21 238:6 244:20 278:12 289:10 299:22 above-entitled 110:3 179:20 264:11 313:14 absolute 9:7 121:21 absolutely 7:15,21 47:14 55:15 70:22 71:16 79:11 146:9,20 147:12 173:14 210:11 237:2 281:7 282:18 283:9 313:2 abstained 150:22 abuse 2:12 25:18 ACA 286:10 Academy 2:6 12:3,18 18:10 19:1 243:12 ACAP 11:21 Accelerator 28:3 98:9 accent-wise 84:11 accept 205:17 226:5 accepted 179:5 184:6 204:15 205:17,20 access 28:14 33:7 76:4 79:18 83:11 89:22 119:1 142:21 143:3 145:8 146:15 154:15 155:16 161:1.11 175:5 192:6 195:10 196:1 197:5,18 198:4 198:13 199:16 200:1 202:19 203:20 206:12 207:12 210:12 211:12 213:7 216:21 217:17 218:5 275:20 294:22 295:3 accessing 72:18 143:5 211:14 298:16 accompanied 176:4 accompanying 307:15 accountability 32:22 179:7 272:13 273:18 274:21 275:11,13 284:5,10,20 285:4

296:14 297:18 accountable 61:4 62:22 275:1 Accreditation 25:6 accrue 233:20 accuracy 104:17 accurate 209:17 224:11 accurately 210:3 achieve 30:9 78:11 achieved 250:19 acknowledge 71:15 81:20 82:2 246:4 acknowledging 112:14 ACO 285:5 ACOG 96:9 170:7 230:3 232:2 ACOs 108:14 Acting 94:5 action 122:17 172:18 176:8 291:5 actionability 299:20,22 actionable 48:22 123:15 135:16 137:4 173:20 241:1,14 242:19 263:16 264:1 294:19.20 actions 301:8 active 310:22 activities 17:7 22:1 24:8 56:10 89:9 90:20 95:16 97:14,16 117:18 272:10 activity 88:12 161:3 actual 110:18 174:17 acute 239:11 267:18 adapted 196:4 add 30:12,20 35:6 38:6 59:5 105:7,18 120:22 127:6 142:5 143:16 156:18 167:13,15 169:12 201:21 230:12 238:2 239:14 251:22 253:7 254:2 256:8 270:5 277:11 292:13 297:11 304:7 added 35:2,3 117:14 128:18 186:19 202:6 222:22 230:11 249:9 277:1 301:20 adding 26:22 127:4 168:16 187:2 224:1 276:19 addition 34:12 97:20 122:9 152:22 153:2 180:6 183:7 197:22 245:22 246:17 259:22 additional 7:20 41:19 44:8 122:10 136:2

177:6 274:5 277:10 280:9 303:16 additionally 294:21 additions 177:8 180:7 address 20:4 27:15 40:13 77:22 89:16 101:21 113:9 122:3 132:8 165:6 181:16 181:20 197:9 217:15 233:19 235:17 250:13 251:6,13 273:13 addressed 25:19 87:2 89:20 105:9 120:13 181:17 183:20 251:14 addresses 176:8 310:9 addressing 6:20 27:18 69:17 120:13 adds 38:13 183:17 adequate 299:5 ADHD 281:13 adherence 251:14,14 Adirim 1:13 18:19,20 76:8,17 141:2 160:17 162:18 190:8 243:11 253:7 254:15 Adjourn 4:20 adjust 300:9,14 adjusting 300:12 adjustments 136:15 Administration 1:22 2:12 14:6 28:7 administrative 51:15 52:7 53:18,19 55:8 122:14 171:11 200:4 202:4 administrator 14:13 admissions 78:22 253:20 admitted 239:10 admittedly 215:21 adolescents 62:1 adopt 6:7 adopted 44:9 181:9 184:4 185:21 255:15 adult-quality 72:13 adults 33:5 40:13,21 59:20 121:12 124:16 160:5,8,13 222:16 253:11,12 263:18,21 advance 43:10 44:19 45:16 87:15 88:15 185:18 230:20 advanced 81:10,14 208:11 advantage 255:16 adverse 239:2 advisory 2:9 17:16 76:2 advocate 244:2

Aetna 2:3 14:20 15:5 Affairs 1:14 15:21 89:5 188:16 196:3 Affiliated 1:21 11:20 affiliates 196:8 African-71:2 African-American 70:16 71:18 afternoon 264:10 266:14 Agarwal 5:7 age 23:11,21 38:6,7,8 44:19 59:21 61:12 71:16 90:8 111:3,4 145:6 146:17 153:21 154:14 158:4 169:19 216:15 217:14 224:11 249:21 255:2 267:5 269:6,18 273:1 274:13 290:8 303:1 age-stratified 194:21 agencies 48:3 109:15 234:18 253:22 agency 1:21 80:7 241:19 agenda 114:19 310:20 agent 130:5 ages 57:20 189:13 235:22 249:13 aggregate 268:21 288:22 aggregated 302:10 ago 37:17 41:15 165:15 165:18 191:16 194:11 195:17 270:19 278:16 AGRAWAL 2:15 5:11 agree 47:8,15 99:8 105:18 129:3 144:6 161:8 172:17 202:18 210:12 242:7 243:13 245:17 246:6 298:9 302:13 agreed 84:3 118:21 AHAB 63:21 ahead 11:8 43:11 45:13 48:11 51:14 53:3 55:10,22 56:12 57:18 59:7 61:3,18 62:7 64:10 142:19 157:18 157:19 158:1 170:11 176:1 178:11 180:1 189:11 237:9,17 245:15 261:2 289:8 310:17,20 AHIP 37:14 231:10 232:12 267:14 AHRQ 40:7,11 231:10 aim 187:1

aiming 281:22 albeit 90:2 alcohol 169:13 alert 23:18 algorithm 181:10,11 182:8 290:10,11,17 303:3 305:18 align 77:3 160:12 181:8 269:11 aligned 46:9 59:8 110:19 122:21 268:9 alignment 37:8,11,12 37:21 38:5,17 46:21 56:1 57:12,17 72:9 182:1 252:21 267:9 267:12,14,22 268:2,4 268:6,10,11,17,20 270:1 271:19 alignments 271:12 alike 131:22 allays 233:6 alleviate 284:19 allow 8:15 97:2 217:4 allowable 250:11 allowed 60:16 135:22 274:3 allows 33:17 79:8 128:3 alternate 142:20 alternative 251:3 255:5 279:7 308:5 alternatives 100:16 altogether 58:2 **AMA/PCPI** 129:9 amazing 76:7 236:19 237:1 ambulatory 188:8 251:3 amendable 79:12 **America** 196:6 America's 14:16 American 2:4,7 12:2,21 13:7 15:8 18:11,22 71:3 243:12 ammonias 104:10 amount 7:10 51:17 90:2 236:22 267:11 268:6 268:10 Amy 2:3,3 14:19 15:20 99:5 158:10 171:18 214:19 218:19 225:6 242:1,2 245:17 Amy's 240:13 analyses 30:17 289:7 analysis 13:17 32:10 36:3 68:13 116:6 181:1,3,5,15 250:10 251:2,6 252:7,11 analyst 2:19 20:16

analytics 36:3 analyze 207:7 and/or 108:14 292:20 Andrea 1:15 16:10,11 16:12 41:5 142:16,18 148:22 149:8 153:7 154:19 157:12,18 160:20 164:14 167:6 176:16 202:12,14 208:3 214:20 222:20 245:14,15 Andrea's 150:14 228:5 anecdotally 107:5 angst 219:9 Ann 1:17 15:15 73:21 82:18 152:3 Ann's 152:14 announce 264:15 annual 196:5 310:1 answer 39:8 78:7 126:12 134:1 140:21 147:10 204:21 205:9 207:20 235:7,14 278:12 answered 202:22 answers 181:12 antenatal 25:1 47:8.11 48:7 91:18 92:20 245:3 267:16 anti-psychotic 300:14 anticipate 307:9 anxieties 282:10 anxiety 146:12 anxious 161:1 anybody 125:11 130:19 136:20 147:15 167:4 170:7,14,14 184:22 223:5 224:4 246:21 258:12,14 308:11 anybody's 144:20 anymore 34:17 60:17 159:18 255:10 anyway 189:9 apologize 224:7 Appalachia 81:22 appeals 107:15 appear 218:13 appears 25:7 81:13 220:8 applaud 73:14 Applause 311:17 Applegate 3:5 4:7 16:4 16:5 41:9,12 68:13 69:21 73:9 74:14 75:9 76:15 77:2 78:12 80:22 83:4 86:9 87:11 87:18 88:20 89:12 93:22 102:2 103:20

105:8.19 107:21 109:22 129:1 146:1 154:4 155:4 156:6.11 159:1 168:3 172:16 212:6 215:15 235:16 235:21 280:13 305:11 Applegate's 180:13 Applegates 108:2 apples 33:18,19 106:12 106:13 **APPLICATION 1:3** applied 221:13 272:11 **applies** 140:6 apply 44:1 appreciate 31:19 38:20 71:1 125:16 240:17 approach 39:22 108:8 140:4 220:3 285:19 292:12,14 298:1 302:12,14 303:8 304:18 approaches 39:19,20 97:18 256:1 appropriate 82:13 109:8 121:5 133:11 133:15 186:6 188:22 220:21,22 297:4,21 appropriately 101:2 appropriateness 221:6 221:18 approval 178:17 219:10 approve 219:4 224:21 250:18 approved 277:3 area 17:21 27:16 28:9 28:17,22 40:12,20 65:9 98:18 111:22 112:17 113:11 115:13 115:19 122:17 190:5 237:18 241:7 258:8 277:5 289:14 areas 6:22 22:20 23:20 25:21 27:5 28:15,16 28:19 40:13 79:17,17 79:19 81:20,21 93:13 101:5 110:9 113:9,18 113:19 116:15,20 180:16,16 182:10 198:17 199:4 241:8 282:15 294:15 arena 236:15 249:5 argue 48:19 argument 220:13,18 arguments 194:16 287:2 arranged 114:17 array 81:11 articulate 159:12 242:9

articulated 295:19 artifact 163:21 artificial 203:3,4 ascertain 210:5 aside 286:10 asked 70:4 71:11 161:17,20 166:15 177:6 184:15 190:9 240:15 251:2 279:20 asking 125:3,4 132:11 134:2,16 159:21 164:14 170:6 176:19 222:20 224:14 234:16 246:9,11 293:9 aspect 96:3 aspects 91:9 97:9 assess 98:20 143:4 206:10 assessed 105:12 assessing 27:17 94:18 307:20 assessment 84:6 92:14 111:15 165:12 176:18 210:8 assessments 86:5 171:8 assigned 49:11 assignment 54:10 83:8 assist 98:15 121:16 assistance 55:17 89:6 Assistant 1:13 19:4 associated 119:3 121:18 154:17 182:11 **Association** 1:16,17,19 1:20 2:4,7 11:14,20 12:8,21 13:7,11 15:9 16:14 18:12 assume 133:2 148:22 assuming 208:8 assumption 102:8 147:5 assure 233:11 asthma 22:6 23:10 110:14 231:14 248:16 248:20,21 249:5,13 249:20 250:15 251:3 251:10,11,15,18 253:2,9,17 255:21 257:2,7,8,22 258:2 259:4 260:15 261:16 262:8 264:16 265:16 asthmatic 257:3 ASTHO 196:1 199:1 atopic 231:13 attached 136:3 222:10 225:10 attachment 114:2 attack 296:15

Neal R. Gross and Co., Inc.

attempt 31:6 attending 5:17 attention 61:11 103:16 129:12 140:10 273:7 attractive 303:20 attribution 49:9 79:8 85:10 audible 148:20 159:4 163:19 176:14 178:5 179:13 247:1 248:2,7 258:13,16 260:20 261:11 308:16 309:4 309:7 audited 289:1 auditor 289:2 August 309:18,20,22 authority 287:16,18 auto 54:5 auto- 54:9 **autonomy** 196:10 availability 214:11 available 93:6 99:1 123:17 126:5 182:20 210:22 237:5 avenues 101:5 average 48:17 103:2 232:2 290:2 avoid 231:22 aware 37:9 38:14 40:2 284:5 awesome 73:11 awful 66:4 В **babies** 41:22 49:2 55:1 63:8 64:20 67:22 112:10 172:5 baby 81:6 91:21 215:20 baby's 215:22 242:22 back 7:22 10:2 11:6 20:6 31:10 79:6 84:10 107:1 117:9 130:17 141:11 157:20 177:12 179:19 180:2 236:14 238:14 240:14 241:16 254:10 265:17 268:13 268:22 272:6 279:17 294:16 298:9 300:22 302:22 background 68:3 139:16 175:13 backwards 87:7 balance 80:15 220:17 balanced 203:18 **bands** 249:21 Bangladesh 71:22 bar 57:15 127:20 134:10 143:18

barometer 42:13 barrier 99:10 **based** 38:9 60:11 79:7 87:17 92:2 93:4 134:22 146:21 240:16 270:14 274:4 286:4 288:15,19 basic 43:20 95:21 basically 9:11 22:13,15 138:18 139:19 165:20 226:5,13 272:16 295:16 basics 66:6 basis 24:9 66:16 274:1 BCMH 44:11 bear 87:2 258:20 bearing 146:20 beat 73:8 Beattie 1:14 14:11,12 15:3 161:6,8,17 207:20 209:15 210:10 beautifully 201:21 becoming 155:10 185:13 187:13 begun 276:5 behalf 11:13 243:12 behavior 220:16 behavioral 13:17 27:8,9 37:16 60:1,6 75:5,10 75:14 78:20 92:14 165:11 171:4,21 172:2,12 176:17 187:17 273:10,11 274:19 277:4 278:16 281:6,11,12 284:13 289:18 293:13 296:1 297:4 298:18 301:19 believe 10:12 16:10,22 17:7 177:11 186:4 236:6 believing 203:15 **bells** 189:1 belong 85:10 benchmark 196:19 198:11 225:4 232:5 beneficiaries 14:10 33:7 88:9,16,18 beneficiary 28:22 90:12 90:15 beneficiary-reported 26:11 benefit 44:13 45:4,10 114:5 295:8 benefits 231:7 233:20 234:7 242:8 Benin 1:15 16:10,12,13 142:16,20 149:2,11 153:6,17 154:19

155:22 156:8 157:11 157:13,19 158:2 160:20 164:12,21 167:7 202:14 214:15 214:21 215:2 245:13 245:16 benzodiazepines 25:14 264:2,20 best 31:7 52:15 71:22 77:12 81:14 130:16 135:3 172:17 186:14 195:21 197:21 277:12 277:13 278:12 279:4 303:9 better 20:3 42:7 43:1 46:4 48:20 51:3,19 62:15 64:15 65:14 69:19 71:13 76:4 77:4 79:9 81:2,5 82:5 84:17 126:4 128:4 136:19 140:11 141:19 143:10,13 146:6 153:22 156:14 172:10 218:1 219:16 236:2 244:4 257:10 280:19 284:22 294:8 302:3 306:12 312:17 beyond 163:7 177:7 bias 20:1 biased 287:22 **bifida** 287:6 big 35:5,14 65:5 71:14 85:22 98:2 113:17 127:22 231:21 233:2 283:1 **bigger** 45:6 **biggest** 81:5 83:6 bill 94:22 100:7 205:11 205:22 206:2 312:15 billing 94:17 99:9,14 102:4,5,22 105:19 106:6 birth 47:21 48:4,5 51:5 54:7,9 58:19 59:6 60:5 63:7 64:14 80:4 93:9 169:19 212:8 218:16,16 232:18 241:8,11 282:20 birthing 97:19 births 48:1 232:16 bit 17:5 21:6 31:17 34:2 35:18,20 38:8 40:8,18 43:18 50:4 55:13 58:17 73:17 78:7 87:8 87:10 89:12 90:18 92:11 94:2 95:12 96:1 106:17 109:9,18 110:13 113:16 116:4

124:2 127:8 161:2 170:10 177:16 179:9 181:3 188:18 189:11 199:20 203:18 217:14 218:1 237:11 239:22 251:22 265:21 266:19 267:8 272:7,20 277:8 278:20 291:3 297:7 black 61:21 blah 219:7,7,7,7 **blew** 9:3 blockage 211:16 blood 267:19 BLS 5:13 blue 45:4 61:20 **BMI** 111:13 228:12 board 37:10 52:2 body 205:5,5 **Boise** 14:14 booked 82:16 born 42:1 49:2 243:1 **Boston** 9:6 18:1 295:13 bottom 56:3 61:13,22 62:11 65:11 115:11 box 56:1 116:13 boxes 56:9 brand 177:14 188:15 break 8:3,12 179:18 248:10,12 262:12 breakfast 149:4,15 breakout 79:16 breakouts 290:8 breaks 238:5 breast 44:10 117:14 121:5 129:13 178:12 178:18,19 186:1 187:19 188:3 228:17 231:1,16 233:9 234:7 234:9 235:4 236:13 236:18 239:3 241:4 242:8,12,15 243:16 243:19,22 244:1 245:18 246:1,2,5 247:8 267:18 bridge 130:6 bridges 188:7 brief 99:1 267:11 268:5 briefly 17:13 88:13 90:17 93:1 bring 11:1 22:14 38:15 41:19 64:22 148:10 165:8 173:12 187:7 271:3 272:3 296:12 bringing 78:13 281:11 brings 271:16 broad 107:19 108:6 122:15 broaden 285:16

broadened 205:4 broader 40:18 81:11 195:14 285:18 287:10 broadly 41:3 167:14 298:11 broke 112:19 brought 72:5 194:1 266:22 289:13 304:21 bucket 75:10 272:12,13 272:16 buckets 272:9 Buckeye 61:17 74:8 budget 46:4 175:7 249:17 bugged 134:3 **build** 23:20 210:11,15 271:20 299:13 building 32:7 97:11 built 82:9 272:16 **bunch** 34:22 42:2 74:19 146:14 216:8 burden 7:11 25:10 51:15 101:17 147:8 168:15 200:3 234:18 234:22 239:15 252:8 277:10.12 280:11 Bureau 3:7 burn 85:3 burnout 29:4 BURSTIN 2:17 10:1 14:22 16:9.19 18:15 19:7,17 119:10 138:18 143:15 169:4 169:11 170:4,6 221:11 228:10 254:21 **business** 65:22 businesses 72:5 **button** 137:6,18 buttons 17:15 buy 9:21 С C 5:1 C's 65:5 C-section 80:8 103:7 cab 62:16 CAHPS 26:6 263:14 264:17 calculation 175:3 CalHospitalCompare 232:17 calibrated 129:4,19 **California** 218:12 call 8:7,12 84:10 138:13 153:5 302:6 called 115:5,20 145:2

calling 291:10 calls 108:7 Calmus 1:16 12:6,6 130:21 131:4 293:22 campaign 199:9 cancer 44:10 231:17 267:17,18 canvassed 71:7 capability 206:3 capacity 297:4 capital 285:4 296:14 297:2,17 capped 45:18 captain 311:20 capture 69:19 136:19 221:15 235:4 241:9 captured 47:13 captures 94:16 122:14 252:2 capturing 152:7 221:5 221:6 card 163:21 242:2 cardiovascular 231:19 281:9 283:22 cards 8:11 careful 145:16 282:4 caregiver 285:6 caregivers 296:18 Carol 2:5 15:11 87:20 119:11 120:20 127:7 133:14 139:14 142:5 142:8,15 143:10 148:9 153:5,18 165:9 167:11 175:21 193:2 193:7.18 227:20 228:18 234:1 carry 193:12 carve-out 293:14 carve-outs 171:4 299:3 299:6,14 carving 281:10 **case** 80:6 98:4 108:22 132:6 143:21 185:16 270:12 cases 126:15 225:1 226:10,11 274:2 cast 138:7 150:6 164:10 176:21 227:16 247:13 catalyze 122:16 catch 307:2 categories 26:22 228:1 category 276:14 catheter-related 104:9 cause 300:15 cautious 161:2 218:17 Cavaliers 73:8 caveats 55:12 CDC 89:3 196:3

celebrating 108:1,8 cell 8:6 81:22 **Celtics** 73:8 Centene 1:18 2:3 12:11 12:12 15:22 16:2 61:17 Center 13:17,21 14:8 16:17 19:12 centered 15:16 44:3 Centering 71:5 centers 2:13 3:11,14,16 13:22 89:3 97:19 284:7 central 15:17 122:2 CEO 5:7 15:15 certain 7:10 52:13 53:21 63:18 97:2 106:21 126:3 175:16 198:16,16 220:2 224:8 230:21 233:3 273:2 279:8 certainly 6:6,19 93:16 93:21 105:8 107:3 133:7 194:8 198:4 202:20 221:2,20,21 277:16.19 306:21 310:20 certificate 241:8 244:18 certified 5:15 37:16 284:13 289:1 cervical 44:10 267:17 cetera 17:10 62:20,20 143:8 CFC 45:11 chair 18:5 295:11 chairing 311:13 chairperson 139:15 **chairs** 10:12 20:1,7 183:1 266:22 311:16 311:19 challenge 87:11 106:19 106:22 181:21 challenges 29:12 51:14 73:16,18 76:19 94:14 107:7 143:5 171:3 198:15 270:2 271:9 271:11 280:18 286:13 challenging 166:2 171:13.16 chance 213:21 247:19 chances 212:18 change 94:11 103:11 107:10 132:18 148:17 199:3 226:8,17 265:21 changed 143:17 147:7 183:20 changes 34:7,11 37:4

55:20 106:20 107:2 199:12 242:16 **chaotic** 105:2 characteristics 121:17 273:2 charge 22:13 240:10 chart 175:5,12 180:14 249:11 charts 52:11 chatting 149:9 check 86:12 146:2 232:16 checking 211:18 checklists 96:20 checkmark 57:14 checks 61:21 Chief 2:15,17 childhood 231:15 children 33:5 44:11 49:19 62:2 74:12,15 91:6 112:5 231:11 245:19 249:13 253:11 253:12 258:6 278:22 279:1 281:5 303:12 children's 1:14,15 9:7 14:14.15 16:14.17 18:2 75:6 295:13 **CHIP** 19:13,15 **CHIPRA** 54:7 **chlamydia** 110:22 choice 44:4 76:5 122:11 196:9 choices 164:12 246:13 247:3 choked 5:14 choose 150:1 233:15 **chose** 54:20 chronic 28:21 59:22 60:8 147:8 213:18 267:19 296:21 CHW 98:11 Cincinnati 65:6,9 69:8 circle 41:10,18 circles 70:19 circumstances 141:20 277:13 cite 244:9 cities 64:14 Citizens 13:1 city 64:15 65:8 70:5 103:6 claim 69:2 75:11,12 claims 68:11 102:7 105:20 129:13 130:11 171:12 200:4 203:12 203:14 205:5,7,12 208:1 209:21 210:7 235:19 240:18 274:2

299:16

174:12 175:12,13

288:16,18 296:17 303:2 305:18 306:3 claims-based 64:3 168.6clarification 154:20 215:7,11 228:20 clarify 137:6 144:2 153:20 154:4 162:7 162:19 207:22 clarifying 153:6 Clark 67:13 74:6 Clarke 2:4 12:20 73:20 285:14 298:9 class 255:1 clean 193:2 cleaner 158:19 172:10 clear 26:8 35:18 135:21 156:12 166:19 173:1 192:20 211:11 226:1 226:2 232:10 246:16 275:3 clearly 88:19 91:4 93:22 98:18 172:4 224:22 Cleveland 65:6 click 39:2 115:14.21 116:1,14,19 117:1 clicker 149:10 152:5,10 152:14 clickers 138:1.8 149:14 150:10 client 307:9 clinic 37:16 clinical 13:22 14:2 17:18 300:6.21 clinician 42:12 49:11 56:4 57:11 77:10,16 clinicians 46:10 57:6 63:2 84:19 85:3 130:13 216:4 clinics 284:14,15 close 28:19 42:14 43:15 52:3 128:15 151:12 173:9 265:8 282:22 closely 36:7 46:9 77:3 closer 84:16 158:15 232:4 clustered 54:3,14 62:3 **CMCS** 87:14 187:10 196:2 CMCS' 195:19 **CMHC** 306:4 CMHCs 301:1 CMS 4:6 6:6 9:22 21:14 21:20,21 22:19 28:3 29:13 30:11 32:9 33:3 36:2 37:12,12 38:7 39:19 40:4 67:11 74:2

87:6 88:1,19 97:17 98:9 107:20 109:21 118:1 132:20 133:5 136:17 138:21 148:12 160:9 162:19 163:14 175:13 183:17 184:4 184:7 185:21 186:19 191:18 219:5 230:12 232:12 240:11 246:16 251:2,8 262:15 263:7 266:2,9 271:14,18 279:20 284:11 286:13 309:21,22 310:17 312:11,22 CMS/State 4:7,8 co-chaired 87:18 co-chairing 9:8 co-chairs 1:9 5:21 co-occurring 13:4 75:1 75:4,8,16 coalition 13:2 code 209:18,20 236:5 coded 236:5,9 codes 120:12 205:16 coding 47:1 52:18 coercion 196:15 198:5 202:17 203:5 205:13 220:12 232:20 coercive 220:16 coffee 149:4,15 151:14 151:18 152:15 Cogan 3:7 217:5 239:21 240:5,6 257:19 278:14 302:13 303:21 304:17 305:1.8 collaborative 1:18 15:16 37:14 47:9 196:8 232:13 colleague 74:2 colleagues 9:22 109:21 138:21 146:4 266:3 collect 90:3 166:8 235:9,13 239:19 collected 25:6 204:20 205:4 232:15 238:3 collecting 189:17 241:13 302:19 collection 165:21 168:15 173:15 174:7 176:7 182:11 229:16 230:10 233:11 235:15 269:12 270:1 collectively 108:11 color 61:7 70:22 color-coded 65:4 **Colorado** 24:4,5 80:3 colorful 183:9 colors 265:1,5

Columbia 18:6 Columbus 65:6,9 69:8 column 74:10 combination 21:17 combined 5:10 249:22 come 11:6 20:1 31:21 41:13,18 43:11 81:17 101:10 102:11 103:2 106:11 130:17 144:16 145:17 155:19 156:22 157:20 162:4 171:3 179:19 187:3 231:18 237:14 240:13,19 247:19 270:3 277:16 281:21 282:21 288:12 306:3,4 comes 37:4 110:6 127:16 220:13 296:21 304:1 comfortable 134:21 161:11 221:17 coming 10:2 37:9 63:3 128:15 144:19 238:9 289:12 294:14 295:14 309:15 comment 4:12.14.15.18 8:18 19:18,21 67:21 99:8,9 102:9 103:20 103:21 119:6 121:1 125:5 128:21 130:20 131:20 136:4 142:5 147:19 148:11 160:21 162:4 170:5,17 172:16 175:21 177:21 178:3 187:15 204:4 206:5 214:16 215:8 215:12 220:19 221:12 236:11 237:15 240:4 245:13 247:17,22 256:19 260:14,16,18 279:21 293:8 297:14 298:2 307:21 308:10 308:12,14 309:1,17 commentary 167:13 266:4,9 commented 69:12 comments 8:14,17,20 39:10,13 41:8 44:5 46:15 47:7 60:7 67:9 99:3 114:21 115:6 121:9 128:20 136:3 138:4,22 139:14 148:19,22 153:5 157:18 158:10 159:2 160:2,19 162:5 163:17 168:11 173:6 176:12 177:22 178:7 178:9 179:10,16

202:18 210:22 216:13 234:1,5 235:7 240:17 244:16 248:4,6 258:11 260:22 261:9 264:22 292:20 308:18 309:5,8 commercial 81:19 234:10 257:22 258:3 258:5 Commission 25:5 232:14 235:1 241:22 commit 289:8 committee 6:19 22:16 91:7 106:10 114:3,15 118:21 120:10 127:12 132:19 133:17,19,21 141:12 142:4,13 143:2,13 210:21 211:2 212:3 219:3 229:14 230:4 232:22 250:8,15 255:7 277:4 285:20 286:8,19 309:19 310:5 311:13 Committee's 17:9 committees 7:4 18:11 common 213:1 282:19 commonly 256:17 Commonwealth 308:1 communicate 85:8 299:9 communicating 85:14 communication 76:5 81:21 254:5 communities 51:8 60:20,21 64:13 65:13 66:14,16 70:2,4,22 213:3 283:4 284:21 community 1:21 11:20 14:7 28:8 37:16 42:15 44:17 56:3 65:2 67:6 70:17 71:5 77:20 95:13 101:13 134:12 170:16 172:22 181:20 196:2 199:2 233:12 282:7,9 283:1 284:7 284:13 community-286:3 community-based 26:7 26:9 27:20 44:6 69:16 70:15 74:18 263:14 263:22 264:18 comorbidities 273:5 274:11 comorbidity 283:18 306:20 companies 80:6 comparable 251:16 compare 33:17 65:5

106:1.12 107:1 compared 60:21 80:1 103:6 254:14 275:21 comparing 106:12 218:11 comparison 255:19 competency 123:8 competing 51:6 80:15 122:4 competitive 218:9 compiled 113:7 complacency 128:3 complaining 233:13 complement 206:9 complementary 194:18 complete 206:14,14 **completed** 252:12 completely 99:8 105:18 221:14 242:7 completing 181:14 182:8 completion 97:3 complex 168:13 286:5 287:9 296:20 complexity 286:14 288:4 complicated 77:5 78:3 172:21 305:12 complications 28:14 component 125:8 192:4 266:16 303:19 304:14 components 32:8 39:21 129:10 167:17 169:5,8,17 208:14 composite 58:15 59:9 comprehensive 175:18 200:7 250:3 computers 104:16 concept 27:11 49:14 166:7 194:5 243:14 concern 19:21 79:19 80:13 121:4 126:10 218:11 219:18 233:2 233:6 263:15 concerned 202:16 210:14 concerns 33:16 79:21 81:3 125:16 126:16 196:14 208:16 232:20 250:8 concludes 260:15 265:14 concrete 291:5 concurrent 25:14 264:2 264:19 condition 60:8 75:14 157:17 162:21 183:8

224:5,18,22 225:9,14 225:22 227:19,20 246:12,22 253:9,17 267:19 269:5 281:6 291:20 296:1 302:5 conditional 24:20 25:12 25:13,15 132:19 136:6 137:5 138:16 157:6 159:9,9,21 160:3,6 161:3,12 163:9,9 183:13,22 223:2,7 227:15 228:2 246:10 259:5 263:2 263:12,17,18,20,22 conditionality 140:5 conditionally 26:5 164:16 165:2 183:3,6 194:12 228:8,10 263:11 conditions 59:22 75:16 137:10,14 148:5,12 160:9 182:11 183:12 213:18 223:5,8,9 224:1,16 258:15 259:7.15 260:5 263:10 295:22 296:21 299:1 condom 201:12 conduct 79:2 conducted 28:6 confer 177:10 Conference 1:8 confidence 122:12 197:2 conflict 11:3 confused 131:5 confusing 241:18 confusion 38:13 **Congress** 218:13 conjunction 66:16 connect 90:15 connected 306:15 Connecticut 16:17 connecting 72:15 95:13 270:4 connections 271:20 connectivity 105:3 106:8 cons 201:22 consensus 120:10 127:17 230:2 250:16 consider 8:20 34:13 36:21 123:11 125:9 152:22 160:10 181:14 182:6 185:6 192:9 193:21 229:12 considerate 34:10 consideration 38:15

55:11 56:13 57:19 59:9 113:10 119:8 123:7 128:17 165:8 167:5 221:12 239:1,5 261:7 considerations 4:6 187:11,12 considered 25:20 37:1 113:11 119:1 189:12 190:2 200:22 228:22 considering 21:11 123:10 180:7 234:2 268:7 consistency 33:17 93:11 96:15 143:19 consistent 33:12 38:12 121:20 148:18 Consortium 13:1 constantly 231:3 **constituted** 136:15,16 constraints 175:7 249:17 construed 220:16 consultant 2:6 12:17 236:21 consulted 18:9 **consulting** 13:13 17:9 contact 310:5,6,7 contain 46:2 contained 112:7 content 95:5 96:2.15 120:13 126:2 128:8 128:18 135:14 220:21 220:22 contention 83:6 CONTENTS 4:1 context 148:8 277:16 279:14 281:3 282:12 285:11 306:10 contextual 195:14 continually 180:21 181:8 continue 93:10 98:19 157:17 184:13 193:4 237:6 244:1 309:13 continued 4:13 119:5 continuity 148:7 continuous 196:6 continuously 144:14 155:8,19 156:21 **continuum** 4:10 27:12 107:15 271:16 contraception 46:13 77:7 89:16 97:8 129:12 178:13 192:5 197:4,5 200:2 202:20 203:2,20 205:20 211:21 212:1,14

213:4 215:7,9 contraceptive 89:22 90:3,6,7 111:2 128:17 178:22 184:5 186:17 188:10 190:19 191:21 192:13 196:1,11 200:6 206:11 210:13 211:14 222:21 227:12 263:12,20 264:21 265:9 contraceptives 204:14 **contract** 36:3,4 53:22 contractors 132:11 contracts 299:14 contrary 7:18 contributed 90:9 198:1 control 89:4 201:19 218:16,16 219:20 220:7 233:14 249:13 251:18 255:3,5,21 267:20,21 275:18,18 279:22 291:11,12,17 301:16,17,21 controller 253:19 255:18 256:21 257:4 258:8 controls 80:2 controversy 84:2 conversation 41:6 129:2 140:22 163:6 169:10 185:11 190:2 190:3 193:1,5 217:7 224:2 238:5,12 248:16 262:7 270:9 271:3.14 272:5 292:21 296:12 298:7 312:18 conversations 124:5 139:3 266:13 284:10 convinced 151:8 cooperation 280:21 coordinate 275:15 Coordinating 22:16 114:15 309:19 coordination 273:10,18 274:19 299:2 306:2 coordinator 95:14 Cornell 307:22 **corner** 116:14 coroner 42:1 Corporation 1:18 2:3 12:11 15:22 correct 147:21 149:2 156:6,6,7 158:21 191:2 226:16 227:18 229:1,3 250:14 correctly 158:8 192:16 291:15,22

correlate 50:18 67:19 69:2 correlated 49:22 290:3 correlates 46:17 correlating 99:12 corticosteroids 255:4 cost 44:15 103:1 212:17 253:17 cost- 57:12 Costello 308:5 **costs** 46:2 **council** 76:2 counseled 205:16 211:22 counseling 97:8 205:14 206:11 count 56:21 104:13 121:3 159:3 256:9 286:16 counties 60:17 78:20 81:2 countries 71:21 **country** 14:9,16 48:2 59:1 75:4 195:13 232:18 287:1,15,16 counts 135:13 305:19 county 42:2 65:12,15 couple 16:20 37:17 67:16 87:19 104:12 128:9 186:21 197:22 199:9 244:16 256:8 266:21 276:22 278:16 283:15 298:9 coupled 172:18 173:8 course 19:20 25:4 42:8 55:1 56:6 76:13 87:21 102:15 108:8,11 120:15 130:7 132:4 155:12 228:15 271:13 308:22 **cover** 43:14 44:20 coverage 38:9 49:2 112:10 covered 142:9 covering 145:14 covers 253:12 **CPC** 75:22 78:9 **CPHQ** 2:9 cracking 32:1 cracks 82:11 Cradle 69:7 Craig 2:7 15:7,8 crazy 62:14 create 101:17 140:9 created 175:13 224:9 287:18 288:1 creates 94:19 171:5 creating 56:21 128:4

creation 258:22 crises 59:1 173:6 crisis 25:18 66:3 195:13 criteria 7:7 118:22 121:11,15 122:6,10 122:22 180:9 181:11 280:16 290:16 criterion 80:15 critical 181:16 190:13 237:3 250:7 critically 171:15 Croix 1:21 11:12,13 24:7 125:15 131:15 131:21 168:12 176:11 190:18 191:6,11 244:15 288:9 292:8 cross-walk 75:8 crossover 23:19 110:15 crowd 29:22 crucial 176:4 194:18 CSAC 120:15 178:17 250:15,17 cultural 123:8 208:14 218:15 cup 67:12 curious 39:16 80:16 86:6 238:22 278:11 292:1 current 19:3 51:10 129:4 153:7 160:21 182:4 203:21,21 270:21 currently 17:16 25:16 26:3 33:21 90:4 113:2 136:14,16 181:17 199:18 206:7 249:6 308:17 **CURRIGAN** 178:10 curve 237:17 cutting 110:12 CV 17:11 CVs 17:12 D **D** 5:1 **D.C** 1:9 13:2 Daniel- 87:5 Daniel-Robinson 3:10 4:9 87:9 100:5,18 105:7 106:15 108:16 189:3 191:3,8,12 197:17 205:1 206:6 208:20 209:19 219:17 dark 235:22 dashboard 74:8,21 244:8 data 30:18 33:3 36:1

57:16 60:14 93:6 101:11 103:18 106:17 107:3 122:14 166:1 168:15 171:11,12 173:15 174:4,9 175:2 182:11 196:5 202:4 203:13,15 205:6,7 207:5,6,7 208:1,10 209:17 210:8 226:15 236:3 238:3,7,8,9 240:18,19 243:8,21 244:17,18 250:10 252:7 269:12 270:1 270:21 274:2 278:8,8 278:15,17 279:4 281:17 288:11,12,16 288:18,19,20 289:5,6 293:13 294:4,8,14,18 294:20 295:4 296:5 296:16,19 301:9 302:10,19 data's 244:12 data- 274:5 databases 270:4 date 89:10 100:9 147:1 dates 58:19 139:7 day 5:9 6:1 22:3 28:11 29:7,9 31:20 37:10 70:17 74:3 85:4,18 104:16 105:1.2 114:18,19 115:10,11 124:20 131:19 192:19 199:8 277:9 313:11 day's 26:16 days 43:2 104:16,20,21 121:3 126:11 132:2 146:19 147:4 155:2 157:3 199:9 242:14 242:15 deal 75:1 79:5 232:1 274:10 dear 23:3 267:7 deaths 26:1 **Deb** 288:6.8 debate 177:10 Debjani 2:20 5:4 21:1 266:18 Deborah 1:20 11:18 87:19 126:8 132:13 143:22 173:22 240:12 293:4 decades 71:11 312:4 decide 85:11 187:14 200:20 239:17 246:9 293:18 297:10 decided 178:15 181:19 decision 35:13 123:18 126:22 181:12 188:20

236:13 276:11 decision-making 190:10 decisions 30:19 77:1 122:1 180:9 259:20 293:17 deck 41:10 67:11 declines 69:14 **dedicated** 6:9,20 deeper 279:7 deeply 291:4 **Defense** 1:13 define 209:18 224:10 271:10 287:8 defined 270:13 defining 270:20 definitely 38:14 121:13 180:8 185:8 217:12 217:12,22 219:11 237:18 248:11,17 258:9 311:15 313:10 definition 208:18 degree 148:6 275:18,19 282:2,3 297:1 deja 21:6 **Delaware** 199:7 delaved 244:18 delaying 71:19 216:15 delays 244:20 delegate 84:6 deliberation 89:13 deliberations 17:9 19:20 92:3 128:1 delighted 41:18 delineation 85:19 deliver 102:18 236:14 **delivered** 23:6 105:12 186:6 188:21 deliveries 212:19 delivering 48:7 81:6 97:18 delivery 92:20 98:14 100:21 101:10 130:8 146:13 189:7 212:17 239:3 267:16 281:4 295:14,17 296:3 297:13 delta 52:6 Democracy 70:17 demographically 66:13 demographics 273:4 demonstrate 285:18 demonstrated 141:7 demonstrating 205:18 demonstration 284:17 demos 286:12 denominations 211:20 denominator 155:6

169:18 203:1 208:19 224:10 226:21 276:9 denominator's 191:4 department 3:5,8 71:17 196:7 240:8 253:20 296:9 departments 206:2 depend 302:9 dependent 294:10 depending 172:21 207:6 282:13 288:13 297:15 299:12 depends 293:10 depiction 59:18 depression 62:18 86:4 97:5 128:9,9,11 129:11 169:13 307:6 307:10,15,19 **Deputy** 19:3 derail 292:22 derived 129:15 dermatitis 231:14 descending 27:6 describe 82:8 described 59:18 design 42:21 60:10,12 171:3 designed 42:22 122:19 desirable 196:22 294:2 desire 26:10 136:12 215:6 294:4 desk 8:8 123:19 destructive 108:5 detail 17:5 details 119:17 224:15 determinants 27:18 68:10 69:11,18 82:3 173:3 269:20 determination 207:1 determine 76:20 198:12 207:11 209:6 279:5 determined 309:20 develop 21:12 40:12 280:16 306:11 308:2 developed 70:14 121:16,16 188:16 205:2 developer 119:7 186:10 196:21 developing 29:16 307:1 development 29:1 40:20 127:17 203:8 203:10 206:7,13 230:2 239:13 242:12 283:17 285:9 development-focused 40:19 developmental 74:12

75:3 231:4 287:17 deviating 132:5 diabetes 129:11 231:15 231:16 267:20.20 275:5,8 281:9 283:21 291:11,12,17 295:20 300:8 301:18,22 diabetic 54:21 102:13 275:18 diagnose 83:12 diagnoses 303:3 diagnosis 274:2,4 283:13 290:21 305:12 305:20 307:14 diagnosis-based 283:12 diagram 112:19 dialogue 221:21 Diane 1:16 12:6 73:21 288:6,8 293:5 dice 282:6 dicing 280:15 297:5 306:9 die 49:20 109:3 239:11 274:15 died 281:5 dies 109:2 diet 300:9 differ 263:10 difference 35:14 48:18 48:21 50:8 51:22 57:20 64:21 145:15 190:21 197:12,13 215:5 283:3 differences 258:4 312:8 different 10:15 12:13 17:2,19 26:22 38:8 39:3,18 40:14 42:10 45:12 53:13 56:18,20 58:276:485:6,7 86:18 96:8,12,13 106:5 111:3 114:12 115:16 116:10 146:9 158:7 186:22 187:8 191:4 194:14 209:1 222:6 229:15 246:18 256:1,3,13 270:4 272:21 273:4,6 276:13 278:9 290:3 290:22 291:19 297:7 302:5 306:8 308:2,4 312:10 differently 79:2 114:17 differs 39:20 difficult 47:6,19 126:22 174:7,9 216:18 245:5 245:11 difficulties 60:14

233:11 245:2 dig 279:6 dignity 213:16 diligence 174:14 dinged 80:5 dire 203:19 direct 71:20 149:17 directed 76:6 direction 50:17 135:15 138:9 149:17 197:2 219:10 289:12 292:10 directly 46:16 76:3 77:9 87:2 126:4 216:16 235:22 237:10 310:5 director 2:20 3:11 5:5 9:6 12:4 13:10,16 14:6,13,21 16:6 18:1 18:6 19:14,16 24:3 165:20 195:5 240:6 295:12 **Directors** 11:15 dis 70:21 disabilities 13:1,5 74:13 75:7 298:15 disability 2:4 12:22 13:3 75:3 287:1.3.5 287:17 disabled 75:13 213:18 216:13 217:20 298:11 discharged 57:7 disclose 10:18 19:2 disclosure 11:4 16:1 17:6 disclosures 4:3 10:5,15 11:10 15:1,4,9,13,19 16:8,13 17:1,21 18:3 18:8,18 19:19 disconnect 284:6,19 discouraged 236:16 discrimination 298:13 298:15 discuss 8:20 166:12 167:21 180:20 181:2 211:3 212:3 228:12 229:18 254:19 265:13 269:7 discussant 184:16 193:4 252:17 253:6 discussed 22:22 77:8 95:8 116:17 118:13 125:10 133:21 143:2 153:1 161:3 180:3 182:17,18 189:14,15 201:22 230:9 245:2 266:22 286:20 discussing 117:7 133:13 144:2 discussion 26:16 32:5

69:20 86:1 89:15 91:11 111:21 112:11 114:1,9,11,13 115:7 124:1 127:3 133:17 135:20 136:6 148:4,5 161:22 177:14 178:11 181:1,2,13 184:13,17 189:22 190:7,13 191:15 193:10,19 196:16 207:21 211:7 211:17,19 221:16 252:18 253:1 262:4 265:15 266:5 267:2 277:9 discussions 70:18 127:3 266:10 311:5 disease 16:15 89:3 147:8 231:5 281:9 disenroll 144:17 disincenting 121:4 disincentivizing 126:15 disorder 103:19 172:3 286.1 disparate 60:20 214:9 disparities 59:2 70:3 78:1 93:14 123:7 271:1 273:21 276:16 276:20 282:16,17 283:10,20 286:19 307:3 disparity 122:18 276:3 distance 87:7 distinctions 254:19 distinguishes 33:10 distrustful 72:17 disturbances 300:16 disturbed 279:1 disturbing 294:13 divide 282:21 divided 227:22 division 3:13 13:16 14:1 19:11,15 240:6,7 doable 103:9 doc 62:14 103:4 173:15 docs 62:4 doctor 16:15 155:14 document 163:15 175:13 219:12 documentation 52:6 244:13 documented 47:13 documenting 154:1 documents 22:8 175:17 doing 34:18 42:14 50:21 51:3,5 53:14 54:11 56:18 58:13 59:14 60:20 61:7 64:7 64:13,15 65:21 68:7

69:5 78:5,8 97:21 104:20 113:10 114:4 146:3 197:16 199:8 214:8 218:7 236:1 239:15 251:6 262:16 278:21 279:16 280:11 280:18 300:18 302:18 304:2,5 305:9,15 **DOIs** 9:20 dollar 84:21 86:20 dollars 140:18 141:16 dot 263:3 dots 26:22 27:7 262:18 262:22 263:4 264:5 265:6 dotted 48:16 double 168:8 downplaying 172:12 downside 254:3 downstream 70:9 233:7 233:17 dozens 37:18,18 **DPA** 2:4 Dr 4:7 5:11 10:1 13:14 13:20 14:22 16:4,9,19 17:12.14 18:15 19:7 19:17 41:12 68:13 69:21 73:9 74:14 75:9 76:15 77:2 78:12 80:22 83:4 86:9 87:11 87:18 88:20 89:11 93:22 102:2 103:20 105:8,18 107:21 108:2 109:21 119:10 129:1 132:1 135:11 138:18 143:15 146:1 148:2 154:4 155:4 156:6,11 158:21 159:1 163:4 168:3 169:4,11 170:4,6 171:2 172:16 180:12 186:21 189:10 204:6 205:9,11 212:6 215:15 217:5 218:3 221:11 222:2 228:10 235:16,21 237:11,15 238:17 254:21 277:14 278:1 280:13 283:15 285:8 286:22 291:2 292:9 301:15 305:11 306:18 311:8 draft 309:17 drawing 270:20 drawn 62:13 DRGs 212:16 drill 290:18 drive 30:6 54:5 61:13 94:7 105:13 107:10

driver 283:19 284:2 driving 52:21 87:13 307:12 drug 59:3 169:14 173:7 254:22 drummed 242:4 dually 286:7,9,10,15 due 120:17 168:13 174:13 175:4 dugout 41:10 duplication 50:10,11 51:15 duplicative 280:3 dyad 91:5 dying 68:15 dynamic 75:8 108:12 Е E 5:1,1 e-measure 186:3 228:16 229:11 230:8 234:3 246:17 247:9 earlier 47:8 60:7 102:9 117:22 119:16 126:15 173:5 175:2 180:10 182:17 188:12 206:19 243:17 274:15 276:6 313:6 earliest 296:19 early 121:7 127:17 176:6 189:7 255:12 285:9 easier 252:4 easily 48:22 273:22 274:3 Eastern 109:20 easy 86:3 125:21 313:3 echo 173:4 197:18 217:9 234:7 241:12 244:16 257:20 313:5 eCQMs 64:4,9 ED 83:21 Edinburgh 97:4 128:12 editorial 276:17 educated 71:19 education 71:7,17 72:8 90:14 199:5 effective 135:16 178:13 186:18 199:21 200:10 204:17 210:13 212:9 212:13 214:12 222:22 227:13 273:14

effectiveness 156:1,3

efficiency 28:17 83:20

effects 95:1

efficient 181:22

234:4

199:3 213:8 281:18

effort 34:6 40:10 42:8 51:15,17 52:8 53:21 65:16 68:7 69:8,9 72:2 88:7,15 89:6 99:16 109:7 144:7 235:4 efforts 43:16 52:10 69:17 70:15 71:6 73:2 82:8 85:13 97:10 301:6 EHR 52:12 83:13 102:19 175:5 232:11 270.3eight 138:13 147:3 154:12 201:17 223:14 232:18 259:11 264:17 eighth 29:2 either 40:6,8 91:18 121:18 135:20 187:14 188:6 295:6 299:7 306:6 elderly 44:21 elect 183:6 184:12 elected 267:16 elective 92:20 189:7 electronic 106:7 129:14 174:4 175:2 210:1.4 elements 97:3 101:8 175:2 269:17 eliciting 26:19 eligibility 64:5,9 79:7 302:22 eligible 49:10 150:20 286:7,9,11,15 290:15 eliminate 50:11 294:4 eliminating 129:6 Elisa 9:20 20:9,11 Elliott 2:9 10:13 17:14 17:15 135:11 148:2 165:22 171:2 218:3 email 39:5 114:1,2 310:9 emailed 114:20 embedded 158:12 embraces 108:10 emergency 83:15 253:19 255:19 296:9 emotionality 141:14 emotionally 214:6 279:1 empirical 119:2 120:17 employed 12:21 employee 15:6 employer 16:2 **EMR** 174:9 enables 123:4 enabling 47:2 141:20 270:22

encompasses 247:9 encounter 288:16,19 encourage 34:9 124:5 206:1 297:6 302:4 encouraging 126:14 276:4 300:9 ended 313:7 endorsed 111:14 113:8 113:9,12,13 122:11 125:17 132:6,21 133:6 141:9 165:13 168:21 178:16 179:5 186:5,9 195:16 248:22,22 249:1 253:16 277:4 endorsement 26:3,13 117:17 118:3,3,17,20 119:5,8,8 120:18 123:2 125:12 127:9,9 133:18 178:16,21 179:4,5 183:14 194:13 204:9 206:15 210:21 249:5,7 250:6 250:18,19,22 264:3 ends 187:13 306:13 energy 40:10 engage 73:19 88:1,8 190:6 192:22 engaging 88:15 enhance 85:2 enhances 299:22 enrolled 130:4 144:15 155:3,7,8,10,12,19 156:1,21 157:4 enrollment 45:1 145:3 154:6,7,9 302:22 ensure 96:4 100:8 101:1 102:20 203:20 211:13 213:9 ensuring 94:20 97:7 101:6 176:7 entertain 162:1 260:16 entire 61:8 67:1 86:21 129:8 154:16 212:17 303:2 312:18 entirely 224:8 entities 48:4 51:11 84:16 285:17 entity 10:19 285:7 entry 296:8 **enumerate** 167:17 environment 51:10 197:4 203:21 episode 57:1 77:17 281:14,16,16 episodes 56:19 81:15 equal 142:14 equally 192:3

equity 70:6 194:10 230:20 ER 78:22 err 21:7 error 52:5 282:2,3 especially 23:17 28:15 51:5 55:16 79:18 250:9 269:9,10,15 276:2 298:11.14 essence 216:20 Essential 14:17 essentially 43:19 54:15 54:20 102:10 139:1 164:1,3,6 214:6 229:14 275:13 278:5 296:7 304:2,5 established 233:16 estate 188:3 243:17,21 et 17:9 62:20,20 143:8 etcetera 203:5,5 296:10 297:22 ethnic 217:18 273:3 283:10 290:6 ethnicity 293:12 evaluate 166:15 evaluating 122:7 evaluation 3:8 13:16 208:12 event 239:6 events 70:17 71:3 eventually 214:7 everybody 5:3,17 10:2 10:11 11:10,11 19:17 43:16,20 49:14 66:5 69:12 75:5 102:18 150:20 232:21 266:8 293:2 303:5 everybody's 218:21 evidence 52:16 107:5 118:22 119:2 120:17 127:16 141:4 142:1 143:16,20 145:15,18 195:10 220:15,22 231:10 242:11.13 250:9 253:14 254:9 evidence-based 36:17 44:1 71:4 102:16 exacerbate 298:22 exactly 142:12 158:11 164:6 200:12 201:2 281:8 282:11 examination 136:10 example 46:20 47:20 51:21 52:10 53:3,16 58:1 62:7,11 77:13,14 77:18 81:13 82:1 83:22 115:21 121:5 144:12 201:7,11

208:21 212:15 213:20 255:1 275:17 276:20 281:4 293:11 297:3 301:17 305:14 307:5 examples 51:12 55:6 59:15 61:1 71:22 Excel 113:17 116:22 117:3 excellent 118:6 310:19 excited 16:3 240:12 exclude 203:1 208:5 excluded 200:17 excluding 151:2 191:9 exclusions 200:14 239:1,5,8 exclusive 178:12,18 185:22 228:17 233:8 236:7 246:1 247:8 297:15 exclusively 188:5 241:4 excuse 183:13 executive 2:16 14:12 exercise 26:21 101:16 exist 107:8 300:22 existence 220:8 existing 280:15 302:16 exists 162:6 expand 100:13 expanded 44:13 45:20 expanding 86:3 expansion 45:5,10 81:9 **expansive** 109:12 expect 10:22 309:22 expectancy 294:15 expectation 107:20 161:13 275:12 expectations 23:14 expected 174:4 201:6 230:15 expecting 233:5 expenditures 45:14 experience 20:3 26:7 26:11 41:19 83:20 139:20 148:10 188:19 205:22 206:11 experienced 167:22 233:1 252:9 experiences 21:11 experiencing 195:12 expert 87:17,20 89:14 127:18 130:15 147:4 168:4 240:9 expertise 134:20 experts 2:8 10:13 16:21 17:2 explain 204:10 254:5 262:13 explaining 200:1 204:5

**explode** 296:2 **explore** 88:5 exploring 289:21 expound 285:3 expressions 101:9 extenders 95:14 extensively 211:3 extent 50:11 66:22 82:20 143:4 187:22 275:10 277:8 288:17 extra 45:21 56:21 extremely 6:5,8 101:15 112:4 F **FAAFP** 2:2 **FAANP** 1:19 **FAAP** 1:13 2:13 3:5 face 99:5 143:5 217:4 298:12 faces 29:13 facilitate 230:9 271:18 facilitating 124:15 facilities 230:22 facility 239:11 241:14 241:16,18 facility-240:15 facing 25:17 197:7 FACP 3:5 fact 20:5 95:3 106:1 112:3 120:12 141:18 158:13 166:10 197:18 211:19 233:5 251:7 276:5 278:4 300:8 factor 99:12 195:14 269:6 factors 47:2 86:19 105:13 122:10 271:5 failing 218:14 failures 295:3 Fair 305:8 fairly 230:22 274:3 fall 82:11 229:6 263:6 falls 284:9 familiar 69:6 256:14 families 2:5 15:12 54:10 55:2 296:17,22 family 12:3 45:1,3,9 72:1,2 196:5 200:21 209:4 family-centered 123:5 fantastic 81:16 313:9 far 66:19 132:2 134:20 180:2 232:8 245:20 267:22 269:2 farther 42:11 fashion 33:19 fast 84:5 248:18 262:12

father 13:4 favor 122:11 129:6 favorable 195:18 227:22 faxes 85:16,17 fear 171:22 feasibility 76:21 92:16 165:21 182:12 feasible 173:21 176:7 239:18 246:2,3 feasibly 182:2 fed 266:4 federal 2:10 63:20 89:2 93:4 151:2 232:8 238:6 268:1 Federation 196:6 feds 11:6 215:4 fee 78:15 79:10 84:20 86:12 96:22 fee- 49:5 53:14 fee-for-service 50:15 feed 79:5 169:10 236:13 243:22 feedback 35:11 62:20 63:1 88:3 173:19 180:11 238:8 281:18 feeding 117:15 121:5 129:13 178:12,19,19 186:1 187:19 188:4 228:18 231:1 233:9 234:8.9 235:5 236:18 239:4 241:4 242:8,12 242:16 243:16,20 244:1 245:18 246:1,2 246:5 247:8 feel 34:16 78:10 134:4 134:10,19,21 148:6 165:17 194:16,19 195:1 197:7 217:6 219:16 221:16 223:12 230:13 264:5 feeling 25:17 134:14 feels 37:10 259:15 297:12 312:10 fees 85:2 felt 142:13 280:2,3,9,12 **FEMALE** 74:5 fertility 201:19 fewer 40:3.9 field 31:13 40:15 96:17 106:9fields 236:4 fifth 28:17 fight 85:9 figure 51:4 53:13 68:11 71:13 88:22 167:15 200:16 242:18 280:22 281:19 294:5 297:18

| 00110  | l  |   |   |
|--|--|---|---|
| 304:13   | Florida 1:21 11:15,16  | 185:19 222:6 223:12   | 313:11  |
| figured 51:7 243:7   | 24:8 168:16 237:21   | 224:4 227:8 228:14  | frequency 93:7 117:18   |
| file 289:5   | 244:17 245:7 288:9   | 230:11 247:13 249:8   | 118:8 131:7 142:14  |
| fill 24:7 26:12 31:6   | 289:16 292:2 303:22  | 250:21 251:7 259:3  | 144:3 146:9 147:12  |
| 81:11  | 305:2  | 259:19 261:4,6,17   | 149:22 159:15   |
| filled 128:5 140:10  | flow 127:17  | 262:5 265:12 266:21   | frequent 253:18   |
| filling 19:13  | flowed 266:9   | 272:4,8 309:13,14   | frequently 92:12,18   |
| filter 77:13   | flows 270:21 296:16  | 311:3,10 312:2,5,8  | fresh 312:11  |
| final 22:14 120:15   | fly 258:21   | 313:12  | friend 9:10   |
| 297:14 309:21  | focus 29:4 55:20 73:2,6  | forces 20:22 110:1,10   | friendly 70:8   |
| finally 29:4 90:16 93:17   | 76:5 78:13 93:20   | 124:4,14 175:14   | frightened 72:17  |
| 313:1  | 101:3 122:2 140:20   | 182:19 185:13 301:7   | front 21:21 123:19  |
| financed 101:2   | 143:20 154:16 156:14   | forever 306:22  | 183:10,12 216:12  |
| finances 103:10  | 173:12 196:9 199:4   | forget 277:17   | 266:6,11 283:3  |
| financial 17:6 79:9 86:2   | 265:21 272:11 306:12   | forgot 11:12  | 312:16  |
| 86:7   | focused 7:3 26:1 32:11   | form 204:15 246:18  | full 41:18 42:17 45:10  |
| financing 98:2   | 37:3 40:4,10 79:16   | formal 133:5 135:10   | 112:13 132:18 292:16  |
| find 54:2 84:6 91:17   | 96:4 100:20 188:8,9  | formally 195:16   | fullest 303:15  |
| 95:6 99:17 114:2   | 191:22 217:19  | forms 205:19,19 273:21  | fully 10:22 136:9   |
| 117:8 152:20 249:11  | focuses 252:3  | formulating 21:14   | fun 38:5  |
| 250:2  | focusing 28:13 32:9  | forth 69:11,15 103:19   | function 91:20  |
| finding 107:20 143:6   | 133:16 135:14 217:22   | 180:15 224:5 243:5  | fundamental 194:6   |
| findings 95:11,12 118:1  | 224:3  | 284:8 285:11  | funded 195:20 197:20  |
| fine 86:12 134:1 185:17  | folks 10:11 15:1 23:17   | fortunate 24:6  | funding 90:1,2  |
| 193:11   | 43:22 44:16 45:2,3   | forum 1:1,8 230:2   | further 29:1 136:6  |
| fire 173:12,13   | 75:2 116:6 124:17  | 285:18 286:5,6,19   | 187:5 268:11  |
| first 5:18 9:21 24:17  | 173:9 211:7 248:6  | 287:7   | future 210:2 241:10   |
| 41:12 59:20 65:8   | 259:14,17 260:3  | forward 20:1 23:4 38:15   | 271:13  |
| 67:18 68:1,1 71:19   | 278:11 291:6 293:2   | 46:12 97:13 126:20  | <b>FY</b> 118:8   |
| 92:9 104:14 115:20   | 306:12   | 140:9 165:8 193:13  | 11110.0   |
| 124:12,17 127:15,22  | follow 56:8 57:21 87:11  | 223:5,8 266:18  | G   |
| 143:21 144:14,21   | 256:19   | 271:12,22 278:2   | <b>G</b> 5:1  |
| 145:7 146:17 154:14  | follow- 82:10  | 298:8 311:6   | gain 79:9 103:1 188:18  |
| 155:1,3,7 157:2,3  | follow-on 271:8  | foster 44:9 303:13  | gained 272:15   |
| 174:18 216:15 218:22   | follow-up 111:12   | found 40:1 62:16 81:9   | game 34:4 243:8   |
| 222:16 227:22 230:16   | 128:12 129:19 291:3  | 95:18,22 96:19 97:10  | gan 22:20 23:20 26:8  |
| 246:9 247:18 255:4   | 301:9  | 100:6,8 118:18 169:5  |   |
|  |  |   | 4013583116011   |
|  |  |   | 40:13 58:3,11 60:11<br>60:18 70:3 71:14   |
| 258:18 261:17 281:14<br>281:15 21 282:19   | followed 96:9<br>following 96:14 123:12  | 248:21 251:8 289:16   | 60:18 70:3 71:14  |
| 281:15,21 282:19   | following 96:14 123:12   | 248:21 251:8 289:16<br>foundation 32:7  | 60:18 70:3 71:14<br>81:11 112:16 113:9  |
| 281:15,21 282:19<br>289:9 291:6  | following 96:14 123:12<br>144:5 182:7  | 248:21 251:8 289:16<br>foundation 32:7<br>foundational 230:14   | 60:18 70:3 71:14<br>81:11 112:16 113:9<br>113:18,19 115:13,19   |
| 281:15,21 282:19<br>289:9 291:6<br>fiscal 93:4   | following 96:14 123:12<br>144:5 182:7<br>follows 82:17   | 248:21 251:8 289:16<br>foundation 32:7<br>foundational 230:14<br>foundations 18:14  | 60:18 70:3 71:14<br>81:11 112:16 113:9<br>113:18,19 115:13,19<br>116:15,20 140:10   |
| 281:15,21 282:19<br>289:9 291:6<br>fiscal 93:4<br>fit 312:15   | following 96:14 123:12<br>144:5 182:7<br>follows 82:17<br>food 297:3   | 248:21 251:8 289:16<br>foundation 32:7<br>foundational 230:14<br>foundations 18:14<br>four 5:19 57:1 74:9   | 60:18 70:3 71:14<br>81:11 112:16 113:9<br>113:18,19 115:13,19<br>116:15,20 140:10<br>158:3 180:16,16  |
| 281:15,21 282:19<br>289:9 291:6<br>fiscal 93:4<br>fit 312:15<br>fits 92:2,2 195:1  | following 96:14 123:12<br>144:5 182:7<br>follows 82:17<br>food 297:3<br>foot 312:19  | 248:21 251:8 289:16<br>foundation 32:7<br>foundational 230:14<br>foundations 18:14<br>four 5:19 57:1 74:9<br>88:14 129:10 174:20  | 60:18 70:3 71:14<br>81:11 112:16 113:9<br>113:18,19 115:13,19<br>116:15,20 140:10<br>158:3 180:16,16<br>195:2,7 198:3 203:9   |
| 281:15,21 282:19<br>289:9 291:6<br>fiscal 93:4<br>fit 312:15<br>fits 92:2,2 195:1<br>fitting 195:8   | following 96:14 123:12<br>144:5 182:7<br>follows 82:17<br>food 297:3<br>foot 312:19<br>for-service 49:6 53:15  | 248:21 251:8 289:16<br>foundation 32:7<br>foundational 230:14<br>foundations 18:14<br>four 5:19 57:1 74:9   | 60:18 70:3 71:14<br>81:11 112:16 113:9<br>113:18,19 115:13,19<br>116:15,20 140:10<br>158:3 180:16,16<br>195:2,7 198:3 203:9<br>208:10 214:5 234:11  |
| 281:15,21 282:19<br>289:9 291:6<br>fiscal 93:4<br>fit 312:15<br>fits 92:2,2 195:1<br>fitting 195:8<br>five 42:18 48:17,20 64:1   | following 96:14 123:12<br>144:5 182:7<br>follows 82:17<br>food 297:3<br>foot 312:19<br>for-service 49:6 53:15<br>force 1:3,8 4:3,4,5 9:8,9   | 248:21 251:8 289:16<br>foundation 32:7<br>foundational 230:14<br>foundations 18:14<br>four 5:19 57:1 74:9<br>88:14 129:10 174:20<br>242:14,15 263:4<br>285:20   | 60:18 70:3 71:14<br>81:11 112:16 113:9<br>113:18,19 115:13,19<br>116:15,20 140:10<br>158:3 180:16,16<br>195:2,7 198:3 203:9<br>208:10 214:5 234:11<br>246:5 251:7 274:13  |
| 281:15,21 282:19<br>289:9 291:6<br>fiscal 93:4<br>fit 312:15<br>fits 92:2,2 195:1<br>fitting 195:8<br>five 42:18 48:17,20 64:1<br>66:10,11 68:8 71:12  | following 96:14 123:12<br>144:5 182:7<br>follows 82:17<br>food 297:3<br>foot 312:19<br>for-service 49:6 53:15<br>force 1:3,8 4:3,4,5 9:8,9<br>10:4,5,6,17 15:1   | 248:21 251:8 289:16<br>foundation 32:7<br>foundational 230:14<br>foundations 18:14<br>four 5:19 57:1 74:9<br>88:14 129:10 174:20<br>242:14,15 263:4<br>285:20<br>four-fold 168:8  | 60:18 70:3 71:14<br>81:11 112:16 113:9<br>113:18,19 115:13,19<br>116:15,20 140:10<br>158:3 180:16,16<br>195:2,7 198:3 203:9<br>208:10 214:5 234:11<br>246:5 251:7 274:13<br>282:22  |
| 281:15,21 282:19<br>289:9 291:6<br>fiscal 93:4<br>fit 312:15<br>fits 92:2,2 195:1<br>fitting 195:8<br>five 42:18 48:17,20 64:1<br>66:10,11 68:8 71:12<br>78:20 102:14 248:22   | following 96:14 123:12<br>144:5 182:7<br>follows 82:17<br>food 297:3<br>foot 312:19<br>for-service 49:6 53:15<br>force 1:3,8 4:3,4,5 9:8,9<br>10:4,5,6,17 15:1<br>20:19 23:6 67:9 87:14  | 248:21 251:8 289:16<br>foundation 32:7<br>foundational 230:14<br>foundations 18:14<br>four 5:19 57:1 74:9<br>88:14 129:10 174:20<br>242:14,15 263:4<br>285:20   | 60:18 70:3 71:14<br>81:11 112:16 113:9<br>113:18,19 115:13,19<br>116:15,20 140:10<br>158:3 180:16,16<br>195:2,7 198:3 203:9<br>208:10 214:5 234:11<br>246:5 251:7 274:13<br>282:22<br>gaps 6:18,20 26:17,18   |
| 281:15,21 282:19<br>289:9 291:6<br>fiscal 93:4<br>fit 312:15<br>fits 92:2,2 195:1<br>fitting 195:8<br>five 42:18 48:17,20 64:1<br>66:10,11 68:8 71:12  | following 96:14 123:12<br>144:5 182:7<br>follows 82:17<br>food 297:3<br>foot 312:19<br>for-service 49:6 53:15<br>force 1:3,8 4:3,4,5 9:8,9<br>10:4,5,6,17 15:1<br>20:19 23:6 67:9 87:14<br>99:4 112:11 114:6,7,8   | 248:21 251:8 289:16<br>foundation 32:7<br>foundational 230:14<br>foundations 18:14<br>four 5:19 57:1 74:9<br>88:14 129:10 174:20<br>242:14,15 263:4<br>285:20<br>four-fold 168:8<br>fourth 28:12  | 60:18 70:3 71:14<br>81:11 112:16 113:9<br>113:18,19 115:13,19<br>116:15,20 140:10<br>158:3 180:16,16<br>195:2,7 198:3 203:9<br>208:10 214:5 234:11<br>246:5 251:7 274:13<br>282:22<br><b>gaps</b> 6:18,20 26:17,18<br>26:20,21 27:3 58:8  |
| 281:15,21 282:19<br>289:9 291:6<br>fiscal 93:4<br>fit 312:15<br>fits 92:2,2 195:1<br>fitting 195:8<br>five 42:18 48:17,20 64:1<br>66:10,11 68:8 71:12<br>78:20 102:14 248:22<br>249:1 264:21 265:10<br>306:7   | following 96:14 123:12<br>144:5 182:7<br>follows 82:17<br>food 297:3<br>foot 312:19<br>for-service 49:6 53:15<br>force 1:3,8 4:3,4,5 9:8,9<br>10:4,5,6,17 15:1<br>20:19 23:6 67:9 87:14<br>99:4 112:11 114:6,7,8<br>114:9 115:12,15,16   | 248:21 251:8 289:16<br>foundation 32:7<br>foundational 230:14<br>foundations 18:14<br>four 5:19 57:1 74:9<br>88:14 129:10 174:20<br>242:14,15 263:4<br>285:20<br>four-fold 168:8<br>fourth 28:12<br>Fox 40:7<br>FQHCs 301:1   | 60:18 70:3 71:14<br>81:11 112:16 113:9<br>113:18,19 115:13,19<br>116:15,20 140:10<br>158:3 180:16,16<br>195:2,7 198:3 203:9<br>208:10 214:5 234:11<br>246:5 251:7 274:13<br>282:22<br><b>gaps</b> 6:18,20 26:17,18<br>26:20,21 27:3 58:8<br>67:2 116:20 180:18  |
| 281:15,21 282:19<br>289:9 291:6<br>fiscal 93:4<br>fit 312:15<br>fits 92:2,2 195:1<br>fitting 195:8<br>five 42:18 48:17,20 64:1<br>66:10,11 68:8 71:12<br>78:20 102:14 248:22<br>249:1 264:21 265:10<br>306:7<br>fix 86:21 139:6 300:4  | following 96:14 123:12<br>144:5 182:7<br>follows 82:17<br>food 297:3<br>foot 312:19<br>for-service 49:6 53:15<br>force 1:3,8 4:3,4,5 9:8,9<br>10:4,5,6,17 15:1<br>20:19 23:6 67:9 87:14<br>99:4 112:11 114:6,7,8<br>114:9 115:12,15,16<br>115:17 116:9,13,16   | 248:21 251:8 289:16<br>foundation 32:7<br>foundational 230:14<br>foundations 18:14<br>four 5:19 57:1 74:9<br>88:14 129:10 174:20<br>242:14,15 263:4<br>285:20<br>four-fold 168:8<br>fourth 28:12<br>Fox 40:7<br>FQHCs 301:1<br>fragile 303:12   | 60:18 70:3 71:14<br>81:11 112:16 113:9<br>113:18,19 115:13,19<br>116:15,20 140:10<br>158:3 180:16,16<br>195:2,7 198:3 203:9<br>208:10 214:5 234:11<br>246:5 251:7 274:13<br>282:22<br><b>gaps</b> 6:18,20 26:17,18<br>26:20,21 27:3 58:8<br>67:2 116:20 180:18<br>180:20  |
| 281:15,21 282:19<br>289:9 291:6<br>fiscal 93:4<br>fit 312:15<br>fits 92:2,2 195:1<br>fitting 195:8<br>five 42:18 48:17,20 64:1<br>66:10,11 68:8 71:12<br>78:20 102:14 248:22<br>249:1 264:21 265:10<br>306:7<br>fix 86:21 139:6 300:4<br>flag 68:4 102:19 128:1  | following 96:14 123:12<br>144:5 182:7<br>follows 82:17<br>food 297:3<br>foot 312:19<br>for-service 49:6 53:15<br>force 1:3,8 4:3,4,5 9:8,9<br>10:4,5,6,17 15:1<br>20:19 23:6 67:9 87:14<br>99:4 112:11 114:6,7,8<br>114:9 115:12,15,16<br>115:17 116:9,13,16<br>117:16 121:14 124:10   | 248:21 251:8 289:16<br>foundation 32:7<br>foundational 230:14<br>foundations 18:14<br>four 5:19 57:1 74:9<br>88:14 129:10 174:20<br>242:14,15 263:4<br>285:20<br>four-fold 168:8<br>fourth 28:12<br>Fox 40:7<br>FQHCs 301:1<br>fragile 303:12<br>fragmentation 295:20   | 60:18 70:3 71:14<br>81:11 112:16 113:9<br>113:18,19 115:13,19<br>116:15,20 140:10<br>158:3 180:16,16<br>195:2,7 198:3 203:9<br>208:10 214:5 234:11<br>246:5 251:7 274:13<br>282:22<br><b>gaps</b> 6:18,20 26:17,18<br>26:20,21 27:3 58:8<br>67:2 116:20 180:18<br>180:20<br><b>gargantuan</b> 282:15  |
| 281:15,21 282:19<br>289:9 291:6<br>fiscal 93:4<br>fit 312:15<br>fits 92:2,2 195:1<br>fitting 195:8<br>five 42:18 48:17,20 64:1<br>66:10,11 68:8 71:12<br>78:20 102:14 248:22<br>249:1 264:21 265:10<br>306:7<br>fix 86:21 139:6 300:4<br>flag 68:4 102:19 128:1<br>212:2   | following 96:14 123:12<br>144:5 182:7<br>follows 82:17<br>food 297:3<br>foot 312:19<br>for-service 49:6 53:15<br>force 1:3,8 4:3,4,5 9:8,9<br>10:4,5,6,17 15:1<br>20:19 23:6 67:9 87:14<br>99:4 112:11 114:6,7,8<br>114:9 115:12,15,16<br>115:17 116:9,13,16<br>117:16 121:14 124:10<br>124:11 130:18 131:3  | 248:21 251:8 289:16<br>foundation 32:7<br>foundational 230:14<br>foundations 18:14<br>four 5:19 57:1 74:9<br>88:14 129:10 174:20<br>242:14,15 263:4<br>285:20<br>four-fold 168:8<br>fourth 28:12<br>Fox 40:7<br>FQHCs 301:1<br>fragile 303:12<br>fragmentation 295:20<br>295:21 296:15,19   | 60:18 70:3 71:14<br>81:11 112:16 113:9<br>113:18,19 115:13,19<br>116:15,20 140:10<br>158:3 180:16,16<br>195:2,7 198:3 203:9<br>208:10 214:5 234:11<br>246:5 251:7 274:13<br>282:22<br><b>gaps</b> 6:18,20 26:17,18<br>26:20,21 27:3 58:8<br>67:2 116:20 180:18<br>180:20<br><b>gargantuan</b> 282:15<br><b>gas</b> 312:19   |
| 281:15,21 282:19<br>289:9 291:6<br>fiscal 93:4<br>fit 312:15<br>fits 92:2,2 195:1<br>fitting 195:8<br>five 42:18 48:17,20 64:1<br>66:10,11 68:8 71:12<br>78:20 102:14 248:22<br>249:1 264:21 265:10<br>306:7<br>fix 86:21 139:6 300:4<br>flag 68:4 102:19 128:1<br>212:2<br>flew 73:7  | following 96:14 123:12<br>144:5 182:7<br>follows 82:17<br>food 297:3<br>foot 312:19<br>for-service 49:6 53:15<br>force 1:3,8 4:3,4,5 9:8,9<br>10:4,5,6,17 15:1<br>20:19 23:6 67:9 87:14<br>99:4 112:11 114:6,7,8<br>114:9 115:12,15,16<br>115:17 116:9,13,16<br>117:16 121:14 124:10<br>124:11 130:18 131:3<br>131:8,10,12 137:17  | 248:21 251:8 289:16<br>foundation 32:7<br>foundational 230:14<br>foundations 18:14<br>four 5:19 57:1 74:9<br>88:14 129:10 174:20<br>242:14,15 263:4<br>285:20<br>four-fold 168:8<br>fourth 28:12<br>Fox 40:7<br>FQHCs 301:1<br>fragile 303:12<br>fragmentation 295:20<br>295:21 296:15,19<br>306:17 308:3   | 60:18 70:3 71:14<br>81:11 112:16 113:9<br>113:18,19 115:13,19<br>116:15,20 140:10<br>158:3 180:16,16<br>195:2,7 198:3 203:9<br>208:10 214:5 234:11<br>246:5 251:7 274:13<br>282:22<br><b>gaps</b> 6:18,20 26:17,18<br>26:20,21 27:3 58:8<br>67:2 116:20 180:18<br>180:20<br><b>gargantuan</b> 282:15<br><b>gas</b> 312:19<br><b>gastroenteritis</b> 231:12  |
| 281:15,21 282:19<br>289:9 291:6<br>fiscal 93:4<br>fit 312:15<br>fits 92:2,2 195:1<br>fitting 195:8<br>five 42:18 48:17,20 64:1<br>66:10,11 68:8 71:12<br>78:20 102:14 248:22<br>249:1 264:21 265:10<br>306:7<br>fix 86:21 139:6 300:4<br>flag 68:4 102:19 128:1<br>212:2<br>flew 73:7<br>flexible 141:22   | following 96:14 123:12<br>144:5 182:7<br>follows 82:17<br>food 297:3<br>foot 312:19<br>for-service 49:6 53:15<br>force 1:3,8 4:3,4,5 9:8,9<br>10:4,5,6,17 15:1<br>20:19 23:6 67:9 87:14<br>99:4 112:11 114:6,7,8<br>114:9 115:12,15,16<br>115:17 116:9,13,16<br>117:16 121:14 124:10<br>124:11 130:18 131:3<br>131:8,10,12 137:17<br>149:13 151:17 152:17  | 248:21 251:8 289:16<br>foundation 32:7<br>foundational 230:14<br>foundations 18:14<br>four 5:19 57:1 74:9<br>88:14 129:10 174:20<br>242:14,15 263:4<br>285:20<br>four-fold 168:8<br>fourth 28:12<br>Fox 40:7<br>FQHCs 301:1<br>fragile 303:12<br>fragmentation 295:20<br>295:21 296:15,19<br>306:17 308:3<br>frames 272:1   | 60:18 70:3 71:14<br>81:11 112:16 113:9<br>113:18,19 115:13,19<br>116:15,20 140:10<br>158:3 180:16,16<br>195:2,7 198:3 203:9<br>208:10 214:5 234:11<br>246:5 251:7 274:13<br>282:22<br><b>gaps</b> 6:18,20 26:17,18<br>26:20,21 27:3 58:8<br>67:2 116:20 180:18<br>180:20<br><b>gargantuan</b> 282:15<br><b>gas</b> 312:19<br><b>gastroenteritis</b> 231:12<br><b>gather</b> 304:3                           |
| 281:15,21 282:19<br>289:9 291:6<br>fiscal 93:4<br>fit 312:15<br>fits 92:2,2 195:1<br>fitting 195:8<br>five 42:18 48:17,20 64:1<br>66:10,11 68:8 71:12<br>78:20 102:14 248:22<br>249:1 264:21 265:10<br>306:7<br>fix 86:21 139:6 300:4<br>flag 68:4 102:19 128:1<br>212:2<br>flew 73:7<br>flexible 141:22<br>flip 185:15 220:18   | following 96:14 123:12<br>144:5 182:7<br>follows 82:17<br>food 297:3<br>foot 312:19<br>for-service 49:6 53:15<br>force 1:3,8 4:3,4,5 9:8,9<br>10:4,5,6,17 15:1<br>20:19 23:6 67:9 87:14<br>99:4 112:11 114:6,7,8<br>114:9 115:12,15,16<br>115:17 116:9,13,16<br>117:16 121:14 124:10<br>124:11 130:18 131:3<br>131:8,10,12 137:17<br>149:13 151:17 152:17<br>152:21 164:7 165:7  | 248:21 251:8 289:16<br>foundation 32:7<br>foundational 230:14<br>foundations 18:14<br>four 5:19 57:1 74:9<br>88:14 129:10 174:20<br>242:14,15 263:4<br>285:20<br>four-fold 168:8<br>fourth 28:12<br>Fox 40:7<br>FQHCs 301:1<br>fragile 303:12<br>fragmentation 295:20<br>295:21 296:15,19<br>306:17 308:3<br>frames 272:1<br>framework 279:15                                       | 60:18 70:3 71:14<br>81:11 112:16 113:9<br>113:18,19 115:13,19<br>116:15,20 140:10<br>158:3 180:16,16<br>195:2,7 198:3 203:9<br>208:10 214:5 234:11<br>246:5 251:7 274:13<br>282:22<br>gaps 6:18,20 26:17,18<br>26:20,21 27:3 58:8<br>67:2 116:20 180:18<br>180:20<br>gargantuan 282:15<br>gas 312:19<br>gastroenteritis 231:12<br>gather 304:3<br>gathered 113:10 175:15                                    |
| 281:15,21 282:19<br>289:9 291:6<br>fiscal 93:4<br>fit 312:15<br>fits 92:2,2 195:1<br>fitting 195:8<br>five 42:18 48:17,20 64:1<br>66:10,11 68:8 71:12<br>78:20 102:14 248:22<br>249:1 264:21 265:10<br>306:7<br>fix 86:21 139:6 300:4<br>flag 68:4 102:19 128:1<br>212:2<br>flew 73:7<br>flexible 141:22<br>flip 185:15 220:18<br>floor 1:8 161:21,22                        | following 96:14 123:12<br>144:5 182:7<br>follows 82:17<br>food 297:3<br>foot 312:19<br>for-service 49:6 53:15<br>force 1:3,8 4:3,4,5 9:8,9<br>10:4,5,6,17 15:1<br>20:19 23:6 67:9 87:14<br>99:4 112:11 114:6,7,8<br>114:9 115:12,15,16<br>115:17 116:9,13,16<br>117:16 121:14 124:10<br>124:11 130:18 131:3<br>131:8,10,12 137:17<br>149:13 151:17 152:17<br>152:21 164:7 165:7<br>177:5 180:18,19                         | 248:21 251:8 289:16<br>foundation 32:7<br>foundational 230:14<br>foundations 18:14<br>four 5:19 57:1 74:9<br>88:14 129:10 174:20<br>242:14,15 263:4<br>285:20<br>four-fold 168:8<br>fourth 28:12<br>Fox 40:7<br>FQHCs 301:1<br>fragile 303:12<br>fragmentation 295:20<br>295:21 296:15,19<br>306:17 308:3<br>frames 272:1<br>framework 279:15<br>framing 200:8                      | 60:18 70:3 71:14<br>81:11 112:16 113:9<br>113:18,19 115:13,19<br>116:15,20 140:10<br>158:3 180:16,16<br>195:2,7 198:3 203:9<br>208:10 214:5 234:11<br>246:5 251:7 274:13<br>282:22<br>gaps 6:18,20 26:17,18<br>26:20,21 27:3 58:8<br>67:2 116:20 180:18<br>180:20<br>gargantuan 282:15<br>gas 312:19<br>gastroenteritis 231:12<br>gather 304:3<br>gathered 113:10 175:15<br>gathering 274:6                 |
| 281:15,21 282:19<br>289:9 291:6<br>fiscal 93:4<br>fit 312:15<br>fits 92:2,2 195:1<br>fiting 195:8<br>five 42:18 48:17,20 64:1<br>66:10,11 68:8 71:12<br>78:20 102:14 248:22<br>249:1 264:21 265:10<br>306:7<br>fix 86:21 139:6 300:4<br>flag 68:4 102:19 128:1<br>212:2<br>flew 73:7<br>flexible 141:22<br>flip 185:15 220:18<br>floor 1:8 161:21,22<br>162:3,6 163:18 164:1 | following 96:14 123:12<br>144:5 182:7<br>follows 82:17<br>food 297:3<br>foot 312:19<br>for-service 49:6 53:15<br>force 1:3,8 4:3,4,5 9:8,9<br>10:4,5,6,17 15:1<br>20:19 23:6 67:9 87:14<br>99:4 112:11 114:6,7,8<br>114:9 115:12,15,16<br>115:17 116:9,13,16<br>117:16 121:14 124:10<br>124:11 130:18 131:3<br>131:8,10,12 137:17<br>149:13 151:17 152:17<br>152:21 164:7 165:7<br>177:5 180:18,19<br>181:5 182:20 184:6,9 | 248:21 251:8 289:16<br>foundation 32:7<br>foundational 230:14<br>foundations 18:14<br>four 5:19 57:1 74:9<br>88:14 129:10 174:20<br>242:14,15 263:4<br>285:20<br>four-fold 168:8<br>fourth 28:12<br>Fox 40:7<br>FQHCs 301:1<br>fragile 303:12<br>fragmentation 295:20<br>295:21 296:15,19<br>306:17 308:3<br>frames 272:1<br>framework 279:15                                       | 60:18 70:3 71:14<br>81:11 112:16 113:9<br>113:18,19 115:13,19<br>116:15,20 140:10<br>158:3 180:16,16<br>195:2,7 198:3 203:9<br>208:10 214:5 234:11<br>246:5 251:7 274:13<br>282:22<br>gaps 6:18,20 26:17,18<br>26:20,21 27:3 58:8<br>67:2 116:20 180:18<br>180:20<br>gargantuan 282:15<br>gas 312:19<br>gastroenteritis 231:12<br>gather 304:3<br>gathered 113:10 175:15<br>gathering 274:6<br>gauge 301:19 |
| 281:15,21 282:19<br>289:9 291:6<br>fiscal 93:4<br>fit 312:15<br>fits 92:2,2 195:1<br>fiting 195:8<br>five 42:18 48:17,20 64:1<br>66:10,11 68:8 71:12<br>78:20 102:14 248:22<br>249:1 264:21 265:10<br>306:7<br>fix 86:21 139:6 300:4<br>flag 68:4 102:19 128:1<br>212:2<br>flew 73:7<br>flexible 141:22<br>flip 185:15 220:18<br>floor 1:8 161:21,22                         | following 96:14 123:12<br>144:5 182:7<br>follows 82:17<br>food 297:3<br>foot 312:19<br>for-service 49:6 53:15<br>force 1:3,8 4:3,4,5 9:8,9<br>10:4,5,6,17 15:1<br>20:19 23:6 67:9 87:14<br>99:4 112:11 114:6,7,8<br>114:9 115:12,15,16<br>115:17 116:9,13,16<br>117:16 121:14 124:10<br>124:11 130:18 131:3<br>131:8,10,12 137:17<br>149:13 151:17 152:17<br>152:21 164:7 165:7<br>177:5 180:18,19                         | 248:21 251:8 289:16<br>foundation 32:7<br>foundational 230:14<br>foundations 18:14<br>four 5:19 57:1 74:9<br>88:14 129:10 174:20<br>242:14,15 263:4<br>285:20<br>four-fold 168:8<br>fourth 28:12<br>Fox 40:7<br>FQHCs 301:1<br>fragile 303:12<br>fragmentation 295:20<br>295:21 296:15,19<br>306:17 308:3<br>frames 272:1<br>framework 279:15<br>framing 200:8<br>Franklin 65:12,15 | 60:18 70:3 71:14<br>81:11 112:16 113:9<br>113:18,19 115:13,19<br>116:15,20 140:10<br>158:3 180:16,16<br>195:2,7 198:3 203:9<br>208:10 214:5 234:11<br>246:5 251:7 274:13<br>282:22<br>gaps 6:18,20 26:17,18<br>26:20,21 27:3 58:8<br>67:2 116:20 180:18<br>180:20<br>gargantuan 282:15<br>gas 312:19<br>gastroenteritis 231:12<br>gather 304:3<br>gathered 113:10 175:15<br>gathering 274:6                 |
|                         |                         |                        | 325                     |
|-------------------------|-------------------------|------------------------|-------------------------|
|                         | 400-4407-0440-0         |                        | 007-7 070-5 070-45      |
| general 9:5 14:19 39:21 | 133:4 137:9 142:3       | grow 108:12            | 267:7 272:5 278:15      |
| 71:7 101:19 108:20      | 149:6 151:1 152:3,9     | growing 195:10         | 284:1 287:2 295:19      |
| 121:22 187:19 237:7     | 153:11 163:12 168:20    | grown-ups 43:8         | 296:13 298:2 311:12     |
| 273:12 274:15,20        | 174:16 177:9,20         | growth 45:20,22 209:4  | Harold's 285:16 287:20  |
| 275:21 298:16 312:13    | 178:8 179:8,14,17,22    | guess 24:11 31:4 63:9  | 288:4                   |
| generally 31:15 34:22   | 185:8 189:20 192:17     | 68:2 72:3 80:16        | Harvard 286:22          |
| 173:18 205:22           | 211:1 217:2 225:21      | 136:22 151:8 158:2     | hat 133:18,19 139:15    |
| generic 83:21           | 227:6 228:11 229:2      | 165:5 185:4 199:19     | 165:19 295:12           |
| geographic 198:17       | 229:17 246:15 248:9     | 202:5 223:22 254:16    | hate 244:2              |
| gestational 129:11      | 253:3 259:19 260:13     | 258:17,18 276:4,7      | hats 146:4              |
| 130:5 145:6 146:17      | 261:1 262:3,10 265:4    | 304:13                 | head 135:16 197:2       |
| 153:21 154:14 158:4     | 265:9 313:5             | guest 8:22             | health- 130:7           |
| getting 27:15 46:13     | <b>Gorman</b> 20:21     | guidance 21:14 121:22  | healthy 9:15 59:19      |
| 47:12 48:6 51:20        | gosh 219:1 277:18       | 198:21                 | 86:11 94:9 147:6        |
| 55:14 57:7 60:14        | gotten 280:7 293:1      | guide 114:1,9,11,13    | 196:20                  |
| 65:14 77:4 79:20 80:5   | <b>GOVERNMENT</b> 2:10  |                        | hear 22:1 24:11 31:13   |
|                         |                         | 115:8 180:9,16 181:1   |                         |
| 84:20 96:5 100:3        | grab 177:15,17,22       | 181:2,13 198:8,8       | 34:1 73:7 79:21 107:4   |
| 109:18 130:1 141:15     | 179:18                  | 206:18 207:13 209:3    | 163:10 169:6 210:17     |
| 143:6,7 150:13 151:3    | gracefully 311:13       |                        | 218:22 240:12 259:16    |
| 151:6,12 155:5,11,11    | <b>gram</b> 186:6       | Н                      | 269:18 270:18 278:11    |
| 157:3 167:12 201:1      | grant 46:21 72:13 77:15 | H&P 102:12             | 291:6,8,15 292:21       |
| 208:4,18 209:16         | 90:1,1,9 170:21,22      | half 14:9 48:1,2 57:7  | heard 24:2 32:15 34:2   |
| 211:4 243:9 246:5       | 188:13 308:1,6          | 68:14 75:12 103:3      | 42:20 52:20 132:2       |
| 250:13 255:18 270:6     | grantees 187:9 206:1    | 270:19 283:2           | 138:20 139:3 145:12     |
| 271:19 300:22 305:3     | grants 17:9 40:11       | halfway 312:2          | 165:22 175:1 184:1      |
| 305:4                   | granular 75:20          | hall 8:5               | 199:7 201:9 236:11      |
| Gigi 3:16 19:8,10 30:12 | graph 45:15 51:22       | hand 36:8,8 107:18     | 269:21 270:2 278:3      |
| 30:20 39:11,15          | 56:11                   | 125:2 126:19 136:11    | hearing 20:5 83:9       |
| give 21:20 22:21 33:14  | graphs 65:3             | 144:9 275:9            | 134:12 158:8 261:12     |
| 41:21 57:22 59:8,15     | grappled 244:6          | handout 123:18 183:10  | 291:22 298:8 312:16     |
| 65:17 66:15 71:12       | grappling 287:8         | hang 58:4              | heart 23:3 90:19 271:17 |
| 75:18 82:4 107:21       | grateful 312:20         | happen 86:17,20 94:1   | HEDIS 38:8 50:9 53:5    |
| 134:13,13 135:22        | gratifying 312:5        | 104:18 126:3 129:20    | 125:21 175:7 249:18     |
| 139:14,15 144:12        | gray 66:13 116:13       | 203:7 269:3 301:22     | 249:19                  |
|                         |                         | 307:11                 | heels 70:5              |
| 169:8,9,19 177:9        | grease 301:2            |                        |                         |
| 188:1 207:16 217:3      | greater 93:14           | happened 44:22 45:14   | Helen 2:17 5:12 9:19    |
| 241:20 247:18 249:3     | greatest 81:17          | 47:10 63:9 72:3 89:17  | 169:7,10 220:11         |
| 255:17 262:3,8,21       | Gregory 2:7 15:7        | 139:20 194:13 211:8    | 221:8 222:3 254:18      |
| 263:7 267:10 268:16     | Greiner 1:17 15:14,15   | happening 62:2 107:6   | 276:7 286:21            |
| 307:5                   | 78:4 201:20             | 163:7                  | Helen's 163:5           |
| gives 34:22 35:12 87:12 | grid 57:13              | happens 8:18 50:5      | helicopter 80:11        |
| 209:4 252:11 275:21     | ground 84:16 130:13     | 53:22 54:10 57:10      | Hello 20:17             |
| 279:10                  | 146:16 281:21           | 94:18 173:20 282:12    | help 6:10 22:10 30:9    |
| giving 144:10           | groundwork 108:7        | 302:8                  | 36:4 40:11,13 42:9      |
| glad 5:7 31:9 73:6      | group 2:9 10:21 17:16   | happy 5:7 39:8 139:14  | 52:14 56:10 63:13       |
| glitch 151:13           | 172:1 189:12,14         | 153:5 162:1 303:4      | 64:16 65:9 66:6 77:21   |
| global 94:17,22 99:9,14 | 195:6 202:21 217:12     | hard 77:6 170:19 172:8 | 77:22 84:13 98:15       |
| 100:7 105:19 187:11     | 217:14 245:1 264:9      | 313:3                  | 99:21 100:2 107:10      |
| 187:15 302:3            | 269:18 274:10 283:17    | harder 171:10          | 109:15 169:2 188:13     |
| <b>go-to</b> 285:7      | 286:6 290:20 291:8      | harm 105:3             | 197:13 201:19 214:13    |
| goal 35:21 100:13       | 292:11                  | harmful 56:9           | 256:10                  |
| 151:16 198:11 208:9     |                         |                        |                         |
|                         | group's 298:4           | Harold 1:9,12 5:21 9:9 | helped 311:5            |
| 225:4                   | groups 22:17 74:9,11    | 18:4,15 22:16,21       | helpful 47:20 48:10     |
| goals 21:16 29:18       | 94:10 109:8 111:4,4     | 23:15,22 31:8 32:1     | 49:16 58:16 96:19       |
| 30:10 123:3             | 114:14 187:4,8          | 35:20 39:14 74:1 99:6  | 97:10 215:3 255:12      |
| GORHAM 2:18 20:20       | 189:16 194:11 217:18    | 123:22 124:15,22       | 280:22 282:14 294:17    |
| 110:16 114:22 115:9     | 222:7 267:5 269:5       | 137:10 138:22 166:19   | 295:4                   |
| 119:14 121:8 131:1,6    | 291:20 302:6,6          | 184:8,18 252:13        | helping 42:6            |
|                         | l                       | l                      |                         |
|                         |                         |                        |                         |

helps 33:14 48:10 231:22 hemorrhage 104:6 140:20 hey 62:5 279:18 HHS 13:19 hi 5:3 12:16,20 13:6 15:20 16:12 18:19 19:10 141:2 142:6 154:19 211:2 high 25:3,20 28:10 34:16 37:2 46:18 69:14 70:1 71:19 74:21 81:6 92:12 106:4 122:3 168:15 182:10 212:7,11,19 212:19 214:3 241:10 253:17 267:19 high-risk 154:18 higher 68:15 80:8 143:18 highest 27:19 49:3 218:10 highlight 99:1 highlighting 105:22 112:3 highlights 66:13 309:16 highly 253:10 historic 230:22 287:19 history 102:12 303:2 305:18 hit 196:12 hitting 9:19 39:13 hoarding 129:2 hold 157:10,15,16 166:17 293:1 holding 61:4 157:22 home 26:6,9 27:20 44:3 44:5 50:5 71:5 74:18 97:19 98:12 101:1 237:5 263:14,21 264:18 286:3 homeless 296:7 homes 78:15 honor 196:9 honors 44:3 hook 109:18 275:22 hope 39:7 109:1 284:18 295:15 306:22 307:13 hopefully 19:16 77:21 107:17 146:6 221:9 238:13 294:5 hoping 63:18 horizontal 150:10 hormones 203:3,4 horrible 80:1 hospice 42:3 hospital 1:15,15 9:7

14:14,15 16:14 18:2,8 54:22 81:7 104:1,2 178:19 188:5,9 232:10 234:12 235:5 236:11,16,17,18 241:5 243:6,22 hospital-based 235:11 245:4,12 hospital-level 186:15 hospital-specific 189:4 hospitalization 111:12 239:12 hospitals 14:17 104:6 232:15 234:13,19 235:9 237:2 243:3 245:5 284:8 hostile 70:20 hour 109:19 270:18 hours 18:21 80:10 household 213:14 housekeeping 8:4 housing 297:3,21 HRSA 89:5 huge 64:6 79:19 84:14 99:10 282:16 human 231:5 hundred 259:10 261:22 hybrid 51:16 53:16 302:12,14 303:8,19 304:8,13,17 305:9 hygiene 298:21 hypertension 275:19 hypertensive 54:21 i.e 160:10 lams's 69:9 ICD-10 236:6 ICD-9 236:6 **ID** 302:21 Idaho 14:14 208:15 **IDD** 303:11 idea 43:19 51:2 62:1 102:13 144:10 169:9 254:8 270:11 296:13 ideal 121:18 ideally 188:6 identical 230:9 252:6 identification 6:14 identified 27:4,5 28:12 176:8 180:17 182:5 195:6 258:7 identify 6:22 27:2 43:22 73:1 87:22 88:9,14 116:21 154:17 252:4 259:6 271:1 272:18 286:17 290:11 295:2 identifying 6:7 22:10

48:5 91:7,12 100:19 121:17 lezzoni 286:22 **ill** 280:1 illicit 169:15 illness 75:4 111:13 273:21 274:9 275:2 276:14 278:19 285:22 286:14 287:4,4,10,11 302:1 305:6 imagine 62:22 157:11 157:14 202:8 253:21 immediate 215:17 283:19 immediately 243:3 impact 55:1 69:18 72:10 80:20 89:21 91:9 94:17 98:7 101:14,20 103:15 182:10 impacting 92:3 impacts 232:17 **impart** 90:14 impede 239:3 implement 36:19 88:10 154:18 implementable 202:3 implementation 170:10 171:14 180:12 182:4 182:12,13,16 195:19 226:9 implemented 191:18 226:7,14 implementing 21:11 24:13 implications 44:15 **importance** 4:10,13 89:12 110:9 112:9 172:12 262:21 important 6:5,6,8 7:1 24:10 30:2 37:22 46:14 50:2 58:20,22 62:21 65:13 103:10 105:1 130:2 134:13 138:19 147:14 156:10 156:16 157:8 166:7 171:16 172:4,5,5 174:8 180:12,13 187:20 190:15 192:2 192:3 194:9 196:15 197:3 214:4 215:13 220:14 231:6 234:14 234:15 243:14 245:18 253:9,21 294:9,12 299:20 impression 7:18 impressive 17:12 78:5 195:18

improve 36:1 42:15 72:14 88:1,6,7 95:16 180:22 276:2 294:7 improved 142:10 improvement 2:11 6:11 7:2,13 12:11 14:7 30:4,7 32:10 52:22 61:13 85:12 88:9 94:7 119:4 122:17 196:7 198:4 222:13 225:2 231:2 232:7 251:20 263:13 272:12 273:17 301:6 improvements 36:18 64:12,19 76:4 improving 62:9 89:7,10 91:15,20 98:16 210:12 234:8 in-depth 87:12 in-hospital 236:12 in-house 288:15 **inaccuracy** 250:10 inappropriate 81:12 249:20 252:5 inappropriately 219:14 229:4 incentive 86:14 94:19 232:11 incentives 85:22 86:3,7 243:4 include 54:7 75:17 83:5 122:11 123:1.12 133:7 163:13 175:1 194:16 198:6 221:20 221:21 246:10 249:16 257:15 included 171:15 205:15 219:6 221:4,6 224:2 includes 117:13 123:6 169:13 including 22:5 83:9 97:3 129:8 146:15 259:3 inclusion 221:18 227:15 258:9 income 112:10 197:8 incorporate 270:15 incorporated 91:16 96:21 97:1 180:22 incorrectly 220:10 increase 26:10 29:19 29:20 30:3 35:21,22 118:9 119:19 120:5 267:2 incredible 55:3 incredibly 187:20 incremental 37:3 independent 2:6 12:17

13:12 102:4 **Indiana** 12:5 Indianapolis 12:5 indicate 10:9 213:2 215:4 292:6 indicated 186:10 200:15 indication 306:2 indicator 244:21 indicators 33:6,12 58:5 71:13 individual 32:22 300:9 individuals 17:3 75:2 274:9 275:1 286:4 291:13 301:22 304:5 305:5 ineffective 201:12 infant 3:11 4:11 49:22 51:6 59:2,3,5 60:5 66:3 67:20 68:4,8 70:3 78:1 87:14 88:2 93:19 98:22 103:15 112:22.22 186:6 195:20 207:14 230:19 271:15 282:20 infants 68:15 93:9 188:21 infection 231:13 infections 104:10 infectious 16:15 influence 108:11 122:10 influences 242:22 influential 112:5 inform 30:18 311:6 information 24:14 65:3 68:10 79:6 83:1 85:15 98:21 116:5 117:8,9 123:15 126:17 168:22 169:2 174:15,18 175:11,14 180:14 197:21 204:20 207:17 209:10 241:1 249:19 252:1.2 282:6 288:21 295:5 300:21 301:2,5 310:6,8,16 informative 76:9 **informed** 310:22 informing 100:14 infrastructure 63:17 82:14,20 83:1,3 inhaled 255:4 inhalers 255:20 initial 47:4 91:5 initially 85:9 205:3 initiative 76:1 87:15,17 88:4 89:10 93:20 98:22 188:13 195:20

197:15 198:7 Innovation 28:3 98:8 285:20 innovations 29:11 innovative 24:5 28:1 inpatient 27:13 47:13 83:21 232:10 253:20 306:6 input 35:11 36:13 187:6 187:9,12 269:8 inguire 300:10 inserted 210:4 insight 41:20 280:16 instance 280:1 Institute 70:6 institution 78:20 instructive 163:7 instrument 207:8 instruments 209:9 insulin 300:12,13 insurance 80:6 155:14 integrate 60:6 integrated 9:6 18:1 295:12 299:8,16,16 299:17 integration 13:8 27:9 27:12 109:9 273:10 301:19 integrative 107:19 intellectual 74:12 287:17 intended 197:9 209:11 209:12 211:5,12 213:7 intensive 303:7 intensively 212:4 intention 196:17 210:12 intentionality 212:21 intentions 210:9 inter-conception 195:2 inter-pregnancy 46:17 192:4,8 212:11 214:3 interacting 24:13 interest 4:3 10:19 22:18 23:7 100:21 101:9 186:16 238:19 269:6 interested 6:1 100:22 145:1 211:14 236:12 270:18 interesting 24:5 28:1 200:13 289:13 299:4 interestingly 72:16 81:15,18 interests 17:7 interface 273:12 interfere 298:22 interim 166:13 intermediate 292:14

internal 303:6 internally 105:9 187:10 289:21 303:22 internist 16:6 254:22 interoperability 270:3 Interpregnancy 58:18 interpretation 198:8 206:18 207:4,13 208:21 209:3 interpreted 226:15 interval 46:17 212:11 215:11 intervals 58:18 214:3 intervene 241:19 intervention 81:13 172:13 214:12 intimate 169:15 intrigued 107:13 introduce 9:16 11:8 18:17 19:9 20:9 217:5 240:3 276:21 introduction 9:4 17:1 Introductions 4:3 intuitively 56:12 59:13 65:4 invest 34:8 **invested** 69:22 investing 63:16 140:17 investment 97:17 invitation 165:6 invite 192:8 invited 193:21 involved 28:4 284:16 **involves** 226:14 isolated 72:16 issue 25:19 81:5 104:18 136:10 156:4 165:11 173:10,15 187:17 197:7,19 215:11 238:2 263:12 274:18 277:7 280:5 284:10 286:19 287:9 298:10 299:3,4 307:7 309:22 **issues** 4:10,13 22:4 29:2,10 33:16 46:8 55:10 57:18 60:1 72:20 77:22 84:11 110:15,18 120:18 121:6 124:6 139:19 140:15 167:21 171:5 172:2 176:5 182:4,12 194:6 196:10 203:5 255:7 266:21 270:1 271:12 273:9,19 274:12,18,20 280:6 283:5 284:1 294:16 **issuing** 40:10

J Jay 69:9 **JD** 1:16,19,20 iibe 241:21 **JMOC** 45:18 **job** 30:8 43:3 54:11,19 79:9 83:7 118:6 138:22 243:3 313:3 **jobs** 141:22 ioin 311:8 joint 1:3 9:9 25:5 28:11 124:13 189:22 190:2 193:9 232:14 235:1 241:22 252:18,22 300:18 ioke 313:6 **Jones** 1:18 12:9,10 79:15 journey 312:3 joy 271:17 judge 294:8 Judy 24:2 **July** 309:18 jumped 189:10 jumping 41:6 261:2 June 285:19 jury's 71:9 Κ Kamila 40:7 Karen 3:13 9:11 19:14 31:6 34:20 39:5 108:18 163:3 195:3 202:2 237:9,12 271:20 277:9 288:6,8 291:1 293:9 298:2 301:12

Karen's 30:22 39:10 243:17 293:6 Kathryn 1:14 14:12 161:6,7 207:18 Kay 1:18 12:10 16:1 keep 8:6,14 38:1,11 73:12 80:5 103:3 193:1 234:16 248:15 310:15,16 keeping 128:2 163:9 214:10 311:14 Kendig 1:19 13:6,6 67:12,15 69:4 103:13 135:5 137:2 191:14 192:12 193:16 220:12 kept 98:3 Kern 307:22 key 4:6 33:6,12 60:3 88:14 89:9 93:2 97:9 101:8 258:7 keypad 308:15

kick 184:16 kids 44:9 58:13 59:20 61:22 303:13 Kilstein 1:20 11:17,18 87:20 126:9 132:15 144:1 174:1 189:18 235:8 293:8 **Kim** 2:9 10:13 16:22 17:13,15 135:10 148:1 171:1 210:19 214:19 218:2 kindergarten 41:15 kinds 39:3 63:14 82:22 101:19 105:5 110:15 187:11 239:5 243:4 244:10 282:19 302:5 302:11 kit 212:17 kitchen 171:21 172:9 knew 170:7 knowing 48:4 193:7 **knowledge** 272:15 known 98:5 knows 10:11 11:11 49:12.15 140:15 214:10 286:21 Kuwahara 2:19 20:14 20:15 137:20 138:5 138:12,17 149:12,19 150:4,9,15 151:15,21 152:2,7,11 164:9,14 165:1 176:16 177:1 222:19 223:11,18 227:11 228:4 247:6 258:20 259:2,10 260:7,11 261:14,22 309:11 L La 1:21 11:12,13 24:6 125:15 131:15,21 168:12 176:11 190:18 191:6,11 244:15 288:9 292:8 lack 28:18 49:21 120:17 lactation 236:21 lag 244:19 landed 70:10 124:17 language 164:4 language-wise 84:12 laptops 8:21 LARC 179:1 198:19 LARCs 190:13 213:19 216:3 large 44:21 86:7 112:6 112:16 140:13 194:9 230:18 232:22 largely 78:15

larger 205:5,5 284:2 largest 12:15 43:13 64:14 Larry 308:5 late 9:17 18:20 194:13 239:22 310:2 lately 273:9 latest 98:3,5 laugh 34:3 launch 9:22 199:9 launched 88:3 laundry 59:16 layer 74:18 layers 41:19 laying 108:6 LCSW 3:16 lead 6:10 7:13 126:4 184:15 193:3,19 252:17 253:6 leaders 108:13 312:22 leadership 6:3 297:16 312:17,21 leading 286:22 Lean 224:6 learn 31:16 72:7 283:9 learned 27:22 71:21 229:13 learning 5:20 89:11 94:5 140:2 196:2,8 199:2 231:4 leave 107:17 137:8 237:5 311:11 leaving 101:4 309:13 led 39:12 283:17 left 124:11.12 legislature 45:19 71:10 Lekisha 3:10 4:9 87:5 118:1,5,13 188:11 189:1 194:17 195:19 197:14 204:4,21 206:4 222:4 let's 11:5 115:17,20 117:9 146:21 152:16 153:3 163:22 177:16 177:20 179:22 192:21 210:17 222:19 233:22 261:4 297:9 303:15 letting 41:13 82:11 leukemia 231:15 level 28:20 30:7 32:19 32:21 33:2 38:1,3 39:22 42:12 46:18,19 51:1 52:16 57:11 74:21 77:9,17,18 81:7 82:14,15 86:1,6 90:13 92:16 104:4 108:12 122:20 129:22 179:7 182:17 186:15 188:22

198:13,14 201:3 207:5,5 208:11,22 220:4 222:12 230:6 238:7 241:14 245:10 245:11 252:7 268:10 268:17 269:10 271:19 288:11,12 289:6 292:4 293:11,15,16 293:19,21 300:2,6,21 301:4 302:19 levels 89:1 186:6 300:12,13 lever 57:9 leverage 53:10 304:3 Leveraging 89:2 levers 56:14 licensure 104:7 lies 268:11 life 5:16 55:2,2 89:19 92:9 97:7 105:2 108:7 108:11 130:7 141:19 221:3 271:13 294:14 lifelong 231:6 light 103:18 liked 188:6 limitation 126:11 limited 45:3.9 120:11 limits 92:10 Lindsay 3:7 217:5 237:14 239:20 240:6 256:5 257:18 266:6 266:11 291:8 303:19 line 48:14,15,16 53:19 55:15 61:22 63:19 107:12 150:10 166:20 178:1 179:9 214:20 248:4 283:6 293:1 lined 77:14 lines 21:21 53:17 130:15 247:18 266:11 312:16 link 71:20 103:9,17 130:10 240:17 linkage 142:10 236:1 305:17 linked 145:19 274:20 linking 176:7 235:18 302:21 links 39:1 Lisa 2:12 13:15 237:9 237:13 238:16 286:22 307:22 list 29:5 59:17 76:15 79:1 113:7 117:11,12 123:8 137:14 169:6 188:2 200:5 201:14 203:9 215:4,10 250:3 250:11 255:8 269:4

270:5 listed 94:15 111:10 115:4,18 122:22 200:6 239:8 310:3,7,8 listen 282:5 listening 23:16 109:20 lists 39:2 113:18 literally 238:12 255:13 literature 108:7 141:8 litmus 52:16 little 12:14 21:6 26:22 27:7 31:16 35:18,20 38:8 40:8,14,18 43:18 50:4,15 68:2 73:17 78:7 87:8,10 90:18 92:11 94:2 106:17 109:9,18 110:13 113:16 114:17 115:16 116:4,10 117:22 119:16 124:2 127:7 158:15 161:2 170:10 177:16 179:9 181:3 188:18 189:11 196:18 199:20 200:9 201:3 203:18 215:11 217:14 217:19,22 237:11 239:14,22 248:18 251:22 252:11 256:20 256:20 258:1 266:18 267:8 272:7,20 277:8 278:20 279:6 282:2 291:3 297:7 livable 163:15 live 80:9 105:1 172:22 lives 58:22 109:4 Living 28:8 load 52:17 local 64:12 94:10 98:10 101:13 207:5 208:22 209:9,9 log 117:2 logged 8:22 logical 306:15 long 40:15 44:16 107:12 125:21 134:3 146:19 250:11 255:3 255:8 306:19 long- 112:8 242:11 251:17 long-standing 9:10 long-term 27:13,19 44:12,20 214:13 243:1,16 255:5,6 286:2,3 longer 125:17 179:9 186:5,9,12 307:17 longer-term 243:19 244:11

longitudinal 61:20 301:9 longitudinally 57:21 look 6:21 7:20 22:20 51:18 57:8 58:8 68:22 79:17,22 91:2,22 93:12 94:3 95:4 105:15 106:2 110:8,8 110:18 112:19 114:22 115:3,17 116:13 118:16 123:21 126:2 156:20,22 180:5 185:18 195:21 198:9 198:14,14 199:3,17 200:2,7 206:19 207:15 209:3,13 236:8 240:15 243:21 244:4,10 245:5 257:5 257:21 258:2 263:22 267:9 272:21 275:17 275:22 277:2 289:11 290:19 294:22 296:4 296:4,5,19 297:9 298:7 303:2 305:5,16 312:6 looked 17:10 42:4 47:10 80:17,17,18,22 132:21 168:14,14 182:9 255:1 301:21 looking 4:10 21:17 26:20 34:19,20 36:20 37:12,21 38:2,16 44:11 46:12 49:12 91:7 97:6,18 100:17 105:9 106:18 110:11 110:14 111:18 135:13 147:7 166:3 176:17 185:4 188:13 198:11 198:19 200:19 208:10 208:13 210:16 211:13 231:17 239:1,8 245:9 254:7,11 257:5,6 263:15 267:4 269:10 270:21 273:5,14 274:7 276:1,8,15 280:3 284:4 288:10 289:21 290:5,6,13,20 294:11,14 295:2 306:16 308:2 312:7 looks 36:14 43:13 144:13 264:16 loop 173:20 281:18 **loses** 279:14,17 losing 67:3 loss 219:20 249:4 **lost** 49:1 60:18 118:2 118:17 190:15 249:7 **lot** 34:3,5,5,6 35:6,10

40:17 51:3 67:17 70:21 79:21 82:7 83:15 89:14 93:14 99:13,15 104:5 106:10,20 117:22 121:4 129:2 140:18 141:14 144:7 145:8 148:10 155:9 168:5 185:13 201:17,21 218:3,8 232:6 245:2 253:14 254:9 269:21 270:2 271:15 272:1 273:9 274:5 287:18 293:10 294:3,13,19 301:7 311:3,4 lots 245:22 284:9 Louis 13:10 Louisiana 165:19 170:13,18 love 107:13 235:3 301:13 low 34:15 36:22 54:7 63:7 93:9 95:18 112:10 122:17 123:14 134:10 197:7 230:22 239:6 241:11 lower 155:18 231:13 234:10 268:9 279:8 lowest 92:15 lowliest 81:17 **luckily** 5:15 Luke's 1:14 14:13 **lunch** 140:12 177:11,12 177:15,17,18,21,22 179:18 Μ MAC 175:14 MACPRO 50:8 53:4 magnitudes 168:7 main 65:22 165:22 186:16 maintain 192:7 252:20 252:21 maintaining 47:5 301:8 maintenance 118:19 249:4 major 25:17 26:16 28:16 97:17 majority 144:18 155:5 make- 290:6 making 62:15 82:19 101:15 102:7 122:1 126:3 134:21 136:15

136:16 162:5 174:6

264:1 291:4 295:5

313:2

252:4,8 256:9 263:15

malpractice 81:3 manage 43:5 46:4,16 53:11 54:16,17,17 60:8 102:10 managed 2:6 12:4,15 12:18 43:15,17 44:12 46:3 49:16 50:9,13,19 50:20 53:11,12 54:16 56:4 61:11 70:1 84:15 94:8 99:11 146:18 245:8 258:6 289:15 289:19 301:4 management 11:19 47:17 83:2,19 84:4,14 167:11 261:15 289:9 299:10 manager 2:18,21,22 20:18,21 142:8 210:20 managing 43:3 52:17 manual 168:5 map 4:4 5:19 6:4,13 22:15 34:22 35:12,15 35:15 36:13 57:12 75:15 93:13 114:14 115:4.7 121:16.20 138:20 181:4,9 183:5 221:12 222:5,7 309:19 mapped 60:19 Marissa 2:6 12:16 132:14 133:9 134:18 184:22 185:9 256:4 mark 103:8 markedly 290:3 marker 49:19 68:12,17 72:21 markers 69:11 241:10 marks 53:21 Marsha 2:13 13:20 202:11 204:4 238:4 Mary 1:18 3:5 4:7 12:9 16:1,5 41:9 67:10 82:7 101:22 128:21 145:22 153:19 156:11 167:21 172:15 202:12 207:19 210:18 212:5 215:16 218:6 235:16 237:16 238:15 240:16 242:2 266:5,11 291:9 305:10 307:22 Mary's 13:9 166:1 217:9 massive 42:18 46:1 58:11,11 59:1 massively 65:15 Match 70:5 matches 53:5 matching 53:4 229:11

material 175:10 250:3 251:5 materials 115:5 310:11 maternal 4:11 22:5 23:10 28:11 87:14 88:1 93:19 97:5 103:17 104:5 105:3 105:10,14,16 110:12 111:19 115:13,19 125:8 184:10 188:13 192:1 195:12,19 207:14 221:1 230:19 244:21 252:15 265:15 271:15 maternal- 3:10 98:21 Maternal/Child 140:13 maternal/infant 187:20 maternity 43:9 46:6 47:22 54:6 58:20 90:22 92:1,6 98:4 112:1,12 113:20 295:1 maternity-related 113:4 math 64:22 Mathematica 18:9 36:4 Matsuoka 3:13 19:14 132:1 163:4 186:21 189:10 222:2 237:11 237:15 277:14 278:1 291:2 292:9 301:15 311:8 matter 2:8 10:13 16:21 17:2,8 50:22 56:2,3 91:3 110:3 132:10 134:14 141:18 151:11 159:18 179:20 240:9 264:11 283:1 300:13 313:14 matters 42:12 146:22 maximize 270:14 **MBA** 1:20 2:2,3 MCOs 108:14 175:6 249:17 **MD** 1:12,12,13,14,15 2:2,3,3,13,15,17 3:5 MDwise 2:2 12:4 mean 57:8 72:19 73:6 77:18 79:16 83:14 85:18 96:14 127:1 130:5 132:16 134:4 138:19 142:9 143:1 150:19 155:2 156:2 157:13 170:17 184:11 190:4 200:18 209:5 216:7 219:5,12,13 220:7 230:15 235:10 235:14 254:16 256:15 265:5 292:2,2 300:5,6

302:13 306:22 311:3 meaning 290:15 297:2 meaningful 52:15 61:2 130:12 132:9 137:4 271:5 281:1,20 meaningfully 72:10 297:3 meaningless 265:2 means 162:22 182:21 200:12 227:20 247:3 254:6,6 285:5 meant 121:22 141:6 measured 130:4 measurement 3:7 6:19 7:3,11 20:12 30:5 32:9,11,14 33:8 41:20 46:18 47:19 73:16 80:14 88:8 123:5 135:17 218:8 238:19 240:7,9 270:15 272:10 measurement's 30:6 measurements 104:8 measuring 33:11 42:5 52:3,7 70:10 71:2 89:7 155:15,20,22 156:2,4,5,9,15 158:6 158:13 159:1 172:9 224:12 242:14 296:10 mechanics 270:16 mechanism 100:8 105:15 mechanisms 51:7 med-surg 299:6,15 media 231:12 median 249:12 mediator-related 274:12 Medicaid 1:3 2:13 3:6 3:12,15,17 5:5,9,19 6:11 11:14,15 12:4,15 14:1,9,20 16:7 17:17 19:12,15 21:22 24:3 24:15 33:9,15 35:15 42:17 43:14 44:13 45:4,10 49:10 59:19 64:1 67:6 68:9 80:7 81:18 98:2 103:22 108:12 109:13,15 112:9 115:4,7 122:15 123:15 155:9 158:22 165:19 168:16 182:9 183:5 194:8 195:4 197:8 202:9 206:1 233:20 234:9,17,18 235:10,13,19 236:12 240:18 241:16 245:6 245:7,10 253:10,22

258:1,3,5 269:9 270:13 279:21 285:19 286:8 288:10 289:16 297:16 302:21 304:14 310:1 312:13,17 Medicaid-specific 182:7 medical 2:3 9:6 12:3 13:21 14:12,20 15:21 16:6,17 18:1 24:3 44:3 78:15 165:20 174:4 195:4 241:6 273:12 286:5 295:12 295:22 298:16 medically 296:7 303:12 Medicare 2:13 3:12,14 3:16 6:13 14:1 35:15 37:19 40:14 50:9 286:7 Medicare- 54:20 medicate 42:9 medication 214:12 249:14,20 251:11,13 251:15 257:21 259:4 261:15 264:17 300:14 medications 250:11.14 251:18 253:19 255:3 255:5,18 256:21,22 298:21 medicine 62:19 meds 255:9 meet 21:15 118:22 169:17 209:17 225:6 290:16 meeting 21:4,10 24:2 39:12 181:8 243:5 250:4 310:11 meetings 75:21 181:9 182:8 183:5 192:19 meets 285:20 290:11 melon 5:15 melts 45:6 members 1:11 2:1,10 4:3,4 10:5,6 21:7 22:15 31:10,12 65:2 114:10 116:9,16 124:12,13 131:10 137:17 138:13 150:17 151:1,17 155:9 165:2 177:2 182:20,21,22 184:9,14,20 185:6 223:14 228:7 247:13 248:13 249:8 259:11 260:12 262:1 266:22 311:2,10 membership 32:7 91:6 memo 54:18 mental 2:12 75:4

Neal R. Gross and Co., Inc.

Washington DC

111:12 273:21 274:8 275:2 276:14 278:19 284:7 285:22 287:3,4 287:10,11,15 289:18 290:8,14 302:1 305:6 307:8 mentally 280:1 mention 42:20 58:21 102:3 119:10 212:20 283:16 mentioned 23:9 52:18 55:21 57:19 58:8 59:4 78:6 90:16 110:21 188:12 195:19 198:10 198:22 202:2 204:7 222:3 224:17 244:16 mentor 9:10,13 message 7:2,8,16 172:2,10 176:4 216:2 messaging 90:11 204:1 216:6 met 1:8 23:7 41:14 57:5 **metabolic** 300:15 method 54:13 186:18 201:12,13 220:15 221:5 302:8 methodological 267:3 268:14 269:1 methodologies 107:2 methodology 51:16 225:3 269:2 methods 199:21.22 200:6 211:14 218:16 222:22 227:13 metric 158:4.6 202:17 203:8,10,17 210:15 215:4,9 245:19 246:6 metrics 161:1 229:6 mic 19:9 158:16 205:10 microbiome 231:5 microloans 72:4 microphone 114:21 115:6 125:5 130:20 131:20 136:4 138:4 147:16,19 160:2 170:5 224:6 247:20 264:22 midwives 242:20 miles 18:21 military 19:5 244:7 milk 117:14 178:19 186:1 228:17 247:8 million 14:8 43:14 55:1 67:22 70:1 240:21 millions 140:17,18 mind 37:5 38:1 63:18 225:4 231:3 242:6 313:10

mindful 23:13 73:13 261:7 312:12 minds 131:22 minimal 252:8 Minnesota 28:5,7 minorities 60:14 minority 273:3 283:11 minute 113:15,22 117:20 177:9 217:3 262:3,8 263:7 minutes 177:15,17 262:11 MIPS 268:2,4 Miranda 2:19 20:15 137:8 222:17 227:9 247:3 260:5 261:13 309:10 mirrors 164:6 missed 54:22 67:20,22 76:12 missing 68:3 96:2 98:2 mission 6:8 47:17 Missouri 69:6 mistaken 100:7 **Mistry** 40:7 misunderstand 242:7 mitigation 140:4 mix 38:6 mobile 90:11 model 49:9 79:8 83:10 101:13 modeling 68:8 models 98:15 100:21 101:19 308:5 moderately 178:13,22 186:18 199:21 200:10 222:22 227:13 modern 114:12 modification 204:11 205:6,12 modified 204:8,9,18 205:7,8 mom 145:6 mom's 239:2 moment 111:18 240:2 258:21 momentarily 262:22 moms 144:16 185:13 185:13 money 34:5 54:16 85:1 103:5,6 monitor 104:9 187:21 month 84:20 86:11 104:15,17 216:11 months 5:20 64:5 92:9 104:14 195:17 233:9 281:13 286:20 morning 5:6 10:1 11:17

12:1,9 13:15,20 14:4 14:11,18 15:7,10,14 16:4,11 19:13 20:11 20:14,20 21:19 87:10 111:20 149:5,15 151:19 163:6 166:1 188:12 266:3 271:14 mortality 26:2 50:1 51:6 59:2,3,5 60:6 66:3 67:20 68:5,9 70:3 78:1 103:15,18 105:10,14 274:14 282:20 284:1 mother 63:12 215:19 mother's 112:4 mothers 68:15 73:3 216:14 motion 125:11 130:19 134:22 135:1,2,5,18 147:16 148:2,17,18 159:6 160:15 161:16 161:18,20 162:6.20 163:18 164:1 174:11 176:1,13 192:11,16 193:9,12 224:21 225:9.12 256:9 257:11.13.14 Motion's 176:9 motions 257:17 move 16:20 41:8 47:22 48:3 55:5 56:1.14 60:3,4 70:13 77:21 99:21 109:8 115:10 121:9 136:17 139:1,8 140:9 147:17 149:21 151:5 159:8,19 160:3 177:7 183:11 237:9 249:5 250:22 251:20 256:10 260:13 265:16 271:22 278:2 283:21 moved 77:20 91:11 movement 88:21 135:12 moves 172:19 moving 41:9 44:9 55:19 56:19 97:13 248:17 264:7 265:18 310:17 310:19 MPH 1:13 2:13,20,21 **MPhil** 2:15 **MSN** 1:19 MSPH 2:5 3:10 Mukherjee 2:20 5:3,4 8:1 20:8 21:1 264:4 266:20 311:15,18 **multiple** 123:12,13 295:22 296:20 Munthali 20:11,12

mutually 56:9 297:14 Mystery 152:12 Ν **N** 5:1 **N.W** 1:9 Nacion 2:21 20:17,18 115:2,7 Nair 2:11 14:4,4 name 10:9 12:14 19:10 20:15,17 34:4 161:5 240:5 name's 5:4 named 123:19 narrative 270:18 narrow 108:4 129:7 national 1:1,8,16,19 2:5 11:14 12:7 13:3,11 14:20 15:11 18:10 33:15 207:5 209:4 230:2 232:2,8 276:19 285:17 286:18 287:7 nationally 54:1 NCQA 128:7 255:14 289:1,5 292:4,7 near 23:3 197:1 239:17 267:6 271:13 necessarily 10:7 34:17 42:22 70:7,20 98:3 200:17 254:8 305:13 necessary 97:22 101:8 175:3 need 8:7 10:7 17:11 22:10 38:1 42:14 43:4 43:10 46:10,11,16 48:21 52:9 57:20 58:4 62:5 64:4 66:8 70:5 73:15 82:12 83:16 84:8,9 86:13,14,15 87:1,1 89:20 100:1,3 102:9,14,17 106:7 122:4 129:5,7 130:1,7 130:14 134:8,15 135:1 136:21 146:16 146:22 147:2 148:7 151:4 152:15 153:15 153:22 154:10,11,13 166:5,7 167:14 173:11 175:4 182:15 191:21 192:13 193:12 199:4 202:19 203:9 203:19 207:12 213:8 218:17 220:17 241:17 243:15 245:20 246:18 248:11 255:19 262:5 271:13 279:6 286:2

MUP 1:17

mute 8:7 149:1

297:10 305:21 306:10 307:4,18 310:4,16 312:17 needed 34:17 70:12 88:15 90:14 96:5 101:10 182:13 257:22 295:7 306:22 needing 153:20 needle 283:21 needs 31:18 43:22 52:2 52:21 64:7 65:9 74:15 75:6,19 86:12 96:17 103:12 132:20,21 133:5 159:20 183:20 215:6 256:7 278:22 279:6 286:5 negotiations 108:13 neighborhood 70:8 nested 292:15 nestle 292:16 net 11:21 network 22:17 neutral 214:6 never 49:3 52:9 72:9 165:14 202:22 211:12 220:4 249:9 Nevertheless 95:6 96:18 new 3:8 6:12 18:7 23:4 28:21 31:12 33:9 54:10,19 78:12 128:18 149:14 177:14 188:15 195:15 204:8 204:9 217:4,5 218:12 219:3 224:14 234:16 240:7,11,22 257:20 271:21 278:5 289:3 newborns 239:9,10,11 newer 255:14 news 66:7 284:3 nice 253:13 NICU 215:20 239:10 **NIDLRR** 28:8 night 256:15 **NIH** 18:14 nine 27:5 151:4 182:22 216:11 233:2 268:3,8 Ninety-two 177:1 nitty-gritty 85:13 noise 55:9 nominated 25:12 non-contraceptive 200:15,22 non-endorsed 132:6 non-health 294:6 non-profit 11:21 non-specific 231:12 NON-VOTING 2:10

Nope 170:3 note 52:20 81:1 133:7 186:9 265:11 noted 120:11 250:8 notes 211:18 notice 53:18 54:2 57:2 59:21 63:5 114:11 noticed 124:8 200:14 noting 250:9 notion 23:2 82:10 271:20 276:22 297:9 NQF 2:14 6:5 7:4 9:11 20:2 111:1,3 115:3 119:6 123:2 124:17 127:17,19 145:3 175:20 194:12 229:5 230:5 255:13 302:7 307:6 310:3,13 311:9 313:1 **NQF-** 132:20 165:12 168:20 NQF-endorsed 25:16 141:5 182:3 183:15 220:9 NQFguest 9:1 NQS 122:4 nuance 224:9 number 7:6 24:16 25:7 26:10 27:7,7,17 29:19 29:20 30:3 35:5,22 40:17 53:1.12 63:5 87:22 92:13.15 99:12 112:16 119:3 120:12 136:13 178:4 201:8 202:7,9 216:9 227:14 227:15,16 228:21 229:5,8,19 241:20 247:10 248:1 260:4 260:19 261:18,19 265:5 274:11 275:22 276:12 277:2 289:18 numbers 51:18 62:15 80:18 115:13 255:11 282:7 numerator 169:17 254:6 nurse 1:19 13:8,11 173:16 236:20 242:20 nurses 2:7 15:8 81:10 81:14 nutshell 301:15 0 **O** 5:1 o'clock 32:3 **OB** 102:17 103:2 295:1 **OB's** 103:1

331

Neal R. Gross and Co., Inc. Washington DC OB/GYN 170:16 232:13

267:15 **OB/GYNs** 242:20 **obesity** 231:14 objective 21:10 181:16 282:13 objectives 21:3 obligations 301:3 observations 285:16 obstetric 80:19 obstetrics 28:15 79:18 **obvious** 65:4 obviously 25:17 30:18 88:8 93:12 125:1,9 155:2 192:1 253:9 255:16 264:10 287:8 287:11 occurred 95:4 104:16 occurrence 95:1 100:10 occurring 97:8 occurs 94:20 295:21 offer 196:10 204:14 offering 197:11 220:15 office 1:13 2:11 62:7 85:6 89:4 188:16 196:2 253:18 286:12 officer 2:16.17 13:21 official 84:4 193:9 281:2 officially 104:14 oftentimes 38:7 **Ohio** 3:5 43:13 44:14 46:1 49:9 56:16 57:6 59:16 64:2 66:3 69:7 69:9.22 70:6 76:14 78:5 107:21 109:22 167:22 212:15 213:22 216:2 237:16 238:15 271:22 283:2 Ohio's 16:7 Ohio-specific 73:18 old 104:16 174:3 231:9 240:19 old-fashioned 262:17 older 61:21 255:2 once 43:21 77:7 91:11 140:4 156:1 219:19 260:8 280:22 one's 191:6 212:16 one-in 34:21 one-out 34:21 ones 60:15 77:3 131:11 172:17 190:22 201:18 213:1 263:11 267:21 283:12 ongoing 117:18 118:9 131:7 139:13 149:22 online 169:5

open 39:10 99:3 101:4 139:13 152:20 153:3 153:4 163:17 164:9 166:18 167:14 178:1 179:8 229:21 234:1,1 234:4 247:16,17 293:6 308:21 opening 107:14 165:6 272:3 opens 236:3 Operational 11:19 operationalize 292:6 **Operator** 178:1,2,6 179:8,11,15 247:17 247:21 248:3 260:17 260:21 308:11,13,17 308:22 309:8 opinion 127:19 130:16 147:5 218:15 244:13 opinions 213:14 opioid 25:18 26:2 28:21 59:3,4 173:7 opioid-challenged 73:3 opioids 25:14 264:2,19 opportunities 23:20 73:18 87:22 88:5.10 100:15 229:15 271:10 opportunity 8:16 31:13 32:4 50:3 89:16 93:22 101:11 107:10 184:20 198:4 230:13 232:7 297:2 312:11 opposed 128:4 188:9 199:21 205:8 optimal 192:7 optimize 270:14 **optimized** 107:18 option 133:1,3 261:17 options 125:10 223:1 227:9,14 230:10 247:11 259:5,7 260:4 or/and 122:20 order 27:6 36:2 100:2 250:17 275:15 281:19 301:1 312:10 organization 10:10 11:9 17:4 18:13 organization's 11:2 organizational 10:18 11:1 300:20 organizations 13:3 94:9 organized 63:4 65:15 310:15 original 186:2 origins 39:17 231:4 Osborne-Gaskin 2:2 12:1,2 201:5 217:8

otitis 231:12 out-performing 81:19 outcome 87:3 91:10 107:22 146:10,13 156:15 181:18,19 305:14 outcomes 3:14 18:7 19:12 27:15 28:22 48:10 55:19 88:2,6 92:4 98:16,20 101:7 101:14,20 105:16 108:10 109:7 119:4 126:4 139:21 141:7 142:11 145:19 195:12 206:8 214:13 216:16 239:2 242:16 254:10 275:7,8 285:1 294:7 outlier 230:6 outpatient 27:13 47:14 236:15 outreach 52:10 86:15 199:6 outset 94:13 outside 8:8 80:2 134:20 235:5 ovarian 231:17 overall 7:3 17:18 21:22 25:9 178:18,20 299:10 overarching 105:15 186:22 187:2 overlap 27:3 110:9 190:5 Oversight 19:5 overview 4:5 21:4 267:11 268:5,16 overwhelming 197:6 owned 104:2 owner 219:21 Ρ **P** 5:1 **p.m** 179:21 264:12,13 313:15 pace 98:3 265:18 package 48:9 284:14 packs 175:12 180:15 249:11 page 114:3 115:1,3 207:14 310:10 paid 62:16 171:9 236:10 painful 57:8 paired 229:11 panel 4:7,8 24:7 31:10 87:18,21 89:14 178:14,15 179:3 panelist 21:20

panelists 22:2 paper 59:11 102:19,20 186:2 228:16 234:3 parallel 257:17 paralysis 287:5 parameters 287:9 parent 229:5,7 247:10 Parenthood 196:6 Parkinson's 287:6 parsimony 23:2 34:4 37:4 187:1 part 30:8,13 35:17 58:9 59:4,6 68:1,21,22 79:10 81:7 84:15 87:13,20 89:5 93:19 102:15 105:13 108:22 125:20 127:16 130:22 131:2 153:9 174:6 187:20 188:17 189:5 199:1 204:12 206:16 216:21 283:16 287:4 298:10 311:1 PARTICIPANT 74:5 170:3 participate 22:7 23:12 31:21 33:11 212:15 particular 22:18,19 29:3,4 51:13 53:5 101:3,13 106:4 116:2 168:4 172:6 187:4,16 211:20 225:4 244:3 250:14 253:15 254:3 254:4 257:20 278:12 particularly 25:22 26:1 27:8 28:10,13 59:2 103:18 172:3 198:13 198:19 234:9 237:4 273:17 281:2 286:3 partly 299:13 partner 107:20 169:16 partnered 94:8,10 partnering 284:11 partners 63:20 66:17 88:6 187:9 199:13 281:12 partnership 1:3 2:5 15:12 40:11 89:1 310:19 312:12 partnerships 89:2 109:14 parts 45:12 pass 103:7 262:22 passing 57:14 passion 234:7 passionate 170:14 path 137:3 145:21 303:9 305:4 pathways 301:2

|   |   |  | 33                                       |
|---|---|--|--|
| patient 16:16 42:12                           | 64:6 67:3 73:2,12                         | 47:9 56:22 81:15                           | 210:3 212:7 213:11                       |
| 56:2 62:10 76:2 83:9                          | 77:4 78:19,21 82:11                       | 91:16 92:6 96:22                           | 216:6 241:15 242:19                      |
| 83:19 102:10 130:1                            | 85:4 87:19 91:14                          | 110:12 111:19,22                           | 243:1 303:19                             |
| 154:13 251:14 253:18                          | 99:19,22 102:8 105:1                      | 112:6,12 113:20                            | pieces 71:15 95:5                        |
| 257:7 275:5 289:6                             | 109:20 136:8,8                            | 127:11 143:12 178:14                       | 156:16 198:20 199:5                      |
| 295:19 300:7 302:19                           | 144:19 147:6 155:5                        | 184:10 232:14 252:15                       | 201:4                                    |
| patient- 15:15 44:2                           | 155:15,18 156:21,22                       | 265:15                                     | pile 106:16                              |
| patient-centered 1:17                         | 158:4 166:11 169:5                        | period 42:4 119:6 129:8                    | pill 213:13                              |
| 15:18 44:2 154:8                              | 196:18,21 199:14                          | 129:18 162:5 169:20                        | <b>pilot</b> 94:11 95:15,15              |
| 213:10  | 201:9 203:2,20                            | 216:11 249:15                              | 97:12                                    |
| patient-family 285:6                          | 208:12 210:18 213:10                      | persistent 251:10 274:8                    | piloting 90:12                           |
| patient-level 289:4                           | 213:11,14,17 232:3                        | 275:2                                      | pinch 9:19 39:13                         |
| patient-reported 206:8                        | 234:2 240:21 247:18                       | person 49:10 52:4 84:3                     | <b>Pincus</b> 1:9,12 9:9,12              |
| patients 14:8 46:10                           | 249:20 252:21 253:17                      | 102:21 135:3 243:6                         | 18:4,4 24:1 29:14                        |
| 47:11 54:21 62:12                             | 257:6 261:16 273:6                        | 307:14                                     | 31:1,3 39:15 82:6                        |
| 78:14 80:9 81:4                               | 273:20 281:6 283:3                        | person's 146:12                            | 85:21 87:4 100:12                        |
| 130:13 169:19 250:13                          | 284:21 285:22 286:1                       | person- 123:5                              | 110:6 125:1,6 126:7                      |
| 252:4 255:2,6,18                              | 286:1,9,11 292:22                         | personal 44:3 134:14                       | 127:1,13 128:20                          |
| 257:4 296:6,20                                | 297:20 298:14,19                          | 218:15                                     | 130:17 131:9 132:13                      |
| patterns 106:6 251:13                         | 301:13 305:20 306:1                       | personally 140:9                           | 133:2,9 134:17 135:                      |
| Patton 2:12 13:14,16                          | 306:12                                    | 230:17 233:8                               | 135:7,9,18 136:5                         |
| 238:17 283:15 285:8                           | people's 26:19                            | persons 75:7 286:7                         | 137:7,18 138:15                          |
| 306:18  | percent 43:15 45:8,19                     | perspective 4:7,8 41:22                    | 139:4 141:1 143:22                       |
| pause 98:20 247:5                             | 45:22 48:21 49:8                          | 125:18 140:6 158:22                        | 145:22 166:22 168:                       |
| 259:1 262:9 292:19                            | 50:12 54:22 57:4,5,15                     | 192:9 215:16,17                            | 184:19 190:4,17                          |
| 308:7 309:3                                   | 75:2,15 93:4,8,12,18                      | 243:6 245:7 278:4                          | 191:13 192:10 193:                       |
| pay 42:21 61:11 62:12                         | 93:21 103:1,7,8                           | 294:1 295:14 304:14                        | 193:14,17 202:11                         |
| 171:7 220:3                                   | 129:20 138:12 144:16                      | perverse 94:19                             | 204:3 205:10 206:4                       |
| pay-for-performance                           | 150:17 165:1 173:9                        | pestered 80:7                              | 207:18 210:17 212:                       |
| 54:14   | 177:1 178:17,20                           | pharmacies 306:7                           | 214:14,18 215:1                          |
| payer 295:15                                  | 182:19 196:17,22                          | Pharmacological                            | 217:1 218:2,19                           |
| payers 64:2 78:17,17                          | 208:9,10 209:12                           | 251:10                                     | 220:11 221:8 222:14                      |
| 81:20   | 211:12 213:4,5 216:9                      | Pharmacy 2:6 12:19                         | 223:3,16,19 225:16                       |
| paying 197:8 281:13                           | 223:14,16 228:6,7,9                       | phase 136:13 242:21                        | 225:20 227:19 252:                       |
| payment 88:11 90:17                           | 230:4 232:3,4,4 233:5                     | 284:17                                     | 254:12,18 256:4,11                       |
| 97:1 100:14 121:19                            | 236:2,18 239:18                           | <b>PhD</b> 1:21 2:5,9,12 3:13              | 257:12,16 258:11,14                      |
| 171:5 219:6 221:13                            | 247:14 249:12,14                          | phenomenal 313:2                           | 258:17 260:8 263:9                       |
| 222:1,10,13 225:3                             | 250:17 257:3 258:4,5                      | phone 16:10 142:4                          | 264:9,14 265:1,7                         |
| 226:22 263:13                                 | 259:10 260:11 261:22                      | 176:17 179:10 208:3                        | 272:6 277:20 292:13                      |
| <b>PC05</b> 117:14 185:22                     | 281:5                                     | 229:3 248:4 309:9                          | 298:6 307:21 308:2                       |
| 187:16 228:17 247:8                           | percentage 48:17                          | phones 8:6                                 | 310:12 313:13                            |
| <b>PCP</b> 313:4                              | 154:22 209:6 255:2                        | phrasing 108:9                             | pinpoint 300:1                           |
| <b>PCPI</b> 165:13,13                         | 258:3 290:14,16                           | physical 102:12 283:18                     | pipeline 26:4,13 128:                    |
| <b>PCPI's</b> 169:6                           | percentages 209:5                         | 298:14 306:5,20                            | pivot 87:5                               |
| pedal 312:19                                  | 211:4                                     | physically 86:16                           | pivoting 9:17                            |
| pediatric 16:15 40:5                          | percentile 54:1,3                         | physician 80:3                             | place 6:17 60:12 74:1                    |
| 58:9 237:6 244:8                              | percolates 240:14                         | Physicians 12:3                            | 86:8 104:8 133:21                        |
| pediatrician 9:5 14:19                        | perfect 16:19 111:21                      | <b>pick</b> 61:6,15,17,18 77:2             | 134:6 154:2 194:19                       |
| 16:3,5 58:12 107:16                           | 228:6 233:18                              | 124:18 173:18 177:22                       | 271:2 283:8 301:4                        |
| 242:4 243:13                                  | performance 14:3                          | picked 91:11,13 165:15                     | places 80:19 166:4                       |
| pediatrics 14:21 19:1                         | 33:18 48:12 49:18                         | 188:4 190:19                               | 239:9                                    |
| 40:3 43:9 243:12                              | 58:11 89:8 122:18                         | picking 70:9                               | plainly 79:14                            |
| peers 116:16 180:17                           | 204:12 220:3 271:21                       | picture 33:15 112:14                       | plan 12:4 51:1,2 56:5                    |
| pending 183:14                                | 281:19 287:14 288:11                      | piece 50:2 79:7 94:22                      | 61:6,18 62:8 72:22                       |
| people 24:11 29:16                            | 288:14                                    | 96:16 98:2 146:21                          | 77:17 82:15 84:1,15                      |
| 34:10 42:7,9,22 43:15                         | performed 169:18                          | 156:16 162:12,14                           | 85:7 122:20 140:14                       |
|   |   |  |  |
|   | performing 289.17                         | 190:14 192 1 194 18                        |  |
| 44:14 45:8 51:21 52:9<br>54:17 56:12 59:13,19 | performing 289:17<br>perinatal 22:5 23:10 | 190:14 192:1 194:18<br>198:5 200:11 201:11 | 146:18 154:8 168:1<br>170:13 172:18 175: |

179:7 245:10 282:22 288:11,12,13 289:15 290:10,12 292:4 293:12,19 299:8 301:4 306:11 plan's 290:4 plan-288:19 plane 248:14 **Planned** 196:5 planning 45:3,9 97:7 196:5 221:4 plans 1:21 11:20,22 12:13,15 17:20 50:20 50:21 51:3,17 53:21 54:16 61:4,11,16 62:11,21 64:16 65:21 75:18 78:16,18 84:13 85:14,17 99:11 125:19 171:6 198:15 198:16 210:6 252:5 289:3,19,22 290:13 299:6,15,16,16 302:9 302:20 304:1,4,9 play 201:2 playing 106:9 please 8:6,10 11:8 15:2 19:19 20:1 22:11 30:11 32:6,13 35:19 36:12 37:6 71:12 90:19 92:5 123:11,21 134:13 138:7 147:16 149:15 150:1,6,11 151:18 157:15 158:16 159:11 160:16 164:8 167:10 176:1 178:1.3 179:10 217:6 224:6 227:10 229:9 242:6 247:4,22 248:12 260:18 308:12,14 **PMP** 1:21 2:18 point 19:19 30:11 48:12 53:10 57:11 77:10 91:14 103:11 115:11 138:8 143:15,16 145:12,13 161:22 163:5 177:7 184:21 190:5 210:7 214:8 217:9 218:7 228:19 233:1 241:2 243:17 258:4 263:9,19 273:15 274:8 276:6 276:15 278:7 279:10 284:3 287:13,21 288:20 296:8 300:10 pointed 250:12 points 9:18 48:17 83:6 283:16 288:4 policies 236:16

policy 2:19 13:10,12 18:9,11 19:4 30:19 39:22 88:5 163:10 294:1 **poll** 298:4 **Polling** 164:9 polypharmacy 25:20 29:5 173:8 pool 73:1 **Poole-Yaeger** 2:3 15:20 15:21 99:7 105:17 144:4 156:17 158:21 159:8,13 160:3,6,11 162:7,15,17 170:12 218:20 224:13 225:7 225:11 226:11,16,19 227:2 234:6 poor 49:17 267:20 279:16,22 291:11,12 291:17 298:21 poorly 241:5 306:13 **pops** 187:13 population 33:20 44:21 45:5,6,21 46:16,18,19 47:17,18 50:1 54:12 54:18 55:19 56:6 58:6 58:17 61:6.9 65:21 67:1 74:9,10,19 75:13 75:16 77:9 79:3 83:19 86:10 89:4 102:5,10 104:3 106:22 122:16 122:20 130:7 144:11 156:4 176:5 182:10 188:16 194:6,8 196:3 208:5 213:19 217:20 230:19 233:21 235:10 235:11,12 245:8 252:7 253:10 269:9 270:12,12 272:22 273:2,22 274:4,16 275:17,21 276:16 279:8,13,16 280:4,7 281:8 283:20 286:15 287:12 289:14 290:14 292:16,17,17 297:8 298:12 299:10 300:2 302:6 307:2 population-186:14 populations 17:19 33:9 38:2 43:4,6 44:8 57:21 78:14 83:3 189:17 208:17 214:9 230:21 234:10 251:17 280:15 283:11 285:21 287:20 289:22 290:2 290:6,7 298:19 299:5 299:9 portfolio 6:21 7:20

portion 26:16 153:12 164:2 266:13 position 19:3 positive 108:1 135:12 possibility 196:15 **possible** 38:12 108:2 122:12 128:16 129:16 132:15,17 150:21 166:13 176:6 279:5 possibly 202:18 post 131:13 posting 198:6 postpartum 28:14 48:13 49:4,22 50:3 51:21 53:6 54:8 57:2 61:14 66:4 67:19 68:3 68:16 72:12,14 77:13 77:21 78:2 89:11,13 90:5 91:13 92:17 93:17,20 94:5,12 95:20 96:6 97:2,4 99:13 100:10 103:8 104:13,18 106:18 111:3,9 117:20 120:2 121:1 126:10,13 128:11,17,18 131:1 131:18 134:8 138:2,6 138:7 146:5 153:4,8 159:17 162:8,8,11 164:17 190:22 191:9 194:19 213:22 215:9 215:17 220:20 221:1 potential 19:22 27:14 123:9,11,20 125:10 128:8,14 157:17 165:7 177:8 180:4,6,7 182:15 203:22 221:18 230:20 253:1 268:11 269:5 300:3 potentially 6:15 91:20 108:5 132:22 150:11 161:15 199:12 203:6 226:14 269:11 poverty 71:20 72:6 216:17 286:14 power 248:10 279:17 powerful 57:9 233:19 279:3 280:12 PowerPoint 258:22 PQMP 40:6 113:8,12 249:2 PQRS 268:2 practical 212:7 298:15 practice 44:1 49:12 52:15 77:16 81:10,14 82:14 83:2,11 86:1,6 102:11 130:16 137:22 197:21 237:7 300:20

307:17 practices 76:1 78:19 84:8 85:16 98:11 195:21 236:16 practicing 208:15 practitioner 86:16 Practitioners 1:19 13:8 13:11 **PRAMS** 212:22 pre- 54:8 113:16 192:3 241:10 pre-meeting 137:12 251:5 pre-pregnancy 192:7 pre-term 91:21 212:8 241:9 282:20 precious 243:20 precise 210:8 precursor 233:17 predictive 68:7 preeclampsia 147:7 preemie 63:12 prefer 213:19 preferable 291:16 292:1 preference 181:19 preferred 233:7 pregnancies 141:21 147:2 154:18 212:8 213:3 217:10 pregnancy 71:20 89:18 89:21 91:10 134:5 145:3 172:14 192:4 201:10 203:11 207:10 208:2,7 209:20,21 211:5 216:15 217:13 217:21 pregnant 63:13 113:1 144:17 147:8 155:10 165:12 172:3 176:18 prejudiced 287:22 preliminary 116:6 181:1,3,4,10,15 premature 210:11 prenatal 53:4 61:14 63:9 65:17 66:3 80:20 91:9 92:10 93:3,7,15 99:19 111:8 117:19 117:20 118:9 119:15 120:9 128:10 130:3,5 131:7,8,13 134:8 138:2,3,6 139:13 141:15,16,19 142:10 144:13,22 145:14,19 146:17 149:22 153:4 153:8,11,14 154:7 155:1,13 159:15,16 159:18 161:10 162:9

162:10.11.13 164:17 164:18 169:20 242:21 prep 39:12 preparation 113:6 preparing 89:18 Presbyterian 18:7 preschool 61:22 62:6 prescribed 255:3,6 prescribers 306:8 prescribing 83:22 251:13,15 prescription 169:15 252:3,5 presence 112:6 present 1:11 2:1,10 3:3 3:21 197:3 237:3 presentation 21:19 39:6 76:9 78:4 82:7 117:6 180:13 266:2 presentations 103:14 presented 24:4 118:1 278:15 presenter 67:11 presenters 111:20 presenting 118:6 204:7 307:14 president 2:15 11:18 12:10 15:15 16:16 20:12 140:12 presiding 1:10 press 149:16,16 150:2 150:2 178:3 179:12 247:22 260:18 308:14 309:1 pressure 9:4 267:19 pressures 312:13 presume 41:4 52:5 296:5 presuming 259:13 preterm 47:21 48:1,4,5 51:5 54:9 58:19 59:6 60:5 64:13,20 pretty 13:14 25:8 28:19 29:6 45:6 76:6 125:20 127:15 128:15 148:4 190:12 200:7 211:3 212:3 235:18 236:19 252:10 266:15 270:17 272:1 279:20 311:19 prevalent 253:11 prevent 48:1 preventing 216:14 Prevention 89:4 preventive 60:4 230:17 275:20 previous 119:19 120:5 120:8 184:3 185:11 241:9

previously 27:4 price 197:9 **primarily** 288:10 primary 1:17 15:16,17 27:9 29:3 49:11 62:4 62:14 63:4,6,16 75:11 75:11,22 77:17 78:6 78:11,12 83:10 84:18 84:19 85:2 197:10 273:7 275:9,14 284:6 300:17 principle 187:2 prior 17:19 31:11 107:1 139:17 182:16 priorities 26:18 29:1 76:22 122:4 195:5 272:18 prioritization 264:15 prioritize 87:1 171:22 262:5 prioritizing 176:6 priority 25:21 27:6,19 28:10,13 70:2 195:2 202:9 276:1 privacy 213:16 private 18:14 78:18 privilege 9:8 probably 8:22 40:2 47:22 71:22 73:22 92:14 93:14 94:13,15 98:1 144:11 160:12 168:7 169:6 170:16 205:12 213:1 219:18 226:20 239:6 256:2 286:21 303:8 probe 140:4 291:3 problem 55:16 59:3 64:6 151:9 197:5 213:7 222:19 244:11 300:7 problematic 150:11 204:1,1 problems 94:21 176:8 217:17 231:22 257:6 272:18 287:18 300:1 proceed 149:5 259:16 260:2 261:10 process 5:19 6:1,5,6 9:21 23:6 30:1 70:7 100:19 121:10 124:3 124:16,18 127:9 139:11 146:19 154:9 165:15 180:22 183:17 185:3 190:5 193:2,13 206:16 214:2 218:6 230:3 240:22 265:12 305:16 311:6 processes 104:8

127:18 236:13 produce 30:16 productive 24:2 298:7 professor 18:5 progesterone 48:7 63:14 65:18 70:11 program 5:10 6:11 14:8 16:7 17:17 21:16 28:3 30:19 32:14 33:11 40:6,6 42:21 45:11 55:5 72:11 84:15 88:5 98:9 121:20 122:8 123:2,3,4,6 156:3,9 157:4 181:17 197:16 221:19 222:15 232:1 232:11 284:12,16 286:10 289:16 programming 204:2 programs 6:15 17:18 37:13,13 39:17 44:10 71:4 82:21,22 109:13 122:22 123:16 140:18 202:9 204:10 232:9 251:20 256:18 268:1 Progress 4:19 project 2:18,21,22 5:6 20:15,18,21 77:16 90:12 115:3 142:7 210:20 211:7 310:3,7 310:10 projects 108:20 promote 73:15 192:15 251:17 promoting 23:3 225:6 243:16 264:6 properly 149:20 properties 122:13 proportion 230:18 proposal 226:5 propose 131:17 224:20 233:17 246:22 proposed 193:18 229:22 proposing 34:14 131:15 pros 201:22 proud 312:20 proven 215:18 provide 21:22 33:3 36:9 121:22 123:15 171:10 197:21 209:9 213:9 231:1 237:3 268:5 269:8 310:15 provided 24:14,20 46:22 90:1 116:5 201:7 209:14 provider 29:3 32:21 84:9 134:12 143:7,7

199:5 233:12 275:10 275:14 300:17 provider's 200:19 providers 7:9 53:13 79:22 80:1 88:8,16,18 171:10 197:10,11 221:3 provides 207:9 providing 47:3 80:4,19 112:9 126:18 provocative 293:7 proxy 69:3 119:1 143:3 286:13 pruning 312:14 pseudo-quality 57:15 Psychiatric 18:12 psychiatrist 275:4 281:15 Psychiatry 18:5 psychosis 281:15,16 psychosocial 27:10 **public** 4:12,14,15,18 8:14,16,18 14:2 59:1 61:16 66:17 78:17 119:6 121:19 163:14 173:6 177:21.22 178:6 179:6,9,16 247:17,22 248:3,6 251:19 260:14,16,18 260:21 282:19 308:10 308:12,14,18 309:1,5 309:8,17 publicly 232:16 pull 59:12 113:22 117:3 166:14 192:21 253:4 274:3 275:16 292:7 297:3 303:3,22 304:4 pulling 51:18 52:11 167:12 201:18 276:13 279:12 Pulmonary 250:7 purchasing 43:3 79:12 146:21 281:13 purple 45:5 purpose 29:16 189:20 purposefully 124:21 purposes 154:1 189:22 192:18 222:13 pursue 101:6 pursued 168:16 purview 221:14 push 137:19 pushed 193:7,8 pushing 129:22 137:6 235:2 241:7 put 8:16 23:18 30:14 46:5 59:11 75:9 82:4 107:7 126:20 133:18

144:8 148:9 157:6 187:14 188:21 194:18 198:21 223:5,8 224:5 224:18 234:18 237:19 244:8 246:12 261:6 263:3,5 264:4 279:16 283:3 287:8 291:7 300:6 301:4 303:11 puts 265:17 putting 86:8 234:17 244:3 Q QI 97:20 267:5 296:14 297:19 quality 1:1,8 2:11 3:7 3:13 6:10 7:2 11:19 12:10 13:17,18,22 14:3,7 16:16 17:20 18:6 19:11,14 20:12 30:4,15,16 32:7,10,13 32:18 33:8.12 36:1 40:5 41:1 46:21 47:9 57:15 63:19 77:15 85:12 88:9 89:7 101:7 112:14 122:3,16 142:12,14 143:19 181:16,21 186:13 196:7 222:12 225:2 230:2 232:11.12.16 240:7,9 251:20 257:5 263:13 272:10,12 273:16 278:18 284:14 285:18 286:18 287:7 297:6 301:6 quantity 143:19 quarterly 66:16 question 58:7 68:2,6 75:1 78:8 83:5 85:22 98:13 101:21 103:13 107:12 108:17 125:2 126:13 128:2 133:11 133:15 141:3 142:17 143:1 151:14 152:15 153:7 174:1 179:12 185:3,3 187:4 189:19 199:20 200:8 204:6 205:9,13 207:21 210:4,19 214:16 222:20 224:1 235:8 235:14 238:19 240:13 265:4 276:7 278:13 291:3 298:3 301:12 302:2 questioning 166:20 questions 36:5 39:6,7 39:10,14 41:8 63:15 67:9,16,17 74:8 76:10

99:3 119:12 120:20 139:13 181:12 201:4 211:3 234:5,16 242:5 248:18 261:10 269:13 271:8 272:2 292:20 293:7 queue 157:22 288:7 293:6 quick 8:2 102:2 103:13 115:2 141:3,3 195:3 221:11 252:10 307:5 quickly 20:9 136:18 137:3 175:21 248:17 quirks 107:3 quite 24:2 31:15 34:2 61:15 79:13 85:3,7 129:9 146:8 177:12 187:22 201:8 232:9 283:5 quorum 150:16 151:4,4 151:11 182:18 quote 286:4 R **R** 5:1 race 60:12,14,15 265:8 293:12 303:1 Rachel 1:21 11:13 24:6 125:14 131:14 168:10 190:17 237:20 244:14 285:14 288:6,8 292:2 293:9 302:17 racial 60:18 282:17.21 283:10 290:6 racism 70:17 raise 144:8 148:11 161:16 165:10 246:8 277:6 raised 127:20 148:7 232:20 284:1 raising 194:4 242:5 ran 72:20 129:17 random 64:22 288:3 Raney 3:16 19:10,11 30:21 31:2,5 40:1 range 209:14 232:5 ranges 38:6,7,9 44:19 rank 262:5,15,21 263:7 ranking 66:15 262:18 264:7 ranks 264:8 rapid 160:10 164:16 ratchet 134:11 rate 25:3 45:20,22 57:3 68:15 80:8 92:17 93:11,18,21 94:7 106:4 111:7 120:2 126:10 131:1,7 138:7

153:13 206:22.22 207:2,15 219:2 239:6 249:22 250:17 279:8 288:13 rates 36:22 37:2 47:21 48:4 64:14 69:14 95:16 99:13 103:8 106:2 126:13 155:18 205:19 218:10 231:1 234:9 236:19 256:3 289:1 290:4 rating 204:16 ratio 251:11 252:3 254:6 256:21 258:2 259:4 264:17 rationale 189:6 raw 207:15 **RD** 2:11 re-echo 211:10 reach 120:10 250:16 310:4 react 297:7 reaction 218:22 reactive 296:8 read 48:16 61:15 123:1 123:21 171:19 175:16 232:10 256:15 readily 263:16 reading 154:21 174:2 reads 154:22 ready 41:11 163:22 176:15 221:9 222:15 258:18 293:3 real 20:4 64:18,19,21 79:5 143:11 154:15 188:3 195:12 197:19 203:6,9 208:16 243:17,21 262:12 306:22 reality 146:1 266:10 realize 42:10 70:20 133:11,20 realized 64:3 70:11 realizing 42:20 103:7 146:5 283:12 realm 88:19 reason 49:16 78:2 95:7 117:4 151:3,5 189:18 190:9 200:22 233:15 236:4 274:7 reasonably 122:15 reasoning 188:11,17 reasons 25:2 46:3 49:1 49:17 77:8 80:2 92:15 118:14,17 123:9,20 175:1,8,15 183:22 200:16 244:9 245:22 249:16 250:1,6 257:9

278:2 279:7 reassurance 233:4 Rebecca 165:18 170:13 recall 189:2,9 191:16 recap 23:16 received 22:8 25:11,13 207:3 265:10 receiving 289:6 reception 8:8 receptivity 297:16 recipients 270:13 recitation 17:11 recognition 82:21 287:19 recognize 41:17 107:8 129:22 196:16 197:3 recognized 122:18 187:19 recommend 119:5 120:16 148:14 176:3 176:6 184:10,15,21 196:13,13 198:18 258:15 261:9 recommendation 120:16 131:10,13 133:5 135:21.22 136:1,17 139:7 161:13 163:11 178:21 192:14 193:8 220:1,5 228:17 252:16 291:5 recommendations 4:17 10:21 21:12 26:20 35:1,2,8,9,10,12,16 178:16 185:19 187:5 228:14 262:14.16 recommended 24:19 24:22 25:9 26:3,6,14 115:12 116:7,8,17 117:13,15 152:17 158:19 179:4 184:3,5 185:5 186:19 193:3 193:22 230:11 249:8 250:21 254:16 255:9 277:22 recommending 34:11 145:10 161:12 185:2 reconsider 230:13 reconsideration 194:4 reconsidered 132:22 194:2 **reconvene** 109:8,19 record 102:20 106:8 110:4 129:15 179:21 195:18,18 210:5 226:1 241:6 243:7 264:12 313:15 records 51:18 174:5 175:3

Neal R. Gross and Co., Inc.

recover 212:10 recreating 83:14 **red** 48:16 57:1,13 68:4 127.22 redo 151:14 reduce 25:9 60:5 253:19 reduced 231:16 294:14 307:3 reduces 231:11 reducing 26:1 reexamination 26:17 refer 16:21 173:19 reference 22:10 69:22 115:2 122:6 referenced 58:14 88:20 206:18 referral 301:2 referring 113:21 reflect 41:3 78:10 99:16 **reflected** 95:12 286:15 reflecting 112:8 266:2 reform 46:1 reforms 97:22 refresher 5:13 regard 24:17 222:4 300:17 regarding 117:18 regardless 169:19 regards 220:19 region 297:17 303:1 regular 24:9 30:14 reimbursement 96:20 98:1.17 reinforce 192:14 285:15 reinforces 287:20 reiterate 247:6 relate 154:6 279:9 related 7:11 17:8 22:1 24:18 47:7 77:22 85:21 91:15 92:6 93:15 98:13 168:5 182:13 252:2 281:9 relates 65:10 130:8 153:16 293:9 relation 252:12 relationship 9:15 81:4 91:5 relationships 300:22 relative 28:18 65:7 66:14 275:17 relatively 125:21 201:12 relevance 22:4 23:21 relevant 28:10 77:9 112:12,21 194:20 230:18

**reliable** 244:12 reliably 44:1 48:6 religious 211:20 reluctant 136:9 rely 62:6 292:4 remain 249:13 remarkable 310:14 remarks 4:2 5:8 9:2 **remember** 125:12 141:11,13 143:11 179:3 190:1 191:15 191:15 202:15 220:14 remembering 191:18 remind 29:15 119:18 175:9 234:2 312:1 **reminder** 104:22 179:11 183:10 194:11 222:4 reminding 95:19 remote 14:15 **removal** 23:1 24:19,22 25:9 34:13,14 37:1 123:10,11,20 127:3 130:19 131:11 136:1 136:2,6 137:10,14,16 138:16 148:14 152:17 152:22 157:7 159:9 160:7 162:20 163:9 164:2 165:8 167:5 180:4 259:21 261:3,9 **remove** 124:2 131:16 134:22 135:1,6 136:9 147:18 150:1,17 159:16 160:9 161:1 161:18 164:19 165:3 172:11,11 176:3,20 177:2 251:7 261:15 262:1 removed 6:15,16 7:1 118:3 119:9 120:18 125:12 164:15,16 176:19 250:6,19,22 251:1 261:18,20 removes 251:8 removing 125:9 127:9 136:14 159:15 161:10 Renee 40:7 reorganized 78:11 reorganizing 63:16 78:6 repeat 118:7 152:15 repeatedly 138:20 replace 137:3 162:22 replacement 126:21 158:20 159:20 160:10 164:16 replacements 127:6 253:1

replacing 136:18 **report** 4:16 30:14,15,16 42:10 56:7 76:14,16 77:14 90:3 106:21 125:22 133:8 137:15 148:12 163:13 174:22 175:6,16 188:14 196:5 197:20 200:3 211:6 218:13 231:10 234:19 237:21 238:14 241:2 244:20 249:15 249:21 265:22 266:17 269:16 276:20 284:3 293:14 304:10 309:18 reported 28:22 29:21 36:1 92:7,12,19 111:4 118:8,10,11,12,14 119:18,20 120:4 165:17 170:15 174:19 174:20,21 182:2 189:8 205:4 232:16 238:3 241:5 245:5 250:2 288:20 reporting 14:2 22:7 23:12 25:3,5,10 29:19 32:14,16,20,22 34:15 34:16 35:22 36:6,10 36:22 37:2,18 38:1,3 38:7,19 40:6 42:19 47:3,5 50:14 51:14 55:11,14,18 56:20 76:18 86:4 92:13 93:2 93:5,8 118:7 121:19 123:14 125:18 168:17 169:2 174:17 175:4 179:6 198:2 202:7 232:11 234:20 240:10 241:21 246:18 251:19 252:8,9 267:1,2 288:22 293:11 302:11 reporting's 42:19 reports 309:21 Repository 117:1 represent 11:21 255:14 274:17 representatives 277:15 310:21 representing 11:4 12:2 12:7,18,22 13:7 14:5 14:16 15:8,11 16:13 17:3 18:22 reproductive 28:11 45:2 54:15 59:21 61:12 71:16 90:8 97:7 115:14,19 120:9 127:12 143:12 178:15 195:5,7,11 197:10 210:6 216:22 221:3

reps 151:2 request 68:22 175:22 requesting 36:13 require 60:16 287:21 required 25:5 76:1 175:6 222:9 249:17 requirement 64:5 131:19 requirements 35:17 46:5 83:11,18 84:5 85:7 104:7 123:4 143:17 requires 275:13 299:1 requiring 289:3 rescue 256:22 258:8 **research** 18:7,9,13 researcher 287:1 resident 254:21 resides 109:5 resource 139:22 303:7 resources 14:5 39:1 46:22 47:4 182:1,13 289:8 295:7 297:22 303:6 respect 148:11 151:11 165:5 213:16 276:18 respectful 248:12 respecting 208:14 respective 108:14 respiratory 231:13 respond 175:22 237:10 301:8 respondents 247:14 response 138:10 148:20 159:4 163:19 176:14 178:5 179:13 247:1 248:2,7 258:13 258:16 260:20 261:11 288:4 308:16 309:4,7 responses 223:12 287:22 293:3 298:8,9 responsibilities 83:8 85:19 responsibility 275:8 **responsible** 14:2 24:12 63:7,8,10 84:19 275:3 275:6 287:13 responsive 84:3 123:3 rest 22:3 55:21 60:22 72:7 199:10 265:13 291:8 resting 175:5 restriction 130:2 restrooms 8:5 resubmission 186:10 result 116:5 274:13 resulted 76:3 results 6:2 71:10

150:16 195:3 213:17 254:7 264:1,15 268:22 resumed 110:4 264:12 resuscitate 42:1 retaining 126:6 161:12 retesting 129:11 retired 145:4 returning 114:10 revamped 63:21 64:2 revenues 86:4 reverse 312:9 review 22:21 112:12 113:7 121:13 127:21 175:5 181:10 204:13 231:11 276:18,18 reviewed 118:19 121:12 180:9 195:3 210:21 211:7 250:15 255:8 reviewing 21:8 36:21 revision 161:13,14 revisit 191:21 192:13 Rich 5:21 9:2,4 16:22 17:22 20:7 21:2 31:8 32:1 123:22 124:18 163:5 223:20 226:2 265:19 269:14 270:8 286:21 311:14 **Richard** 1:9,12 Richardson 2:3 14:18 14:19 15:5 147:17,20 158:11,17 171:19 224:7 242:3 rid 55:8 130:1 ride 62:16 rides 199:13 **riff** 301:13 right-hand 74:9 **rigorous** 7:14 101:15 ringing 188:22 **risk** 46:18 48:5 49:3 81:6 83:18 84:22 86:18 92:14 165:11 176:18 187:18 201:9 202:17 203:11 207:9 207:10 208:2,22 209:6 210:9 212:8,11 212:19,19 214:3 215:19 231:11,16 241:10 269:6,18 271:4 290:2 risks 203:4 **RN** 1:20 road 282:3 Roanne 2:2 12:2 210:18 214:19 217:1,2 Robinson 87:6

robust 32:4 148:4 164:3 190:12 271:21 role 138:20 186:14 194:9 269:20 295:11 roles 26:12 83:8 85:19 roll 228:1 rolled 293:19 rolling 64:8 79:7 rolls 77:8 228:2 room 1:8 10:16 36:17 87:19 152:4 178:8 190:6 247:19 248:6 278:11 291:7 309:6 312:6,14 rooms 83:15 298:20 **Ross** 2:4 12:20,20 74:7 74:22 285:15 round 143:21 243:2,3 rounds 141:11 230:3 **RPh** 2:6 rulemaking 222:9 rules 121:21 run 62:18 149:14 187:11 289:9 303:2 running 9:17 288:15 rural 1:16 12:7 28:15 79:17.19 80:14.18 81:2 98:14 236:17 273:1 290:5 294:15 295:1 rurality 294:11 ruthless 82:10 S **S** 5:1 sadly 61:12 safe 65:18 71:6 safety 11:21 16:17 51:7 Sakala 2:5 15:10,11 87:20 119:11 120:22 127:11,14 134:2 139:18 140:8 141:10 148:13 153:19 165:10 167:16,20 170:21 176:2 193:11,20 199:19 204:19 227:21 228:19 229:12,20,22 239:7 sake 10:10 30:6 42:20 148:6 167:11 174:13 234:4 271:6 SAMHSA 13:18 284:11 satisfaction 62:10 satisfactorily 169:16 satisfy 162:22 save 10:14 64:20 141:16 178:10 179:2 saved 5:16

saving 58:22 saw 116:22 119:16 120:3 166:1 254:3 312:21 saying 63:7 66:5 107:21 136:8 137:3 137:13 153:21 163:1 165:20 172:1 208:4 218:21 219:11 244:3 295:16 says 80:9 116:19 196:21 221:15 279:18 scale 65:18 97:4 scene 41:20 schedule 31:22 119:3 265:17 scheduled 177:11 schedules 31:21 schizophrenia 275:5,7 295:19 Schlaifer 2:6 12:16,17 133:10 134:19 135:8 185:1 256:6,12 257:14 school 58:10.14 62:5 71:19 86:16 science 64:22 70:9 scientific 2:17 122:13 scientifically 7:14 scorecard 66:12 70:14 scores 105:4 290:2 scrambling 297:20 screen 97:4 174:16 261:6 268:19 307:7 307:10.16 309:15 screening 110:22 111:13 128:11,13 129:12 169:13,14,14 169:15,16,17 172:13 267:17,17,18 283:22 screenings 171:7 screens 60:4 167:10 Scroll 116:4 Sean 230:3 search 248:20 seating 124:9 seats 180:3 second 26:5 27:19 75:1 135:7,8 144:19 148:2 157:16 160:15,17 176:10,11 192:19 193:14,16 255:4 286:6 292:19 seconded 135:19 seconds 147:22 308:21 **Secretary** 1:13 19:4 section 32:11 260:15 267:2

sector 43:9 security 297:4 seeing 126:12,14 127:21 150:9,12 261:13 290:1 294:2 294:13 seen 6:13 62:11 102:18 102:21 129:7 147:2 154:6 169:20 174:13 201:16 256:16 segment 122:15 274:4 276:9 segmentation 267:4 299:21 301:10 segmented 274:1 292:17 segments 106:21 272:22 segue 111:21 select 30:8 176:20 selected 177:2 selection 121:11,15 122:1,3,6,9 180:8 self- 76:5 SEM 56:17 send 7:2.8.16 263:7 sending 203:22 295:5 senior 2:18,20,22 5:4 12:3 14:20 16:16 20:2 20:21 142:7 210:20 sense 26:8 49:7 69:19 99:22 133:13 145:9 192:21 219:15 227:3 238:14 255:17 266:10 272:10 283:19 285:5 312:18 sensitive 105:3 sent 113:17 114:1 175:10,12 250:3 251:4 sentiment 173:4 241:13 sentinel 274:18 separate 68:7 73:3 75:5 97:1 102:21 147:12 190:1 276:10,11,14 279:12 302:7,15 303:10 304:4 310:9 separated 50:19 191:10 294:18 307:4 separately 74:16 105:10 124:7 133:12 190:7 193:10 252:18 series 89:11 94:5 serious 278:19 285:22 302:1 305:5 seriously 279:1 280:1 serve 13:10 14:8 16:6 33:7 42:16 78:14

served 197:8 service 77:11 78:16 79:11 81:22 86:12 103:11 134:12 171:9 171:11 services 2:9,12,13 3:12 3:15,17 14:1,6 17:16 19:4,13 26:7,9 27:10 27:14,20,21 42:21 44:6,12 74:19 80:5,20 101:1 123:6 130:9 140:13 195:11 206:12 207:3 209:14 213:10 216:22 237:4 263:14 264:18 275:20 281:11 286:2,4 294:6 295:1 298:17 Session 4:5 sets 4:11,17 6:7,16 21:12,13 23:13 29:17 33:4,10 34:8 37:9,15 37:17 38:19 41:2 46:7 47:18 96:13 111:1.5 111:11 112:13 121:19 126:3 194:1,20 211:9 253:13 266:1 267:14 268:7,18 310:2 setting 48:8 188:5 251:3 276:1 279:18 settings 47:14 50:6 188:7 settles 18:17 seven 72:1 96:12 181:10 182:21 248:22 249:1 264:18.20 seventh 28:19,21 43:13 Seventy-five 165:1 severe 231:13 273:20 274:8 275:2 276:14 287:3,3,4,5,10,10,12 severity 283:13 286:14 Shaconna 2:18 20:21 110:15 169:8,11 174:13 177:8 225:14 254:17 Shantanu 2:15 5:7,10 share 22:17 92:22 103:1 109:6 117:17 140:11,21 169:1,4 174:14 185:14 232:21 275:10 301:1 303:4 shared 4:10,13 22:4 23:7 110:17,19 111:10 113:3,5 124:6 175:8 268:19 275:12 **shareholder** 15:6 16:2 SharePoint 114:3 310:6 sharing 301:5,6

Shawn 170:2.7 she'll 19:16 **sheet** 113:18 shifted 43:3 shifting 281:10 ship 311:19 shoes 31:7 shout 311:12 **show** 44:15 45:15,18 49:3 50:7,17 51:12,22 61:1,19 62:5,8 64:11 66:2 68:16,19 71:3 74:20 86:16 101:12 103:12 107:7 146:10 154:11 231:2 showed 70:16 78:21 278:17 showing 57:4 shown 56:22 shrieking 281:7,7 side 21:7,9 60:2 84:1 92:1 107:18 116:9 125:3,7 140:6 166:20 167:4 184:10 191:16 193:15,18 200:19 220:18 223:4 259:18 268:1.3 295:15.17 296:4 297:6,13 306:5 sides 190:6 221:10 **SIDS** 231:15 sign 9:14 signal 132:20 signed 8:9 significant 95:19 231:2 significantly 143:17 signifies 19:22 silo 288:1 silos 273:6 294:5 similar 66:13 69:5 139:11 208:3 245:4 307:7 similarities 251:12 312:7 simple 76:10 132:10 278:6,6 303:3 313:3 simpler 256:2 **simply** 11:3 51:16 71:2 83:16 85:5 86:5 Simultaneous 304:22 311:22 single 49:9 55:13 111:6 213:13 236:20 296:8 sink 171:21 172:9 sit 17:3,3 43:11 312:6 site 310:6 sites 94:9 sitting 5:12 119:11 127:18 128:3 297:20

312:14 situation 160:21 six 32:3 35:2 96:12,12 113:1 129:19 147:2 154:11 233:9 281:13 306:7 Sixteen 249:15 sixth 28:19,20 size 72:1,2 288:14 skipped 19:8 sleep 65:18 **slice** 126:12 278:9 282:5 slicing 280:14 297:5 306:9 **slide** 22:9,9,12 23:5,9 29:15 30:11 31:3 32:6 32:13,14 35:19 36:12 36:14 37:6 38:22 43:12 44:19 53:6 67:20 74:8 76:18 87:16 88:12 90:19 92:5,17,22 93:7,9 94:4 95:9 96:1 97:11 110:16 111:10.17 112:18 113:6 117:10 117:21 118:4,5,16,16 119:15,16,17,22 120:1,6,7 123:1,9 137:11,21 181:7 184:1 185:18 186:20 189:11 248:19 249:3 249:6,10,10 250:5,5 251:1,21 271:7 308:10 310:8 slides 30:22 43:10 166:1 183:11 269:1 slight 107:2 slightly 10:15 17:2 94:19 small 90:1 95:18 103:4 282:7 285:5,10 296:15 smart 59:7 **SME** 16:20 SMI 283:17,20 289:13 289:15 290:9,10,16 291:14,20 298:11 303:3,11 304:5 306:20 Smith 2:13 13:20,21 204:6 205:9,11 smoke 173:10 snapshot 43:12 44:18 **SNF** 54:22 snowstorm 80:10 **so-** 299:15 social 27:10,18 58:14

68:10 69:1,11,18 71:14 82:3 86:18,21 105:4 173:2 269:20 274:12 294:6 solicit 157:18 solidified 64:1 **solve** 64:9 solved 152:12 **solving** 102:6 somebody 49:12 99:15 108:10 145:12 150:21 159:6 162:18 200:20 235:14 259:15 272:4 somebody's 145:20 159:17 219:1 somewhat 39:18 108:5 136:9 222:6 son 13:4 soon 18:16 19:16 sorry 11:13 18:20 73:9 138:3 141:10 142:16 150:18 153:1 157:14 158:17 167:16 181:13 209:16 224:14 234:15 239:21 254:16 261:1 305:8 sort 5:22 8:20 21:3 23:18 25:12 26:12 27:2,5 28:12 29:12,15 30:1,12 34:21 39:21 53:19 68:4 78:13 82:12,13 83:1 85:21 94:16,19 95:11 96:22 97:13 99:20 103:15 108:1 109:4 110:7.15 136:2,5 138:15 157:1 172:1 187:15 193:19 204:5 234:12 235:2 252:20 264:6,6,7 266:1,21 267:1,2,4,10 267:11,18 268:5,6,9 268:10,13,16,19,21 269:7,19,22 270:3,4,5 270:19 271:8 272:8,9 272:14,15,16 274:17 276:17,19,21 277:6 279:12 284:2 292:13 292:16 295:8 299:21 300:7,11 301:7,9 308:4,6 310:14,16 sorting 201:14 sorts 75:21 135:16 198:17 sound 158:5 177:18 **sounding** 148:14 sounds 106:9 135:1 136:8 292:3 source 166:1 174:4

238:7 252:7 sourcing 29:22 **space** 79:19 80:14 266:14 278:21 297:19 **spaces** 41:2 296:11 **Spacing** 212:8 speak 8:10 30:21 40:7 41:13 73:7 160:15 194:7 278:14 speaking 243:11 258:12,14 304:22 311:22 spec 154:21,22 156:19 292:4 **special** 43:22 74:15 75:6 213:18 278:22 311:12 specialist 13:9 77:17 specialty 284:6 289:15 290:10,12 **specific** 24:16,18 110:11 119:12 123:3 136:2 216:21 277:17 290:7,20 292:17 specifically 10:17 23:19 25:19 43:9 58:19 63:17 70:2 74:11 75:18 85:12 190:22 198:20 217:11 245:6 255:17 282:17 282:22 291:13 301:21 specification 226:6 specifications 33:14 90:10 115:22 116:1 141:13 154:5 198:7 253:4 specified 128:10 139:2 189:6 210:1 specify 183:13,19 specifying 282:11 specs 46:13 77:7 116:3 132:5 169:22 171:20 174:17 192:21 spectrum 23:11,22 speedometer 42:13 spend 236:22 spending 85:1 spent 10:3 103:6 133:16 sphere 97:15 219:20 spina 287:5 split 111:7 153:13 156:20 SPMI 281:8 306:1 spoke 117:11 sponsored 196:7 spot 75:12 148:10 157:22 188:2

**spread** 303:4 spreadsheet 117:1,3 228:20 **SSM-St** 13:9 St 1:14 13:10 14:13 staff 2:14 6:9 9:11 20:2 20:9 22:11 85:6 113:7 163:12 166:14 167:12 174:11 175:20 227:4 230:5 251:2 269:15 310:4,13,18 311:9,15 staff's 170:9 staffed 142:4 staffing 141:11 stakeholder 35:11 75:20 stakeholders 30:17 31:14 33:5 40:16 282:5 stand 8:11 302:14 standard 57:5 96:7,14 106:9 233:9 289:19 307:12,17 standardize 52:13 53:14 standardized 48:9 67:1 standards 13:22 96:10 96:13 standing 112:9 210:20 229:13 232:22 250:8 277:4 279:13 standpoint 171:14 star 178:3 179:12 247:22 260:19 308:14 309:1 start 11:5 20:10 79:5 94:9 97:17 108:19 117:5 149:6 151:12 177:14 187:21 246:8 268:12 270:9 272:5 278:21 283:9 297:17 297:19 303:16 started 5:9 8:2 21:3 70:15 180:1 181:5 238:12 267:10 268:15 289:5,20 starting 74:17 279:10 state 3:8 18:10 21:20 22:2 29:21 30:7 32:19 33:1 38:3,18 43:14 49:21 50:12 55:13 60:20,22 69:9 73:17 75:2 76:19 80:7 87:13 88:6,7,16 92:16 96:8 98:15 99:14 100:6 101:2 103:2 106:3,4,6 108:12 109:13,15,22 123:15 125:18 165:19

180:11 182:16 183:7 187:8 198:14 201:3 204:12 208:13,13 213:8 217:6 222:11 224:22 229:4 235:9 235:18 238:10 240:8 240:14 241:19 245:10 253:21 257:20 258:8 269:10 271:19 277:15 278:3,11 287:15,15 287:16 288:1 291:6 293:2,13,15,16,20 297:17 299:13 302:10 303:21 304:7,14,19 312:22 state's 23:12 101:3 215:5 State-collected 249:18 state-specific 76:21 stated 137:10 142:15 statement 107:14 144:7 146:2 147:11 states' 4:16 21:11 265:22 **statewide** 288:13 statistics 13:18 79:22 244:17 stats 130:11 235:19 236:1 240:18,19 241:3 status 57:4 244:21 273:3 304:15 statute 38:18 stay 118:5 178:20 staying 124:19 stays 83:21 306:6 **steep** 197:9 stem 140:19 step 8:7 109:11 248:11 262:11 stepped 81:10 276:7 stepping 67:10 295:10 steps 139:5 309:12 steroid 91:18 steroids 25:1 47:8,11 48:7 92:20 245:3 267:16 steward 183:21 186:11 205:1 steward's 186:16 stick 55:7 sticking 32:2 stigma 298:13 stole 253:8 **stood** 169:22 stop 80:4 107:17 109:17 113:15 120:19 145:14 146:3 248:17

stopping 80:19 straight 8:5 41:10 53:17 148:15 strategic 21:14 124:9 267:1 272:2 strategically 21:18 124:21 266:15 strategies 88:11,13,14 strategy 90:17 212:9 219:6 252:14 300:18 stratification 252:2 267:4 269:3,17 270:9 270:11,14,16,22 271:4 278:4 279:2 280:11 282:12,14 289:14 293:10 295:9 298:1 302:17 305:15 stratifications 280:4 stratified 278:17 279:13 289:7 305:22 stratify 278:18 288:18 302:4,15 304:1,11,16 stratifying 269:5 291:19 stream 67:1 streams 61:6 Street 1:9 Strengthen 4:17 strengthening 21:13,15 89:6 266:1 strengths 122:7 stripe 45:4 59:20,22 stripes 61:5 strong 97:17 127:21 136:17 139:7 146:2 147:11 230:7 strongly 202:16 245:17 264:6 279:11 struck 42:5 structural 76:3 82:13 structure 23:5 46:5 97:1 structuring 85:12 struggle 143:11 struggling 200:9 stuck 226:20 studies 231:18 study 250:9 stuff 28:1 59:17 68:20 82:18 108:15 146:3 204:5 subcriteria 182:7 subject 2:8 10:13 16:20 17:2,8 240:9 submit 175:7 223:12 249:18 302:10 **submitted** 100:10 206:15 255:13 309:21

submitting 101:9 subsequent 89:21 241:10 subset 189:17 191:1 substance 2:12 103:19 172:3 286:1 substantive 139:8 success 233:17 successful 246:2 Sue 1:19 13:6 67:12,13 102:1 135:4 137:1 191:13 214:19 220:11 suffers 274:10 suggest 47:16 65:8,19 84:14 145:15,19 167:4 236:4 252:20 291:18 302:4 suggesting 228:21 suggestion 303:17 suggestions 127:4 166:11 suicidality 307:20 suicide 307:6,10,16 suicides 103:19 **suitability** 178:18,20 suitable 162:21 179:6 Suma 2:11 14:4 summarize 4:19 136:7 226:2 summarized 127:15 summarizes 29:6 summarizing 138:22 summary 248:19 252:11 summit 278:16 super 282:4 super-high 215:19 super-important 215:18 superimpose 296:1 superior 123:16 supplementary 175:10 support 11:19 24:21 25:12,13,15 27:20 28:20 36:5,9 98:9 100:20 108:22 109:15 121:5 129:14 132:18 132:18,19 137:5 171:12 181:22 183:4 183:7,13,22 188:14 194:12 223:1,2,2,6,7 223:10,10,14,20 227:14,15,16,20 228:7,8,9,10 230:4,6 231:1,2 236:22 237:4 243:4 246:10,12 247:12,12,15 257:20 258:9 259:5,5,6,7,8

259:11 260:4,5,12 261:8 263:2,2 289:4 supported 18:14 28:5,7 132:17 196:2 230:1 232:2 233:2 236:15 237:6 263:11 supporting 4:16 22:6,8 23:11 40:19 46:3 109:10 183:2,3 199:1 258:15 265:22 supports 44:12,17 88:7 192:5 286:2 suppose 41:16 200:18 282:11 supposed 53:2,8 208:14 surprise 280:14 surprised 81:1 surprisingly 86:2 surrogate 39:11 192:6 survey 209:4,7 213:1 surveys 212:22 213:2 survive 215:22 Suzanne 2:22 142:3,7 211:1 229:2,3,9 Suzanne's 143:16 SVP 15:21 sweated 35:6 Sweep 71:7 synergy 108:1 synthesize 269:15 system 19:5 43:20,21 43:22 49:5,15 55:9 56:4 70:20 72:18 83:1 86:21 103:11 129:18 146:5 154:9,16 171:3 173:2 213:9 229:9,11 244:7 281:4 295:3,14 295:17 296:3,9 297:13 306:13 systematic 127:21 231:11 systematically 306:11 systemic 211:15 systems 37:19 49:7 63:2 65:16 75:3 104:3 129:3 288:2 т TA 77:14 tab 113:20 116:19 table 11:5 59:11 119:12 135:19 148:18 217:4 232:22 tacking 303:16 tactical 266:16

takes 34:5 99:16 117:2 240:22 256:20 talk 36:15 43:7,8,18 50:4 51:4 58:10 73:17 83:16 88:13,17 113:15 121:10 124:2 127:7 177:7 209:2 252:17 256:13 267:8 269:19 275:14 278:20 283:9 299:6 talked 67:17,18 89:12 93:22 96:1 103:14 110:17 117:22 272:7 294:3,22 305:17 talking 5:12 9:17 32:18 32:19,21 46:7 66:20 69:10 82:18 147:20 159:6 178:12 222:8 229:8 260:9 271:14 277:18 294:19 304:18 talks 198:8 206:19 226:8 308:10 Tallahassee 11:16 target 52:8 251:17 252:6 305:21 targeted 74:10 285:21 286:10 targets 64:19 task 1:3,8 4:3,4,5 9:8,9 10:4,4,6,16 15:1 20:19.22 23:6 67:9 99:4 110:1,10 112:11 114:6,7,8,9 115:12,15 115:16,17 116:9,13 116:16 117:16 121:13 124:4,10,11,14 130:18 131:2,8,10,11 137:17 149:13 151:17 152:17,21 164:7 165:7 175:14 177:5 180:18,19 181:5 182:19,19 184:6,9,13 184:20 185:5,10,12 185:19 222:5 223:11 224:4 227:8 228:14 230:10 247:13 249:8 250:21 251:7 259:3 259:19 261:4,6,17 262:5 265:11 266:21 272:4,8 309:13,14 311:3,10 312:2,5,8 313:12 team 142:8 225:14 271:1 team-based 83:18 tease 241:15 tech 95:18 technical 3:11 36:3

55:16 89:6 151:9 technically 172:7 tee 164:7 298:3 teed 296:13 teeing 262:4 teen 217:20 teenagers 62:6 213:12 217:11 teens 217:11 teleconference 3:21 telephone 308:15 tell 31:5 62:4 64:6,12 65:13,20 78:18 96:7 99:11 133:14 134:7 139:22 145:5 153:10 214:7 219:1 225:21 236:20 241:17 243:6 249:12 283:13 telling 5:12 31:15 tells 145:5 146:11 154:15 213:6 temporarily 139:5,6 ten 41:14 94:4,8 95:11 96:6,11,11 97:13 156:15 213:5 216:9 233:2 236:6 268:8 tend 255:20 272:11 tends 75:5 tenet 43:20 tension 103:22 128:4 239:13 tent 8:11 term 44:16 59:11 82:10 226:10 241:11 242:12 251:18 255:3 296:6 terms 18:8 25:18 26:8 27:6 28:1,9,20 29:9 30:14 32:6 38:5 39:19 73:14 82:8,22 92:15 94:20 100:14 127:5 139:6 143:6 174:7 189:14 198:1,5 204:4 205:6 207:4,12 208:21 212:21 235:15 270:20 271:4 272:20 273:5,18 274:13,18 274:22 277:10 298:10 298:16 300:20 301:5 308:3 310:18,19 terrible 57:4 106:3 305:14 Terrific 82:6 Terry 1:13 18:16,20 73:21 141:1 243:10 245:17 253:6 test 52:16 77:12 108:22 137:21 149:13 152:14 tested 205:3

Neal R. Gross and Co., Inc. Washington DC

taken 62:17 71:11

216:7,10

testing 165:14 206:14 267:20 281:20 308:4 tests 94:11 thank 5:11,21 6:2 7:9 7:19 8:1 10:2 16:9 17:13 18:15 19:17,18 39:8,11,11 41:13 67:6 67:7,10,15 74:7 76:9 87:4 99:2,7 102:3 109:16,21,21,22 111:20 134:2,15 149:11 164:21 166:9 168:9,18,18 172:15 175:19 177:4 179:17 199:22 204:3,19 228:3 233:21 234:1 237:8 238:17 239:21 242:1,3 246:6 248:5 266:5 288:5 301:11 305:7 310:13,17 311:2,6,9,11,12,14,16 311:20 312:11 313:11 313:13 thanking 266:8 thanks 5:17 16:18,19 31:2 119:13 144:4 175:20 179:7 312:8 313:2.6 Theberge 2:22 142:6,7 142:22 211:2 229:10 theirs 63:22 theme 132:1 themes 73:15 **Therapy** 251:10 They'd 156:19 things 20:4 24:17 31:15 34:19 37:6,20 38:12 38:17 42:6,10 48:9 52:13 54:4 55:4 68:17 69:3,7 72:22 82:4 84:7,9,12 87:1 89:20 93:18 95:21 96:18,20 98:5,12 102:14 104:12 106:11 107:22 126:3 128:14 140:1 146:15 158:14,18 171:15 172:20 173:11 173:17 181:14 183:14 185:5,6 186:22 187:3 187:13 197:14 198:17 199:14 202:1 206:7 212:7 231:20 233:14 237:17 239:14 242:18 245:19 256:8,10 269:7 278:19 290:19 296:2 299:12,20 300:4 301:3 303:1 305:11,15 310:15

thinks 274:21 third 27:19 71:21 84:22 228:21 286:18 thought 9:12 18:21 85:1 128:6 140:14 157:7,16 256:20 293:2 thought-provoking 293:7 thoughtful 34:10 thoughts 26:19 76:22 108:18 126:7 202:3 288:3 292:12 298:4 301:14 threat 182:14 three 29:18 32:8 35:4,5 35:6 43:14 45:19,22 46:7 61:5,5 64:14 65:5 71:6,12 104:14 113:2,4 115:18 124:12 216:11 225:19 227:9,13,16 230:1 246:13 247:12 262:11 263:1,4,10 264:5 272:9 285:17 three- 5:22 168:7 three-quarters 76:16 three-year 140:16 threefold 283:2 thriving 58:13 throw 292:11 thrust 163:10 thunder 253:8 tie 47:18 195:10 tied 97:2 98:17 141:6 201:6 216:16 tier 84:22 tiering 83:19 tight 31:22 tightly 172:18 173:8 timeline 309:15 timeliness 53:4 93:3 111:8 117:19 119:15 130:3 138:2 144:3.12 146:14 147:13 154:15 159:16 162:10,11 164:4,18 timely 63:8 79:6 160:10 162:9 240:20 times 8:3,12 42:2 68:15 83:15 99:16 114:12 146:11 147:7 timing 13:15 146:18 tiny 36:14 50:15 **Title** 196:4 204:10,18 205:2,3,8 tobacco 169:14 today 5:13,21 8:12 9:20

10:5 21:9 22:2 23:7 23:18,19 28:11 31:22 32:10,18 34:2 39:11 39:12 40:8 43:10 65:17 73:7 74:4 111:18 116:18 121:11 149:14 194:4 210:14 238:12 239:22 267:1 269:22 270:2 312:21 313:9 today's 22:9 312:18 told 33:6 61:10 246:17 tolerate 60:11 tomorrow 23:7 32:19 40:8 99:5 180:19 264:10 265:13 278:20 309:14 313:12 tonight 32:3 309:12 tons 212:22 tool 254:5 tools 128:13 279:3 top 45:4 53:17 56:7 60:10 61:21 64:1 66:10,11 109:19 297:11 304:9 topic 111:17 123:17 232:19 267:6 topics 212:3 topped 7:13 25:8 total 113:11 117:12 168:3 248:21 255:6 totally 47:8 53:8 63:16 63:19,21 68:14 73:3 86:11 155:4,20 172:17 173:4 185:17 279:9 touch 90:17 300:16 town 103:4 track 83:3 102:5,8 214:10 284:22 tracking 87:7 94:22 95:2 100:1,9 191:18 tracks 95:3 tract 231:13 trade-offs 239:16 training 34:6 trains 248:14 trajectory 55:2 transcript 149:8 transferred 239:10 transform 282:9 transformation 42:19 281:3 transformed 49:8 transition 55:18 129:5 140:17 146:6 159:22 164.4transitional 136:13

139:5 translate 56:5 transparency 149:7 281:17 transparent 57:16 transportation 68:18 81:21 84:10 143:8 traumatized 72:18 treat 83:12 treating 146:12 257:2 treatment 154:18 249:15 252:5 tremendous 312:12 trend 65:12 trends 50:16 106:18 triage 146:10 tribe 242:5 tried 6:12 44:10 57:16 233:16 trimester 144:14,19 155:1,3,7 tripping 194:14 trouble 55:14 306:4,6,8 true 155:5 233:16 truly 186:13 203:10,16 208:2 try 8:13 20:4 27:2 40:11 40:12 42:8 46:2 53:13 68:11 72:13 83:16 99:16,21 106:11 136:7 150:5 157:9 180:21 181:8 210:11 216:18 234:22 280:16 trying 37:3 38:11 40:22 44:7 47:21 48:15 64:3 75:19 78:11 79:3 82:15 86:22 134:11 135:15 137:5 144:8 156:14 158:13,18 174:8 177:10 191:14 200:16 212:10 214:2 234:21 269:11,14 279:5 282:8 283:21 290:18 304:13 tubes 201:6 turn 7:21 9:1 20:6 21:2 123:22 124:22 184:8 184:18 252:13 253:5 265:18 269:14 270:8 277:14 turning 291:4 turns 47:11 65:14 85:5 tweak 131:19 132:10 **two** 5:9 18:21 24:20 25:11 27:17 35:7 56:18 59:1 68:14,14 72:3 74:7 76:10 80:9 82:4 90:3 92:7 111:11

342

113:4 117:13 118:2.2 125:9 131:6 141:11 146:8 147:11 158:14 158:18 164:19 165:18 174:19 175:17 185:22 194:4,11 206:7 211:8 227:22 228:11,13 229:6 240:20 242:14 242:15,18 244:19 246:14 247:3,11 251:8 252:1,12 255:11 256:2,3,13 257:10 259:20 261:19 263:1 268:18 283:2 287:20 288:1 292:15 296:1 TY 77:15 tying 50:1 96:19 101:6 type 95:14 220:3,5 231:14,14,16 250:14 252:3 types 69:1 85:6 256:18 271:5,12 273:19 typical 278:8 typically 88:17,18 129:5 288:22 U **UHC** 61:17 ultimate 212:10 276:10 ultimately 30:4 246:3 299:4 unanimously 187:18 unavailable 175:4 unbundled 96:22 uncertain 105:2 uncertainty 160:22 186:12 uncomfortable 161:9 196:18 uncoordinated 305:19 undercurrent 82:9 underneath 229:7 underplay 272:19 underscore 222:2 understand 7:10 59:13 83:17 84:11 125:15 199:22 203:14 208:18 209:8 214:5 215:3,13 217:16 230:5 242:6 283:6 300:3 understanding 29:9,12 33:1 40:22 90:10 158:8 208:5 209:16 245:21 268:16 272:15 272:17,21 273:15 understands 32:17 understood 48:22

215:10 undertaking 29:11 undertook 72:2 **underway** 43:16 unendorsed 253:16 uniform 33:13 unintended 95:1 201:10 203:11 207:9 207:10 208:2,6,22 209:19,21 210:3 211:5 217:9,13 unintentional 213:3 unique 222:6 287:21,21 unit 285:6 universe 49:6 113:16 248:22 **University 28:5,6** unmet 207:11 287:11 unrelated 279:9 unreliable 201:13 untenable 85:18 untrusted 70:21 update 8:3 21:22 249:4 310:1 updated 170:1 231:9 updates 117:17 **upper** 116:14 ups 290:7 upstream 70:9 uptake 169:9 **upwards** 268:8 urban 79:17 80:1 290:5 294:12 urban- 272:22 urging 139:1 use 8:10 19:9 25:14 26:2,6 28:21 42:13 54:13 66:18 83:21 97:21 98:19 102:4 103:19 107:10 115:20 122:13,20 129:21 139:22 149:9 169:13 169:14,14 172:3 173:7,8 181:22 183:4 198:12,18 204:10,18 207:11 209:5 211:21 213:4 218:16 220:1 222:4 225:1 226:9,10 226:11,21 249:19 251:17,19 255:20 262:18 264:2,19 285:3 286:1 294:4 296:6 299:22 301:16 303:15 304:15 useful 29:9 36:16 46:22 52:21 55:7,13 66:21 67:4 68:19 94:13 95:7 95:15,22 96:21

usefulness 50:14 user 219:22 **uses** 287:3 **usually** 183:4 Utah 208:16 218:12,14 uterus 212:9 utilization 174:15 296:5 306:7 utilized 181:4 utilizing 300:11,12 V valid 7:15 validate 241:5 validity 120:11,18 valuable 35:8 188:3 245:9 value 158:6,13 235:1 value- 146:20 value-based 43:2 79:12 88:11 90:16 100:14 108:4.10 281:12 variable 182:15 305:13 variables 156:13 variation 182:14 232:6 258:1 272:17,21 varied 290:20 varies 106:5 various 30:17 100:16 105:16 187:7 vendors 52:13 ventilator-associated 104:10 venue 131:17 version 154:13 196:4 versions 210:2 versus 53:17 104:2 156:21 200:7 246:14 253:16 254:14 290:5 294:11 296:14,14 VH 84:9 vibrant 15:17 vice 11:18 12:10 16:16 18:5 20:12 140:12 view 21:21 22:18,19 30:12 58:3 59:10 61:8 61:20 62:1,4 67:6 75:18 82:5 87:12 112:16 150:16 154:8 194:10 221:5 272:9 273:15 274:8 276:15 278:7 300:10 306:19 viewpoint 11:2 vignette 295:18 violence 169:16 **virtual** 109:18 virtually 212:18 213:21 vision 312:21

visit 49:4,22 50:3 51:21 57:3 65:17 68:3,16 72:12 77:21 89:13,15 94:1,7 95:4,16,20 96:3,6 97:2,3 100:11 103:8 104:13,17 119:2 121:2 126:10 129:17 130:5 144:22 146:17 154:7,14 155:1,13 221:1 310:10 visiting 71:6 97:19 98:12 101:1 visits 53:6 54:8 62:7 66:4 67:19 69:15 72:14 78:22 92:8 99:19 104:19 107:6 119:3 120:14 126:15 129:20 135:17 141:16 141:21 199:14 253:18 253:18 vital 6:8 130:10 235:19 236:1 240:17,19 241:3 244:17 **vocal** 31:15 279:20 voice 83:9 voluntarily 33:2 voluntary 23:14 32:15 38:19 55:11,14 222:14 **volunteer** 47:3 60:15 vote 124:7,7,14 132:17 135:10 136:21,22 137:21 149:5,7,9 150:1,5,14,21 151:6 151:10,13,18 152:4,8 153:15 162:3 163:8 163:18,22 164:2 176:15 190:7 193:5 193:10 221:9 222:15 223:6 225:10,14,15 225:16 228:5 229:18 246:8,19,20 247:11 247:11 252:18 258:18 259:17,18,18 260:2 261:3,8,10 **voted** 116:17 120:16 138:13,15 150:17 160:9 165:2 189:15 194:11 223:14 228:7 228:8,9 247:15 259:11 260:12 261:8 262:1 voter 150:21 votes 138:7 149:17 150:7 151:3 164:10 176:21 227:17,22 247:13 251:7 264:17

265:10 voting 2:8 8:19 123:18 124:16,18 133:12 137:9,11,14,15,17 138:11,13 144:2 149:8,18 150:3,8 151:17,20 164:11,22 165:2 176:22 177:2 182:17,21,22 190:1 223:9 227:8,14 228:6 246:13 247:3 259:9 259:11,21,22 260:4 260:10,12,15 261:14 261:21 262:1 vu 21:6 vulnerability 58:15 69:1 71:14 105:4 w wait 292:21 308:20 waiting 138:9 150:5 216:1 223:13 228:5 298:20 waiver 45:3,9 walk 10:8 114:5,16 walked 114:12 wanted 9:16 35:6 45:18 92:22 99:8 105:17 106:16 117:5 123:21 141:21 144:5 153:19 178:11 182:6 184:2 188:1,18 190:8 204:17 205:21 206:5 206:17 211:10 213:22 217:9 238:1 243:4 244:8,10 267:10 268:5,12,15 276:21 277:6 285:15 305:1,2 wants 41:5 69:13 71:10 106:10 130:19 159:1 285:6 **Washington** 1:9 13:2 73:7 294:3 295:6 wasn't 47:12 133:20 141:12 143:20 201:8 232:9 280:5 way 6:10 8:11 33:13 41:6 44:2 51:11 56:20 58:7,12 59:12 60:22 61:12 63:5 67:12 73:1 73:4 79:6 88:4 95:9 101:14 102:5,6 105:20 108:4 109:6 137:11 142:2 166:11 180:2 188:20 193:5 194:21 199:16,17 200:9 203:13 209:13 212:14 220:2,21

221:13 229:5 233:18 237:17 240:16 262:17 271:21 272:20 273:14 278:9 279:3,5 280:19 280:19,20 292:6 294:8,21 295:2 299:8 302:7,16 305:2,2 306:15 ways 25:7 40:4 51:8 56:18 78:9 86:3 88:22 90:13 94:6 108:19 110:7 198:17 199:18 209:2,7 214:2 266:1 269:4,5 273:13,22 284:22 298:22 299:11 300:3 308:2 weaknesses 122:8 wearing 165:19 295:11 web 115:1,3 webinar 193:21 195:4 website 99:1 WEDNESDAY 1:5 weed 166:3 weeds 201:1 238:18 week 129:19 weeks 145:2 147:3 154:12 157:2 278:16 weigh 41:5 163:2 173:3 217:6 229:9 259:14 308:12 weight 54:7 63:8 93:9 111:15 241:11 weighted 122:5 288:13 weights 54:9 weighty 264:3 Weill 307:22 welcome 5:3 10:4 20:13 31:9 welcoming 4:2 5:8 9:2 went 26:18,21 35:20,21 72:2 91:11 104:17 110:4 127:12 140:5 165:14 178:17 179:21 180:18 181:2 190:10 243:2 250:17 254:22 264:12 268:21 313:15 weren't 187:22 when's 277:12 Whew 152:16 whichever 92:1 whip 32:2 WHNP-BC 1:19 whoops 266:7 wide 232:6 widespread 251:19 wilderness 57:8 win 231:21 window 129:7 144:18

winter 80:8 wise 57:13 130:7,8 wish 167:16 184:21,22 286:21 withdrawn 125:14 withdrew 119:7 within-hospital 105:5 **WOEP** 145:2 woman 28:13 111:3 113:1 134:5 154:2 205:16 208:1 221:1 231:7 woman's 139:20 women 2:5 15:12 48:5 49:1,3 59:21 61:11 70:16 71:3,15,18 72:4 72:11,15,15 89:18 90:7 95:13,19 96:5 112:10 128:11 141:19 143:5 147:9 154:11 165:12 172:4 176:18 191:1,9,22 192:6,15 194:19 197:8 201:19 202:20,21,21 203:11 204:15 207:2 211:13 212:7,12 214:3 216:8 216:10 217:18 224:11 231:16 237:1 243:22 women's 1:20 13:9,12 63:6 196:9 206:10 210:5 221:2 wonder 128:21 292:10 wondered 205:13 wonderful 19:7 wondering 59:5 69:5,10 100:12 103:16 133:14 191:20 254:13 word 34:2 37:4 224:8 252:21 285:3 worded 192:16 words 219:5 work 6:14 7:19 11:15 15:16,22 17:15 19:11 22:3,9,22 24:5 28:2,4 31:16 36:7 38:20,21 40:19 47:1,4 51:8,9 51:11 52:17 56:22 69:5,13 74:20 78:22 97:12,12,20 107:16 113:17 114:14 141:22 146:4 156:13 159:21 168:5 170:22 186:11 187:8 197:15 204:11 213:11 229:14 241:17 286:6 311:3 312:4 worked 17:17,19 87:21 89:3 94:4 96:7,17 199:13

workers 71:5 95:13 workforce 29:2 81:12 working 37:7 65:19 77:6 98:8 128:7 149:20 152:5 177:18 188:19 195:22 241:18 243:15 307:8,19 works 38:9 86:12 88:19 156:9 269:8.8.17 world 18:12 71:21 72:8 306:5 worried 159:14 215:21 worry 99:18 145:11 163:8 303:9 worse 79:20 worst 283:5 worth 185:3 235:1 243:20 worthwhile 7:8 wouldn't 85:2,4 158:19 163:8 201:6 307:4 wound 121:6 wow 279:15 wrapping 66:8 write 269:16 writing 59:10 166:16 written 58:17 171:17 202:17 203:13 wrong 145:21 wrote 253:8 Х **X** 57:14 196:4 204:10 204:18 205:2,3,8 220:4 Y y 79:17 year 6:13 33:2 35:3 36:14 37:15 53:20 64:4,8 87:22 93:4 102:15 106:20,20 107:1 175:5,6 180:17 180:21 181:6 184:1 190:11,12,20 194:13 194:19 199:10 207:3 230:3,10,16 238:13 262:14 274:13 289:4 year's 113:7 year-old 13:4 years 17:17 31:12 37:8 37:17 41:15 42:18 48:13,19 68:8 71:12 98:6 119:20 120:5 123:13,13 127:19 144:6 165:15.18 184:4 185:11 191:16 194:11,14 240:20

|  |                               |   | 345   |
|--|-------------------------------|---|---|
|  |                               | I   | 1   |
| 244:19 249:9 274:15                                  | 151:3,17 152:6 165:2          | 174:19  | <b>38</b> 119:18                                |
| 302:20   | 177:2 248:21                  | <b>2014</b> 44:14 88:4 118:11                 |   |
| yellow 56:1,8 265:2                                  | <b>12-month</b> 169:20        | 119:21 174:20 250:20                          | 4   |
| <b>yes/no</b> 138:19                                 | <b>12:23</b> 179:21           | <b>2015</b> 93:5 118:7,8                      | <b>4</b> 4:2                                    |
| yesterday 10:3,6 11:10                               | <b>12:30</b> 177:11           | 119:18 120:3 174:20                           | <b>4:03</b> 313:7                               |
| 23:1,7,16,21 24:1                                    | <b>13</b> 90:2 147:18 151:1   | 174:21 185:20 194:11                          | <b>40</b> 75:2                                  |
| 31:11 34:2,21 69:20                                  | 195:20 197:19 198:22          | 250:20  | <b>41</b> 4:7                                   |
| 71:10 86:1 114:6                                     | 201:17 228:6 247:14           | <b>2016</b> 113:9 117:13                      | <b>411</b> 304:8                                |
| 121:12 124:17 140:12                                 | 260:12 262:1                  | 118:3 143:18 185:20                           | <b>42</b> 146:19 155:2 157:3                    |
| 167:1,3 180:18 195:6                                 | <b>1391</b> 139:12 147:21,21  | 249:7 250:20                                  | <b>42-day</b> 144:18                            |
| 245:2 262:19 272:7                                   | 148:8,13 149:21,21            | <b>2017</b> 1:6 235:17 237:16                 | <b>44</b> 189:13 208:1                          |
| 277:18,19 294:19                                     | 150:18,18 152:18              | 301:20 310:2                                  | <b>45</b> 174:21                                |
| 313:7  | <b>15</b> 17:17 18:21 92:9    | <b>208</b> 185:18                             | <b>47th</b> 255:13                              |
| York 3:8 18:7 217:5                                  | 177:17 189:13 208:1           | <b>21</b> 121:3                               | 47 (11 200.10                                   |
| 218:12 240:8,11,22                                   | 208:9 217:15 228:6            | <b>22</b> 84:21 86:17 113:11                  | 5   |
| 257:20 271:21  | <b>15-minute</b> 179:18       | <b>223</b> 284:12                             | <b>5</b> 249:13 253:12 255:2                    |
|  |                               | <b>223</b> 12:12 99:11 228:9                  |   |
| <b>young</b> 216:14,14                               | <b>1500</b> 186:5             |   | <b>50</b> 57:4,15 103:1,7,8                     |
| younger 185:14 217:15                                | <b>1517</b> 138:2,6 153:1,3,4 | <b>24</b> 1:6 4:5                             | 213:3 281:5                                     |
| 280:7  | 153:15 159:7 162:16           | <b>24-7</b> 83:11                             | <b>51</b> 104:20 108:2                          |
| youth 213:17   | 164:2,17                      | <b>247</b> 4:14                               | <b>53</b> 232:3                                 |
|  | <b>1571</b> 162:14            | <b>25</b> 14:8 118:10                         | <b>56</b> 104:21                                |
| Z  | <b>15th</b> 1:8               | <b>25th</b> 54:1,3                            | <b>58</b> 93:18,21                              |
| zero 209:13 212:18                                   | <b>163</b> 67:20              | <b>26</b> 13:4 70:1                           |   |
| 213:21   | <b>171</b> 74:8               | <b>2607</b> 292:7 301:20                      | 6   |
| Zerzan 24:3  | <b>177</b> 4:12               | <b>261</b> 4:15                               | <b>6</b> 4:4                                    |
|  | <b>1799</b> 249:6 251:14      | <b>265</b> 4:17                               | <b>60</b> 11:21 250:17 258:5                    |
| 0  | 252:6,9,13 253:16             | <b>27</b> 33:22 118:10 196:3                  | 60th 104:15                                     |
| <b>0024</b> 111:16                                   | 255:14 256:2 259:18           | 303:14  | <b>62</b> 228:7                                 |
| <b>0033</b> 111:1                                    | 259:21 260:2 261:3,6          | 27-member 178:14                              | <b>63</b> 223:13,16                             |
| <b>0047</b> 251:9,9,12,16                            | 261:9,15 262:1                | 179:3   | <b>64</b> 93:8 253:12                           |
| 252:1 254:14,15,22                                   | <b>180</b> 4:13               | <b>28</b> 4:6 118:11                          | <b>66</b> 182:19                                |
| 255:12 256:15 257:3                                  | <b>1800</b> 251:9,11,12,16    | <b>2830</b> 228:15 234:3                      | 6th 285:19 309:18                               |
| <b>0341</b> 229:8                                    | 252:3,6,16,17 253:5           | 247:9   |   |
| <b>0476</b> 25:1                                     | 254:14 255:14 256:1           | <b>29</b> 11:22 118:8                         | 7   |
| <b>0477</b> 186:4,5                                  | 259:4,22 260:9,9              | <b>2902</b> 111:3                             | <b>70</b> 213:4 232:4,4                         |
| <b>0480</b> 228:15 247:7                             | 261:8 264:16                  | <b>2903</b> 184:5 186:17                      | 700,000 44:14 45:21                             |
| <b>0576</b> 111:11                                   | <b>187</b> 117:10             | 188:10 189:10 190:9                           | <b>75</b> 57:5 144:16 249:14                    |
|  | <b>19-1/2</b> 240:21          | 192:22 222:21 227:12                          | 7th 285:19 309:18                               |
| 1  | <b>1998</b> 48:14             | 265:10  |   |
| <b>1-800</b> 65:16                                   |                               |   | 8   |
| <b>1:00</b> 8:13                                     | 2                             | 3   | <b>8.9</b> 93:11                                |
| <b>10</b> 113:12 274:13,15                           | <b>2</b> 114:18,19 115:10,11  | <b>3</b> 55:1 67:22 223:2                     | <b>80</b> 44:16 45:8 129:19                     |
| <b>10,000</b> 10:19                                  | 149:16 150:2 176:21           | 225:17 259:6,8 260:4                          | 178:20 232:4 236:18                             |
| <b>10:00</b> 74:1                                    | 223:1 225:16 227:15           | <b>3:25</b> 313:10,15                         | 258:4   |
| <b>10:20</b> 74:2                                    | 231:14,16 259:5               | <b>3:59</b> 313:8                             | <b>800</b> 212:16                               |
| <b>10:46</b> 110:4                                   | <b>2:26</b> 264:12            | <b>30</b> 33:22 85:4 98:6                     | <b>82</b> 93:3                                  |
| <b>100</b> 49:8 50:12 54:22                          | <b>2:33</b> 264:13            | <b>30's</b> 268:8                             | <b>85</b> 196:22 208:9 247:14                   |
| 138:12 150:16 173:9                                  | <b>2:50</b> 8:13              | <b>30,000</b> 53:13                           | <b>87</b> 4:9                                   |
| 196:17 209:12 211:12                                 | <b>20</b> 48:13,19 62:12 98:6 | <b>300</b> 232:15                             | 07 7.3  |
| 233:5 239:18 260:11                                  | 146:10 196:8 249:13           | <b>3041</b> 247:10                            | 9   |
| <b>100,000</b> 44:16                                 | 258:3 274:13,15               | <b>308</b> 4:18                               | <b>9:00</b> 1:9                                 |
| <b>1030</b> 1:8                                      | <b>20's</b> 268:8             | <b>31</b> 119:20 309:22                       | 9:00 1.9<br>9:03 5:2                            |
| <b>108</b> 4:11                                      | <b>200,000</b> 85:17          | <b>312</b> 4:19                               | <b>90</b> 43:15 236:2                           |
| <b>10</b> 4:5 111:22 112:15                          | <b>2009</b> 231:10            | <b>313</b> 4:20                               | <b>90</b> 43.15 236.2<br><b>91</b> 178:17 230:4 |
| <b>11:00</b> 8:13 109:19 110:2                       | <b>2011</b> 286:9             | <b>313</b> 4.20<br><b>32</b> 113:10 117:12,12 | 91 178.17 230.4<br>9th 1:8                      |
| <b>11:00</b> 8.13 109.19 110.2<br><b>11:03</b> 110:5 | <b>2012</b> 118:10 119:20     | <b>33</b> 119:20                              | <b>JUL</b> 1.0                                  |
| <b>113</b> 13:2                                      | 143:17 170:1                  | <b>35</b> 120:3 282:3                         |   |
| <b>113</b> 13.2<br><b>12</b> 64:5 86:18 150:17       | <b>2013</b> 118:10 119:21     | <b>36</b> 119:21                              |   |
| 12 04.0 00.10 100.17                                 | 2010 110.10 113.21            |   |   |
| Ш  |                               |   |   |

## CERTIFICATE

This is to certify that the foregoing transcript

In the matter of: Measure Application Partnership Medicaid Adult and Child Task Force

Before: NQF

Date: 05-24-17

Place: Washington, DC

was duly recorded and accurately transcribed under my direction; further, that said transcript is a true and accurate record of the proceedings.

near Rans &

Court Reporter

## **NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

www.nealrgross.com

(202) 234-4433